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A bstract
CC chemokine receptor 5 (CCR5) is a G protein-coupled receptor (GPCR) 
involved in the recruitment o f a subset of leukocytes to sites of 
inflammation. In addition, CCR5 functions as a co-receptor for several 
strains o f the human immunodefic iency virus (HIV). The f ind ing that 
agonist-induced internalisation o f CCR5 can protect susceptible cells from 
infection in  vitro  has stimulated research demonstrating that activated 
receptors are phosphorylated on C -ta il serine residues and bind p-arrestins, 
which couple them to the c la thrin -m edia ted endocytic machinery. After 
internalisation, receptors are recycled to the cell surface via a perinuclear 
recycling compartment, identified as the recycling endosome. Here, I extend 
these findings, demonstrating tha t CCR5 also traffics through the trans- 
Golgi network (TGN), and thus, the perinuclear recycling compartment can 
be considered to comprise both recycling endosome and TGN elements. 
Moreover, I show that R a b l l  regulates trafficking through this compartment 
and that dynamin inhib it ion blocks the recycling o f CCR5. In combination 
with other electron microscopy studies, my data support the notion that 
clathrin and dynamin are involved in the recycling o f CCR5 from the 
recycling compartment. Through morphological and biochemical analysis, I 
also show that p-arrestins maintain an interaction with CCR5 into the 
recycling compartment. Kinetic analysis o f receptor recycling suggests that 
p-arrestin2 acts a negative regulator o f CCR5 recycling but my data do not 
discount the possibility that p-arrestins couple CCR5 to clathrin to effect 
recycling. In keeping w ith the sustained p-arrestin interaction, CCR5 
molecules remain phosphorylated as they traffic to the recycling 
compartment, but contrary to previous reports showing that receptor C-tail 
phosphorylation is required fo r  h igh-a ff in ity  p-arrestin binding, I show that 
a phosphory la tion-defic ient CCR5 mutant undergoes p-arrestin-dependent 
agonist-induced internalisation. In addition to its relevance for HIV biology 
and inflammation, this study contributes to an understanding o f GPCR 
traffick ing in general.
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TFP Tetrafluorophenyl
Tf Transferrin
TfR Tf receptor
TIR-FM Total internal reflection fluorescence microscopy
Tris Tris[hydroxymethyl]aminomethane
TSH Thyro trop in -s tim u la ting  hormone
V2R Vasopressin type 2 receptor
wt Wild-type
YFP Yellow fluorescent protein
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“Thepoint ofphtl&yyphy iyto- btcut xvith Knnethtng^  ^  yimple ci^  not 
to-beewv worthsstating', OA^to-enttwithsomethtng^so-paraxloiUcat 
that no-one\uCHbelieve/ it. ”
8 ertrcond/KuteeZL, pKCLoyypher (1872 -1970 )
CC chemokine receptor 5 (CCR5) is a G protein-coupled receptor (GPCR) 
that is principally involved in the recruitment o f leukocytes to sites o f 
inflammation. The human gene fo r  CCR5 was cloned in late 1995 and the 
protein product functionally assigned to a growing family o f receptors 
mediating the recruitment o f cells involved in immune and inflammatory 
processes (Samson, Labbe et al. 1996). But within a few months, CCR5 was 
catapulted into the limelight w ith the discovery of its role as a co-receptor 
for the human immunodeficiency v irus-type 1 (HIV-1) (Alkhatib,
Combadiere et al. 1996; Choe, Farzan et al. 1996; Deng, Liu et al. 1996; 
Dragic, Litwin et al. 1996). A round the same time, it was found that 
^  individuals homozygous for a 32 base-pair deletion in the CCR5 gene, 
which results in a truncated protein that, unlike the w ild-type receptor, is 
not expressed on the cell surface, displayed significant resistance to HIV 
infection (Dean, Carrington et al. 1996; Liu, Paxton et al. 1996). In addition, 
it had previously been reported that certain chemokines - later assigned as 
CCR5 agonists - were able to inh ib it HIV infection o f susceptible cells in 
vitro  (Cocchi, DeVico et al. 1995). With the subsequent demonstration that 
chemokine-induced internalisation o f CCR5 provides the major component 
o f such resistance (Mack, Luckow et al. 1998), the notion was born that 
down-regulating CCR5 cell surface expression could be an effective an ti­
viral strategy. This has fostered an interest in understanding the post-
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translational mechanisms contro ll ing CCR5 cell surface expression, which 
are intimately related to the control o f its signalling activity. Indeed, 
desensitisation o f agonist-activated GPCRs is often followed by their 
endocytosis. Internalised receptors are then either targeted to lysosomes for 
long-term  down-regu la tion  or reprogrammed and recycling back to the cell 
surface in a state competent to respond to further agonist stimulation 
(resensitisation) (Drake, Shenoy et al. 2006; Hanyaloglu and von Zastrow 
2007). Previous studies have shown that agonist-activated CCR5 undergoes 
clathrin-mediated endocytosis and that after internalisation, CCR5 
molecules are rapidly recycled to the cell surface (Signoret, Pelchen- 
Matthews et al. 2000; Signoret, Christophe et al. 2004; Signoret, Hewlett et 
al. 2005). However, little is currently known about the regulation o f the 
post-endocytic trafficking o f CCR5. In addition to its relevance to HIV 
biology, a clear description o f th is process is needed to understand how 
CCR5 contributes to leukocyte tra ff ick ing. Moreover, such a description 
should add to our understanding o f the trafficking of GPCRs in general, o f 
significant import, given their prevalence - there are approximately 1000 
genes coding fo r GPCRs in the human genome.
Chemokines and chemokine receptors
Chemokine (chemoattractant cytokine) activation of chemokine receptors 
coordinates leukocyte traffic  th roughou t the body during immune 
surveillance, inflammation and in the establishment o f immunity. Binding o f 
chemokines to their cognate receptors initiates a series of cellular events 
that include cytoskeletal rearrangements, increased cellular adhesion and 
directed cell movement along a chemoattractant gradient (chemotaxis). 
Additional roles of chemokines and the ir receptors in angiogenesis, 
haematopoiesis, organogenesis and metastasis have also been described 
(Gerard and Rollins 2001; Yoshie, Imai et al. 2001).
Classification of chemokines and their receptors
Chemokines are small, highly basic proteins o f 70-125 amino acids (8 -10  
kDa). There are currently 45 known human chemokines, which are 
structurally classified into 4 subfamilies (CC, CXC, CX3C and XC) based on
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the arrangement o f conserved am ino-term inal cysteine residues. The 2 
major groups are the CC and CXC chemokines, which have either adjacent 
am ino-term inal cysteine residues (CC) or am ino-term inal cysteines 
separated by a single amino acid (CXC). Additional related molecules, 
fractalkine and two lymphotactins (splice variants o f the same gene), 
represent the CX3C and XC families, respectively (Bacon, Baggiolini et al.
2002 ).
Eighteen chemokine receptors have thus far been identified and their 
nomenclature follows that o f the ir ligands, giving the chemokine receptors 
CCR1 to 10, CXCR1 to 6, CXC3CR1 and XCR1.
Chemokines have also been historically divided into inflammatory and 
homeostatic groups based on the ir  proposed functions (Muller, Hopken et 
al. 2002; Moser, Wolf et al. 2004). The inflammatory chemokines, involved 
in leukocyte accumulation at inflammatory sites, were the f irs t discovered, 
after the realisation in the late 1980s that they are induced by major 
inflammatory cytokines, which themselves lack the ability to directly induce 
leukocyte chemotaxis. Homeostatic chemokines, on the other hand, are 
produced under normal conditions and are responsible for leukocyte 
recirculation, homing into the lymphoid organs and organisation o f 
functional lymphoid microenvironments under steady-state conditions and 
during lymph organogenesis (Cyster 2003; Ohl, Bernhardt et al. 2003). 
However, this definition is somewhat artificial, since some so-called 
homeostatic chemokines are produced in inflammatory lesions and 
contribute to leukocyte recruitment (Chiu, Shang et al. 2002; Eddleston, 
Christiansen et al. 2002; Odemis, Moepps et al. 2002; Obermeier, Schwarz 
et al. 2003; Kailinich, Schmidt et al. 2004; Ohl, Mohaupt et al. 2004) and 
some so-called inflammatory chemokines are produced under normal 
conditions with undefined homeostatic functions (Jones, Webb et al. 1995; 
Glatzel, Wesch et al. 2002; Sallusto, Ceginat et al. 2004; Zhang, Shimoya et 
al. 2004).
The greater number o f chemokines compared with their receptors suggests 
that multiple chemokines may be able to engage single chemokine 
receptors and indeed this is the case, although the promiscuity is 
bidirectional, with particular chemokines also having the ability to bind 
different receptors. Some monogamous chemokine-chemokine receptor
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interactions are found amongst the homeostatic group members, whereas 
overlapping specificities are more characteristic o f the inflammatory group 
(Bacon, Baggiolini et al. 2002).
Although most chemokines are secreted proteins, it must be appreciated 
^  that in order to function in vivo to recruit leukocytes from the blood stream, 
for instance during inflammation, there must be a mechanism for their cell 
surface retention, since in the absence o f such a mechanism, they would be 
washed away from the ir site o f production by blood flow and unable to 
maintain a chemoattractant gradient. The retention o f chemokines is 
achieved by interaction with surface glycosaminoglycans (CACs), which are 
linear, heterogeneous polysaccharides with an overall negative charge 
conferred by the presence o f carboxylate and sulphate groups (Middleton, 
Patterson et al. 2002). They therefore bind positively charged chemokines 
primarily th rough electrostatic interactions. The main GACs expressed by 
endotheial cells are heparan sulphate proteoglycans (Ihrcke, Wrenshall et al. 
1993).
Role of chemokines in recruitm ent of leukocytes to sites of 
inflammation
One of the best described roles -  yet by no means a complete description - 
o f chemokine/chemokine receptor function is in the recruitment o f 
leukocytes circulating in the bloodstream to sites o f inflammation (Figure 
1-1). The specificity o f leukocyte recruitment is achieved by the 
combinatorial action o f leukocyte and endothelial cell adhesion molecules 
and their counter-ligands, as well as the chemokines presented on the 
luminal endothelial surface (Ley, Laudanna et al. 2007). Recruitment begins 
with the capture o f free-flow ing leukocytes to the vessel wall, typically o f 
inflamed postcapillary venules, followed by rolling along the endothelium, 
both processes mediated by selectins binding to their counter-receptors. 
While rolling, leukocytes come into close contact with the inflamed 
endothelium, enabling them to interact with immobilised chemokines. The 
binding o f chemokines to their cognate receptors leads to the activation o f 
integrins, resulting in firm leukocyte arrest and eventual transmigration.
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However, to date, only a few chemokines have been demonstrated to be 
capable o f arresting rolling leukocytes in vitro or in vivo (Ley 2003).
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Figure 1-1 Leukocyte recruitment during inflammation
Intravital m icroscopy w ith  su per im p o sed  cartoon features il lustrating the process o f  
leukocyte re c ru i tm e n t  a t sites o f  in f la m m a t io n . See main te x t  for details.
Chemokines released at the site of injury within the tissue are then 
responsible for guiding leukocyte chemotaxis to this site, with chemokine 
receptors able to translate a chemokine gradient into directed cell migration 
in a process that is poorly understood. Presumably, within the inflamed 
tissue, a GAG immobilisation mechanism for chemokines also restricts the 
radius of chemokine activities and is probably a part of the mechanism for 
establishing a chemokine gradient.
CC chemokine receptor 5 (CCR5)
Expression pattern and function
CCR5 is expressed on a subset of leukocytes, namely monocytes, 
macrophages, immature dendritic cells and memory T-lymphocytes, which
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are recruited to sites o f inflammation by the CC chemokines and CCR5 
agonists, CCLB (macrophage inflammatory protein [MIP]-lcx), CCL4 (MIP-1|3), 
CCL5 (regulated on activation normal T-cell expressed and secreted 
[RANTES]) and CCL8 (monocyte chemoattractant protein [MCP]-2) (Murphy, 
Baggiolini et al. 2000). CCR5 knock-out mice attest to its role as an 
inflammatory chemokine receptor (Floess, Rot et al. 2005). These mice show 
a defect in macrophage recruitment, with reduced efficiency o f Listeria 
monocytogenes clearance, decreased protection against LPS-induced 
endotoxemia and an inability to eliminate cryptococcal microorganisms, 
leading to an increased morta lity  rate of infected mice (Zhou, Kurihara et al. 
1998; Huffnagle, McNeil et al. 1999; Huffnagle and McNeil 1999). CCR5 
knock-out mice also present with an inability to regulate T cell responses, 
leading to an enhanced delayed-type hypersensitivity (DTH) response and 
an increased response to T cell-dependent antigen challenge. Moreover, 
after Mycobacterium  bovis infection, higher numbers of primed T cells were 
observed in CCR5 knock-ou t mice, attributed to an increase in activated 
dendritic cells (Zhou, Kurihara et al. 1998; Algood, Lin et al. 2004).
As previously mentioned, in addition to its role as a chemokine receptor, 
human CCR5, in concert w ith CD4, has been shown to function 
pathologically as a co-receptor fo r  R5-tropic (macrophage-tropic) strains of 
HIV-1 and HIV-2, as well as for simian immunodeficiency viruses (SIV) 
(Berger, Murphy et al. 1999). R5-tropic strains of HIV-1 appear to be 
responsible for virus transmission and are the prevalent virus type isolated 
from asymptomatic individuals (Roos, Lange et al. 1992; Schuitemaker, Koot 
et al. 1992; Connor, Mohri et al. 1993). This role for CCR5 in virus 
transmission is h ighlighted by the resistance to HIV-1 infection of 
individuals homozygous for a 32 base-pair deletion mutant of the CCR5 
gene, CCR5A32, which results in a truncated protein that is not expressed 
on the cell surface (Dean, Carrington et al. 1996; Liu, Paxton et al. 1996; 
Samson, Libert et al. 1996). Disease progression in HIV-infected CCR5A32 
heterozygotes is also slower than normal, most probably due to reduced cell 
surface levels o f CCR5 (Benkirane, Jin et al. 1997). Interestingly, 1% of 
Caucasians are homozygous for the CCR5A32 allele and, despite some of 
the defects reported in mice lacking CCR5, there appear to be no major 
deleterious effects o f lacking a functional version o f CCR5 in humans (Liu,
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Paxton et al. 1996).1 Indeed, homozygosity may confer some advantages to 
individuals, rendering them less susceptible to rheumatoid arthritis 
(Pokorny, McQueen et al. 2005) and childhood asthma (Hall, Wheatley et al. 
1999), and is also associated with a reduced likelihood o f renal transplant 
rejection (Fischereder, Luckow et al. 2001). Moreover, the high prevalence of 
the CCR5A32 allele in some populations - up to 18% of individuals are 
heterozygotes in some North European countries - has led some researchers 
to suggest that the allele m ight have become fixed as the result o f a 
selective pressure exerted by an unknown pathogen that utilised CCR5 in 
the past (Dean, Carrington et al. 1996; Samson, Libert et al. 1996).
Over the course o f an HIV infection, typically after several years, X4-trop ic  
(T ce ll-tropic) strains often emerge in infected individuals that are better 
able to infect certain CD4-positive cells, correlating with accelerated disease 
progression (Tersmette, de Coede et al. 1988; Tersmette, Cruters et al. 
1989). X4-trop ic  virus strains use the chemokine receptor, CXCR4, as a co­
receptor for entry. As for CCR5, chemokine-induced internalisation of 
CXCR4 protects susceptible cells from infection in vitro (Signoret, Oldridge 
et al. 1997). This re-enforces the notion that reducing cell surface 
expression o f chemokine receptors involved in HIV entry could be an 
effective anti-v ira l strategy. However, although CCR5A32 homozygotes 
tolerate the loss o f functional CCR5, compensatory mechanisms may come 
into play during immune system development and the loss of cell surface 
CCR5 may not be so well tolerated in normal individuals whose immune 
systems have developed with functional CCR5.
Although several chemokine receptors have been shown to function as HIV 
co-receptors in vitro, only CCR5 and CXCR4 appear to function in vivo 
(Zhang and Moore 1999; Zhang, Lou et al. 2000).
1 CCR5A32 is, however, associated w ith  an increased susceptib il i ty to sarcoidosis and increased morta l i ty 
rate in individuals with multip le  sclerosis (Petrek, M., J. Drabek, et al. (2000). "CC Chemokine Receptor 
Gene Polymorphisms in Czech Patients with Pulmonary Sarcoidosis." American journal of Respiratory and 
Crit ical Care Medicine 1 6 2 : 1000-1003, Gade-Andavolu, R., D. E. Comings, et al. (2004). "Association of 
CCR5 delta32 Deletion with Early Death in Multiple Sclerosis." Genetics in medicine 6 (3): 126-131.)
25
CCR5 structure
Chemokine receptors belong to the superfamily o f C prote in-coupled 
receptors (CPCRs), a group o f 7 transmembrane domain-contain ing proteins 
that signal th rough heterotrimeric C proteins. They can be fu rther 
structurally classified as family l b  GPCRs, with which they share a common 
molecular architecture (Bockaert and Pin 1999). All chemokine receptors are 
between 340 and 370 amino acids in length and, in addition to having 7 
transmembrane spanning domains, they have an extracellular N-term inal 
domain and a cytoplasmic C-ta il (Murphy, Baggiolini et al. 2000).
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Figure 1 -II Two dimensional topology diagram of the human CCR5 sequence
T h e  g rey  b ox  m arks  th e  a p p r o x im a te  p os it ion  o f  the m e m b ra n e  bilayer, w i th  the  
e x tra c e l lu la r  space at th e  to p  and  th e  in tra c e l lu la r  space (cy top lasm ) at th e  b o t to m .  
T h e  N -te rm in a l d o m a in ,  e x t ra c e l lu la r  loops (ECLs), in trace llu la r  loops (ICLs) an d  C-
26
tail are  in d ica ted . T ra n s m e m b r a n e  d o m a in s  are n u m b e re d  1-7 beg in n in g  f ro m  the  
m ost N -te rm in a l ( le ft  to r ig h t  in the  d iag ram ; not labelled). Key a m in o  acids  
discussed in the m ain  te x t  are  ind ica ted  by fi lled circles. CCR5 conta ins  4 cyste ine  
residues in its e x tra c e l lu la r  d o m a in s ,  w h ich  fo rm  d isu lph ide  bonds as ind ica ted  by 
the  lines e x te n d in g  b e tw e e n  th e m . T h e  a m in o -te rm in a l d o m a in  o f  CCR5 is post-  
tran s la t io n a lly  m o d if ie d  by ty ros in e  su lp h a tio n  o f  the h ig h ligh ted  tyros ine  res idues  
and O -linked  g lyco sy la t ion  o f  Ser6 . T h e  second in trace llu lar loop conta ins  a 
conserved  D R Y L A V V H A  m o t i f  im p l ic a te d  in G prote in  in terac tion . C yste ines 3 2 1 ,  
3 2 3  and 3 2 4  are p a lm ito y la te d  and  insert ion of p a lm ita te  m o ie t ies  in to  the  
cytop lasm ic  lea f le t  o f  th e  m e m b r a n e  bilayer is believed to c reate  a fo u r th  
in trace llu la r  loop. T h e  C-tail conta ins  4 serine residues th a t have been show n to  
u n d e rg o  a g o n is t - in d u c e d  p h o s p h o ry la t io n ,  involved in recep to r d esen s it isa t io n  and  
in te rn a l isa t io n .  See m ain  te x t  fo r  fu r th e r  details .
F igure a d a p te d  f r o m  O p p e rm a n n  ( 2 0 0 4 ) .  “C h e m o k in e  receptor CCR5: insights into  
s truc ture , fu n c t io n , and re g u la t io n .” C e llu la r  S ignalling 16:1 201 -1 21 0.
Human CCR5 is composed o f 352 amino acids, with a predicted molecular 
mass o f 40.6 kDa. The 3-d imensional structure of CCR5 (or that o f any 
chemokine receptor) has not yet been determined, due to difficulties with 
crystallisation o f integral membrane proteins. However, domain-specific 
antibodies confirm the general 7 transmembrane-spanning topology o f 
CCR5 (Lee, Sharron et al. 1999; Blanpain, Vanderwinden et al. 2002) and 
structural models have been produced based on the available structure o f 
rhodopsin (Govaerts, Blanpain et al. 2001; Paterlini 2002). A 2-dimensional 
topology diagram is shown in Figure 1—II (Oppermann 2004).
A structural hallmark o f the CPCR superfamily is the presence o f a 
disulphide bridge between conserved cysteine residues on the second and 
third extracellular loops. In addition, chemokine receptors contain two extra 
cysteine residues that are thought to form a disulphide bond between the 
N-terminal domain and the th ird  extracellular loop. Since mutation of any of 
the extracellular cysteines in CCR5 resulted in an inability to bind M I P - l c x  or 
respond functionally to other CCR5 agonists, these disulphide bonds appear 
necessary for maintaining a receptor conformation capable o f agonist 
binding and/or signalling (Blanpain, Lee et al. 1999). Other features 
conserved among members o f the chemokine receptor family include a 
DRYLAVVHA sequence in the second intracellular loop, which has been
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implicated in C protein interaction, and an unusually short third intracellular 
loop, which is enriched in positively charged residues (Murphy, Baggiolini et 
al. 2000).
The am ino-term inal domain o f CCR5 undergoes certain post-translational 
modifications, which are crucial fo r CCR5 function. One modification is the 
addition o f sulphate residues to several tyrosines (Farzan, Mirzabekov et al. 
1999). This sulphation confers negative charge to the am ino-term inus and 
contributes significantly to chemokine binding (Farzan, Mirzabekov et al. 
1999; Farzan, Chung et al. 2002), as well as binding to the HIV envelope 
protein (Farzan, Mirzabekov et al. 1999; Cormier, Persuh et al. 2000; 
Farzan, Chung et al. 2002; Huang, Lam et al. 2007). It is not known whether 
all o f the tyrosines in the am ino-term inal domain are sulphated, but s ite- 
directed mutagenesis indicated that Tyr3 almost certainly undergoes 
sulphation (Farzan, Mirzabekov et al. 1999) and sulphation o f TyrlO and 
T y r l4  appears to be important fo r chemokine binding and HIV co-receptor 
activity, since only sulpho-peptides that contained at least two sulphate 
moieties at these residues could substitute for the CCR5 am ino-term inus in 
chemokine binding or HIV co-receptor assays (Cormier, Persuh et al. 2000; 
Farzan, Chung et al. 2002). More recently, structural data has confirmed the 
importance o f sulphation at tyrosines 10 and 14 in co-receptor activity 
(Huang, Lam et al. 2007). Using a computer simulation, Huang et al. docked 
the nuclear magnetic resonance (NMR) structure o f a 14-residue peptide of 
CCR5 covering residues 2 -15  and sulphated at tyrosines 10 and 14 ( fu l l-  
length CCR5 protein numbering) obtained in the presence of CD4 and the 
viral envelope protein, g p l2 0 ,  to a crystal structure of CD4 complexed with 
g p l2 0  crystallised in the presence o f an antigen-binding fragment o f a 
functionally tyrosine-sulphated antibody that binds to a CD4-induced 
epitope that overlaps the site o f co-receptor binding on HIV-1 g p l2 0 .  This 
analysis showed that su lpho-tyros ine 10 forms a salt bridge with an 
arginine residue o f the g p l2 0  core and, more interestingly, su lpho-tyrosine 
14 is completely sequestered in a binding pocket, the formation o f which 
requires the structural rearrangement of g p l2 0 , contributing to HIV entry. 
The am ino-term inal domain o f CCR5 is also post-translationally modified by 
O-linked glycosylation, preferentially on Ser6 (Farzan, Mirzabekov et al. 
1999; Bannert, Craig et al. 2001). O-linked glycans significantly contribute
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to chemokine binding, with terminal sialic acid moieties being particularly 
important. However, removal o f O-linked oligosaccharides has little effect 
on HIV co-receptor activity (Bannert, Craig et al. 2001). Although a potential 
N-glycosylation site exists on the third extracellular loop, the asparagine 
residue does not appear to be modified, probably due to its proxim ity to 
one o f the d isu lph ide -b r idge-fo rm ing  cysteines, rendering it inaccessible to 
modifying enzymes (Farzan, Mirzabekov et al. 1999).
The CCR5 C-tail is also post-translationally modified, through 
palmitoylation o f cysteine residues. Indeed, many chemokine receptors 
contain one or more cysteine residues in their C-tails compatible with 
receptor palmitoylation, although CCR5 is the only chemokine receptor for 
which palmitoylation has been demonstrated (Neel, Schutyser et al. 2005). 
Palmitoylation o f CCR5 occurs on cysteines 321, 323 and 324 and is 
believed to anchor the C-tail of the receptor to the cytoplasmic leaflet o f the 
membrane, resulting in the creation o f a fourth intracellular loop (Blanpain, 
Wittamer et al. 2001; Kraft, Olbrich et al. 2001; Percherancier, Planchenault 
et al. 2001). Unlike some other GPCRs, palmitate turnover is not affected by 
agonist binding. Palmitoylation appears to be required for efficient 
biosynthetic transport o f CCR5 to the plasma membrane (Blanpain, Wittamer 
et al. 2001; Percherancier, Planchenault et al. 2001). Non-acylated receptors 
that do reach the cell surface are slightly affected in their ability to couple to 
certain signalling pathways and are impaired in desensitisation and agonist- 
induced internalisation (Blanpain, Wittamer et al. 2001; Kraft, Olbrich et al. 
2001 ).
^  Finally, there is now significant evidence that CCR5 can form hom o- or 
heterodimers, as has been reported for many other GPCRs (Angers, 
Salahpour et al. 2002). Bioluminescent resonance energy transfer (BRET) 
experiments have demonstrated that CCR5 homo-oligomers form early 
during biosynthetic maturation in the endoplasmic reticulum and that there 
is no additional increase in oligomerisation upon agonist stimulation 
(Blanpain, Vanderwinden et al. 2002; Issafras, Angers et al. 2002; 
Huttenrauch, Pollok-Kopp et al. 2005). CCR5 has also been shown to form 
constitutive oligomers in HEK293 cells by co-immunoprecip itation of 
d ifferentia lly-tagged receptors (Chelli and Alizon 2002). Moreover, 
immunogold electron microscopy has provided some evidence for CCR5
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homodimerisation in human macrophages and T cells, in that CCR5 was 
frequently found in pairs on microvilli and in biosynthetic vesicles 
originating from the trans-Go\g\ network (TGN) (Singer, Scott et al. 2001). 
The evidence fo r hetero-o ligomerisation is discussed below.
Signalling through CCR5
Chemokine binding to CCR5 activates a host of intracellular signalling 
pathways that co-ord inate the cellular processes required for the 
recruitment o f leukocytes to sites o f inflammation. Chemokine binding to 
CCR5 has been proposed to occur via a two-step mechanism, whereby there 
is an initial interaction between the chemokine core and both the am ino- 
terminal domain and the second extracellular loop of the receptor, the latter 
interaction conferring agonist specificity. This is followed by the binding of 
the am ino-term ina l domain o f the chemokine molecule to the 
transmembrane helix bundle o f CCR5, which triggers a conformational 
change in the receptor that results in its activation (Blanpain, Doranz et al.
2003). In the classical model o f chemokine receptor signalling, receptor 
activation promotes exchange o f GDP for GTP on pertussis toxin-sensitive 
heterotrimeric C proteins that engage the cytoplasmic face of the receptor, 
leading to the dissociation o f Ga, and Gpy subunits, which can then regulate 
downstream effectors, such as adenylyl cyclase and phospholipase Cp 
(PLCp). Interestingly, it has been shown that for Gcx-coupled receptors, it is 
release of the Gpy subunit rather than the Ca, subunit that is important for 
mediating chemotaxis (Neptune and Bourne 1997). Following CCR5 
activation, Gpy activates PLCp, leading to the hydrolysis o f 
phosphatidylinositol (4,5)-bisphosphate (PIP2) to inositol trisphosphate (IP3) 
and diacylglycerol (DAG). IP3, in turn, leads to the release of calcium ions 
from intracellular stores, which has multiple cellular effects (Aramori, 
Ferguson et al. 1997; Zhao, Ma et al. 1998). In addition, DAG production 
leads to the activation o f protein kinase C (PKC), which, in te r alia, 
phosphorylates CCR5 on its C-ta il, contributing to its desensitisation and 
internalisation (see below) (Pollok-Kopp, Schwarze et al. 2003).
RANTES binding to CCR5 also leads to the activation of class I 
phosphatidylinositol 3-kinase (PI3K), required for RANTES-induced T
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lymphocyte migration (Turner, Ward et al. 1995). Moreover, in T cells, CCR5 
activates RhoA (Ras homologue A) (Bacon, Schall et al. 1998) and the two 
focal adhesion kinases, proline-rich tyrosine kinase 2 (Pyk2) and focal 
adhesion kinase (FAK) (Bacon, Szabo et al. 1996; Canju, Dutt et al. 1998), 
which, together with RhoA, play important roles in cell motility.
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Figure 1 -III Signalling through CCR5
The  cartoon  illu s tra tes  th e  s ig n a llin g  pathw ays know n to  be activated  by C C R 5. 
Solid brow n arrow s in d ica te  d ire c t re g u la to ry  effects; dashed arrow s ind icate  e ffects  
m ed ia ted  th ro u g h  o th e r s ig n a llin g  m o lecu les . All o f the  pathw ays are believed to  be  
activated  th ro u g h  classical C p ro te in  s ig n a llin g , excep t JA K /STA T ac tiva tio n , w h ich  
m ay proceed via a G p ro te in -in d e p e n d e n t m echan ism . In rat basoph ilic  le u k a e m ia  
(RBL) cells, CCR5 also s tim u la tes  S rc -m ed ia ted  g ran u la r en zym e  release (n o t show n) 
(K raft, O lbrich  e t a l. 2 0 0 1 ) .
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In addition to signalling pathways linked to cell motility, CCR5 activates the 
three main members o f the mitogen-activated protein kinase (MAPK) family, 
extracellu lar-regulated kinase 1/2 (ERK1/2), p38 and c-jun N-terminal 
kinase (JNK), which have proposed roles in T cell proliferation and the 
transcriptional activation o f cytokine genes (Dairaghi, Franz-Bacon et al. 
1998; Kraft, Olbrich et al. 2001) (Del Corno, Liu et al. 2001; Misse, Esteve et 
al. 2001; Wong, Uddin et al. 2001).
Unlike the signalling pathways described above, which are all mediated 
through classical C pro te in-dependent pathways (they can be blocked with 
pertussis-toxin, which affects G a-coupled GPCRs), CCR5 may also signal in 
a G prote in-independent fashion in its activation of the janus kinase/signal 
transducers and activators o f transcription (JAK/STAT) pathway. RANTES 
activation o f CCR5 in PM1 T cells leads to the phosphorylation of JAK2/JAK3 
in a pertussis-tox in  insensitive manner (Wong, Uddin et al. 2001).
Control of CCR5 signalling activity
A cell’s sensitivity to GPCR agonists depends, in part, on the number of 
receptors present at the cell surface that are capable of binding agonist and 
transmitting a signal. After agonist exposure, a series of mechanisms, 
operating on d ifferent time-scales, act to regulate the number of functional 
receptors at the cell surface. The firs t o f these follows shortly after agonist 
stimulation (seconds to minutes), whereby cell surface receptors are 
uncoupled from further G protein activation, in a process termed 
desensitisation. After this, tra ff ick ing mechanisms result in the clearance of 
desensitised receptors from the cell surface and either lead to receptor 
degradation or to resensitisation and return to the cell surface (within 
minutes to hours) (Hanyaloglu and von Zastrow 2007).
Desensitisation and in terna lisation
Desensitisation is initiated by phosphorylation of serine and threonine 
residues in the intracellular loops and carboxyl tails of activated GPCRs 
(Ferguson 2001). The principal mediators of this phosphorylation are a 
family o f serine/threonine kinases, known as the G protein-coupled 
receptor kinases (GRKs). GRKs carry out what is termed homologous
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receptor phosphorylation, since they are specifically recruited to agonist- 
activated receptors. Seven mammalian GRKs have so far been identified 
(GRKs 1-7), which all share a highly homologous kinase domain as well as 
an am ino-term inal regulator o f G protein signalling (RGS) homology (RH) 
domain. Based on other structural features, they are divided into subfamilies 
consisting of GRKs 1 and 7, GRKs 2 and 3 and GRKs 4-6 . Aside from GRKs 1 
and 7 and GRK4, which are restricted to the retina and testes, respectively, 
the GRKs are ubiquitously expressed (Krupnick and Benovic 1998; Ferguson 
2001). Second messenger-activated kinases, such as PKC, can also mediate 
receptor phosphorylation. These kinases can be activated downstream of 
the receptor that is their substrate for phosphorylation or they can 
contribute to heterologous receptor desensitisation if activated through a 
different means, fo r example, another GPCR.
Alanine scanning mutagenesis o f CCR5 identified four C-tail serine residues 
at positions 336, 337, 342 and 349, which are phosphorylated in a non- 
hierarchical manner upon receptor activation. Moreover, agonist-activated 
CCR5 has been shown to be a substrate for both GRKs and PKC, which is 
activated downstream of the receptor (see above). Blocking of GRKs 2 and 3, 
but not o f GRKs 4 and 6 with inh ib itory antibodies led to a reduction in 
CCR5 phosphorylation, suggesting that GRKs 2 and 3, which are highly 
expressed in human leukocytes, are responsible for the GRK-mediated 
phosphorylation (Oppermann, Mack et al. 1999). Additionally, using 
phospho-site specific antibodies, Ser337 has been identified as a PKC 
substrate and Ser349 as a GRK substrate (Pollok-Kopp, Schwarze et al.
2003). GRK-mediated phosphorylation o f Ser349 proceeds with a t 1/2 ~ 2 
min, whereas PKC very rapidly phosphorylates Ser337 after receptor 
activation, with a t 1/2 ~ 20 s.
For some GPCRs, phosphorylation itself results in the uncoupling of the 
receptor from G protein activation (Krupnick and Benovic 1998). In addition, 
the phosphorylation of many agonist-activated GPCRs facilitates the binding 
of an arrestin molecule to the cytoplasmic face of the receptor, which 
sterically hinders the binding and activation of G proteins (Moore, Milano et 
al. 2007). Indeed, for the (32-adrenergic receptor (p2AR), the prototypical 
GPCR, phosphorylation o f the agonist-activated receptor itself causes only 
minor impairment o f its capacity to activate heterotrimeric G proteins, and
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full desensitisation is only achieved with subsequent arrestin binding 
(Lohse, Benovic et al. 1990). Arrestins comprise a family o f four members: 
visual arrestin, cone arrestin, (3-arrestinl (arrestin2) and (3—arrestin2 
(arrestin3). The expression o f visual and cone arrestin is restricted to the 
visual system, whereas p-arrestins 1 and 2 are ubiquitously expressed, 
although with variable expression levels (Lohse, Benovic et al. 1990; 
Attramadal, Arriza et al. 1992; Krupnick and Benovic 1998).
A sequential m u lt i-s ite  binding model explaining arrestin selectivity for 
agonist-activated, phosphorylated receptors was first proposed in 1993, 
based primarily on biochemical data from studies of the visual arrestin- 
rhodopsin system (Gurevich and Benovic 1993). This model, which appears 
to hold true fo r the non-visual arrestin proteins as well, posits that the 
arrestin molecule has 2 sensor sites: an activation recognition site that 
binds receptor elements that change conformation upon activation and a 
phosphorylation recognition site that detects phospho-residues on the 
receptor. The sensors, by themselves, mediate low affinity binding to either 
activated or phosphorylated receptors, allowing arrestins to probe the 
functional state o f receptor molecules and rapidly dissociate from receptors 
that do not meet the two conditions o f being in the active conformation and 
in a phosphorylated state. Simultaneous engagement of the 2 sensor sites 
promotes a transition into an active, high affinity receptor-binding state, 
resulting in a semi-irreversible interaction. In this model, receptor 
deactivation is required for arrestin dissociation.
Several X-ray crystal structures o f arrestin proteins in the basal 
conformation have now been solved and the data have contributed to a 
better molecular understanding o f the mechanism of receptor interaction 
(Granzin, Wilden et al. 1998; Hirsch, Schubert et al. 1999; Han, Gurevich et 
al. 2001; Milano, Pace et al. 2002; Sutton, Vishnivetskiy et al. 2005). In the 
basal conformation, the arrestins have an elongated shape and are 
composed almost exclusively o f p-sheets and connecting loops, which form 
two major globular domains, the N- and C-domains, connected by a short 
hinge. These domains are held together by several intramolecular 
interactions, including a polar core in the centre of the molecule that must 
be destabilised to promote high affin ity receptor binding. In addition, there 
is a C-tail, connected by a flexible linker to the C-domain, which locks back
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onto the globular domains through hydrophobic interactions with (3-strand I 
and a-he lix  I in the N-domain -  the so-called B-element interaction. The C- 
tail also contributes an arginine residue to the polar core. Based on the 
available biophysical and biochemical data, a model for arrestin-receptor 
interaction has been proposed (Gurevich and Gurevich 2004). Arrestin 
binding to an activated, phosphorylated receptor via its activation 
recognition site localised w ith in  its N-domain, is thought to weaken the 
interaction between its 2 g lobular domains. At the same time, receptor- 
attached phosphates interact with lysine residues in the arrestin N-terminus 
and indirectly destabilise the 3-element interaction, releasing the C-tail 
and, in the process, removing its arginine residue from the polar core. 
Moreover, the lysine residues steer the phosphates towards the primary 
phosphorylation recognition site deep in the polar core, where they 
neutralise the charge o f the so-called phosphate-sensitive residue A rg l6 9  
((3-arrestinl numbering), which initiates arrestin activation.2 With the 
interactions holding arrestin in the basal state now disrupted, the mutual 
repulsion o f the 3 remaining negatively charged asparagine residues in the 
polar core facilitates a gross structural rearrangement of the 2 globular 
domains, transform ing the arrestin molecule into an ‘open’ or active 
conformation and promoting additional interactions that result in high 
affin ity receptor binding. The structural rearrangements in the arrestin 
molecule upon receptor binding are summarised in Figure 1-IV.
As well as contributing to receptor desensitisation, (3-arrestin binding links 
many activated GPCRs to the endocytic machinery. The release of the C-tail 
o f p -a rre s t in l /2  upon binding to activated GPCRs is believed to unmask 
binding sites located in the C-tail fo r clathrin heavy chain and the (32-
: Although for most GPCRs, relevant phosphates appear to be added by GRKs (Carman, C. V. and J. L. 
Benovic (1998). "G -pro te in -coup led receptors: tu rn -ons  and turn-o ffs ."  Current op in io n in neurobio logy 
8(3): 335-344.),  arrestin activation is not restricted to CRK-phosphorylation events, since phosphates 
introduced by PKC on the D2 dopamine receptor (Namkung, Y. and D. Sibley (2004). "Protein Kinase C 
Mediates Phosphorylation, Desensit ization, and Trafficking of the D2 Dopamine Receptor." J_. JJjoLjChem. 
279(47): 49533-49541.)  or by casein kinase II on the thyrotropin-releasing hormone receptor 
(Hanyaloglu, A., M. Vred, et al. (2001). "Casein Kinase II Sites in the Intracellular C-terminal Domain of 
the Thyrotrop in-re leasing Hormone Receptor and Chimeric Gonadotropin-releasing Hormone Receptors 
Contribute to be ta-Arrest in -dependent Internalization." j. Biol. Chem. 276(21): 18066-18074.)  also 
promote h igh-a f f in i ty  arrestin binding.
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Chapter 1: Introduction
adaptin subunit o f the heterotetrameric adaptor complex, AP-2, which 
couple activated receptors to the clathrin-mediated endocytic machinery 
(Lohse, Benovic et al. 1990; Pippig, Andexinger et al. 1993; Goodman, 
Krupnick et al. 1996; Laporte, Oakley et al. 1999). Indeed, it has recently 
been shown that an isoleucine-valine-phenylalanine (IVF) motif in the C-tail 
o f the p-arrestin molecule, which is involved in the docking of the C-tail to 
the N-domain in the basal conformation, also mediates binding to the p2- 
adaptin subunit of AP-2 (Burtey, Schmid et al. 2007). Thus, the activation of 
the p-arrestin molecule, where the C-tail is released, is coupled to its role 
as an endocytic adaptor.
Agonist
GPCR
C o n fo rm a tio n a l chan ges  
upon  ac tiva tio n
N-domain
rearrangement
Polar core disruption
Exposed C-tail
C-domain
Figure 1 -IV Arrestin engagement with an activated, phosphorylated GPCR
T h e  fig u re  shows a m odel fo r a rres tin  in te rac tio n  w ith  an ac tivated , p ho sp hory la ted  
GPCR. The a rres tin  m o lecu le  is o rie n ta te d  w ith  its C -dom ain  on the le ft and its N- 
d om ain  on the rig h t. A rres tin  e n g a g e m e n t w ith  the recep to r results in th e  
d estab ilisa tio n  o f the  basal, ‘c lo s e d ’ co n fo rm a tio n  o f the arrestin  m olecu le , w ith  
d is ru p tio n  o f th e  p o lar core , re a rra n g e m e n ts  o f the N- and C -dom ains and  
tran s itio n  in to  an ‘o p e n ’, active c o n fo rm a tio n  th a t binds the recep to r w ith  h igh  
a ffin ity . In the active c o n fo rm a tio n , th e  a rrestin  C -tail is re leased, exp osing  b in d in g  
sites in p -arrestins 1 and 2 fo r p 2 -a d a p tin  and c la thrin  heavy chain .
F igure from  M oore  et al. (2 0 0 7 ) . “R egu la tio n  o f recep to r tra ffic k in g  by GRKs and  
a rre s tin s .” A nnual Review o f Physio logy 6 9 :4 5 1  -4 8 2 .
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Both p -a rre s t in l  and p-arrestin2 have been shown to interact with agonist- 
activated CCR5, and intact C-tail phosphorylation sites have been shown to 
be required fo r h igh -a ff in ity  (3—arrestin binding (Kraft, Olbrich et al. 2001). 
Moreover, using various serine to alanine replacement mutants of CCR5, 
Huttenrauch et al. (2002) found that in vivo, p-arrestin recruitment to 
activated CCR5 required at least two intact phosphorylation sites, although 
the exact position o f these sites did not appear to be critical. This flex ib il ity  
in choice o f phosphorylation sites with respect to p-arrestin binding has 
also been observed for the A/-formyl peptide receptor (FPR) (Bennett, Foutz 
et al. 2001). An additional phosphorylation-independent p-arrestin binding 
^  site, encompassing the DRY m otif in the second intracellular m otif (see 
Figure l - l l )  has also been reported, consistent with the model of sequential 
m u lt i-s ite  arrestin binding. This m otif is conserved among chemokine 
receptors (and all GPCRs o f the rhodopsin family) and is involved in the 
activation o f CCR5 (Gosling, Monteclaro et al. 1997).
Like the majority o f GPCRs, CCR5 is internalised shortly after agonist- 
activation and p-arrestins are required for this process, since the receptor 
does not internalise in p-arrestin 1 and 2 knock-out mouse embryonic 
fibroblasts (MEFs), whereas it does internalise in w ild-type MEFs (Fraile- 
Ramos, Kohout et al. 2003). Moreover, it has been convincingly 
demonstrated in Chinese hamster ovary (CHO CCR5) and mink lung 
endothelial cells stably expressing CCR5, that the receptor internalises in a 
clathrin-dependent fashion, possibly involving the initial lateral 
redistribution o f activated receptors into flat clathrin lattices at the plasma 
membrane (Signoret, Hewlett et al. 2005). Thus, it seems likely that p- 
arrestin binding links activated CCR5 molecules to the clathrin-mediated 
endocytic pathway.
There have been some reports suggesting that CCR5 is internalised through 
a c lathrin-independent mechanism that depends on lipid rafts and caveolae 
(Mueller, Kelly et al. 2002; Venkatesan, Rose et al. 2003). However, Signoret 
et al. (2005) saw no evidence for CCR5 association with caveolae or 
caveolin-positive structures before or after agonist treatment and 
expression o f a dom inant-negative form of CFP-tagged caveolin-1 did not 
interfere with agonist- induced internalisation. Moreover, the evidence in 
favour of a ra ft-dependent mechanism was based on the finding that CCR5
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endocytosis was inhibited by interfering with or removing cholesterol, a 
component o f lipid rafts. Significantly, results obtained using several 
d ifferent compounds that interfere with membrane cholesterol suggest that 
cholesterol is required to maintain CCR5 (Nguyen and Taub 2002; Nguyen 
and Taub 2003; Nguyen and Taub 2003) and other GPCRs (Gimpl, Burger et 
al. 1997) in a conformation that supports agonist binding, so the major 
effect of cholesterol perturbation may be to abrogate chemokine binding. 
Also, cholesterol extraction can interfere with the formation o f c lathrin- 
coated vesicles (CCVs) (Rodal, Skretting et al. 1999; Subtil, Gaidarov et al.
1999), and the cholesterol sequestering compound, fi lipin, which inhibited 
CCR5 internalisation, also inhibited transferrin (Tf) uptake, which occurs via 
a clathrin-dependent mechanism (Signoret, Hewlett et al. 2005). Despite 
this, CCR5 has been seen to accumulate at the leading edge of leukocytes 
undergoing RANTES-induced chemotaxis, where it colocalises with markers 
for raft domains (Nieto, Frade et al. 1997; Gomez-Mouton, Lacalle et al. 
2004). It has also been suggested that raft localisation may be required for 
this polarisation (Manes, Mira et al. 1999; Gomez-Mouton, Lacalle et al.
2004). Palmitoylation o f CCR5 may drive this association with lipid rafts. 
A lthough the role o f (3-arrestins in CCR5 internalisation is clear, their role in 
desensitisation is less clear. CCR5 mutants lacking 3 or 4 phosphorylation 
sites are reported to be defective in their ability to recruit (3-arrestins and to 
undergo desensitisation. A lthough CCR5 mutants that lack any two 
phosphorylation sites retain the ir ability to bind (3-arrestins and internalise, 
RANTES stimulation o f a S336A/S349A mutant triggered a sustained calcium 
response and enhanced granular enzyme release in RBL cells stably 
expressing the receptor. This suggests that CCR5 internalisation largely 
depends on a (3-arrestin-mediated mechanism that requires the presence of 
any two phosphorylation sites, whereas receptor desensitisation is 
independently regulated by the phosphorylation of distinct serine residues 
(Huttenrauch, Nitzki et al. 2002).
In addition to (3-arrestin-sponsored clathrin-mediated endocytosis, other 
chemokine receptors may effect internalisation by directly interacting with 
AP-2, through C-tail d i-leucine sequences (Signoret, Rosenkilde et al. 1998; 
Fan, Yang et al. 2001). A lthough CXCR2 undergoes agonist-induced 
phosphorylation and (3-arrestin binding, it also directly interacts with AP-2:
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mutation o f an LLKIL m otif shown to mediate AP-2 binding resulted in a 
severe impairment o f receptor internalisation. In contrast, a C-terminally 
truncated mutant receptor lacking phosphorylation sites in its C-tail and the 
ability to support robust (3-arrestin recruitment, but with an intact LLIKL 
motif, did undergo agonist-induced internalisation, underscoring the 
importance o f the direct interaction with AP-2 in receptor internalisation 
(Fan, Yang et al. 2001). For CXCR4, in addition to a p-arrestin-mediated 
mode of internalisation that results from agonist binding, internalisation can 
be effected by treatment w ith phorbol esters that results in the activation of 
PKC and presumed phosphorylation o f CXCR4 on (a) serine residue(s) w ithin 
an SSLKIL sequence that is assumed to interact with AP-2 (Signoret, 
Rosenkilde et al. 1998). Although there is a di-leucine m otif in the C-tail o f 
CCR5, it is not in the context o f upstream serine residues and CCR5 surface 
expression is not affected by phorbol ester treatment (Signoret, Rosenkilde 
et al. 1998).
Resensitisation
After internalisation, GPCRs can either be targeted for degradation or 
recycled back to the plasma membrane. Degradation results in long-term  
down-regulation o f receptor signalling by decreasing the number o f 
functional receptors at the cell surface and thus reducing the cell’s 
responsiveness to subsequent agonist challenge. Sorting for degradation 
involves m ono-ub iqu it ination , and is well described for the chemokine 
receptor, CXCR4 (Marchese, Raiborg et al. 2003). Agonist-activated CXCR4 
is ubiquitinated at the plasma membrane by a Nedd4-like E3 ubiquitin 
ligase, AIP4. After internalisation, CXCR4 localises to endosomal 
microdomains that are positive fo r AIP4 and hepatocyte growth fac to r- 
regulated tyrosine kinase substrate (HRS), a mono-ubiquitin  binding protein 
that is responsible for recognising proteins destined for degradation. Here, 
CXCR4 is sorted away from the recycling pathway into luminal vesicles 
during early endosome maturation into multi-vesicular bodies (MVBs), a 
process that is dependent on the action of the ESCRT (endosomal sorting 
complex required for transport) machinery. Interestingly, AIP4 also mediates 
HRS ubiquitination in a CXCR4-dependent manner, suggesting that 
ubiquitination of HRS is important fo r CXCR4 sorting. In addition, a more
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recent study has shown that AIP4 interacts directly with the am ino-term inal 
half o f |3-arrestinl via its WW domains and siRNA depletion of (3—arrestin 1 
blocked agon is t-prom oted degradation of CXCR4 by preventing CXCR4 
trafficking from early endosomes to lysosomes (Bhandari, Trejo et al. 2007). 
CCR5 contains cytoplasmic domain lysine residues that could potentially be 
ubiquitinated, but there is no evidence to suggest that they are. Indeed, it 
has been shown that there is no agonist-induced degradation of CCR5 
(Signoret, Pelchen-Matthews et al. 2000; Delhaye, Cravot et al. 2007) and 
CCR5 recycling after agonist- induced internalisation has been demonstrated 
in lymphocytes and monoctyes (Mack, Luckow et al. 1998). Moreover, 
recycling is fa ith fu lly  recapitulated with similar kinetics in a CHO cell system 
(Signoret, Pelchen-Matthews et al. 2000; Signoret, Christophe et al. 2004), 
which has been used extensively to map out the post-endocytic trafficking 
^  pathway taken by CCR5 molecules. In these cells it has been shown that 
after internalisation, receptors are delivered to early endosomes, often 
located in the periphery o f the cell, from where they are sorted to a 
perinuclear recycling compartment, whence they recycle back to the cell 
surface. In the constant presence o f agonist in the extracellular medium, 
receptors accumulate in this recycling compartment (receptors that recycle 
to the cell surface are re-internalised due to the presence of agonist), and 
show significant overlap with steady-state transferrin receptor (TfR) 
staining, which predominantly localises to recycling endosomes. Recycling 
endosomes are a distinct population o f perinuclear endosomes often found 
close to Colgi stacks that were f irs t characterised in CHO cells (Yamashiro, 
Tycko et al. 1984). They have a more tubular morphology than early 
endosomes, a higher pH (~ 6.5, similar to the TGN; compare pH of early 
endosomes o f 5.9-6.0) and are enriched for recycling receptors but have 
low levels o f flu id phase material destined for the lysosome (Yamashiro, 
Tycko et al. 1984; Hopkins, Gibson et al. 1994; Marsh, Leopold et al. 1995). 
Observations of immunolabelled cryosections showing the accumulation of 
down-modulated CCR5 in small membrane-bound vesicles and tubules in 
the perinuclear region o f the cell and colocalisation o f TfR in the same 
clusters confirmed the tra ff ick ing o f CCR5 through recycling endosomes and 
provided the first evidence for a GPCR taking such a route (Signoret, 
Pelchen-Matthews et al. 2000).
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As alluded to above, internalisation and recycling are generally considered 
to be necessary for GPCR resensitisation, which involves agonist 
dissociation, conformational change back to an inactive conformation, 
dephosphorylation o f C-ta il Ser/Thr residues and recycling back to the 
plasma membrane in a state competent to respond to further agonist 
stimulation (Hanyaloglu and von Zastrow 2007). For several GPCRs, vesicular 
acidification has been shown to regulate their recycling (Grady, Garland et 
al. 1995; Pippig, Andexinger et al. 1995; Hsieh, Brown et al. 1999). The low 
pH of the early endosome is assumed to induce agonist dissociation, as has 
been demonstrated fo r other receptors (Maxfield 1982; Stein, Bensch et al. 
1984), which presumably involves a conformational change, that in the case 
o f the p2AR, the prototypical GPCR, results in a direct interaction with a 
protein phosphatase 2A (PP2A)-like GPCR phosphatase (GRP). Raising 
endosomal pH blocks the association of (32AR with GRP and inhibits both 
receptor dephosphorylation and recycling to the cell surface (Pippig, 
Andexinger et al. 1995; Krueger, Daaka et al. 1997; Signoret, Christophe et 
al. 2004). This has led to the suggestion that dephosphorylation is required 
for recycling, which would seem to be a reasonable check-point as this may 
be the last step in resensitising a receptor before its return to the plasma 
membrane, although subsequent conformational changes may take place 
after receptor dephosphorylation to achieve the resting state.
Unlike the (32AR, recycling o f CCR5 is not affected by raising endosomal pH 
and a pH-dependent agonist-d issociation mechanism does not operate for 
CCR5 agonists, since CCR5-bound chemokines only exhibit pH-dependent 
dissociation below pH 4 (Signoret, Christophe et al. 2004). Furthermore, it 
has been shown that CCR5 molecules can recycle to the plasma membrane 
in an agonist-bound form (by ligand displacement assays), which results in 
their re-internalisation (Signoret, Pelchen-Matthews et al. 2000). 
Dephosphorylation of CCR5 is also unaffected by raising endosomal pH 
(Signoret, Christophe et al. 2004) and may not be required for recycling 
either, since CCR5 bound to an N-term inally modified form of RANTES, 
AOP-RANTES (aminooxypentane-RANTES), which mediates enhanced 
association o f CCR5 with GRKs and increased phosphorylation o f C-tail 
serine residues (Oppermann, Mack et al. 1999; Vila-Coro, Mellado et al.
1999), recycles with similar kinetics to RANTES-treated CCR5 (Signoret,
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Pelchen-Matthews et al. 2000). Resensitised receptors that can respond to 
further agonist stimulation do re-appear on the cell surface after agonist 
wash-out (Signoret, Pelchen-Matthews et al. 2000) but it may take several 
cycles of internalisation and recycling for an activated CCR5 molecule to be 
fully resensitised and to be retained on the cell surface in a state competent 
to respond to fu rther agonist stimulation. Agonist dissociation (and 
subsequent resensitisation steps) could result from iterative cycling and 
could simply be a function o f the off-rate of the agonist. Alternatively, 
agonist dissociation could be dependent on proteolysis of the bound 
chemokine, which may take place in recycling endosomes. The pH of 
recycling endosomes is around 6.5, so if a protease were acting there then 
its activity would probably be unaffected by weak bases, which inhibit the 
recycling o f the (32AR.
There is currently no explanation for why CCR5 should exhibit such 
seemingly odd behaviour when expressed in CHO cells; however, it must be 
pointed out that this does not seem to be peculiar to CHO cells or to be a 
function o f CCR5 over-expression. CCR5 stimulated with AOP-RANTES, 
which has a higher affin ity for CCR5 than RANTES and results in a higher 
proportion o f receptors returning to the cell surface being agonist-occupied 
in CHO CCR5 cells (Signoret, Pelchen-Matthews et al. 2000), takes longer to 
recover to the cell surface after agonist wash-out in lymphocytes than 
RANTES-stimulated CCR5 (Mack, Luckow et al. 1998). Given that CCR5 
down-modulated with AOP-RANTES has been shown to recycle with similar 
kinetics to CCR5 down-m odula ted with RANTES in CHO CCR5 cells 
(Signoret, Pelchen-Matthews et al. 2000), this result is explained by more 
efficient re-internalisation o f AOP-RANTES occupied receptors upon 
recycling, and, hence, suggests that CCR5 can recycle in an agonist-bound 
state in primary cells.
Some details regarding CCR5 dephosphorylation are known but these have 
been obtained under relatively artificial conditions and shed little light on 
the tim ing o f the dephosphorylation event(s) in vivo. Significantly, though, 
the dephosphorylation o f serines 337 and 349, phosphorylation substrates 
for PKC and CRK2/3, respectively, appears to be mediated by different 
phosphatases. After stimulation o f rat basophilic leukaemia cells stably 
expressing CCR5 (RBL CCR5 cells) with RANTES for 2 min, followed by
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incubation  w ith  the CCR5 antagon is t, T A K -779 , Ser337 was rap id ly  and
v
1 completely dephosphorylated within 3 min (t1/2 ~ 90 s), whereas 
dephosphorylation o f Ser349 proceeded much slower (t1/2 ~ 12 min). 
Moreover, in an in v itro  assay, okadaic acid, a potent inh ib itor o f protein 
phosphatases 1 (PP1) and 2A (PP2A), significantly inhibited
dephosphorylation o f Ser337 but had little effect on the dephosphorylation 
o f Ser349. The okadaic-acid sensitive protein phosphatase(s) was shown to 
be different from GRP, because whereas GRP dephosphorylates receptors 
only in the acidic milieu o f early endosomes and, thus, requires receptor 
endocytosis (Pitcher, Payne et al. 1995), the phosphatase(s) that 
dephosphorylated Ser337 was active at neutral pH and efficiently 
dephosphorylated receptors at the cell surface that were phosphorylated by 
a heterologous mechanism (phorbol myristate acetate [PMA] treatment). In 
contrast to the ability o f Ser337 dephosphorylation to proceed at neutral pH 
in v itro , Ser349 was much less efficiently dephosphorylated by 
phosphatase(s) present in RBL cells lysates at neutral pH than Ser337 
(Pollok-Kopp, Schwarze et al. 2003). It may be that resting cell surface CCR5 
molecules are subject to some level o f background phosphorylation by PKC 
activated by other means in the cell and that a phosphatase that is active at 
the cell surface is required to maintain resting receptors in a 
dephosphorylated state. This cell surface dephosphorylation may or may not 
be relevant fo r activated receptors. Such a mechanism need not operate for 
the GRK phosphorylation site(s), since GRKs only recognise and 
phosphorylate activated receptors.
Despite the ability to undergo dephosphorylation at the cell surface, S337, 
as well as S349, has been shown by immunofluorescence to maintain its 
phosphoylated status, on at least some receptors, as they accumulate in the 
perinuclear region o f RBL CCR5 cells in the constant presence of agonist 
(Pollok-Kopp, Schwarze et al. 2003). Such conditions, where agonist is 
constantly present in the medium better reflect the situation in which CCR5 
would function in a physiological setting than a pulse of chemokine 
exposure. For instance, a cell undergoing chemotaxis would be constantly 
exposed to agonist (of increasing extracellular concentration) as it migrates 
towards a site of inflammation.
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Chapter 1: Introduction
A model integrating the current data on CCR5 trafficking, as discussed 
above, is shown in Figure 1-V.
fysosome
nucleus
Figure 1-V Model for CCR5 trafficking
The  cartoon  p resen ts  a m odel fo r  th e  ag on is t-induced  tra ffick in g  o f CCR5 as 
described  in th e  m ain  te x t . M ost o f th e  d eta ils  o f the in trace llu la r tra ffick in g  have  
been derived  fro m  stud ies using C H O  cells s tab ly  expressing  CCR5. Briefly, ag on is t 
b ind ing  leads to  the  ac tiva tio n  o f CCR5 (illu s tra ted  by a co lour change from  black to  
red) and th e  in itia tio n  o f s ig n a llin g  pathw ays su m m arised  in Figure 1 -III. R eceptors  
are rap id ly  d esen s itised , a process th a t is in itia ted  th ro u g h  phosphorylation  o f C -tail 
serine residues by PKC and GRKs 2 and 3. This leads to  the  b ind ing  o f p -arrestins, 
w hich  ta rg e t recep to rs  fo r  c la th r in -m e d ia te d  endocytosis . In terna lised  receptors are  
d e livered  to  early  en do so m es fro m  w h ich  th ey  are sorted  to  p erinuc lear recycling  
endosom es; th e re  is no ev id en ce  fo r ag on is t-ind u ced  lysosom al ta rg e tin g . From  
recycling en do so m es, recep to rs  can recycle to  th e  cell surface. Receptors can re tu rn  
to  th e  cell su rface in a resen sitised  fo rm  or in an ag on is t-b o un d , and p resu m ab ly  
p ho sp h o ry la ted , s ta te , in w h ich  case, th e y  can re-engage the  endocytic  m ach inery  
and und erg o  a fu rth e r  ro u nd  o f  in te rn a lisa tio n  and recycling. It m ay take  several 
cycles o f in te rn a lis a tio n  and recycling  fo r  the  average CCR5 m olecu le  to  be re tu rned
tarty
endosoma
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to  th e  su rface  in a re sen s itised  fo rm . T h e  sites o f ag o n is t d isso c ia tio n  and re c e p to r  
d e p h o s p h o ry la tio n  a re  c u rre n tly  u n d e te rm in e d . T he  m ic ro tu b u le -o rg a n is in g  ce n tre  
(M T O C ) is show n  in th e  b o tto m  rig h t co rner; dashed g re y  lines re p re s e n t 
m ic ro tu b u le s  e m a n a tin g  fro m  th e  M TO C .
It must be remembered that CCR5 functions in relaying extracellular cues in 
the form o f chemokines into a cellular response and that the trafficking 
pathways described above are subordinate to this role, responsible for 
regulating the response to chemokine challenge. One o f the major 
physiological roles o f chemokine receptors is to mediate chemotaxis in 
response to a chemokine gradient. However, whether chemokine receptor 
internalisation and recycling are necessary for optimal chemotaxis as a 
general rule fo r  chemokine receptors is controversial (Neel, Schutyser et al.
2005). For CCR5, C-terminal truncation mutants lacking the serine 
phosphorylation sites supported a higher chemotactic response than the 
w ild - type  receptor in RBL cells and a CCR5 mutant with all 4 
phosphorylatable C-tail serines mutated to alanines had a similar ability to 
mediate chemotaxis towards RANTES as w ild-type CCR5 (Kraft, Olbrich et al.
2001). In this study, chemotaxis was assessed by measuring the number o f 
cells moving through a membrane into a chamber containing a certain 
concentration o f chemokine in a given amount o f time. The results suggest 
that in RBL cells, a ce ll- l ine o f haematopoietic lineage, cell migration does 
not depend on C-ta il phosphorylation or p-arrestin association and can 
presumably occur w ithou t receptor desensitisation or internalisation. 
Although interesting, the limitations o f such a study and its relevance to 
chemotaxis in vivo are obvious and it would be dangerous to extrapolate 
these results to conclude that desensitisation and internalisation o f CCR5 
are not required for the chemotactic activity of cells in a physiological 
setting.
The regulation o f endocytic recycling
Although the route that CCR5 takes through the cell after its internalisation 
has largely been mapped, the key molecules involved in regulating this 
pathway have not been identified. The basis of our knowledge on the
45
recycling o f endocytosed receptors has largely been drawn from studies on 
the transferrin receptor (TfR). More recently, studies on numerous GPCRs 
have identified diverse cytoplasmic domain sequences involved in recycling 
and there is also a growing appreciation o f the role o f p-arrestins in the 
regulation o f GPCR intracellular trafficking. The key regulatory roles o f 
members o f the Rab family o f small GTPases are also becoming clearer.
Transferrin receptor recycling
The TfR is constitutively endocytosed by clathrin-mediated endocytosis and 
delivered to early endosomes. From here it can either undergo rapid 
recycling to the plasma membrane (t1/2 ~ 2 min) or transfer to recycling 
endosomes, from where it recycles to the cell surface more slowly ( t1/2 ~ 10 
min) (Dunn, McGraw et al. 1989; Mayor, Presley et al. 1993).
Sorting o f recycling membrane proteins in the early endosome is believed to 
be achieved by a geometric process, although specific mechanisms for 
cargo sorting via sorting motifs may be superimposed on this geometric 
sorting mechanism. Early endosomes accept incoming material for about 5 
to 10 min before maturing into MVBs/late endosomes, which involves 
centripetal translocation along microtubules, acidification and acquisition o f 
acid hydrolases. Before endosome translocation, most membrane proteins 
that are to be recycled are removed by the extrusion and scission o f 
narrow-diameter tubules (Dunn, McGraw et al. 1989; Mayor, Presley et al.
1993). Because the surface area:volume ratio o f the tubules is greater than 
that o f the vesicular portion o f the early endosome, recycled membrane is 
preferentially sorted from soluble material, w ithout the need necessarily for 
a specific mechanism for cargo recognition. This is in contrast to membrane 
receptors that are to be degraded, which requires ubiquitination that leads 
to recognition and sorting to intraluminal vesicles of the maturing early 
endosome/MVB by the ESCRT machinery, as already discussed for CXCR4 
(see above).
A recent study has implicated sorting nexin-4 (SNX4) in the early endosome 
to recycling endosome tra ff ick ing o f the TfR. SNX4 associates with tubular 
and vesicular elements o f early endosomes and also associates with the 
minus end-directed microtubule motor protein, dynein. By driving
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membrane tubulation at the early endosome, it is proposed that SNX4 
coordinates iterative, geometric-based sorting o f the TfR with the long- 
range transport o f carriers from early endosomes to recycling endosomes 
(Traer, Rutherford et al. 2007).
It was initially thought that the recycling o f the TfR was signal-independent 
because a truncated TfR lacking the whole of its cytoplasmic tail recycles at 
the same rate as the w ild - type  receptor Qohnson, Dunn et al. 1993). 
However, more recent studies have identified bone fide recycling 
determinants in the TfR cytoplasmic tail, in the form of two phenylalanine- 
based signals that interact w ith ACAP1 (ARFGAP with coiled coil, ANK repeat, 
and pleckstrin homology domains), which is a GTPase-activating protein for 
ADP-ribosylation factor 6 (ARF6). Disruption of ACAP1 binding to TfR slows 
recycling from the recycling endosome to the plasma membrane (Dai, Li et 
al. 2004). More recently, there has also been a report that ACAP1 acts as a 
clathrin adaptor protein in stimulation-dependent integrin recycling and 
insu lin-stimulated recycling o f glucose transporter type 4 (GLUT4) from 
recycling endosomes (Li, Peters et al. 2007). Endosomal clathrin-coated 
buds that label positively for TfR have also been observed in A431 and HeLa 
cells (Stoorvogel, Oorschot et al. 1996; van Dam and Stoorvogel 2002), and 
TfR recycling from recycling endosomes has been shown to be clathrin- and 
dynamin-dependent (van Dam and Stoorvogel 2002). However, although 
likely, a role for ACAP1 as a clathrin adaptor for TfR has not been formally 
demonstrated. In polarised cells, another clathrin adaptor protein has been 
implicated in c lathrin -dependent TfR exit from recycling endosomes 
towards the basolateral membrane. A variant o f the heterotetrameric 
adaptor complex 1 (AP-1) containing the ^ilB subunit, AP-1B (Folsch, Ohno 
et al. 1999), has been shown to mediate TfR recycling from the recycling 
endosome to the basolateral membrane (Rodriguez-Boulan, Musch et al.
2004) and has been suggested to function in the basolateral delivery of 
newly synthesised proteins in epithelial cells (Folsch 2005).
Interestingly, Signoret et al. (2000) noted, from their observations o f 
immunolabelled cryosections, prominent coats on many o f the vesicles 
containing down-m odula ted CCR5 in the perinuclear region. Although no 
immunolabelling was carried out at the time to confirm the identity o f the 
coat, clathrin would be the most likely candidate; thus, CCR5 may access a
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clathrin-dependent recycling mechanism (Signoret, Pelchen-Matthews et al. 
2000).
The discovery o f recycling signals in the TfR C-tail and the finding that a 
complex named CART (cytoskeleton-associated recycling or transport), 
consisting o f HRS, actin in-4 , brain-expressed RINC-finger protein (BERP) 
and myosin-V, is involved in sorting TfR into the fast recycling pathway, are 
d iff icu lt to reconcile with the efficient recycling o f the C-term inally 
truncated TfR. The simplest explanation is that the C-tail also contains a 
retention signal. Such signals have been identified in insulin-regulated 
aminopeptidase, a slowly recycling membrane protein, one consisting o f an 
acidic cluster and one consisting o f a di-leucine motif (Johnson, Lampson et 
al. 2001).
GPCR intracellular trafficking: sequence-directed recycling
Although the presence o f endocytic recycling signals in the cytoplasmic tail 
o f the TfR were only demonstrated in 2004, such signals had previously 
been identified in several GPCRs (Sorkin and von Zastrow 2002) and many 
more have now been discovered (Marchese, Paing et al. 2007; Hanyaloglu 
and von Zastrow 2008). A summary of some of the known recycling 
sequences and proteins that have been demonstrated to interact with these 
sequences is shown in Table 1-1 (Hanyaloglu and von Zastrow 2008).
Despite the diversity o f the identified sequences, a number correspond to 
conventional PDZ (post-synaptic density 95/d isc large/zonula occludens-1) 
ligands, including sequences present in the f^AR, (32AR and thyro trop in - 
stimulating hormone (TSH) receptors (Cao, Deacon et al. 1999; Hu, Tang et 
al. 2000; Lahuna, Quellari et al. 2005). PDZ ligands, which are bound by PDZ 
domain-contain ing proteins, are short, linear sequences, classified as either 
type I (X-[S/T]-X-(f)), type II (X—<j>—X—4>), or type III (X—[D/E]—<f>, where X is any 
amino acid and <}> is a hydrophobic amino acid), typically located at the 
receptors’ C-term in i. This distal location is necessary for PDZ-domain 
interaction, as the free carboxylate group forms an ionic bond with the 
ligand-b inding groove o f the PDZ domain. However, internal PDZ ligands, 
which fold into the (3-finger structure required for PDZ domain interaction, 
have been identified in several GPCRs, one o f which, in the endothelin A
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(ETA) receptor, has been shown to be necessary for recycling (Paasche, 
Attramadal et al. 2005). The distal recycling sequence o f the K-opioid 
receptor, despite not conforming to a typical PDZ ligand sequence, is 
thought to bind to PDZ domain-contain ing proteins (Li, Chen et al. 2002; 
Huang, Steplock et al. 2004). Several such proteins, which mediate PDZ- 
ligand-directed recycling, have now been identified. For instance, the C- 
terminal DSLL sequence in the p2AR is bound by NHERF/EBP50 (Na+/H + 
exchanger regulatory factor / ezr in /rad ix in /m oes in-b ind ing  
phosphoprotein o f 50 kDa), which promotes recycling o f the receptor. 
Ser411 in the -2  position o f the PDZ ligand is a substrate for GRK5 
phosphorylation and over-expression o f GRK5 inhibits recycling. Moreover, 
replacement o f Ser411 with a phospho-mimetic aspartic acid residue 
blocked the interaction o f the receptor with NHERF and also inhibited 
recycling, leading to the degradation o f internalised receptors (Cao, Deacon 
et al. 1999). Thus, for the p2AR, dephosphorylation o f Ser411 may be 
required fo r interaction with NHERF. Consistent with this notion, 
crystallographic and mutational studies indicate that PDZ-mediated 
interactions w ith type 1 PDZ ligands involve hydrogen bonding with the free 
hydroxyl group at the -2  position (Doyle, Lee et al. 1996; Songyang, 
Fanning et al. 1997). Phosphorylation o f proximal serine residues has also 
been shown to d isrupt the binding o f PDZ domain-containing proteins to 
the pxAR and serotonin 5-HT2C receptor (Hu, Chen et al. 2002; Parker, 
Backstrom et al. 2003).
The last four amino acids o f CCR5, SVCL, which contain Ser349, conform to 
a type II PDZ ligand and a recent study showed that they were crucial fo r 
receptor recycling, in that the ir removal resulted in the re-routing o f 
internalised receptors fo r lysosomal degradation (Delhaye, Cravot et al. 
2007). Despite the fact that Ser349 undergoes GRK-mediated 
phosphorylation after receptor activation, Delhaye et at. found that CCR5 
recycling was independent o f the phosphorylation state o f this residue: in 
Jurkat cells, a CCR5 phospho-m im etic  mutant in which Ser349 had been 
mutated to Clu, recycled jus t  as well as the w ild-type receptor and the 
recycling o f a Ser349-»Ala mutant was only partially inhibited in its ability to 
recycle.
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Table 1-1 Summary of recycling sequences identified in GPCR C-tails and known 
interacting partners
From  H an y a lo g lu  and  von Z a s tro w  (2 0 0 8 ) . “R egu lation  o f GPCRs by m e m b ra n e  
tra ffic k in g  and  its p o te n tia l im p lic a tio n s .” A nnu. Rev. Pharm aco l. T o x ic o l. 4 8 :1 9 .1 -
1 9 .3 2 .
Protein(s)
Recycling interacting
Receptor sequence (amino 
acid number)
with
recycling
sequence
References
(Hu, Tang et al. 2000;
Xu, Paquet et al. 2001;
Hu, Chen et al. 2002;
fa-adrenergic S (312) and ESKV (474- 477)
PSD-95, SAP97, 
GIPC, CAL, MAGI- 
2, MAGI-3
Gardner, Santos et al. 
2004; Gage, Matveeva 
et al. 2005; He, Bellini 
et al. 2005; Gardner, 
Tavalin et al. 2006; 
Gardner, Naren et al. 
2007)
(Cao, Deacon et al.
fa -adrenerg ic DSLL (410-413) NHERF-1, NHERF- 2, PDZK1, NSF
1999; Cong, Perry et al. 
2001; Gage, Kim et al.
2001; He, Bellini et al. 
2005)
g-opioid LENLEAE Unknown (Tanowitz and von Zastrow 2003)
(Li, Chen et al. 2002;
K-opioid NKPV NHERF-1 Huang, Steplock et al. 
2004)
D1 dopamine IETVSINNNGAAMFSSHH EPRGSISKE (360-382) Unknown
(Vargas and von 
Zastrow 2004)
(Galet, Min et al. 2003;
Lutenis in ing L—GT............C (683- GIPC Hirakawa, Galet et al.horomone (LH) 699) 2003; Galet, Hirakawa 
et al. 2004)
Follicle- 
s t im u la t ing  
hormone (FSH)
PL-H-QN Unknown (Krishnamurthy, Kishi et al. 2003)
Thyro trop in -
s t im u la t ing TVL (762-764) hScrib (Lahuna, Quellari et al. 2005)hormone (TSH)
ETA S—-L-T-V—GT—-K (390- Unknown (Paasche, Attramadal etendothelin 408) al. 2005)
CAL, cystic fibrosis transmembrane conductance regulator-associated ligand: ETA, 
endothelin A; GIPC, GAIP-interacting protein, carboxyl terminus: hScrib, human 
homologue of the D rosoph ila  protein, Scribble: MAGI, membrane-associated guanylate 
kinase inverted: NHERF, Na+/H + exchanger regulatory factor; NSF, N-ethylmaleimide- 
sensitive fusion protein; PDZK1, PDZ domain containing 1; PSD-95, post-synaptic 
density 95; SAP97, synapse-associated protein 97; TSH, thyrotropin-stimulating 
hormone. _____________
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p-arrestins and GPCR intracellular trafficking
p-arrestins couple numerous agonist-activated GPCRs to the c la thrin- 
mediated endocytic machinery but their role in receptor trafficking may not 
be limited to simply facilitating internalisation. There is now various 
evidence to suggest that the nature of the interaction o f a GPCR with p- 
arrestin may, in part, regulate the subsequent trafficking itinerary o f the 
receptor. The f irs t realisation o f this potential role for p-arrestins came from 
work by Laporte and co-workers. By following the recruitment o f 
fluorescently-tagged p-arrestins to various activated GPCRs by live cell 
microscopy, they identified 2 major classes of GPCRs, which differed in the 
nature o f the ir interaction with p-arrestins (Oakley, Laporte et al. 2000). 
Class A receptors, including the p2AR, ^-op io id  receptor (MOR), and 
endothelin type A receptor, have a higher affinity for p-arrestin2 compared 
with p -a rre s t in l  and they dissociate from the p-arrestin during, or 
immediately after, endocytosis. Class B receptors, including the angiotensin 
II type 1 receptor, vasopressin type 2 receptor (V2R) and neurotensin 
receptor, bind both p -a rre s t in l  and p-arrestin2 with equally high affin ity 
and maintain an interaction with p-arrestins into endosomes. Whereas Class 
A receptors recycle rapidly to the plasma membrane after internalisation, 
Class B receptors recycle very slowly, if at all, presumably undergoing 
eventual degradation (Oakley, Laporte et al. 1999; Anborgh, Seachrist et al.
2000). Receptor mutagenesis performed on the C-tails o f a variety o f Class 
B receptors showed that specific clusters of phosphorylated 
serine/threonine residues (Ser/Thr residues occupying 3/3, 3/4, or 3/5 
consecutive positions), which are conserved in their position relative to an 
NPXXY m otif in the 7th transmembrane domain, are responsible for the 
sustained p-arrestin association (Oakley, Laporte et al. 1999; Oakley, 
Laporte et al. 2001). These clusters are absent from Class A receptors, 
although potential phosphate acceptor sites are present. Mutation o f the 
serine/threonine residues in these clusters to alanines converts many Class 
B receptors into Class A receptors in terms o f the nature o f their association 
with p-arrestins (Oakley, Laporte et al. 1999; Oakley, Laporte et al. 2001; 
Vilardaga, Krasel et al. 2002). Interestingly, swapping the C-tails o f the 
Class A receptor, p2AR, and the Class B receptor, V2R, not only reversed the
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stability o f the receptor-p-arrestin complex but also the corresponding 
rates o f receptor dephosphorylation, recycling and resensitisation (Oakley, 
Laporte et al. 1999). Hence, it was suggested that the stability o f the 
receptor-p-arrestin  interaction regulates the rate o f receptor 
dephosphorylation, recycling and resensitisation. The simplest mechanism 
through which p-arrestins were suggested to operate in this capacity was by 
restricting access to the receptor o f phosphatases involved in receptor 
resensitisation. In addition, it has been shown more recently that p-arrestin 
binding facilitates the ub iquit ination o f the p2AR and V2R, targeting the 
receptors for degradation (Shenoy, McDonald et al. 2001; Martin, Lefkowitz 
et al. 2003). Importantly, fo r  the p2AR, a Class A GPCR that recycles rapidly 
after agonist-induced internalisation and only undergoes appreciable 
degradation after prolonged agonist stimulation, p-arrestin mutations that 
render p2AR-p-arrestin  complexes more stable enhance degradation (Pan, 
Gurevich et al. 2003), whereas p-arrestin mutations that make the complex 
even less stable prevent receptor degradation (Shenoy and Lefkowitz 2003). 
A lthough early data linked sustained p-arrestin interaction with very slow 
receptor recycling/degradation (Oakley, Laporte et al. 1999; Anborgh, 
Seachrist et al. 2000), more recent studies have identified receptors that 
despite maintaining an interaction with p-arrestins in endosomes, 
nevertheless recycle rapidly to the cell surface. These include members o f 
the kinin family, such as the bradykinin type 2 receptor (B2R) (Simaan, 
Bedard-Goulet et al. 2005) and the neurokinin 1 receptor (Garland, Grady et 
al. 1996; McConalogue, Dery et al. 1999), as well as the SST2A somatostatin 
receptor (Tulipano, Stumm et al. 2004). The activity of these receptors has 
led Laporte and colleagues to suggest an extension o f their initial 
classification system to include a third group, the so-called Class C 
receptors (Simaan, Bedard-Goulet et al. 2005). These GPCRs internalise with 
p-arrestins into endosomes but the p-arrestin can dissociate from the 
receptor in endosomes and the receptor can recycle rapidly to the cell 
surface. Interestingly, expression o f a p-arrestin2 mutant that has an 
increased affin ity for agonist-activated receptors, prevented recycling o f the 
B2R, which remained colocalised with the mutant p-arrestin2 on endosomes 
after agonist wash-out. From this, it was concluded that dissociation o f p-
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arrestins from the B2R is necessary for its recycling (Simaan, Bedard-Goulet 
et al. 2005), which is in keeping with the initial proposal that p-arrestin 
association impedes receptor recycling. However, there is evidence fo r p- 
arrestins acting as facilitators o f GPCR recycling. The first o f this evidence 
came from work on the trafficking o f the A2B adenosine receptor, where it 
was found that the expression o f p-arrestin anti-sense constructs in 
HEK293 cells led to a significant reduction in receptor recycling, which was 
restored by either p -a rre s t in l  or p-arrestin2 reconstitution, although to a 
greater extent with p-arrestin2 than p-a rres t in l (Mundell, Matharu et al.
2000). More recently, a role fo r p-arrestins in the recycling o f the FPR, which 
can also be considered a Class C receptor, has also been demonstrated 
(Vines, Revankar et al. 2003). Although p-arrestins are not required for the 
internalisation o f the FPR, it nevertheless co-internalises with p-arrestins 
and maintains this interaction into a R ab ll-p o s it ive  compartment. From 
here, the FPR recycles efficiently to the plasma membrane. Recycling o f the 
FPR is completely blocked in p-arrestin 1 and 2 knock-out MEFs, but can be 
rescued by co-expression o f either p -a rres t in l or p-arrestin2, suggesting 
that p-arrestins are required for the recycling of the FPR. In support o f this 
notion, the authors also found a greater concentration o f the FPR in the 
perinuclear recycling compartment in p-arrestin 1 and 2 knock-out cells 
compared with w ild - type  MEFs. However, a subsequent study from the same 
group also concluded that dissociation o f p-arrestin from the FPR is 
required for its recycling (Key, Vines et al. 2005).
What is clear from  all o f these studies is that a full description of the role o f 
p-arrestins in the intracellular trafficking o f GPCRs is lacking. It is hard to 
reconcile data suggesting that they impede receptor recycling/promote 
GPCR degradation w ith that suggesting that they act as facilitators o f 
recycling. It is thus likely that p-arrestins regulate the intracellular 
trafficking o f specific GPCRs through multiple mechanisms and p -a rres t in l 
and p-arrestin2 may function differently in this respect.
Interestingly, Mueller et at. have observed the colocalisation o f GFP-p- 
a rres t in l with CCR5 on vesicular compartments by immunofluoresence after 
60 min M IP - la  treatment in CHO cells, suggesting that at least p -a rre s t in l 
may remain associated with CCR5 after internalisation (Mueller, Kelly et al.
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2002). However, this study was limited in the extent to which it 
characterised this interaction, providing no information on the compartment 
in which the two proteins colocalised, whether the interaction was 
maintained th roughou t trafficking to the compartment, or whether p- 
arrestin2 exhibited similar behaviour.
A potential involvement o f p-arrestins in CCR5 function is particularly 
interesting given the increasing importance that is ascribed to these 
proteins as central regulators o f chemotaxis. A requirement for p-arrestins 
in this process was firs t observed with CXCR4-mediated chemotaxis, which 
was defective in lymphocytes isolated from p-arrestin2, but not p -a rres t in l,  
knock-ou t mice (Fong, Premont et al. 2002) or after siRNA knock-down of 
p-arrestin2 in HEK293 cells (Cheng, Zhao et al. 2000). Subsequently, p- 
arrestins have been shown to play a role in CXCR1- and CXCR2-mediated 
chemotaxis (Barlic, Khandaker et al. 1999; Richardson, Marjoram et al. 
2003; Su, Raghuwanshi et al. 2005). Their involvement in chemotaxis was 
initia lly thought to reflect their role as terminators o f receptor signalling and 
mediators o f receptor internalisation, fitting into a model that 
desensitisation and recycling o f chemokine receptors is required for 
leukocytes to maintain an ability to sense a chemokine gradient. However, 
more recently it has been appreciated that p-arrestins scaffold and activate 
a variety o f signalling molecules, which contribute to a second wave o f 
signalling after C protein signalling is terminated (Lefkowitz and Shenoy
2005), and, based on many lines o f evidence, a second theory has emerged 
that p-arrestins scaffold signalling molecules involved in cytoskeletal 
reorganisation to promote localised actin assembly events leading to the 
formation o f a leading edge (Defea 2006). For instance, p-arrestins scaffold 
non-receptor tyrosine kinases and in the case of the neutrophil platelet- 
activating factor (PAF) receptor, p-arrestin dependent p38 activation induces 
actin bundle formation and cell polarisation (McLaughlin, Banerjee et al.
2006). Another study showed that in migrating NIH3T3 cells, the protease 
activated receptor 2 (PAR2) uses a p-arrestin-dependent mechanism to 
sequester activated ERK1/2 in pseudopodia at the leading edge, required for 
actin cytoskeleton reorganisation and polarised pseudopod extension (Ge, 
Ly et al. 2003). In addition, p-arrestins can activate the small GTPase RhoA 
(Barnes, Reiter et al. 2005) and have been shown to bind to the actin-
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scaffolding protein, filamin A (Scott, Pierotti et al. 2006), and thus regulate 
changes in cell shape and motility. Chemokine receptor trafficking, perhaps 
regulated by p-arrestins, has the potential to influence the localisation o f 
signals involved in chemotaxis.
Regulation of membrane traffic by Rab GTPases
The Rab (Ras-like protein from brain) family of small GTPases comprises 
over 60 members that regulate virtually all membrane trafficking steps 
w ithin the secretory and endocytic pathways. They co-ordinate sequential 
stages in tra ff ick ing: the formation of transport vesicles, their transport 
along cytoskeletal filaments and their docking and fusion with target 
membranes (Pfeffer 2001; Zerial and McBride 2001). Rab proteins are post- 
translationally modified by geranylgeranyl addition, which enables them to 
associate w ith membranes (Andres, Seabra et al. 1993; Alexandrov, Horiuchi 
et al. 1994). Each Rab protein is characterised by a specific intracellular 
d istr ibution, w ith individual family members associating with particular 
membrane-bound compartments or domains within a compartment 
membrane (Zerial and McBride 2001; Pfeffer and Aivazian 2004). They cycle 
between an inactive, GDP-bound state and an active, GTP-bound state, in 
which they can interact with effector proteins that mediate downstream 
processes, such as vesicle budding, motility or fusion (Pfeffer 2001; Zerial 
and McBride 2001). They undergo cycles o f activation and inactivation (GTP 
binding and subsequent hydrolysis), controlled through catalysis by GTP 
exchange factors (GEFs) and GTPase activating proteins (GAPs) (Seabra and 
Wasmeier 2004). In addition, their membrane binding is subject to 
regulation by GDP dissociation inhibitors (GDIs), which bind to Rabs in their 
inactive state and chaperone their shuttling between the cytosol and their 
target membranes, and GDI displacement factors (GDFs), involved in 
membrane delivery (Sasaki, Kikuchi et al. 1990; Sivars, Aivazian et al. 2003). 
One o f the best described Rab proteins is Rab5, which regulates early 
endocytic events (Bucci, Parton et al. 1992). Rab5 on early endosomes binds 
to type I PI3K, which leads to the formation of phosphatidylinositol 3 -  
phosphate (PI(3)P) (Miaczynska and Zerial 2002). Rab5 and PI(3)P recruit 
various effector proteins, such as early endosome antigen 1 (EEA1), which
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binds to PI(3)P via a FYVE (Fablp, YOTB, Vaclp, EEA1) domain, and also to 
Rab5. These effector proteins then stimulate early endosome fusion 
(Nielsen, Christoforid is et al. 2000). Internalisation of CCR5, the chemokine 
receptors, CXCR2 and CXCR4, and the TfR, is inhibited by expression o f a 
dominant negative form  o f Rab5 (Stenmark, Parton et al. 1994; Fan, Lapierre 
et al. 2003; Venkatesan, Rose et al. 2003).
Two Rab proteins have been implicated in controlling the recycling o f 
membrane proteins from endosomes. Rab4 appears to mediate the fast 
recycling o f membrane proteins from early endosomes (Sheff, Daro et al. 
1999), whereas R a b l l ,  which is mainly found on recycling endosomes, 
mediates traffic  th rough that compartment (Ullrich, Reinsch et al. 1996; Ren, 
Xu et al. 1998). Both Rab4 and R a b l l  have been shown to control TfR 
recycling (Ullrich, Reinsch et al. 1996; Ren, Xu et al. 1998; Sheff, Daro et al. 
1999). R a b l l  has also been implicated in the recycling of CXCR2, where the 
expression o f a dominant negative R a b l l  mutant significantly impairs 
CXCR2 recycling. Moreover, myosin Vb and R a b l l - fa m ily  interacting protein 
2 (FIP2), proteins that interact with R a b l l ,  have been shown to play a role in 
CXCR2 recycling (and resensitisation). In addition, expression o f the myosin 
Vb tail, which acts as a dominant negative since it lacks the motor domain, 
impairs CXCR2- and CXCR4-mediated chemotaxis in HEK293 cells, which 
highlights the potential importance of chemokine receptor recycling in 
chemotaxis (Fan, Lapierre et al. 2004). Interestingly, recycling through 
recycling endosomes in particular, not jus t recycling in itself, may be 
necessary fo r chemotaxis. The small GTPase RhoB, which localises to 
endosomes and is activated after CXCL8 stimulation o f CXCR2, appears to 
play a role in the sorting decision between recycling and degradation o f this 
receptor, facilitating sorting o f CXCR2 to the degradative pathway after 
prolonged agonist stimulation. Interestingly, although expression o f 
constitutively active RhoB appeared to block the passage o f CXCR2 to the 
recycling endosome, it did not impair receptor recycling, which was 
probably because the receptor was routed to alternative recycling pathways, 
including the Rab4-dependent fast recycling pathway. Despite CXCR2 
recycling being unaffected by constitutively active RhoB expression, CXCR2- 
mediated chemotaxis o f HEK293 cells was impaired, suggesting that 
trafficking through the recycling endosome is important for chemotaxis
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(Neel, Lapierre et al. 2007). This may be a reflection o f a resensitisation step 
that occurs in the recycling endosome or may have to do with targeted 
recycling o f CXCR2 to the leading edge of migrating cells. Some chemotactic 
receptors have been found to accumulate at the leading edge o f migrating 
cells (Nieto, Frade et al. 1997; Gomez-Mouton, Lacalle et al. 2004) and there 
is some evidence fo r polarised delivery of recycling vesicles from recycling 
endosomes to the leading edge during cell migration (Hopkins, Gibson et al.
1994). However, concentration o f chemotatic receptors at the leading edge 
o f migrating cells is a controversial issue, with several studies suggesting 
that chemotactic receptors are evenly distributed across the surface o f 
migrating cells (Xiao, Zhang et al. 1997; Servant, Weiner et al. 1999; Jin, 
Zhang et al. 2000; Janetopoulos, Jin et al. 2001).
Sorting to the biosynthetic pathway
Although the intracellular trafficking o f many proteins that cycle over the 
cell surface is restricted to the endosomal system, several proteins exhibit 
more complex recycling itineraries that involve passage through the TGN. 
Two such proteins are TGN38 and the cation-independent mannose 6 -  
phosphate receptor (CI-MPR).
The traff icking itinerary o f TGN38 was deduced from a kinetic analysis o f 
the trafficking o f a hybrid construct consisting of the cytoplasmic domain of 
TGN38 and an extracellular interleukin-receptor-a-chain domain (Tac) 
(Ghosh, Mallet et al. 1998). Tac-TGN38, like TGN38, was predominantly 
found in the TGN, with around 10% of the total pool found at the plasma 
membrane at steady-state. By labelling surface receptors with a high affin ity 
anti-Tac antibody, it was shown that after internalisation, Tac-TGN38 
trafficked to recycling endosomes from where around 80% of receptors 
returned to the cell surface with a t 1/2 ~ 10 min, similar to the kinetics o f TfR 
recycling, with the remainder trafficking to the TGN. When longer fil l ing 
pulses and chases were used to load anti-Tac into the TGN (steady-state 
distribution achieved), it returned to the cell surface with a t 1/2 ~ 45 min. 
Thus, on average, a TGN38 molecule initially at the plasma membrane will 
recycle several times before it reaches the TGN. A steady-state distribution
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where TCN38 is predominantly localised to the TGN is achieved because 
TGN exit is far slower than recycling from recycling endosomes.
The trafficking itinerary o f the CI-MPR further highlights the complexity o f 
the trafficking pathways that integral membrane proteins can take within 
the cell and also illustrates the bidirectionality between the biosynthetic and 
endocytic pathways. CI-MPR delivers lysosomal enzymes to late endosomes 
and lysosomes and traffics between the TGN and late endosomes, and over 
the plasma membrane. TGN to late endosome trafficking delivers newly 
synthesised lysosomal enzymes to late endosomes and trafficking over the 
plasma membrane allows the capture of enzymes that have been secreted 
(Ghosh, Dahms et al. 2003). It has been shown in CHO cells that rather than 
be delivered to late endosomes through retention in early endosomes as 
they mature into late endosomes, internalised CI-MPRs traffic from early 
endosomes to recycling endosomes. From there, most o f the receptors 
recycle to the surface, but during each cycle o f internalisation a small 
fraction o f receptors are delivered to the TGN and then onto late endosomes 
(Lin, Mallet et al. 2004).
Currently, there is no evidence fo r a GPCR recycling through the TGN. 
However, it should be noted that Neel et al. (2007) have reported data that 
they say suggests that in the presence o f constitutively active RhoB, CXCR2 
may be forced to recycle through the TGN. As partly described above, the 
authors showed that expression o f RhoB blocked passage o f CXCR2 to the 
recycling endosome (through which it usually recycles) and led to an 
increased colocalisation o f the receptor with Rab7, a marker o f late 
endosomes. However, subsequent delivery to lysosomes was impaired and 
receptor recycling was still able to occur. The authors also noted that there 
was a much-increased colocalisation o f CXCR2 with both Rab4, and the CI- 
MPR, the latter, they suggest, indicating that under these conditions, CXCR2 
may be forced through a TGN recycling route. However, CI-MPR 
colocalisation is probably more reflective of an increased late endosomal 
localisation, which would correlate well with the increased colocalisation o f 
CXCR2 with Rab7 in the presence o f constitutively active RhoB. Moreover, 
the authors found no evidence fo r such a recycling pathway operating in 
cells expressing endogenous levels o f w ild-type RhoB and if the receptor did 
traffic through the TGN under these conditions, this was probably a
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reflection o f aberrant trafficking events occurring in the presence o f 
blockades to multip le trafficking pathways. Lastly, chemotaxis was defective 
in cells expressing constitutively active RhoB, suggesting that alternative 
recycling routes taken by CXCR2 in the presence of constitutively active 
RhoB are not physiologically relevant.
Heterologous receptor regulation: implications for CCR5 
trafficking
Leukocytes express CCR5 in the context o f many other GPCRs, including 
many Gaj-coupled chemoattractant receptors, which may be simultaneously 
activated during a response to inflammation. Activation of other GPCRs can 
lead to heterologous desensitisation o f CCR5 via PKC-mediated 
phosphorylation o f C-ta il serines (Mashikian, Ryan et al. 1999; Grimm, 
Newman et al. 2003; Szabo, Wetzel et al. 2003). Since PMA treatment, which 
results in PKC activation, does not lead to CCR5 internalisation by itself 
(Pollok-Kopp, Schwarze et al. 2003), it is interesting that the activation o f 
\  CXCR1 and FPR have been shown to not only lead to cross-phosphorylation 
and desensitisation o f CCR5 but also cross-internalisation o f the receptor 
(Shen, Li et al. 2000; Li, Wetzel et al. 2001; Richardson, Tokunaga et al.
2003). A recent study has shed light on the possible mechanism of cross­
internalisation, suggesting that it may involve receptor hetero­
oligomerisation (Huttenrauch, Pollok-Kopp et al. 2005). In this study, CCR5 
was found to form  hetero-dimers with the complement factor 5a receptor 
(C5aR) when both were expressed in RBL cells, whereas CCR5 failed to show 
an association with the type la angiotensin II receptor (ATlaR). Whereas C5aR 
stimulation led to the PKC- and GRK-mediated cross-phosphorylation o f 
CCR5 in a heterologous manner in cells expressing CCR5 and C5aR, in cells 
expressing CCR5 and ATlaR, angiotensin II treatment resulted only in PKC- 
mediated CCR5 phosphorylation. Moreover, co-expression o f C5aR, but not 
o f ATlaR, promoted CCR5 co-internalisation upon agonist stimulation; 
however, CCR5 cross-phosphorylation was not required for this co­
internalisation. Co-internalisation o f phosphorylated CCR5 was also 
observed in C5a-stimulated macrophages, demonstrating that such a co-
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internalisation mechanism operates in cells where CCR5 is endogenously 
expressed.
How such hetero-o ligomerisation affects the subsequent intracellular 
trafficking o f CCR5 has not been addressed, but it must be borne in mind 
that the tra ff icking o f CCR5 in vivo may be very different from when it is 
expressed in cell—Iines, where other chemotactic receptors are not 
expressed/expressed at low levels and high CCR5 expression levels 
probably favour homo-o ligomerisation and reduce the confounding effects 
o f hetero-d imerisation with other GPCRs.
Outline o f this investigation
As described above, although the basic outline o f CCR5 post-endocytic 
traffick ing has been elucidated, many of the details regarding the control o f 
this traff icking are currently unknown. In this thesis I further characterise 
the intracellular trafficking o f CCR5, with a particular focus on the 
involvement o f the clathrin adaptor proteins, p-arrestins 1 and 2, and the 
molecular machinery regulating the progression of the receptor through the 
recycling compartment.
I begin in Chapter 3 by describing a morphological investigation into the 
receptor’s tra ff icking itinerary, with the finding that in addition to trafficking 
through recycling endosomes, CCR5 also passes through the TCN - a very 
similar membrane system. To my knowledge, this is the first real 
demonstration o f an agonist-activated GPCR trafficking through the TGN 
and changes our perception o f the perinuclear recycling compartment, 
which must now be considered to comprise both recycling endosome and 
TGN elements. Here, I also describe a role for R a b l l  as a regulator o f CCR5 
trafficking through the recycling compartment.
Given the ever-growing appreciation o f the role o f p-arrestins in controlling 
the intracellular tra ff ick ing o f GPCRs, and the observation by Mueller et al. 
(2002) o f a sustained interaction between GFP-p-arrestinl and CCR5, much 
o f this thesis describes an investigation into the role of p-arrestins in CCR5 
trafficking. I begin in Chapter 4, where I detail a characterisation o f the 
nature o f the interaction between CCR5 and p-arrestins, showing that CCR5 
exhibits behaviour compatible with membership o f the so-called Class C
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group o f GPCRs, which maintain an interaction with p-arrestins on 
endosomes, but nevertheless recycle rapidly to the cell surface. As CCR5 
phosphorylation has been shown to mediate high affinity p-arrestin binding, 
I assess the role o f C-ta il phosphorylation in supporting this sustained 
association, describing data that suggest that although receptors remain 
phosphorylated during trafficking with p-arrestins, this phosphorylation is 
not required for p-arrestin interaction.
After the observation that p-arrestins accompany CCR5 to the perinuclear 
recycling compartment, in Chapter 5, I show that this compartment is 
extensively coated with clathrin, which raises the tantalising possibility that 
p-arrestins may function to couple CCR5 to clathrin in a step required for 
CCR5 recycling, akin to the role they perform for CCR5 at the cell surface. I 
also detail an investigation into a role for dynamin in the scission o f nascent 
c lathrin-coated vesicles formed at the recycling compartment and largely 
discount the possible involvement in CCR5 recycling o f the clathrin adaptor, 
AP-1, which also localises to this compartment and has recently been shown 
to interact with p-arrestins.
Finally, in Chapter 6, I return to the CCR5-p-arrestin association, where I 
recount my search fo r a functional role for this interaction in CCR5 
intracellular traff ick ing through the acquisition of kinetic data on the 
recycling o f CCR5 in cells over-expressing p-arrestin2 or expressing 
constitutively active p-arrestin2 mutants.
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Chapter 2: M a te r ia ls  
and M ethods
“Whewyow know they notey to- btnfy, you/ caw yiwg/ ‘moyt aw/thing'. ”
Maria/, The/Sound/ of Mutio
General reagents
All chemicals were purchased from Sigma-Aldrich Company Ltd. (Poole, 
Dorset, UK) unless otherwise stated. Recombinant CCL3 (M IP-la), CCL4 
(M IP-ip) and CCL5 (RANTES) were provided by A. E. I. Proudfoot (Serono 
Pharamceuticals Research Institute, Geneva, Switzerland). TAK-779 was 
purchased from  the NIH AIDS Research and Reference Reagent Programme 
(Germantown, Maryland, USA). B is-T-23 and Dyngo-4a were gifts from P. 
Robinson (Children’s Medical Research Institute, Westmead, Australia). 
Formaldehyde fixative was purchased from TAAB Laboratories (Aldermaston, 
Berks, UK).
General solutions 
Phosphate-buffered  saline (PBS)
137 mM NaCI, 2.7 mM KCI, 10 mM Na2HP04, adjusted to pH 7.4 
Binding m edium  (BM)
RPMI-1640 w ithout bicarbonate, 0.01 M HEPES (pH 7), 0.2% BSA, adjusted to 
pH 7
T ris -b u ffe re d  saline (TBS)
137 mM NaCI, 2.7 mM KCI, 25 mM Tris base, adjusted to pH 7.4
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Cell culture
Reagents
Tissue culture medium and supplements were purchased from 
Cibco/lnvitrogen (Paisley, UK).
Cell-lines and maintenance
The cell-lines used in this thesis are detailed in Table 2-1. Adherent cells 
were grown in 10 ml o f growth medium in 9 cm dishes (Falcon, Becton 
Dickinson, Oxford, UK) at 37°C in an atmosphere containing 5% C02. All 
cell-lines were passaged twice weekly. Here, medium was removed by 
aspiration and cells were detached by the addition of 2 ml o f trypsin/EDTA 
solution (0.05% trypsin and 0.7 mM EDTA in PBS) at 37°C. Eight millilitres o f 
growth medium pre-warmed to 37°C was added to the detached cells before 
re-p la ting into 9 cm dishes at an appropriate dilution in a final volume o f 10 
ml. In addition to this, rat basophilic leukaemia CCR5 (RBL CCR5) cells were 
washed with 10 ml o f PBS at 37°C before the addition o f trypsin/EDTA and 
detached cells were pelleted by centrifugation (800 rpm for 3 min) and 
resuspended in fresh medium before being plated. Both steps were 
performed to remove cellular secretions/debris before re-plating.
All cell-lines were regularly screened for Mycoplasma infection using the 
VenorGem® PCR assay (Cambio Ltd., Cambridge, UK).
Table 2*1 Details of cell-lines
Cell-line Genetic
manipulation
Growth medium Source
Chinese hamster ovary (CHO) cells
CHO (DHFR) 
CCR5
CHO (DHFR) 
CCR5 p a r r  1-YFP
CHO (DHFR) 
CCR5 parr2-GFP
Stably expressing 
human CCR5
Stably expressing 
human CCR5 and 
bovine parrl-YFP 
or parr2-GFP
MEMa containing 
Glutamax, 10% FCS, 100 
U/ml penicillin and 100 
ng/ml streptomycin
MEMa containing 
Glutamax, 10% FCS, 100 
U/ml penicillin, 100 
ng/ml streptomycin and 
1 mg/ml G418.
M. Mack, University 
of Munich,
Germany (Mack, 
Luckow et al. 1998) 
N. Signoret, MRC 
LMCB, UK. 
Generated by 
transfection of 
CHO (DHFR) CCR5 
cells from M. Mack
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Cell-line Genetic Growth medium Source
_______________manipulation____________________________
CHO (DHFR) 
CCR5 c la th r in  
lig h t cha in  a- 
dsRed
Stably expressing 
human CCR5 and 
clathrin light 
chain a-dsRed
MEMa containing 
Glutamax, 10% FCS, 100 
U/ml penicillin, 100 
Ug/ml streptomycin and 
1 mg/ml G418
DMEM/F12 containing 2 
mM glutamine, 10% FCS, 
100 U/ml penicillin and 
100 ug/ml streptomycin
Mouse embryonic fibroblasts (MEFs)
MEF w t 
MEF f ia r r  1 KO 
MEF p a r r2 KO 
MEF p a r r l  +2 KO
Embroyonic 
fibroblasts 
obtained from 
wild-type or (3- 
arrestin knock­
out mice
DMEM containing 2 mM 
glutamine, 10% FCS, 100 
U/ml penicillin and 100 
ug/ml streptomycin
Human osteosarcoma (HOS) cells
HOS CD4 CCR5 
(ARP078)
Stably expressing 
human CD4 and 
CCR5 proteins
DMEM containing 2 mM 
glutamine, 10% FCS, 100 
U/ml penicillin, 100 
ug/ml streptomycin, 0.5 
mg/ml G418, 100 ug/ml 
hygromycin and 1 ug/ml 
puromycin
Other cell-lines
Rat basophilic  
leukaem ia CCR5 
(RBL CCR5)
HeLa Kyoto
M C-5-producing  
hybridom a (from  
BALB/c mice)
Stably expressing 
human CCR5
Hybridoma 
producing MC-5 
antibody
80% RPMI 1640 
Glutamax/20% Medium 
199 containing 10% FCS, 
100 U/ml penicillin, 100 
Ug/ml streptomycin and 
0.6 mg/ml G418
DMEM containing 2 mM 
glutamine, 10% FCS, 100 
U/m l penicillin and 100 
ug/ml streptomycin 
RPMI Glutamax 
containing 10% FCS, 100 
U/m l penicillin, 100 
ug/ml streptomycin, HT 
(hypoxanthine and 
thymidine) supplement 
and 1 mM sodium 
pyruvate ________
C. Merrifield, MRC 
LMB, UK. Generated 
by transfection of 
CHO (DHFR) CCR5 
cells from M. Mack 
A. Trkola, 
University 
Hospital, Zurich, 
Switzerland 
(Trkola, Gordon et 
al. 1999)
R. Lefkowitz, Duke 
University Medical 
Center, Durham, 
USA (Kohout, Lin et 
al. 2001)
Centre for AIDS 
Reagents (EU 
Programme 
EVA/AVIP). Original 
source: Littman 
and Kewalramni, 
courtesy of NIH 
AIDS Research and 
Reference Reagents 
Programme
M. Oppermann,
Georg August
University,
Goettingen,
Germany
(Huttenrauch,
Nitzki et al. 2002)
L. Pelkmanns, ETH 
Zurich, Switzerland
M. Mack, University 
of Munich,
Germany (Segerer, 
Mack et al. 1999)
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Cell freezing and thawing
For freezing, adherent cells attached to a 9 cm dish were detached in the 
same manner as for passaging and resuspended in a total o f 10 ml o f 
growth medium pre-warmed to B7°C. Cells were then pelleted by 
centrifugation (800 rpm, 3 min) and resuspended in 5 ml o f growth medium 
containing 50% foetal calf serum (FCS). 1 ml aliquots were frozen at -80°C 
in cryovials (Nunc, Gibco/lnvitrogen, Paisley, UK) for 1 week before being 
transferred to a liquid nitrogen tank.
One millilitre aliquots o f frozen cells were thawed rapidly in a 37°C water- 
bath and diluted with 9 ml o f growth medium pre-warmed to 37°C. Cells 
were then pelleted by centrifugation (800 rpm, 3 min), resuspended into 10 
ml o f medium at 37°C and plated into a 9 cm dish.
Antibodies
The various antibodies used in this thesis are detailed in Table 2-11.
Table 2-11 Details of antibodies
Antigen Antibody Species/
isotype
Conc.n
used*
Source
Primary antibodies
CCR5 N- MC-5 (hybridoma Mouse 1:500 
1 ug/ml
te rm inus supernatent) IgG2a
Produced in-house
CCR5 N- 
te rm inus MC-5 (purified)
Mouse
IgG2a
(IF, IB),
7.5 ,ug/ml 
(IP)
from hybridoma cells1
CCR5 N- Alexa Fluor® Mouse 1 ug/ml
Alexa fluor 488
te rm inus 488-MC-5 IgG2a coupled to purified MC-5 in-house*
CCR5 P-S349 E ll /1 9 Mouse IgGl 5 ug/ml M. Oppermann, Georg
CCR5 P-S337 V14/2 Mouse 5 ug/ml
August University,
IgG2b Goettingen, Germany
C la th rin  heavy 
chain X22 Mouse IgGl 6 ug/ml
Affinity Bioreagents, 
Nottingham, UK 
Transduction
C la th rin  heavy 23 Mouse IgGl 0.25 Laboratories, BDchain Ug/ml Bioscience, Oxford, 
UK
T ra n s fe rrin
receptor H68.4 Mouse IgGl 2 ug/ml
Zymed
Laboratories/Invitrog 
en, Paisley, UK
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Antigen Antibody Species/ Cone.® 
isotype used*
Source
y-adaptin  (AP-1) Mary
y-adaptin (AP-1) Adaptin y
p lA -a d a p tin
(AP-1)
p -a rre s tin l
p -a rres tin2
A rres tin
c-myc
EEA1
GFP
TGN46
R a b l la
p230
a -tu bu lin
\xlA
178
182-4
Arrestin (pan)
p -a rre s tin l +2 21-B1
9E10
EEA1 MAb
Anti-GFP Mab
Sheep anti­
human TGN46
Anti-Rabl 1
Lgp-B (LAMP2-) 3E9 (hybridoma
v supernatent)
Rabbit
polyclonal
Mouse
IgG2a
1:500
0.25
Ug/ml
Rabbi,' , 1:1000polyclonal
Rabbit j . 200
polyclonal 
Rabbit 2 Q
polyclonal
Rabbit , , .
polyclonal
Mouse IgGl 1.1 ug/ml
Mouse IgGl 1 ^g/ml
Mouse IgGl 1.25ug/ml
Mouse IgGl 0.4 ug/ml
polyclonal 5|ig/ml
Rabbit 0.25
polyclonal mg/ml
Mouse IgGl 1:2
p230 trans Golgi Mouse IgGl 0.5 ug/ml
Anti-a-tubulin
Secondary antibodies
R abbit lgG (H+L) IRDye® 680 GAR
Mouse IgG (H+L) IRDye® 800 GAM
w r ^ /„  ,. GAM AlexaMouse IgG (H+L) FluQr@ 4g8
. .  , n  GAM Alexa
Mouse IgG (H+L) Fluor@ 594
Mouse IgGl 1:500
polyclonal 0 2 “g/ml
polyclonal 0 2 ^ /m l
polyclonal 4 ^ /m l
Goat
polyclonal 4 (ig/m l
M. S. Robinson, 
University of 
Cambridge, UK 
Transduction 
Laboratories, BD 
Bioscience, Oxford,
UK
Ira Mellman, Yale 
University School of 
Medicine, New Haven, 
USA
J. Benovic, Thomas 
Jefferson University, 
Philadelphia, USA
Affinity Bioreagents, 
Nottingham, UK 
M. Oppermann, Georg 
August University, 
Goettingen, Germany 
Transduction 
Laboratories, BD 
Bioscience, Oxford,
UK
Transduction 
Laboratories, BD 
Bioscience, Oxford,
UK
Roche Diagnostics, 
West Sussex, UK 
AbD Serotec, 
Kidlington, UK 
Zymed
Laboratories/Invitrog 
en, Paisley, UK 
S. Schmid, California 
Institute of 
Technology,
Pasadena, USA 
(originally from B. 
Granger, University of 
Montana, USA) 
Transduction 
Laboratories, BD 
Bioscience, Oxford,
UK
Sigma-Aldrich, Poole, 
UK
Li-cor Biosciences, 
Lincoln, Nebraska, 
USA
Molecular 
Probes/Invitrogen, 
Paisley, UK
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Antigen Antibody Species/
isotype
Cone.®
used*
Source
Mouse IgG (H+L) GAM Alexa Fluor® 647
Goat
polyclonal 4 ug/ml
Mouse IgG Ig G l GAM IgGl Alexa Fluor® 488
Goat
polyclonal 4 ug/ml
Mouse IgG Ig G l GAM IgGl Alexa Fluor® 594
Goat
polyclonal 4 ug/ml
Mouse IgG Ig G l GAM IgGl Alexa Fluor® 647
Goat
polyclonal 4 ug/ml
Mouse IgG  
IgG 2 a
GAM IgG2a Alexa 
Fluor® 488
Goat
polyclonal 4 ug/ml
Mouse IgG  
IgG 2a
GAM IgG2a Alexa 
Fluor® 594
Goat
polyclonal 4 ug/ml
Mouse IgG 
IgG 2 a
GAM IgG2a Alexa 
Fluor® 647
Goat
polyclonal 4 ug/ml
Mouse IgG 
IgG2b
GAM IgG2b Alexa 
Fluor® 594
Goat
polyclonal 4 ug/ml
Mouse IgG  
IgG 2 b
GAM IgG2b Alexa 
Fluor® 647
Goat
polyclonal 4 ug/ml
R abbit IgG (H+L) GAR Alexa Fluor® 594
Goat
polyclonal 4 ug/ml
R abb it IgG (H+L) GAR Alexa Fluor® 647
Goat
polyclonal 4 ug/ml
Mouse IgG (H+L) Anti-mouse HRP Goatpolyclonal 2 ,ug/ml
R abbit IgG (H+L) Anti-rabbit HRP Donkeypolyclonal 2 ug/ml
Pierce, Perbio Science 
UK Ltd., Cramlington, 
UK
IB, immunoblot; IP, immunoprecipitation; IF, immunofluorescence; GAM, goat anti­
mouse; GAR, goat anti-rabbit; RAM, rabbit anti-mouse; RAG, rabbit anti-goat; HRP, 
horse radish peroxidase; H+L, heavy and light antibody chains.
* Concentrations of antibodies used for experiments in this thesis are listed; where 
different concentrations have been used for specific applications, they are indicated 
separately. Concentrations are given in mass per volume units; where a concentration 
has not been determined, a dilution at which the antibody solution has been used is 
indicated.
1 See Production  o f  MC-5 fro m  h yb ridom a  cells
* See C oupling o f  MC-5 to Alexa F luo r®  488
Production of M C-5 from hybridoma cells 
Collecting M C -5  from  hybridom a cell m edium
The mouse monoclonal antibody, MC-5, was harvested from the growth 
medium of hybridoma cells producing the antibody (Segerer, Mack et al. 
1999; Blanpain, Vanderwinden et al. 2002). The cells were grown in 
suspension in an INTEGRA CELLine 350 system (INTEGRA Biosciences AG, 
Switzerland). This system houses the cells in a small volume of growth 
medium separated from a larger pool o f nutrient medium (growth medium 
minus FCS) by a size-exclusion membrane, which allows the passage o f 
nutrients into the cell compartment but prevents antibody exchange. Thus,
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a high cell density and high concentration o f antibody can build up within 
the cell compartment. Cells were grown according to the manufacturer’s 
instructions, w ith an aliquot o f medium from the cell compartment collected 
every 7 d for a period o f a month. Cells were pelleted by centrifugation (800 
rpm, 3 min) and the antibody-containing supernatants stored at 4°C.
Purification o f M C -5
Before purification, the concentration of antibody in the supernatants was 
estimated by running aliquots on a non-reducing sodium dodecyl sulphate 
(SDS)-polyacrylamide gel and comparing antibody band intensities with a 
dilution series o f a human IgC antibody (Sigma-Aldrich, Poole, UK) o f known 
concentration (protocol described in Preparation o f  samples fo r pro te in  
electrophoresis and Protein electrophoresis).
Antibody purification from the hybridoma supernatant was achieved using 
the ImmunoPure® (A/C) IgC Purification Kit from Pierce (Perbio Science UK 
Ltd., Cramlington, UK), where the antibody is captured on a Protein A/G 
column, washed and then eluted at low pH. Following the manufacturer’s 
instructions, fo r each purification, 14 mg of antibody diluted in binding 
buffer (pH 8) was loaded onto a 2 ml Protein A/G column (binding capacity 
o f 7 mg o f antibody per ml o f gel matrix) and washed with 10 ml o f binding 
buffer. The antibody was eluted with elution buffer (pH 2.8) and collected in 
0.5 ml fractions. Fifty microlitres o f 1 M Tris, pH 7.5, was added to each 
fraction to raise the pH o f the elution buffer towards neutral. The antibody- 
containing fractions were identified by SDS polyacrylamide gel 
electrophoresis (PAGE) and by protein assay (DC Protein Assay, Bio-Rad 
Laboratories Ltd., Hemel Hemstead, UK).
In order to make the purified antibody preparation compatible with chemical 
coupling reactions involving primary amine groups on the antibody 
molecule, the am ine-conta in ing buffer was exchanged for PBS using a D- 
Salt™ Dextran Desalting Column (Pierce, Perbio Science UK Ltd., 
Cramlington, UK) with a molecular mass exclusion limit o f 5 kDa. The 
antibody-contain ing solution was allowed to enter the PBS-equilibrated 
column before the addition o f further PBS to wash the antibody through. 
Half millilitre fractions were collected and the presence o f antibody
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determined by protein assay. The purity of the antibody-conta in ing 
fractions was assessed by non-reducing SDS PAGE. Figure 2-1 A shows a gel 
where fractions 4 -8  from a representative antibody purification were loaded. 
The fractions contained a single predominant band o f approximately 150 
kDa, demonstrating the purity o f the preparation.
Antibody-conta ining fractions were snap frozen in liquid nitrogen and 
stored at -80°C.
Coupling of MC-5 to Alexa Fluor® 488
MC-5 was coupled to Alexa Fuor® 488 using a protein labelling kit (A- 
10235) from Molecular Probes (Paisley, UK). The Alexa Fluor® 488 reactive 
dye has a tetrafluorophenyl (TFP) ester moiety that reacts with primary 
amines, i.e., lysine side-chains o f the antibody molecule. The coupling 
reaction was performed according to the manufacturer’s instructions. 
Briefly, 50 \i\ o f a 1 M sodium bicarbonate solution was added to 0.5 ml o f a 
2 m g /m l MC-5 solution. This raised the pH of the solution, in order to 
increase the rate o f the coupling reaction. The protein solution was then 
transferred to a reaction vial containing the reactive dye in solid form. The 
reaction mixture was stirred at ambient temperature for 1 h, before 
separation o f the unreacted dye from the antibody by passing the reaction 
mixture through a size-exclusion matrix (Bio-rad BioCel P-30 Fine size 
exclusion purification resin, 40 kDa molecular mass exclusion limit, Bio-Rad 
Laboratories Ltd., Hemel Hemstead, UK). A PBS elution buffer (pH 7.2, 
containing 2 mM sodium azide) was used to elute the labelled antibody, 
named 488MC-5. The passage o f 488MC-5 through the column was followed 
as a coloured band and collected as a single fraction.
The concentration o f antibody and the degree of coupling were calculated 
from meausrements using a Nanodrop spectrophotometer (Thermo Fisher 
Scientific, Loughborough, UK), according to the following equations, based 
on the Beer-Lambert law:
[A 28o _ (A 494x 0 .1 1 )] x d i lu t io n  fa c to r
p ro te in  c o n c e n tra t io n  (M) =  ------------------------------------------------------------------
203,000
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, where 203,000 c m ^ M '1 is the molar extinction coefficient o f a typical IgC 
and 0.11 is a correction factor to account for absorption o f the dye at 280 
nm.
A494 x dilution factor 
molar dye:antibody ratio = -----------------------------------------------
71 ,000 x concentration (M)
, where 71,000 cm ^M "1 is the approximate molar extinction coefficient o f 
the Alexa Fluor® 488 dye at 494 nm.
This gave an antibody concentration o f 1 m g/m l and a coupling ratio o f 5.5 
dye molecules to 1 antibody molecule.
Specificity and binding characteristics of MC-5 and 488MC-5
Several experiments were performed to assess the specificity and binding 
characteristics o f MC-5 and 488MC-5 to CCR5, using CHO CCR5 cells, which 
stably express high levels o f the receptor on their surface.
Firstly, the binding o f purified MC-5 to CCR5 on the surface o f CHO CCR5 
cells was assessed by immunofluoresence; representative images from one 
purification are shown in Figure 2-1 B. MC-5 labelled the surface o f the CHO 
CCR5 cells in a concentration-dependent manner, with maximum staining 
intensity reached around 1 ^ig/ml. The secondary antibody alone gave no 
visible staining using the same microscope acquisition settings. The binding 
o f MC-5 was specific to CCR5 because CHO-K1 cells, which do not express 
CCR5, gave no fluorescence signal when stained with 10 ^g /m l MC-5 - the 
highest concentration tested.
Next, the CCR5-binding characteristics o f M C -5 ,488MC-5 and S94M C-53 were 
determined by fluorescence-activated cell sorting (FACS). Figure 2-1 C is a 
graph showing mean fluorescence intensity against concentration o f 
antibody. The data points represented by squares (solid trend lines) show 
the mean fluorescence intensity fo r CHO CCR5 cells, corrected for non­
specific antibody binding to CHO-K1 cells, relative to the mean fluorescence
3 Alexa Fluor® 594 was also coupled to  CCR5 to  produce 594MC-5 but the antibody conjugate generated 
was not used fo r experim ents described in this thesis.
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intensity measured with 100 ug/m l o f antibody, which was arbitrarily set to 
a value o f 100. The data points represented by triangles (dotted trend lines) 
represent the non-specific binding o f antibody on CHO-K1 cells relative to 
the specific binding o f the antibody on CHO CCR5 cells at 100 ug/m l, also 
set to a value o f 100.
MC-5 demonstrated a typical sigmoidal binding curve, plateauing at around 
3 ug/m l (20 nM), with an apparent Kd o f ~ 0.2 ug/m l (~ 1.3 nM). This 
compares well w ith the Kd o f 0.35 ± 0.21 ug/m l calculated by Blanpain et al. 
(2002). 488MC-5 also showed a sigmoidal binding curve, but the curve was 
slightly r igh t-sh ifted  compared with that o f MC-5, indicative o f a loss o f 
affinity due to coupling to Alexa Fluor® 488, and accordingly, the Kd for 
488MC-5 was increased to ~ 0.7 (ig/m l (~ 4.7 nM). Although 594MC-5 also 
showed a concentration-dependent increase in binding to CCR5, saturation 
binding was not observed at 100 ^ig/ml and the curve was significantly 
r igh t-sh ifted  relative to MC-5 and 488MC-5, demonstrating a significant loss 
o f affin ity fo r the receptor due to coupling to Alexa Fluor® 594. The 
coupling ratio for 594MC-5 was 3:1, lower than that o f 488MC-5 (5.5:1), so the 
reduced affin ity fo r CCR5 is likely to result from the larger size o f the Alexa 
Fluor® 594 molecule relative to the Alexa Fluor® 488 molecule (see Figure 
2-1 D), which presumably is coupled to at least one lysine residue near to 
the CCR5 binding interface in at least some of the antibodies within the 
preparation.
From the graph, it can be seen that fo r all o f the antibodies, non-specific 
binding, as assessed on CHO-K1 cells, was minimal, and was still negligible 
at high concentrations o f antibody relative to binding to CHO CCR5 cells. 
Lastly, the binding o f 488MC-5 and 594MC-5 to CHO CCR5 cells was assessed 
by immunofluorescence. As can be seen in Figure 2-1 D, 488MC-5 displayed 
concentration-dependent binding over the range tested (0.5-10 ^g/m l), 
with a maximum fluorescence signal observed at 5 ug/ml, which agreed well 
with the FACS data. 594MC-5 showed concentration-dependent binding over 
the whole range o f concentrations tested, with a larger difference in 
fluorescence intensity between 0.5 ^g /m l and 10 j^g/ml than 488MC-5, also 
agreeing well with the FACS data.
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Figure 2-1 Specificity and binding characteristics of MC-5 and MC-5 conjugates
A. C oom assie -s ta ined , non -reduc ing  polyacry lam ide gel showing fractions 4 -8  
collected from  a desa lt ing  co lu m n  fro m  a representative  sam ple  o f  purified MC-5
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a n t ib o d y . A lso show n is a d i lu t io n  series o f  hum an  IgC (h lgC), w h ich  has 
a p p ro x im a te ly  the  sam e m o b il i ty  as M C-5. M o lecu lar mass s tandards  w e re  run in 
the  le f t -m ost  lane (M); m asses are  ind icated  to the left o f  the gel. B. C H O  CCR5 cells  
g ro w n  on coverslips  w e re  f ix e d  and  s ta ined w ith  various concentra t ions  o f  p ur if ied  
M C-5 and 4  u g /m l  G A M  A le x a  5 9 4  seco nd ary  an tibody . T he  secondary  a n t ib o d y  
contro l represen ts  C H O  CCR5 cells in cub ated  w ith  4  u g /m l  C A M  A lexa  5 9 4  only. In 
a contro l to  assess non -sp ec if ic  b in d in g  o f  MC-5 to C H O  cells, CHO-K1 cells w e re  
incubated  w ith  10  ^ig /m l M C -5  and 4  ^ig/ml GAM  A lexa  5 9 4  secondary  an tib o d y .  
Coverslips w e re  o bserved  by ep if lu orescence  m icroscopy (b righ t- f ie ld  v iew  also  
show n fo r  contro ls ) .  Bar, 5 0  ^im. C. Equal num bers  o f C H O  CCR5 or CHO-K1 cells 
w ere  in cub ated  w ith  various co n cen tra t io n s  o f  M C-5, 488MC-5 and 594MC-5 in 96 -w e ll  
plates fo r  1 h a t  4 °C . Cells w ere  w ash ed  and then M C -5- and 594M C -5 -lab e lled  cells 
incubated  fo r  a fu r th e r  h our w ith  a C A M  A lexa  4 8 8  a n t ib o d y  at 4°C. Cell-associated  
f lu o rescence  was m e a s u re d  by FACS. Details  o f  the d ata  points p lo tted  are g iven in 
the  te x t .  D a ta  f r o m  one rep resen ta t ive  e x p e r im e n t  are shown; error  bars rep resen t  
one s tan d ard  d ev ia t io n  o f  the  m ean  o f  tr ip licate  sam ples. D. Cells g ro w n  on  
coverslips w e re  f ix e d  and sta ined w ith  various concentra tions  o f  e ithe r  488M C-5 or  
594M C -5 .  C overs lips  w e re  observed  by ep ifluorescence. Bar, 2 0  ^m . T h e  chem ica l  
structures  o f  A le x a  F luo r®  4 8 8  and A le x a  F luor®  5 9 4  are shown above the f ig u re .  
T he  u n c o n n e c te d  a m id e  b ond  represents  w h e re  the prim ary  a m in e  g ro u p  o f  a lysine  
side chain  w o u ld  co u p le  to the  A lexa  F lu o r®  m oiety.
Expression o f exogenous proteins in cell-lines 
DNA constructs
The table below details the DNA constructs used in this thesis.
Table 2-111 Details of DNA constructs
Protein Expression Species Source
_________________ vector_________________________________________
CCR5
C C RSwl s Human M. Oppermann Georg August
CCR5 4S^*A University, Goettingen, Germany
p-arrestins
GFP-fiarr2 w t 
G FP-fia rr2(l-380)
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Protein Expression
vector
Species Source
w t p a rr  2 -GFP 
pa rr2(IVF/AAA)-GFP 
w t parr-GFP  
parr2(R396A)-GFP  
p a rr  2 (LIEF/AAEA) - 
GFP
parrl-Y F P  
parr2-GFP
pEGFP Clontech
pNSINeo 
pEGFP Clontech
Rat
Cow
A. Benmerah, Institut Cochin, Paris, 
France
Nathalie Signoret, MRC LMCB, UK 
Julie Pitcher, MRC LMCB, UK
R a b ll
m yc-R abl 1 w t 
m y c -R a b ll (Q70L) 
m yc-Rabl 1 (S25N)
pCMV-Tag3 Human R. Prekeris, University of Colorado Denver School of Medicine, USA.
Other
Cl-GFP pEGFP Clontech n/a BD Biocience, Oxford, UK
wt, wild-type
Amplification of plasmids
Chemically competent E.coli (One Shot® TOPIO, Invitrogen, Paisley, UK) 
were transformed using the heat-shock method. Five hundred nanograms of 
DNA was added to 50 [i\ o f bacterial suspension and incubated on ice for 30 
min. The mixture was then incubated for 30 s in a 42°C water-bath before 
cooling on ice for 2 min. Two hundred and fifty microlitres o f SOC medium 
(2% tryptone, 0.5% yeast extract, 10 mM NaCI, 2.5 mM KCI, 10 mM MgCI2, 
10 mM MgS04, 20 mM glucose; Invitrogen, Paisley, UK) pre-warmed to 37°C 
was added and the bacteria incubated on a shaker at 37°C for 1 h. One 
hundred microlitres o f transformed bacterial suspension was then plated on 
a 10 cm LB Agar plate (15 g / 1 agar in Luria Broth [LB; 10 g / l  bacto-tryptone, 
5 g / l  bacto-yeast extract, 10 g/NaCI]) containing 50 ug/m l kanamycin and 
grown overnight in a 37°C incubator. Single colonies were picked and grown 
in 2 ml o f LB containing 50 ^ig/ml kanamycin at 37°C with shaking for 8 h. 
One hundred microlitres o f bacterial suspension was then transferred to 250 
ml o f LB containing 50 pg /m l kanamycin and the bacterial suspension 
incubated at 37°C overnight, with vigorous shaking. The bacteria were 
pelleted by centrifugation (4,200 rpm, 30 min) and plasmid DNA was 
purified using the Qiagen QIAfiIter plamsid purification kit (Qiagen, Crawley,
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West Sussex, UK) according to the manufacturer’s instructions. Purified DNA 
was resuspended in TE buffer (10 mM Tris, 1 mM EDTA; Qiagen, Crawley, 
West Sussex, UK) and the DNA concentration determined using a Nanodrop 
spectrophotometer (Thermo Fisher Scientific, Loughborough, UK).
Transfections
CHO CCR5 cells, CHO-K1 cells and MEFs were transfected using FuGENE® 
HD (Roche Diagnostics, West Sussex, UK), according to the manufacturer’s 
instructions, with optimisations o f cell seeding density and DNA/FuGENE 
ratio. Three hundred thousand cells were seeded into a well o f a 6-well 
plate (Nunc, G ibco/lnvitrogen, Paisley, UK) and grown for 24 h before 
transfection. For each transfection, 2 ^g o f DNA was diluted in 100 i^l of 
Opti-MEM (Invitrogen, Paisley, UK). Six microlitres o f FuGENE HD 
transfection reaction was added to the DNA solution and mixed by flicking 
vigorously. The mixture was incubated at ambient temperature for 15 min 
to allow the DNA:FuGENE complexes to form. The medium on the cells was 
replaced with 2 ml o f growth medium minus antibiotics and the 
DNA:FuGENE complexes added drop-wise. Cells were then incubated at 
37°C for 24 h hours, after which the cells were detached with trypsin/EDTA 
and replated into fresh dishes appropriate to the experiment in which the 
cells were to be used.
siRNA knock-downs 
Details of siRNAs
The target sequences used to create siRNA oligonucleotides were as follows:
A P -1  (xlA (D h a rm a l)
T T C G T T T C A T G T G G A T T A A  
A P -1  j i lA  (D harm a2)
G T T C G T T T C A T G T G G A T T A
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A P -1  (xlA  (Inv)
C C A C T A C A T C A C T C A G G A A
AllStars Negative Control siRNA
Proprietary sequence
siRNA oligonucleotides targeting the adaptor protein 1 (AP-1) ^1A subunit 
were designed using the s\DESIGN® Center (Dharma 1 and Dharma 2; 
Dharmacon RNAi Technologies, www.dharmacon.com) or the BLOCK-iT™ 
RNAi Designer (Inv; Invitrogen, www.invitrogen.com) using the mouse AP-1 
[ i l A  subunit DNA sequence (NM_007456) as a target. All designed siRNAs 
were purchased from Dharmacon RNAi Technologies (Chicago, USA). AllStars 
Negative Control siRNA was purchased from Invitrogen (Paisley, UK).
Knock-down protocol
CHO CCR5 cells were transfected with siRNA oligonucleotides using 
Oligofectamine (Invitrogen, Paisley, UK). Cells were detached from a 
confluent 9 cm dish with trypsin/EDTA and re-seeded at a dilution o f 1:30 
into wells o f a 6-well plate (Nunc, Gibco/lnvitrogen, Paisley, UK) and grown 
for 5 h. siRNA:Oligofectamine complexes were prepared by incubating for 
20 min at ambient temperature a mixture of a dilution o f 10 i^l o f a 20 i^M 
siRNA solution (200 pmol) in 175 jxl o f Opti-MEM (Invitrogen, Paisley, UK) 
with 3 nl o f Oligofectamine reagent diluted in 12 i^l o f Opti-MEM (pre­
incubated at ambient temperature for 5 min). Growth medium was removed 
from the cells and replaced with 800 of medium w ithout antibiotics and 
FCS and siRNA:Oligofectamine complexes were added drop-wise to the 
cells, giving a final concentration o f 200 nM siRNA. Cells were incubated for 
3 h at 37°C before the addition o f 3 ml o f complete growth medium to each 
well and re-incubation at 37°C. Sixteen hours later, another knock-down 
transfection was performed as above w ithout detaching cells. After a further 
24 h, cells were detached with trypsin/EDTA and split at an appropriate 
dilution onto coverslips for an immunofluorescence assay, or several wells 
combined appropriately in 9 cm dishes for a FACS assay or for a cell lysate 
24 h later. The extent o f knock-down was determined from quantification o f
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immunoblots o f cell lysates using the Odyssey infra-red detection system, 
as described below.
Preparation o f cell lysates and immunoprecipitations 
Preparation of lysates
RIPA buffer (150 mM NaCI, 50 mM Tris [pH 8.0], 5 mM EDTA [pH 8.0], 1% 
v /v  NP-40, 0.5% w /v  sodium deoxycholate, 0.1% w /v  SDS, adjusted to pH 
8.0) was used as the standard lysis buffer fo r preparation of cell lysates.
In general, 80% confluent 9 cm dishes o f cells were cooled on ice and 
washed twice with ice-cold PBS. Protease inhibitors (Complete Protease 
inhibitor cocktail, Roche Diagnostics, West Sussex) and phosphatase 
inhibitors (Halt Phosphatase Inhibitor Cocktail, Pierce, Perbio Science UK 
Ltd., Cramlington, UK) were added fresh to the lysis buffer according to the 
manufacturer’s instructions. Immediately before lysing cells, 
phenylmethanesulphonylfluoride (PMSF, final concentration 1 mM) was also 
added to the lysis buffer to inhibit serine proteases. PBS was removed from 
the dish by aspiration and cells were lysed by addition o f 1 ml o f ice-cold 
lysis buffer. Cells were scraped into pre-chilled 1.5 ml microfuge tubes and 
sonicated twice for 10 s to shear DNA and fragment large cellular debris. 
Insoluble debris was removed by centrifugation at 13,000 rpm for 10 min at 
4°C. Lysates were either snap-frozen in liquid nitrogen or used 
appropriately for the particular experiment. Frozen lysates were thawed 
quickly at 37°C for subsequent use.
Immunoprecipitations
Protein concentrations o f cell lysates were determined by protein assay (DC 
Protein Assay, Bio-Rad Laboratories Ltd., Hemel Hemstead, UK) and equal 
amounts o f protein were used for each immunoprecipitation. Lysates were 
pre-cleared in 1.5 ml microfuge tubes with Protein A sepharose beads 
(Sigma-Aldrich Company Ltd., Poole, Dorset, UK) or Protein G sepharose 
beads (Zymed/lnvitrogen, Paisley, UK) for 30 min on a rotating wheel at 4°C. 
Protein A sepharose was used for immunoprecipitations with MC-5 (mouse 
lgC2a) and Protein G sepharose was used for immunoprecipitations with
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anti-GFP (mouse IgGl). After pre-clearing lysates, beads were pelleted by 
centrifugation (8000 rpm, 3 min, 4°C) and the supernatants transferred to 
fresh microfuge tubes. The immunoprecipitating antibody was added to the 
lysates, which were incubated for 30 min at 4°C on a rotating wheel, before 
being transferred to protein A/G sepharose-containing tubes and further 
incubated for 1.5 h at 4°C on a rotating wheel. Beads were then pelleted by 
centrifugation (8000 rpm, 3 min, 4°C) and washed 3 times for 5 min with 
ice-cold lysis buffer. Finally, beads were re-suspended in 2x reducing 
sample buffer (2xRSB; 4% SDS, 20% glycerol, 10% 2-mercaptoethanol,
0.004% bromophenol blue, 0.125 M Tris HCI, pH ~ 6.8) and heated at 95°C 
for 5 min.
Preparation of samples for protein electrophoresis 
N on-reducing  conditions
Prior to loading on a gel, protein samples were mixed 1:1 with 2x non­
reducing sample buffer (4% SDS, 20% glycerol, 0.004% bromophenol blue, 
0.125 M Tris HCI, pH ~ 6.8) and incubated at ambient temperature for 5 
min.
Reducing conditions
Prior to loading on a gel, protein samples were mixed 1:1 with 2x reducing 
sample buffer (2xRSB; 4% SDS, 20% glycerol, 10% 2-mercaptoethanol,
0.004% bromophenol blue, 0.125 M Tris HCI, pH ~ 6.8). Standard protocols 
recommend heating lysates in sample buffer to 95°C for 5 min to ensure 
complete denaturation o f proteins. However, it was discovered that this 
resulted in a significant loss o f CCR5 from cell lysates (see Figure 2-11). This 
loss of CCR5 was not observed in heated tubes containing CCR5 
immunoprecipitated from cell lysates. As CCR5 is a 7 trans-membrane 
domain protein with considerable hydrophobicity, the most likely 
explanation for these observations is that heating favours aggregation of 
CCR5 with other proteins in cell lysates, through non-specific hydrophobic
interactions, but that this does not occur in solutions containing the
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immunoprecipitation reaction, where most o f the cellular proteins have been 
removed by washing.
Cell lysates mixed with sample buffer that were to be run for the purpose o f 
detecting CCR5 were, therefore, incubated at ambient temperature and not 
heated to 95°C. However, cell lysates from which cytoplasmic proteins were 
to be detected by immunoblot were heated to 95°C. Immunoprecipitates 
were also heated to 95°C as no loss o f CCR5 was observed upon heating 
and heating assisted denaturation of both CCR5 and the 
immunoprecipitating antibody, resulting in single bands for CCR5 and both 
the antibody heavy chain and light chain, which were also recognised by the 
secondary antibody (see Figure 2-11).
lysates IP: CCR5
markers RT 95‘C markers RT 95‘C
C-HC
MC-5 (whole) 
MC-5 (2xHC)
50
37
25 
20
Figure 2-11 Heating cell lysates to 95°C leads to loss of CCR5
Supernatants  o f  C HO  CCR5 cells lysed in RIPA buffer w ere  e ither  m ixed  w ith  an  
equal vo lu m e o f  2xRSB (lysates) or lysate conta in ing  0 .5  mg o f  p ro te in  was  
incubated w ith  MC-5 (7 .5  pg) and im m u no co m p lexes  captured on p ro te in  A- 
sepharose beads (1 .5  h, 4°C ) before  being  e luted by resuspension in RSB (IP:CCR5). 
Samples w ere  e ither  heated at 9 5 °C  or incubated at a m b ie n t  te m p e ra tu re  (RT) for 8 
min, before  equal vo lum es w e re  loaded on a 10% SDS polyacry lam ide gel. Proteins  
were transferred  to  n itrocellu lose by im m u n o b lo tt in g  and p robed  for e ither  CCR5 or  
clathrin heavy chain (C-HC). A fte r  subseq uen t incubation w ith  IRDye® 8 0 0  C A M ,
Mr (kDa) 
150
100
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prote ins w e re  v isua lised  using th e  O dyssey infra-red  d e tec tion  system .
HC, heavy-chain; LC, l ight-cha in .
Protein electrophoresis
The method for sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS PACE) was based on that o f Laemmli (1970). Minigels were cast with a 
10% polyacrylamide resolving gel (pH 8.8) and a 4% polyacrylamide stacking 
gel (pH 6.8) (Protogel acrylamide solution [37.5:1 acrylamide:bis- 
acrylamide] and resolving/stacking gel buffer, Gene Flow, National 
Diagnostics, Fradley, UK; 0.1% w /v  ammonium persulphate; and 0.1% v /v  
TEMED). Cels were run in a Hoefer SE260 m ini-gel system (Hoefer Inc., San 
Francisco, California, USA) in running buffer (25 mM Tris, 192 mM glycine, 
0.1% SDS) at 80 V while proteins migrated through the stacking gel and at 
120 V when the proteins had entered the separating gel.
Coomassie staining
Gels were stained with 0.05% w /v  Coomassie blue in 40% v /v  methanol, 10% 
v /v  acetic acid fo r 15 min at ambient temperature and destained fo r 2 h in 
50% v /v  methanol, 10% v /v  acetic acid. Gels were dried on Whatman paper 
(Whatman, GE Healthcare Ltd., Little Chalfont, UK) using a gel drier (Bio-Rad 
Laboratories Ltd., Hemel Hemstead, UK).
Western blotting
Proteins were transferred to a nitrocellulose membrane (Schleicher and 
Schuell, Whatman, Dassel, Germany) using a semi-dry transfer system (Bio­
rad Laboratories Ltd., Hemel Hemstead, UK; transfer buffer consisting of 
0.25 M Tris, 1.92 M glycine, 0.1% SDS and 20 v /v  methanol) run at 10 V for 
40 min. Nitrocellulose membranes were blocked with blocking buffer (TBS 
containing 5% milk powder [Marvel, Spalding, UK]) for 30 min at ambient 
temperature before incubation with primary antibodies4 in blocking buffer 
containing 0.1% Tween20 overnight at 4°C. Blots were subsequently washed 
3 times for 15 min in wash buffer (TBS containing 0.1% Tween20) and then
4 Primary antibodies and concentrations at which they were used are listed in Table 2-11.
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incubated with secondary antibody in wash buffer fo r 1 h, all at ambient 
temperature. Blots were either incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibodies (Pierce, Perbio Science UK Ltd., 
Cramlington, UK) or f luorophore-conjugated secondary antibodies 
compatible with the Odyssey infra-red detection system (Li-cor Biosciences, 
Lincoln, Nebraska, USA).5 Following this, blots were washed 3 times fo r 15 
min in wash buffer before a final rinse in PBS, all at ambient temperature. 
Blots incubated with HRP-conjugated secondary antibodies were developed 
by 5 min incubation with either Super Signal® West Pico Chemiluminescent 
Substrate or Super Signal® West Dura Extended Duration Substrate (Pierce, 
Perbio Science UK Ltd., Cramlington, UK). Chemiluminescent films 
(Amersham Bioscience, Little Chalfont, UK) were exposed to the blot in a 
film cassette and developed in an X-ograph X-ray film developer (Xograph 
Imaging Systems, Tetbury, UK).
Blots incubated with Odyssey-compatible secondary antibodies were 
scanned in an Odyssey infra-red scanner (Li-cor Biosciences, Lincoln, 
Nebraska, USA) at either 680 nm or 800 nm. Band intensities were 
quantified using the Odyssey software, by defining a rectangular region 
around each band and summing the fluorescence intensities o f each pixel 
corrected for the average background pixel intensity value. The average 
background pixel intensity value was calculated individually for each band 
from the average pixel intensity o f pixels within a distance o f 3 pixels above 
and below the defined region.
Details of specific assays
C o-im m unprec ip ita tion  o f p -a rres tin s  w ith CCR5
CHO K l,  CHO CCR5, CHO CCR5 parrl-YFP or CHO CCR5 |3arr2-GFP cells 
were grown in 9 cm dishes for 2 d to 80% confluency. Cells were washed in 
5 ml o f BM at 37°C and incubated for various time periods with 125 nM 
RANTES in BM at 37°C. Some dishes containing cells were also subsequently 
washed 4 times with ice-cold BM and re-incubated with 400 nM TAK-779 in 
BM at 37°C for 60 min. A fter the incubation period, the dishes containing
5 Details o f secondary antibodies and concentrations at which they were used are given in Table 2-11.
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the cells were transferred to ice and washed twice with ice-cold PBS before 
adding 5 ml o f ice-cold PBS to each dish. Four hundred microlitres o f 25 
mM dithiobissuccinimidylpropionate (DSP) in DMSO was added to each dish 
(final concentration 2 mM) and cells were incubated at 4°C for 2 h. The 
cross-linking reaction was then stopped by adding 100 |d o f 1 M Tris, pH 
7.5 to each dish and further incubating for 15 min at 4°C. Cells were then 
washed twice with ice-cold PBS, lysed in RIPA buffer and 
immunoprecipitations were carried out as described above.
CCR5 degradation
Cells from a confluent 9 cm dish were detached with trypsin/EDTA, seeded 
into wells o f a 6-well plate at a 1:30 dilution per well and grown for 24 h. 
Cells were incubated in 100 ng /m l cycloheximide (CHX) with or w ithout 125 
nM RANTES in BM at 37°C for various time-periods, after which plates were 
placed on ice, washed twice with ice-cold PBS, lysed in 200 pil o f RIPA buffer 
and supernatants obtained as described above. Equal volumes o f cell lysates 
from the different t im e-po in ts  were mixed with 2xRSB, run on a gel and 
blotted for CCR5.
Immunofluorescence
Basic fixation and staining protocol
Cells on coverslips were fixed in 3% paraformaldehyde (PFA) for 20 min on 
ice. All subsequent washes and incubations were carried out at ambient 
temperature. Cells were washed in PBS and free aldehyde groups quenched 
by incubation in 50 mM NH4CI for 20 min. Cells were again washed with PBS 
and incubated with blocking buffer (0.2% gelatine, 0.05% saponin in PBS) for 
20 min to block non-specific sites and permeabilise cellular membranes. 
Cells were then incubated in blocking buffer containing primary antibodies6 
for 1 h at ambient temperature, followed by 3 washes o f 5 min in blocking 
buffer, before being incubated with secondary antibodies7 in blocking buffer
6 Details o f prim ary antibodies and the concentrations at which they were used are given in Table 2-11.
7 Details o f secondary antibodies and the concentrations at which they were used are given in Table 2-11.
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for 45 min. Finally, cells were washed 3 times in blocking buffer and then 
once in PBS before rinsing in water and mounting in Mowiol (Calbiochem, La 
Jolla, USA) on a microscope slide.
Image capture and processing 
Epifluorescence microscopy
Mounted cells on coverslips were viewed at ambient temperature using a 
63x oil immersion lens on a Zeiss Axioskop microscope (Zeiss, Welwyn 
Carden City, UK) and 8 -b it  images captured using a CCD camera operated 
through the Openlab software (Improvision, Coventry, UK). Images were 
exported as TIFF files and processed in ImageJ (NIH) before being assembled 
into figures using Adobe Illustrator.
Confocal fluorescence microscopy
Mounted cells on coverslips were imaged at ambient temperature using a 
63x oil immersion lens on a Leica TCS SPE confocal microscope (Leica 
Microsystems (UK) Ltd., Milton Keynes, UK). E ight-bit images were acquired 
using the Leica software, either taking single confocal sections (1 Airey unit) 
or stacks o f confocal sections (step size 0.5 ^m). Images were exported 
from the software as TIFF files and processed in ImageJ (NIH); here, 
projection images were formed from stacks o f confocal sections. Images 
were assembled into figures using Adobe Illustrator.
Trafficking assays 
Preparation o f cells
Cells were detached from a confluent 9 cm dish using trypsin/EDTA and 
seeded at a 1:20 dilution onto glass coverslips placed in a new 9 cm dish 
and grown for 2 d to reach approximately 50% confluence. Cells that had 
been transfected using the FuGENE HD protocol (see Transfections) were 
detached from 6-well plates 24 h post-transfection and re-seeded onto 
glass coverslips in wells o f a new 6-well plate at a 1:10 dilution and grown 
for 1 d to reach approximately 50% confluence.
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P re-labelling  o f cell surface CCR5
Cells grown on coverslips were transferred to 4-well plates (Nunc, 
Gibco/lnvitrogen, Paisley, UK) and washed twice in BM at ambient 
temperature and then incubated with 1:500 MC-5 hybridoma supernatent in 
BM at room temperature for 40 min. Unbound antibody was then removed 
by 3 washes with BM at ambient temperature before a trafficking assay was 
performed.
P re-clearing o f biosynthetic CCR5 w ith  cyclohexim ide
Cells grown on coverslips in 9 cm dishes were incubated with 100 ^g /m l 
cycloheximide (CHX) in their normal growth medium for 2 h at 37°C. Cells 
on coverslips were then transferred to 4-well plates (Nunc, 
Gibco/lnvitrogen, Paisley, UK) and washed twice in BM at ambient 
temperature before a trafficking experiment was performed. One hundred 
micrograms per millilitre CHX was included in the BM used fo r all 
subsequent steps throughout the trafficking assay.
Disruption o f m icrotubules w ith nocodazole
Cells grown on coverslips in 9 cm dishes were incubated with 1 pig/ml 
nocodazole in their normal growth medium for 3 h at 37°C (control cells 
were incubated with a 1:1000 dilution o f DMSO [the solvent for nocodazole] 
at all stages instead of nocodazole). Cells on coverslips were then 
transferred to 4-well plates (Nunc, Gibco/lnvitrogen, Paisley, UK) and 
washed twice in BM at ambient temperature before a trafficking experiment 
was performed. One microgram per millilitre nocodazole was included in the 
BM used for all subsequent steps throughout the trafficking assay.
CCR5 dow n-m odu la tion
Cells grown on coverslips were either untreated or pre-treated as described 
above. The cells were then incubated in 4-well plates (Nunc, 
Gibco/lnvitrogen, Paisley, UK) for various time periods with 125 nM RANTES, 
M IP - la  or M IP-ip  in BM at 37°C to induce CCR5 internalisation. At the end 
o f the time period, cells were placed on ice and washed twice with ice-cold
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BM followed by two washes in ice-cold PBS, before being fixed and stained 
as described above.
The effect o f various drugs on CCR5 internalisation
CHO CCR5 cells grown on coverslips were incubated in BM containing either 
MC-5 and 100 i^M dynasore monohydrate, 100 jiM Bis-T-23, 40 i^M Dyngo- 
4a or an appropriate dilution o f DMSO for 20 min at 37°C. Alternatively, 
cells were incubated for 15 min in BM containing MC-5 at 37°C followed by 
a 5 min incubation in BM containing either 100 ^M Bis-T-23, 40 i^M Dyngo- 
4a or an appropriate d ilution o f DMSO at 37°C. In both cases, cells were 
then washed and incubated with 125 nM RANTES in BM containing either 
100 i^M dynasore monohydrate, 100 i^M Bis-T-23, 40 i^M Dyngo-4a or an 
appropriate dilution o f DMSO for either 30 or 40 min at 37°C. Cells were 
then placed on ice and washed twice with ice-cold BM followed by two 
washes in ice-cold PBS, before being fixed and stained as described above.
CCR5 recycling
Cells that had been treated with RANTES for 60 min were transferred onto 
ice and washed rapidly 4 times with ice-cold BM. Ice-cold BM containing 
400 nM TAK-799 was added to the cells before returning them to 37°C and 
incubating for either 30 or 60 min. After this incubation, the cells were 
placed on ice and washed twice with ice-cold BM followed by two washes in 
ice-cold PBS, before being fixed and stained as described above.
The effect o f various drugs on CCR5 recycling
Cells were assayed for recycling as described above, with the inclusion in 
the BM containing 400 nM TAK-779 o f either 10 ^ig/ml BFA, 100 j^M 
dynasore monohydrate, 100 i^M Bis-T-23, 40 ^M Dyngo-4a or an 
appropriate dilution o f ethanol (BFA) or DMSO (dynasore monohydrate, Bis- 
T-23  and Dyngo-4a) as a control.
85
C hapter  2: Mater ia ls  arc! M ethods
The effect o f BFA on y -ad ap tin  d istribution
CHO CCR5 cells grown on coverslips were either untreated or treated with 1, 
10 or 100 (xg/ml BFA in BM at 37°C for 1 or 5 min. After the incubations, the 
cells were placed on ice and washed twice with ice-cold BM followed by two 
washes in ice-cold PBS, before being fixed and stained as described above.
Lysosomal degradation assay
Cells were seeded onto coverslips in 9 cm dishes as described above and 
grown for 32 h. One hundred micromolar leupeptin, 1 ^M pepstatin and 10 
i^M E64 were then added to the growth medium and the cells incubated for a 
further 16 h. Cells on coverslips were then transferred to 4-well plates and 
washed twice with BM at ambient temperature. Some cells were fixed at this 
stage as described above and stained for total CCR5 and the lysosomal 
marker, Igp-b. Others were pre-labelled for cell surface CCR5 and then 
assayed fo r CCR5 internalisation and recycling, all as described above, 
except that 100 m-M leupeptin, 1 ^M pepstatin and 10 ^M E64 were added to 
the BM during CCR5 surface labelling and both RANTES and TAK-779 
incubations.
FACS analysis
Basic procedure for CCR5 trafficking assay
CHO CCR5 cells were grown in 9 cm dishes for 2 d to reach a confluency o f 
80%. Cells were washed with PBS pre-warmed to 37°C and then detached by 
incubation with 10 mM EDTA in PBS at 37°C (trypsin was omitted from the 
detachment step to avoid cleavage o f extracellular domains o f CCR5). 
Detached cells were diluted in PBS at 37°C, pelleted by centrifugation (3 min, 
800 rpm), resuspended in 2 ml o f binding medium at 37°C and transferred 
to a 37°C water-bath.
A 50 1^ aliquot o f the cell suspension was removed and transferred to a 96 - 
well plate (Nalgene, Loughborough, UK) on ice, prepared with 100 1^ o f cold 
binding medium in each well, to serve as a 0 min t im e-po in t. 50 pil aliquots 
o f cell suspension were also removed at this stage to later determine non­
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specific secondary antibody binding (where the d irectly-coupled 488MC-5 
antibody was used, non-specific antibody binding was assessed on a s im ilar 
number o f CHO-K1 cells). To elicit agonist-stim ulated internalisation o f 
CCR5, 0.5 ml aliquots o f cell suspension were added to 0.5 ml o f b inding 
medium containing 250 nM RANTES in an assay tube (5 ml polystyrene 
round-bo ttom  tube, Falcon, BD Biosciences, Oxford, UK) to achieve a final 
RANTES concentration o f 125 nM. One hundred m icrolitre aliquots o f 
RANTES-treated cell suspension were removed at various tim e-po in ts  over 
the course o f 60 min and transferred to the 96-well plate on ice. A fter 60 
min, the assay tube containing RANTES-treated cells was transferred to ice 
and 4 ml o f ice-cold binding medium added to inh ib it fu rthe r tra ffick ing  
events. Cells were pelleted by centrifugation (5 min, 1200 rpm) and washed 
in 5 ml o f binding medium before being pelleted again, resuspended in ice- 
cold binding medium containing 400 nM TAK-779, and returned to the 37°C 
w ater-bath. 100 i^l aliquots o f TAK-779-treated cell suspension were 
transferred to the 96-w ell plate on ice at various time points up to 120 min. 
A fter the final a liquot had been removed, cells in the 96-w ell plate were 
pelleted by centrifugation and washed w ith ice-cold binding medium. Cells 
were then incubated w ith 1 ng/m l purified MC-5 or 488MC-5 fo r 1 h at 4°C 
on a reciprocal shaker (controls to determine non-specific secondary 
antibody binding on CHO CCR5 cells were incubated w ith 1 |ig /m l a n ti-y - 
adpatin [mouse lgG2a, BD Biosciences] instead o f MC-5 primary antibody). 
Cells incubated w ith MC-5 were washed w ith ice-cold binding medium and 
further incubated w ith a GAM Alexa Fluor® secondary antibody in ice-cold 
FACS wash buffer (1% FCS, 0.05% NaN3 in PBS) fo r 1 h at 4°C on a reciprocal 
shaker. Cells were then washed 3 times w ith ice-cold FACS wash buffer and 
then fixed overnight in FACS wash buffer containing 1% PFA at 4°C.
Fixed cells were washed once with ice-cold FACS wash buffer before being 
transferred to mini FACS tubes (Falcon, BD Bioscience, Oxford, UK) fo r 
measurement o f cell-associated fluorescence w ith a FACSCaliber flow  
cytometer (Becton Dickinson UK Ltd., Oxford, UK). Unless otherwise 
specified, 10,000 events were counted fo r each condition. Events 
representing cells were selected using a gate based on the fo rw ard - and 
side-scatter characteristics o f the events.
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Details of specific assays
The effect o f p -a rres tin 2  and p -a rre s tin 2  m utants on CCR5 tra ffick in g
CHO CCR5 cells were transfected in 6-w ell plates according to the FuGENE 
transfection protocol detailed above. One day post-transfection, cells were 
detached w ith trypsin/EDTA and the contents o f 2 wells re-seeded into one 
9 cm dish and grown fo r 1 d to achieve cells at 80% confluency fo r the 
tra ffick ing assay. The tra ffick ing  assay was performed as described above, 
using a CAM Alexa 647 antibody to detect MC-5. 15,000 events were 
counted and transfected cells were identified based on the ir GFP 
fluorescence relative to a sample o f cells that had been treated w ith the 
FuGENE transfection reagent only. Subsequent analysis o f CCR5-associated 
cell surface fluorescence was performed on the subset o f transfected cells. 
An estimate o f transfection efficiency was also obtained by comparison o f 
the GFP fluorescence d is tribu tion  o f transfected cells w ith cells treated w ith 
the FuGENE reagent only.
The effect o f various drugs on CCR5 recycling
CHO CCR5 cells were prepared and treated w ith RANTES as above. A fter 60 
min RANTES treatm ent, cells in assay tubes were washed twice w ith ice-cold 
BM then re-suspended in ice-cold binding medium containing either 10 
^ig/ml BFA or 100 i^M dynasore monohydrate, or as a control, a 1:1000 
d ilu tion o f e ither ethanol or DMSO, the solvents fo r BFA and dynasore 
monohydrate, respectively. Cells were then transferred to the 37°C w ater- 
bath and 100 i^l aliquots removed at various tim e-po in ts  up to 60 min. Cells 
treated w ith BFA were labelled with 488MC-5; those treated w ith dynasore 
were labelled w ith MC-5 and GAM Alexa 647, as it was found that the 
dynasore molecule has an intrinsic fluorescence when stimulated w ith  the 
488 nm laser.
88
...ha p i e M a t e r : a is an a  M e tn o a s
FACS data analysis
Graphical representation o f FACS data
Cell surface fluorescence corrected fo r non-specific antibody binding was 
normalised to the cell surface fluorescence fo r untreated cells, expressed as 
a percentage, and plotted against time.
Calculation o f CCR5 tra ffick ing  rates
Initial rates o f internalisation (rint) and recycling (rrec) were calculated on the 
background-corrected, normalised cell surface fluorescence values, as 
follows:
/ a /  • - 1 \  1 0 0 ~ f l l O m mrinl (% min =----------------------------
r„, (% m in '1) =
10
f 1 70 m in — ^ 6 0  m in
10
, where f lt = cell surface fluorescence at the indicated tim e -po in t (t).
A rate constant fo r recycling (krec) was calculated by fitting  the recycling 
curve (60 min -*  180 min) to a firs t-o rd e r rate equation, where the rate o f 
recycling is proportional to a single, firs t-o rd e r rate constant and the 
difference between the maximum cell surface fluorescence reached after 
recycling and the cell surface fluorescence at any tim e -po in t. Algebraically,
dfl  = krec.($\max — fl)
dt
, where fl = cell surface fluorescence, f lmax is the asymptotic value towards 
which cell-surface fluorescence tends ove rtim e , and t = time.
Rearranging and integrating yields the equation:
-In  |flmax -  fl | = krecx + constant
Where, t= 0 , fl = f l0,
.-.constant = -In  flmax -  fl0
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Which yie lds the equation describ ing the recycling curve:
fl = fimax fl0
This linearises to give:
flmax - ^ -krec. t + In f lm a x  f  10
This is o f the form  y = m x + c, and thus, the slope o f the straight line from  
a plot o f In ((flmax - f l ) / f lmax) against t gives the rate constant krec.
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The tra ffick ing  itinerary o f CCR5 has been best described in Chinese 
hamster ovary cells (CHOs), where it has been demonstrated that agon is t- 
activated receptors undergo clathrin-m ediated endocytosis and tra ffic  to 
perinuclear recycling endosomes, whence they can recycle back to the cell 
surface (Signoret, Pelchen-Matthews et al. 2000; Signoret, Hewlett et al.
2005). Here, principally through morphological techniques, I expand this 
description o f the intracellular tra ffick ing  o f CCR5 in CHO cells and present 
a model where CCR5 traffics through a recycling compartment comprising 
both recycling endosome and trans-Qo\g\ network (TGN) elements. Finally, I 
extend the analysis o f CCR5 intracellular tra ffick ing to a human cell line, 
which may be more amenable to RNAi studies in the future.
CHO CCR5 cells as a system for studying CCR5 trafficking
Since the in itia l functional expression in 1995 o f the newly-cloned human 
CCR5 gene in CHO-K1 cells by the group o f Marc Parmentier (Samson, 
Labbe et al. 1996), CHO cells have been a popular system fo r studying CCR5 
function. The CHO cells stably expressing human CCR5 (CHO CCR5 cells)
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used fo r experiments described in this thesis have been extensively 
employed in studying CCR5 function and in generating our current picture 
o f agonist-activated CCR5 tra ffick ing  (Mack, Luckow et al. 1998; Signoret, 
Pelchen-Matthews et al. 2000; Signoret, Christophe et al. 2004; Signoret, 
Hewlett et al. 2005).
Although chemokine receptors are not naturally expressed in CHO cells, the 
system has several practical advantages over cells that endogenously 
express the receptor, e.g. primary cells or leukocyte cell—lines. Apart from  
being easy to culture, CHO cells maintain high levels o f chemokine receptor 
expression, an advantage w ith  respect to detection o f CCR5 in commonly 
used tra ffick ing  assays in comparison w ith primary cells and leukocyte cell— 
lines, where endogenous receptor levels are far lower. Moreover, CCR5 has 
been shown to undergo internalisation and recycling in CHO CCR5 cells w ith 
sim ilar kinetics to those exhibited in lymphoctyes/monocytes, where the 
receptor is endogenously expressed (Mack, Luckow et al. 1998), suggesting 
that, at least on a basic level, physiological CCR5 tra ffick ing is fa ith fu lly  
recapitulated in the CHO cell system. Finally, removing CCR5 from  its 
physiological background, reduces the complicating effects o f interactions 
w ith other chemotactic receptors, such as that demonstrated w ith the C5a 
receptor (C5aR), where the activation o f one receptor has been shown to 
influence the tra ffick ing  o f the other through cross-phosphorylation and /o r 
hetero-o ligom erisation (Huttenrauch, Pollok-Kopp et al. 2005). A lthough 
physiologically relevant interactions and cross-regulation by other 
chemoattractant receptors that may be engaged simultaneously by m ultip le 
mediators present at inflam m atory sites w ill u ltim ately have to be 
considered when developing a fu lly  integrated model fo r CCR5 tra ffick ing , 
simple systems are necessary in itia lly  to understand the fundamental 
properties o f the receptor.
One distinct disadvantage o f the CHO cell system is that the hamster 
genome has not yet been sequenced, making RNAi knock-downs, which are 
routine in cell-lines from  species w ith sequenced genomes (e.g. human ce ll— 
lines) d ifficu lt to perform, and also meaning that reagents generated against 
proteins from  other species w ith known sequences, such as antibodies, 
must be rigorously tested to ensure specificity.
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r^The CHO cells used in this thesis express an average o f 100-200,000 copies 
o f CCR5 per cell, w ith the m ajority present on the cell surface in 
unstimulated cells, although a very small intracellular pool can be observed 
in the perinuclear region by immunofluorescence in some cells. This 
intracellular pool can be cleared by treatm ent w ith cyclohexim ide (CHX), an 
inh ib itor o f protein translation, and probably represents newly synthesised 
CCR5 passing through the biosynthetic route towards the cell surface (data 
not shown). Thus, fo r some o f the experiments described below, cells were 
incubated w ith CHX before and during an immunofluorescence-based 
tra ffick ing assay to ensure that only receptors in itia lly  localised to the cell 
surface were followed.
Another method routinely used fo r the same purpose was to pre-label cell 
surface receptors by incubating cells in binding medium containing MC-5, 
an antibody that recognises the extreme N-term inus o f CCR5 (Blanpain, 
Vanderwinden et al. 2002), fo r 40 min at room temperature. These 
conditions were found to result in negligible internalisation o f an tibody- 
bound receptors, but resulted in suffic ient binding o f antibody to be easily 
detected (data not shown). MC-5 does not interfere w ith agonist (RANTES, 
M IP -la  and M IP -lp ) binding, or internalisation and recycling o f CCR5 
(Blanpain, Vanderwinden et al. 2002). MC-5 binds specifically to CCR5 w ith 
very little  non-specific  binding to other cellular epitopes (see Chapter 2) 
and, im portantly, has a high a ffin ity  fo r the receptor (Kd ~ 1 nM, see Chapter 
2), so remains bound to CCR5 as it traffics w ith in the cell, as evidenced by 
immunofluorescence o f cell surface receptors before and after 
internalisation and recycling (data not shown).
All tra ffick ing assays described in th is thesis were performed using cells 
incubated in an RPMI-based binding medium. For consistency, the CCR5 
agonist, RANTES (regulated on activation normal T cell secreted; also known 
as CCL5) was used fo r most o f the tra ffick ing assays, at a concentration o f 
125 nM. This is a saturating concentration o f RANTES, used to achieve as 
near a synchronous wave o f CCR5 internalisation as possible (Signoret, 
Hewlett et al. 2005). In all experiments, the binding medium was adjusted to 
pH 7, since RANTES has been shown to form  h igh-o rder oligomers above 
this pH, which may influence binding to CCR5 (Duma, Haussinger et al.
2006). Incubation in BM or pre-labelling CCR5 w ith MC-5 did not induce
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down-m odulation o f the receptor itself, as shown in Figure 3-1 A. Here, CHO 
CCR5 cells were pre-labelled fo r surface CCR5 with 488MC-5, which, like 
unconjugated MC-5, has a high a ffin ity  fo r the receptor (Kd ~ 4.7 nM, see 
Chapter 2) and incubated in BM at 37°C fo r the indicated tim e-periods 
before being fixed. A fter 60 min or 120 min o f incubation in BM, CCR5 
remained principally localised to the cell surface. A small amount o f
receptor probably underwent constitutive endocytosis by b u lk -flow  during 
the incubation, but this was presumably recycled efficiently, since no
intracellular pool o f CCR5 accumulated during the incubation.
Internalised, agonist-activated CCR5 passes through early 
endosomes
Agonist-activated CCR5 has been shown to colocalise w ith the early 
endosome marker, EEA1, shortly after agonist addition, suggesting that 
internalised receptors are in itia lly  targeted to early endosomes (Signoret, 
Hewlett et al. 2005). I in itia lly  sought to confirm  this observation in
RANTES-treated CHO CCR5 cells. Figure 3-1 B shows CHO CCR5 cells that
were pre-labelled fo r cell surface CCR5 w ith MC-5 and treated w ith RANTES 
fo r e ither 5 min or 60 min before being fixed and co-stained fo r EEA1. In 
unstimulated cells, EEA1 was present on punctate structures th roughout the 
cytoplasm, a pattern expected fo r early endosome staining. A fter 5 min 
RANTES treatm ent, CCR5 was found distributed d iffusely on the cell surface 
as well as in punctate structures at or ju s t under the cell surface. Some o f 
these puncta at the cell surface presumably represent activated receptors 
that had clustered in clathrin-coated pits (CCPs) or fla t clathrin lattices 
previously observed in CHO cells by ‘ r ip -o f f ’ electron microscopy (Signoret, 
Hewlett et al. 2005). The CCR5-positive puncta ju s t under the plasma 
membrane may represent clathrin-coated vesicles (CCVs). CCR5 was also 
observed in punctate structures that colocalised with EEA1 in the periphery 
o f the cell, suggesting that CCR5 is targeted to early endosomes soon after 
internalisation.
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Figure 3-I Agonist-activated CCR5 traffics through early endosomes
A. CHO  CCR5 cells w ere  p re -labe lled  fo r cell surface CCR5 w ith  488M C-5 and th en  
incubated  fo r the ind icated  tim e -p e rio d s  in b ind ing  m ed iu m  (BM) at 3 7 °C  b e fo re  
being fix e d . B. C HO  CCR5 cells w ere  p re -labe lled  fo r cell surface CCR5 w ith  M C -5  
and th en  incubated  fo r th e  ind icated  tim e -p e rio d s  in BM co nta in in g  RANTES at 3 7 °C . 
Cells w ere  then  fixed  and incubated  in p erm eab ilis ing  b locking  b u ffe r w ith  an ti- 
EEA1. CCR5 and EEA1 w ere  d e tec ted  w ith  A lexa  4 8 8  GAM  lg G 2a  and A lexa  5 9 4  G AM  
Ig G l , respective ly . Single confocal sections are show n. Bars, 5 pm
t y  .> ,ot% % -•
i ) •■rv
*1 %
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It has been previously shown that after 60 min o f continuous RANTES 
stim ulation, CCR5 establishes a new steady-state d is tribu tion , determ ined 
by the rates o f internalisation and recycling (receptors that recycle to  the 
plasma membrane re-internalise due to the presence o f agonist in the 
medium) (Mack, Luckow et al. 1998). A fter 60 min RANTES treatm ent, CCR5 
had accumulated in perinuclear structures that were largely negative fo r 
EEA1 staining, suggesting that CCR5 moves through early endosomes and 
traffics to a d istinct perinuclear compartment. However, a small amount o f 
EEA1 staining did colocalise w ith CCR5 in the perinuclear region, so some o f 
this perinuclear CCR5 may retain an early endosomal character. A small 
amount o f punctate CCR5 staining was still visible in the rest o f the 
cytoplasm after 60 min, much o f this staining colocalising w ith EEA1, 
suggesting that at steady-state, at least some o f the internal receptor 
population is found in more peripherally-located early endosomes. A small 
amount o f CCR5 was also observed on the cell surface.
In the constant presence o f agonist, CCR5 accumulates in a 
perinuclear, TfR-positive compartment
Under constant agonist treatment, CCR5 was found, by electron microscopy 
observations o f immunolabelled cryosections, to accumulate in a tu b u lo - 
vesicular, perinuclear compartment that was positive fo r steady-state 
transferrin receptor (TfR) (Signoret, Pelchen-Matthews et al. 2000). 
Moreover, CCR5 was previously found to show a good overlap w ith steady- 
state TfR staining in RANTES-treated CHO cells by immunofluorescence 
(Mack, Luckow et al. 1998). In CHO cells, it has been shown that the vast 
majority TfR population is located in recycling endosomes, making steady- 
state TfR staining a good marker o f recycling endosomes (Yamashiro, Tycko 
et al. 1984). Therefore, these observations suggested that CCR5 
accumulated in recycling endosomes under conditions o f constant agonist 
stim ulation.
Figure 3-11 shows the results o f an immunofluorescence experim ent 
designed to verify these observations, where CHO CCR5 cells were pre­
labelled fo r cell surface CCR5 w ith MC-5. In untreated cells, the TfR 
population was often clustered in the perinuclear region but there was
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significant punctate staining observed throughout the rest o f the cytoplasm. 
CCR5 was present over the whole o f the cell surface, including tubu la r 
membrane protrusions, presumably m icrovilli, which can be seen in the 
maximum intensity projection image o f unstimulated cells. CCR5 labelling 
on m icrovilli has also been observed in w ho le-m ount electron microscopy 
studies o f CHO CCR5 cells (Signoret, Hewlett et al. 2005) and CCR5 has 
been shown to preferentially localise to m icrovilli in human macrophages 
and T cells, and also when expressed in HeLa cells (Singer, Scott et al. 
2001).
In cells treated w ith RANTES fo r 60 min, CCR5 accumulated in a perinuclear 
compartment that almost completely colocalised w ith steady-state TfR, 
suggesting that receptors had accumulated in recycling endosomes. It is 
noteworthy that the TfR d is tribu tion  appeared to be more focussed around 
the nucleus after 60 min RANTES treatment. A plausible explanation fo r this 
^  is that a large amount o f flux through the recycling endosome modifies its 
gross m orphology. A lternatively, signalling from  activated CCR5 molecules 
may lead to a m odification o f the compartment.
To confirm  the ab ility  o f CCR5 to recycle in CHO CCR5 cells, some cells were 
treated w ith RANTES fo r 60 min to induce dow n-m odulation o f the receptor 
and then subsequently incubated in BM containing the CCR5 antagonist, 
TAK-779. TAK-779 has been reported to inh ib it the binding o f RANTES to 
CHO CCR5 cells w ith an IC50 o f 1.4 nM and to inh ib it chem okine-induced 
Ca2+ m obilisation (Baba, Nishimura et al. 1999). Moreover, we have 
demonstrated that TAK-779 is capable o f e ffic iently displacing RANTES 
bound to CCR5 (N. Signoret, unpublished data). It has previously been 
demonstrated that CCR5 molecules are capable o f recycling back to the cell 
surface in an agonist-bound state (Signoret, Pelchen-Matthews et al. 2000); 
in this case, the receptors can engage the endocytic machinery and re - 
internalise. The addition o f TAK-779 in the medium during recycling 
prevents re-internalisation o f receptors that have recycled back to the cell 
surface by displacing agonists bound to the receptors.
In cells that had been treated w ith RANTES fo r 60 min, almost all o f the 
CCR5 returned to the cell surface after 60 min incubation in the presence o f 
TAK-779. This is in contrast to cells that had been treated with RANTES fo r 
a total o f 120 min, where the CCR5 d is tribu tion  was very sim ilar to cells that
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had been treated with RANTES fo r 60 min. Thus, apparently, the receptor 
w ill continue to cycle over the cell surface in the constant presence o f 
RANTES fo r at least 120 min w ithout significant alteration o f internalisation 
or recycling rates, or diversion to a different pathway.
confocal section
m ax. projection CCR5 TfR  m erge
Figure 3-11 In the constant presence of agonist, CCR5 accumulates in a 
perinuclear, TfR-positive compartment
C HO  CCR5 cells w ere  p re -labe lled  fo r cell surface CCR5 w ith  MC-5 and th en  
incubated  fo r the  ind icated  tim e -p e rio d s  in BM conta in ing  RANTES a t 3 7 °C , o r 
incubated  w ith  BM co n ta in ing  RANTES fo r 6 0  m in fo llo w ed  by b ind ing  m e d iu m  
conta in ing  T A K -7 7 9  fo r 6 0  m in a t 3 7 °C . Cells w ere th en  fixed  and in cu b a ted  in 
perm eab ilis ing  b locking  b u ffe r w ith  an ti-T fR  (H 6 8 .4 ) . CCR5 and TfR  w ere  d e te c te d  
w ith  A lexa  4 8 8  GAM lgG 2a and A lexa  5 9 4  GAM Ig G l,  respective ly . M a x im u m  
in tens ity  p ro jections  o f stacks o f confocal sections are  show n in the  le ft p ane l. A
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sing le confocal section  a t a p p ro x im a te ly  the  sam e h o rizo n ta l p lan e  th ro u g h  th e  
cells in each co n d itio n  is a lso  show n . Bars, 5 |im
Interestingly, after CCR5 had recycled to the plasma membrane, the TfR 
d istribu tion  appeared to revert back to a d istribu tion  sim ilar to that in 
unstimulated cells, where it was less concentrated around the nucleus.
There is no agonist-induced degradation o f CCR5
Agonist binding targets many CPCRs fo r lysosomal degradation (Marchese, 
Paing et al. 2007). The results presented in Figure 3-11 suggest tha t the 
majority o f internalised, agonist-activated CCR5 recycles back to the cell 
surface. However, they do not exclude the possibility that a small amount o f 
CCR5 is targeted fo r degradation by RANTES treatment. Several studies have 
addressed whether CCR5 undergoes agonist-stim ulated degradation by 
fo llow ing total receptor levels in the presence o f CHX, where new protein 
synthesis is blocked. Signoret et al. determined that CCR5 had a h a lf-life  o f 
6 -9  h in CHO CCR5 cells and that treatm ent o f cells w ith RANTES did not 
significantly affect the turnover o f CCR5 after 6 h (Signoret, Pelchen- 
Matthews et al. 2000). Similarly, Delhaye et al. found that there was no 
agonist-induced degradation o f CCR5 in HEK293 cells, but the turnover o f 
CCR5 was far slower in this ce ll-line , w ith negligible loss o f the receptor 
during 4 h incubation w ith CHX (Delhaye, Gravot et al. 2007).
To determine if there was any agonist-induced degradation o f CCR5 in CHO 
CCR5 cells under the conditions used in my experiments, I incubated equal 
numbers o f CHO CCR5 cells in BM containing CHX at 37°C fo r various tim e 
periods in the presence or absence o f RANTES. Cell lysates were prepared 
and the proteins separated on a gel, transferred to nitrocellulose and 
probed fo r CCR5 (Figure 3-111). CCR5 migrated as a broad band, a 
characteristic feature o f a glycosylated protein, w ith an apparent molecular 
mass o f 30-35 kDa. The predicted molecular mass o f the unprocessed 
protein is 40.6 kDa; the discrepancy in molecular mass is probably due to 
^  post-translational modifications, including tyrosine sulphation (Farzan, 
Chung et al. 2002) and O -linked glycosylation (Bannert, Craig et al. 2001; 
Farzan, Chung et al. 2002). The band shown on the blot represents CCR5
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protein, since this band is absent from CHO-K1 cell lysates -  where there is 
no CCR5 expressed - probed with MC-5 (data not shown). It was also noted 
that in the presence o f RANTES, there was a decrease in the electrophoretic 
m obility o f CCR5, which is most likely due to C-ta il phosphorylation 
(Oppermann, Mack et al. 1999).
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Equal num bers o f C HO  CCR5 cells w ere  incubated  in BM co n ta in in g  CHX w ith  or 
w ith o u t RANTES at 3 7 °C  fo r the ind icated  tim e-p erio d s , a fte r  w hich cell lysates w ere  
p rep ared . Proteins fro m  equal vo lum es o f lysates w ere  separated  on a ge l, 
transferred  to  n itroce llu lose  and probed  fo r CCR5 w ith  M C -5 p rim ary  an tib o d y . M C -5  
was detec ted  w ith  IR D ye®  8 0 0  GAM and v isualised  using the  Odyssey in fra -red  
detec tion  system . Band in tens ities  w ere  q u a n tifie d  and th e  a m o u n t o f  CCR 5, 
expressed  as a percen tage  o f  th e  in itia l a m o u n t, p lo tted  ag a in s t tim e . In d iv idua l d a ta  
points rep resen t th e  m ean o f 6  in d e p e n d e n t sam ples fro m  2 in d e p e n d e n t 
exp e rim e n ts . Error bars rep resen t 1 standard  d ev ia tion  o f the m eans. A lso show n is 
a rep resen ta tive  b lo t, cropped fo r th e  bands rep resen ting  CCR5.
As can be seen in Figure 3—III, there was no significant difference in the 
turnover o f CCR5 in the presence o f RANTES compared with untreated cells. 
In contrast to the estimated ha lf-life  calculated fo r CCR5 in CHO CCR5 cells 
by Signoret et al. (2000), here, CCR5 had a slightly longer estimated h a lf- 
life o f 10-12 h.
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Degradation o f CCR5 -  agonist-stim ulated or constitu tive -  would be 
expected to occur in lysosomes (Marchese, Paing et al. 2007). Signoret et al. 
(2000) assessed whether any agonist-activated CCR5 was routed to  the 
lysosome by observing CHO CCR5 cells that had been treated w ith RANTES 
fo r 4 h and stained fo r CCR5 and the lysosomal markers, LBPA 
(lysobisphosphatidic acid) and Igp-b  (lysosomal glycoprotein b, also known 
as LAMP-2). CCR5 did not colocalise w ith either lysosomal marker and, 
hence, it was suggested that there was no agonist-induced CCR5 
degradation. However, in this experiment, cells were not treated w ith 
lysosomal protease inhib itors, so it is possible CCR5 could have been 
delivered to the lysosome but that the antibody epitope was rapidly 
degraded.
To address the possibility tha t agonist-activated CCR5 is targeted to 
lysosomes, I fed the lysosomal protease inh ib itors, leupeptin, pepstatin and 
E64, to CHO CCR5 cells fo r 16 h to allow uptake o f the protease inh ib itors 
by flu id -phase endocytosis and delivery to the lysosome, before perform ing 
a tra ffick ing assay. I firs tly  demonstrated tha t the CCR5 epitope recognised 
by the anti-CCR5 antibody, MC-5, was detectable in lysosomes under these 
conditions by fix ing  cells after this 16 h incubation and staining fo r CCR5 
and the lysosomal marker, Igp -b  in permeabilising conditions (Figure 3—IV 
A). In cells that were not treated w ith lysosomal protease inhib itors, CCR5 
was predominantly present on the cell surface, whereas Igp-b  staining was 
mainly punctate and cytoplasmic, although some larger ring structures were 
observed in confocal sections. In cells that had been incubated w ith the 
lysosomal protease inh ib itors, Igp -b  predom inantly stained larger 
structures, suggesting that in the absence o f protein degradation, 
lysosomes had increased in size. Moreover, CCR5 was found to colocalise 
w ith Igp-b, demonstrating that under these conditions, CCR5 that 
accumulates in lysosomes is detectable by immunofluorescence. The CCR5 
that accumulated over the period o f lysosomal protease inh ib ito r incubation 
represents the pool o f CCR5 that would have been constitutively degraded 
in that time period. There did not appear to be any significant decrease in 
CCR5 surface fluorescence intensity relative to cells that were not treated 
with lysosomal protease inh ib itors, suggesting that CCR5 synthesis 
proceeded normally in the absence o f degradation.
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A. C H O  CCR5 cells w ere  e ith e r  in cu b a ted  in n orm al g ro w th  m e d iu m  o r g ro w th  
m ed iu m  co n ta in in g  lysosom al p ro tease  in h ib ito rs  (le u p e p tin , p e p s ta tin  and  E 64) fo r  
16 h b e fo re  being  fix e d . Cells w ere  th en  p e rm e a b ilis e d  in b lo ck in g  b u ffe r  and  
in cubated  w ith  M C-5 and 3E9 p rim a ry  a n tib o d ie s  ag a in s t CCR5 and  Ig p -b , 
respective ly . P rim ary  an tib o d ies  w ere  d e te c te d  w ith  A le x a  4 8 8  C A M  lg G 2a  and  A le x a  
5 9 4  C A M  I g C l , respective ly . S ingle co nfoca l sections are show n. Bar, 5 jim . B. C H O  
CCR5 cells w ere  in cu b ated  in g ro w th  m e d iu m  co n ta in in g  lysosom al p ro te a s e  
in h ib ito rs  (le u p e p tin , p epsta tin  and  E64) fo r 16  h. Cells w ere  then  lab e lled  fo r  cell 
surface CCR5 w ith  M C -5 . Som e cells w ere  th en  fix e d  (u n s tim u la te d ), w h ile  o th ers  
w ere  tre a te d  w ith  RANTES in BM fo r  6 0  m in (6 0  m in  RANTES) or tre a te d  w ith  RANTES  
fo r 6 0  m in fo llo w ed  by a 6 0  m in in cu b a tio n  in BM co n ta in in g  T A K -7 7 9  (6 0  m in  
RANTES + 6 0  m in  T A K -7 7 9 ), b e fo re  being  f ix e d . Lysosom al p ro tease  in h ib ito rs  w e re  
inc luded  in all th e  incubations  d e s c rib e d . Cells w ere  th en  p e rm e a b ilis e d  in b lo ck in g  
b u ffe r and in cu b ated  w ith  3E9 p rim a ry  a n tib o d y  ag a in s t Igp -b . P rim ary a n tib o d ie s  
w ere  d e te c te d  w ith  A le x a  4 8 8  C A M  lg C 2 a  (C CR 5) and A lexa  5 9 4  GAM Ig C l (3E 9). 
Single confocal sections are  show n . Bar, 5 urn. C. A series o f confocal sections fro m  
th e  6 0  m in R A N TE S-treated  cells show n in B. T h e  step s ize  be tw een  sections is 0 .5  
^im. A lso show n a t the  to p  o f the  m o n ta g e  is a m a x im u m  in ten s ity  p ro jec tio n  o f the  
confocal sections . Bars, 5 |xm.
To determine whether any CCR5 was directed to lysosomes in an agon ist- 
dependent fashion, cells were pre-incubated w ith lysosomal protease 
inhibitors, labelled fo r cell surface CCR5, and tra ffick ing  o f the receptor 
followed by immunofluorescence w ith co-sta in ing fo r Igp-b  (Figure 3-IV  B). 
In cells treated with RANTES fo r 60 min, CCR5 predominantly accumulated 
in punctate structures in the perinuclear region, often in close proxim ity, 
but not overlapping w ith Igp -b  positive structures (Figure 3-IV  C shows a 
stack o f confocal sections through the group o f 60 min RANTES-treated 
cells in B, which illustrate this point). Cells treated w ith RANTES fo r 60 min 
followed by a 60 min incubation w ith TAK-779 showed mainly cell surface 
CCR5 staining, demonstrating that down-m odulated receptors had recycled 
back to the cell surface. These cells also showed no colocalisation o f CCR5 
w ith Igp-b.
A ltogether, these results demonstrate that there is no agon ist-induced 
degradation o f CCR5 in CHO CCR5 cells. Moreover, they show that pre­
labelling cell surface CCR5 w ith MC-5 does not result in lysosomal targeting
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o f CCR5, which could occur, fo r instance, if  the antibody were to cause 
cross-linking o f receptors.
R a b ll regulates CCR5 trafficking through the recycling 
endosome
The above data support the view that internalised, agonist-activated CCR5 
molecules tra ffic  to perinuclear recycling endosomes, from  where they 
recycle back to the cell surface. At present, there are few known markers fo r 
this perinucuclear compartment, although there is strong evidence that the 
small GTPase, R a b ll,  is predom inantly localised to recycling endosomes 
and regulates the tra ffic  o f several receptors through the compartment, 
including the TfR (Ullrich, Reinsch et al. 1996; Ren, Xu et al. 1998) and the 
chemokine receptor, CXCR2 (Fan, Lapierre et al. 2003; Fan, Lapierre et al. 
2004).
To determine whether R a b ll plays a role in regulating CCR5 tra ffick ing , I 
transiently transfected m yc-tagged R a b ll w ild -type  and mutant constructs 
into CHO CCR5 cells and observed CCR5 tra ffick ing by immunofluorescence 
(Figure 3-V). In unstimulated cells (Figure 3-V  A), w ild -type  R a b ll 
displayed a largely perinuclear d is tribu tion , w ith some more dispersed 
punctate, cytoplasmic staining, suggesting that most o f the R a b ll is 
membrane-bound. In some cells, w ild -type  R a b ll staining was seen in 
tigh t, perinuclear clusters, characteristic o f clustering around the 
m icrotubule-organising centre (MTOC). An active-site mutant o f R a b ll,  
Q70L, which is incapable o f hydrolysing bound GTP, so is constitu tive ly 
active, was also expressed: this mutant adopted a d istribu tion  that was very 
tigh tly  clustered in perinuclear accumulations, w ith far less punctate, 
cytoplasmic staining. In contrast, a R a b ll mutant that is locked in the GDP- 
bound form , S25N, showed a more disperse staining pattern, which was, 
nevertheless, punctate. These observations are sim ilar to those o f Ullrich et 
al. (1996), who expressed sim ilar R a b ll mutants in CHO and BHK (baby 
hamster kidney) cells. The authors made the fu rther observation that 
although the d istribu tion  o f the R a b ll mutants differed from  w ild -typ e  
R a b ll by immunofluorescence observation, the morphology o f the 
compartments labelled by the transiently-expressed R a b ll proteins was
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indistinguishable by EM, suggesting that both R a b ll mutants localise to 
recycling endosomes and alter the positioning rather than the m orphology 
o f compartment.
A fter 60 min RANTES treatm ent (Figure 3-V  B), CCR5 dow n-m odulated in 
cells expressing each o f the R a b ll constructs. In cells expressing w ild -typ e  
R a b ll, CCR5 accumulated in the perinuclear region and showed a partial 
colocalisation with R a b ll staining in this area, suggesting that at least some 
o f the CCR5 was present in R a b ll-p o s itiv e  recycling endosomes. In cells 
expressing R a b ll Q70L, this overlap was increased, w ith almost all the 
CCR5 colocalising w ith R a b ll Q70L in large perinuclear clusters. In contrast, 
in cells expressing R a b ll S25N, CCR5 largely failed to cluster around the 
nucleus and did not colocalise w ith  R a b ll S25N, which, like in unstimulated 
cells, had a punctate staining pattern that was present th roughout the 
cytoplasm.
The effect o f R a b ll over-expression and mutant R a b lls  on CCR5 recycling 
was assessed by treating cells in which CCR5 had been down-m odulated 
with RANTES, w ith TAK-779 fo r 60 min (Figure 3-V  C). Ordinarily, CCR5 
recycles back to the plasma membrane under these conditions (Figure 3-11) 
and in cells that were not expressing the exogenous R a b ll proteins on the 
same coverslips as transfected cells, CCR5 cell surface staining was 
recovered. In cells over-expressing w ild -type  R a b ll,  CCR5 also fu lly  
recycled to the cell surface. In cells expressing R a b ll S25N, most o f the 
CCR5 recycled back to the plasma membrane, although a small amount o f 
internal CCR5 was frequently observed, suggesting that the rate o f recycling 
was slightly slower in these cells. Strikingly, in cells expressing R a b ll Q70L, 
although some CCR5 returned to  the cell surface, a large amount was 
retained in perinuclear clusters that stained fo r R a b ll Q70L, demonstrating 
a significant inh ib itory effect o f constitu tive ly active R a b ll on CCR5 
recycling.
The increased overlap and concentration o f internalised CCR5 in the 
perinuclear region in the presence o f increased levels o f R abll:G TP and 
failure o f agonist-activated CCR5 to colocalise w ith R abll:G D P (or cluster in 
the perinuclear region in the presence o f high levels o f Rabll:GDP), suggest 
that the GTP-bound form  o f R a b ll is required fo r transport o f CCR5 to 
recycling endosomes. The dispersed CCR5 staining pattern in cells
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expressing R a b ll S25N treated fo r 60 min with RANTES, which does not 
overlap with R a b ll S25N, presumably represents CCR5 that has failed to 
tra ffic  to the recycling endosome and may be retained in early endosomes, 
as appears to be the case fo r the TfR in cells expressing R a b ll S25N 
(Ullrich, Reinsch et al. 1996). That there is a significant inhib itory effect o f 
R a b ll Q70L expression on CCR5 recycling suggests that hydrolysis o f 
R a b ll-b o u n d  CTP to GDP is required for trafficking o f CCR5 from  the 
recycling endosome to the cell surface, again consistent with the mechanism 
of R a b ll functioning in TfR tra ffick ing (Ren, Xu et al. 1998).
A
Rab11 CC R5 m erge
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Figure 3-V Rabl 1 regulates CCR5 trafficking
CHO CCR5 cells w ere  transfec ted  w ith  m yc-tagged  R abl 1 constructs w ith  FuCENE
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HD. Cells w ere p re -lab e lled  fo r  cell surface  CCR5 w ith  M C -5 and  th en  e ith e r  fix e d  
(A), trea ted  w ith  RANTES in BM fo r  6 0  m in and  th en  fix e d  (B), o r tre a te d  w ith  
RANTES in BM fo r 6 0  m in fo llo w e d  by an in cu b a tio n  in BM co n ta in in g  T A K -7 7 9  fo r  
6 0  m in, befo re  being  fix e d  (C). Cells w ere  th en  p erm eab ilised  in b lo ck in g  b u ffe r  
and incubated  w ith  9 E 10  a n ti-m yc  p rim a ry  a n tib o d y , fo llo w e d  by in c u b a tio n  w ith  
A lexa  4 8 8  GAM lgG 2a and A le x a  5 9 4  GAM Ig G l to  d e te c t M C -5 (C CR 5) and  m yc  
(R ab l 1), respective ly . S ingle confocal sections a re  show n. Bars, 5 |im .
Down-modulated CCR5 partially colocalises with 
endogenous R a b ll
Although the above results demonstrate that R a b ll affected the passage o f 
CCR5 through the recycling endosome, only a partial overlap o f CCR5 w ith 
over-expressed w ild -type  R a b ll was observed after 60 min RANTES 
treatment. It is possible that this overestimates the colocalisation o f CCR5 
with R a b ll after RANTES treatm ent as over-expression o f Rab proteins, 
which are regulators o f membrane tra ffick ing , may alter intracellular 
tra fficking on a gross level, w ith, fo r instance, effects on the steady-state 
size o f m embrane-bound organelles. Therefore, I stained cells fo r 
endogenous R a b ll and assessed colocalisation w ith RANTES-activated 
CCR5 by immunofluorescence (Figure B-VI). Here, I pre-treated cells w ith 
CHX to clear any internal CCR5 from  the biosynthetic pathway, stimulated 
with RANTES fo r 60 min (in the continued presence o f CHX) and then stained 
fo r CCR5 and R a b ll post-fixa tion . The commercially-available R a b ll 
antibody used was specific fo r R a b ll,  since no staining was observed on 
R a b ll knock-down cells (R. Prekeris, personal communication).
In unstimulated cells, R a b ll staining was punctate and largely confined to 
the perinuclear region, w ith some smaller puncta visible throughout the rest 
^ -o f the cytoplasm. CCR5 was restricted to the cell surface, w ith no internal 
staining seen, suggesting that any CCR5 present inside cells had been 
chased through the biosynthetic export route. Again, CCR5 was found to 
't-decorate cell membrane protrusions, highly likely to be m icrovilli. A fte r 60 
min RANTES treatment, CCR5 had accumulated in perinuclear structures, 
some of which colocalised w ith endogenous R a b ll,  whose d is tribu tion  was 
unchanged by RANTES treatm ent, although a lot o f the CCR5, despite being
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perinuclear, did not colocalise w ith R a b ll. Moreover, R a b ll puncta that 
were negative for CCR5 were also seen.
Rab11
R a b il
Figure 3-VI Agonist-activated, internalised CCR5 partially colocalises with 
endogenous Rabl 1
C H O  CCR5 cells w ere  trea ted  w ith  CHX to  c lear new ly synthesised  CCR5 fro m  th e  
biosyn thetic  pathw ay. Cells w ere  then  e ith e r fixed  (u n s tim u la te d ) or tre a te d  w ith  
RANTES in BM co n ta in ing  CHX fo r 6 0  m in  (6 0  m in RANTES) and then  fix e d , b e fo re  
being p erm eab ilised  in b locking  b u ffe r and incubated  w ith  M C -5 and a n t i - R a b l la  
prim ary  an tib o d ies  to  d e tec t CCR5 and R abl 1, respective ly . M C-5 and a n ti-R a b l l a  
w ere detec ted  w ith  A lexa  4 8 8  GAM  and A lexa  5 9 4  CAR, respective ly . A s ing le  
confocal section fo r each c o n d itio n  is show n in la rge , w ith  a m erged  ch ann e l 
m o n tag e  o f confocal sections th ro u g h  th e  sam e g roup  o f  cells (0 .5  pm  step  s ize )  
show n in sm all. Bar fo r large im ages , 5 pm .
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These data suggest that agonist-activated, internalised CCR5 tra ffics 
through a R a b ll-p o s itiv e  compartment. That a significant am ount o f the 
down-m odulated CCR5 that clustered perinuclearly did not colocalise w ith  
R a b ll and that R a b ll-p o s itive , CCR5-negative structures were observed, 
suggests that either a significant amount o f steady-state dow n-m odulated 
CCR5 resides in a non-recycling endosome compartment or that only a 
portion o f the recycling endosomes containing CCR5 are R a b ll-p o s itive .
TfR and R a b ll show only a limited overlap in different cell- 
lines
Recycling endosomes are often defined as R a b ll-p o s itive , perinuclear, 
tubulo-vesicular compartments. The transferrin receptor has also been used 
as a marker fo r the compartment and CCR5 is found prim arily in recycling 
endosomes in CHO cells (Yamashiro, Tycko et al. 1984). However, despite 
showing a very strong overlap w ith TfR in the perinuclear region, the CCR5 
that accumulates there under constant agonist treatm ent only showed a 
partial overlap w ith R a b ll.  I therefore investigated the possibility that 
R a b ll is only present on a subset o f perinuclear, TfR-positive structures. 
Figure 3—VII A shows a confocal immunofluorescence m icrograph o f a CHO 
CCR5 cell stained fo r both TfR and R a b ll.  The two proteins showed a 
typical punctate, perinuclear d isposition, but the R a b ll staining was less 
extensive than the TfR staining, w ith fewer peripheral puncta observable. 
There was some overlap between TfR and R a b ll staining in the perinuclear 
region; however, there were significant numbers o f solely TfR-positive and 
solely R a b ll-p o s itiv e  puncta.
I then investigated the d istribu tion  o f R a b ll and TfR in two other human 
cell—lines, HeLa cells (Figure 3—VII B) and human osteosarcoma (HOS) CD4 
CCR5 cells (Figure 3—VII C). In these two cell-lines, R a b ll and TfR were also 
concentrated in the perinuclear region, although there were s ign ificant 
amounts o f surface TfR staining in the HOS cells. As in the CHO cells, only a 
partial overlap o f TfR and R a b ll was observed in the perinuclear region. In 
the HeLa cells, a stronger overlap was observed near the tops o f the cells, 
although this may be a reflection o f cell shape, as the cytoplasmic volume
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becomes smaller towards the top, restricting the space between d iffe rent 
membrane-bound compartments.
A
Rab11 m erge
B
m erge
TfR
Rab11
c
o
'•*->o<D
OL_
CL
><ro
E
c
o
oQ></>
Q)
O)C
'55
Rab11 m erge
bottom  -----------------------------------------------------------------► top
112
bottom
</>
co
o<u(/)
0)U)CO-*-»
co
E
merge
TfR
Rab11 j H l '
TfR Rab11 merge
c 
o
‘<Ho
G>
O c  a
>< to
E 
c o
99 OmU)
0)
o> c
c/5
Figure 3-VII Perinuclear, steady-state TfR shows only a partial colocalisation 
with Rabl 1 in different cell types
CHO CCR5 (A), HeLa (B) or HOS (C) cells w ere  fixed , perm eab ilised  in b lo ck in g  
buffe r and incubated  w ith  H 6 8 .4  and a n ti-R a b l l a  p rim ary  an tib o d ies  to  d e te c t T fR  
and R abl 1, respectively . H 6 8 .4  and a n ti-R a b l l a  w ere d e tec ted  w ith  A lexa  4 8 8  C A M  
and A lexa  5 9 4  GAR, respective ly . A. A s ing le confocal section th ro u g h  a cell is 
show n. B. and C. Shown at th e  to p  is a m o n tag e  o f confocal sections th ro u g h  a 
group  o f cells; 0 .5  ^m  step s ize  betw een  sections. Below is show n an e n la rg e d  
m ax im u m  in ten s ity  p ro jec tio n  o f the stack o f confocal sections and an e n la rg e m e n t  
o f section 2. Scale bars fo r en la rg ed  im ages, 5 urn.
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Altogether, these data suggest that only part o f the perinuclear, TfR- 
containing endosomal pool is positive fo r R a b ll.
Some down-modulated CCR5 accumulates in A P -l-po s itive  
structures
The heterotetrameric clathrin adaptor protein complex, adaptor protein 
complex 1 (AP-1) has been shown to mediate tra ffic  between endosomes 
and the TCN. A lthough in itia lly  assumed to function at the TCN (Heilker, 
Spiess et al. 1999), AP-1 has also been found on TfR-containing tubu la r 
endosomes in Madin-Darby kidney (MDCK) cells, where it is involved in 
basolateral sorting o f the TfR (Futter, Gibson et al. 1998), and it has been 
implicated in retrograde endosome to TGN transport (Meyer, Eskelinen et al. 
2001; Valdivia, Baggott et al. 2002). To fu rther characterise the intracellular 
tra ffick ing route taken by agonist-activated CCR5 and to see if AP-1 would 
be correctly localised to play a role in CCR5 intracellular tra ffick ing (see 
Chapter 5), I co-stained cells tha t had been treated w ith RANTES fo r TfR and 
y-adaptin, a component o f AP-1 (Figure 3—VI11). Here, I pre-treated cells w ith 
CHX to clear any internal CCR5 from  the biosynthetic pathway. In 
^unstim u la ted  cells, CCR5 was only present on the cell surface and y-adaptin 
had a predom inantly punctate, perinuclear staining pattern, w ith some more 
peripheral, punctate staining. As seen before, TfR also showed some 
accumulation in the perinuclear region, but was also present on other 
punctate structures in the cytoplasm. The m ajority o f the staining fo r the 
two proteins was separate but some colocalisation was observed in both the 
perinuclear region and throughout the cytoplasm.
That the staining patterns fo r TfR and y-adaptin were largely d istinct, 
suggests that in CHO cells, the m ajority o f the AP-1 staining is on the TCN 
rather than on endosomes, where an overlap w ith TfR would be expected. 
Peripheral structures where the two proteins colocalise are likely to  be early 
endosomes and perinuclear colocalisation may represent AP-1 on recycling 
endosomes.
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y-adaptin CCR5 TfR m erge
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Figure 3-VIII In the constant presence of agonist, some CCR5 accumulates in a 
perinuclear compartment positive for AP I but negative for steady-state TfR
CHO CCR5 cells w ere trea ted  w ith  CHX to  c lear new ly synthesised CCR5 fro m  the  
biosyn thetic  pathw ay. Cells w ere  th en  e ith e r fixed  (u n s tim u la ted ) or tre a te d  w ith  
RANTES in BM co nta in in g  CHX fo r 6 0  m in (6 0  m in RANTES), before  b e ing  f ix e d . 
Cells w ere then  perm eab ilised  in b locking  b u ffe r and incubated  w ith  M C -5 , H 6 8 .4  or 
M ary p rim ary  an tibod ies  to  d e te c t C CR 5, T fR  or y-adaptin , respective ly . M C -5 , H 6 8 .4  
and M ary w ere  d e tected  w ith  A lexa  4 8 8  GAM lgG 2a, A lexa  6 4 7  C A M  Ig C l and A le x a  
594  GAR, respectively. S ingle confocal sections are show n, w ith  tw o sections, 0 .5  
pm a p art, show n fo r the  R ANTES-treated co n d itio n . D ual channel, g reen -red  m erges  
betw een CCR5 and TfR  or y -adaptin  fo r R A N TE S -treated  cells are also  show n. T h e  
area o f in te res t re fe rred  to  the  m ain  te x t is ind icated  by a w h ite  box Bar, 5 pm .
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In cells treated with RANTES for 60 min, CCR5 accumulated in the 
perinuclear region as well as in peripheral structures throughout the 
cytoplasm. Some triple colocalisation between CCR5, y-adaptin and TfR was 
observed in both peripheral and perinuclear structures, suggesting the 
presence o f AP-1 on CCR5-containing early and recycling endosomes, 
respectively. However, distinct populations o f CCR5-positive, y -adap tin -  
positive but TfR-negative, and CCR5-positive, TfR-positive but y -adap tin -  
negative structures were observed. This is best observed in the dual colour 
merges, where it can be seen that CCR5 and y-adaptin displayed a very 
strong overlap in parts o f the perinuclear region, but that some of the y- 
adaptin-positive, CCR5-positive structures were negative for TfR, 
suggesting that these structures were not endosomal (see indicated region 
o f interest). However, CCR5 colocalised almost completely with TfR in the 
more peripheral structures and some perinuclear structures, which were, 
therefore, presumably endosomal in nature.
This result is in contrast to Figure 3-11, where practically all o f the internal 
CCR5 was found to colocalise with TfR. The difference has recently been 
found to be due to the way in which the experiments were performed. In 
Figure 3-11, cell surface CCR5 was pre-labelled with the anti-CCR5 antibody, 
MC-5, before inducing down-modulation; in Figure 3-VIII, cells were 
labelled for CCR5 after fixation. Although CCR5 internalises and recycles 
similarly whether labelled before agonist stimulation or post-fixation (data 
not shown), and MC-5 pre-labelling does not target the receptor fo r 
lysosomal degradation (Figure 3-IV), it does appear to subtly alter the 
steady-state distribution o f the receptor in the presence o f agonist. In cells 
pre-labelled with MC-5, treated with RANTES for 60 min, and stained fo r 
both TfR and y-adaptin, CCR5 showed a very strong colocalisation with TfR 
in the perinuclear region and very weak colocalisation with perinuclear y- 
adaptin (data not shown). When CCR5 was labelled post-fixation, a pool o f 
perinuclear CCR5 that did not colocalise strongly with TfR, but overlapped 
well with y-adaptin was revealed.
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CCR5 traffics through the trans-Golgi network
The accumulation o f CCR5 in TfR-negative, y-adaptin-positive perinuclear 
structures suggested that CCR5 may traffic through the TGN. To test this 
hypothesis, I performed a trafficking assay by immunofluorescence, staining 
for both y-adaptin and p230 (Figure 3-IX). p230 is a protein that cycles 
between the cytosol and the TGN and is involved in the formation o f distinct 
populations o f non-c la thrin  coated vesicles at the TGN (Erlich, Gleeson et al. 
1996; Kjer-Nielsen, Teasdale et al. 1999; Kjer-Nielsen, van Vliet et al.
1999). The antibody showed a nearly complete overlap with the classical 
TGN marker, TGN46, in HeLa cells (data not shown). TGN46 could not be 
used as a marker o f the TGN in CHO cells as the antibody against this 
protein does not recognise the equivalent protein in hamster cells.
Again, cells were pre-treated with CHX to clear CCR5 from the biosynthetic 
pathway and CCR5 was found only on the cell surface in unstimulated cells. 
p230 was found exclusively in the perinuclear region, y-adaptin showed a 
very strong overlap with p230 in the perinuclear region, but, as before, y- 
adaptin was also observed on more peripheral punctate structures.
After 60 min RANTES-treatment, CCR5 largely accumulated in a perinuclear 
compartment, although some more peripheral CCR5 staining was also 
observed as previously described. Much of this perinuclear CCR5 showed a 
strong overlap with p230 and most of the CCR5-positive, p230-positive 
structures also colocalised with y-adaptin, as would be expected. In 
addition, there were some perinuclear puncta that were only positive for 
CCR5 and some that were positive for CCR5 and y-adaptin, but not p230, 
presumably representing CCR5 in recycling endosomes. Interestingly, most 
of the p230-associated fluorescence was co-incident with CCR5 staining, 
suggesting that steady-state, agonist-activated CCR5 fills most of the TGN 
elements in the CHO cells.
117
Chapter 3: Morphological Outline of CCR5 Trafficking
DMSO nocodazole DMSO nocodazole
Y-adaptin CCR5 p230 merge
CCR5 + y-adaptin CCR5 + p230
Figure 3-IX Agonist-activated CCR5 traffics through the TGN
CHO CCR5 cells w ere  e ith e r tre a te d  fo r 3 h w ith  n oco dazo le  or D M SO in n o rm a l 
grow th  m ed iu m . For th e  last tw o  hours o f th is incu b atio n , CHX was ad ded  to  c lear  
newly synthesised CCR5 from  the  b iosyn th etic  pathw ay. Cells w ere  th e n  e ith e r  fix e d  
(u n stim u la ted ) o r trea ted  w ith  RANTES in BM co nta in ing  CHX and e ith e r n o c o d a zo le  
or DMSO fo r 6 0  m in (6 0  m in RANTES), before  being  fix e d . Cells w e re  th e n  
perm eab ilised  in b locking  b u ffe r and incubated  w ith  M C -5, M ary, o r a n t i-p 2 3 0  
p rim ary  an tib o d ies  to  d e te c t C CR 5, y -adaptin  or p 2 3 0 , respective ly . M C -5 , M ary  and
118
Chapter 3: Morphological Outline of CCR5 Trafficking
a n ti-p 2 3 0  w ere  d e tec ted  w ith  A le x a  4 8 8  GAM  lg G 2a , A le x a  5 9 4  GAR and  6 4 7  GAM  
Ig G l,  respective ly . S ingle confocal sections are  show n. D ual ch a n n e l, g re e n -re d  
m erges be tw een  CCR5 and y -adap tin  or p 2 3 0  fo r  R A N TE S -trea ted  cells a re  a lso  
show n. Bar, 5 pm .
The TGN and recycling endosome are closely apposed organelles, the 
maintenance o f both in the perinuclear region being dependent on the 
organisation o f microtubules originating at the MTOC (Rogalski and Singer 
1984; Turner and Tartakoff 1989; Sakai, Yamashina et al. 1991; McGraw, 
Dunn et al. 1993). To increase the separation o f the two organelles and rule 
out spurious overlap between CCR5 and the TGN markers cause by close 
proximity o f the TGN and recycling endosome, cells were treated with 
nocodozole before and during stimulation with agonist (Ullrich, Reinsch et 
al. 1996). In unstimulated cells, nocodazole treatment led to a dispersal o f 
p230 and y-adaptin staining throughout the cytoplasm, although some 
staining remained close to the nucleus. The majority o f the p230 staining 
still overlapped with y-adaptin, though, confirming the presence o f AP-1 on 
TGN elements.
In cells treated with RANTES for 60 min, nocodazole treatment also led to a 
dispersal o f p230 and y-adaptin staining throughout the cytoplasm. CCR5 
was successfully down-modulated from the cell surface and puncta were 
observed throughout the cytoplasm. Many o f the CCR5 puncta colocalised 
with p230 and y-adaptin, representing CCR5 in the TGN. Also, CCR5- 
positive, y-adaptin-positive, p230-negative puncta were observed, 
confirming the presence o f AP-1 on some CCR5-containing endosomes. 
CCR5 puncta devoid o f y-adaptin and p230 were also observed, presumably 
representing CCR5-containing endosomes that had not recruited AP-1.
CCR5 traffics through R ab ll-positive  recycling endosomes 
and the TCN
The above data suggest that in the perinuclear region, where CCR5 
accumulates in the constant presence o f agonist, the receptor traffics 
through both recycling endosomes, at least some of which are R a b l l -
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positive, and the TCN. These data also suggest that down-modulated CCR5 
should be observable in both R a b l l-p o s it ive  and p230-posit ive 
compartments at steady-state. To confirm this, I performed similar 
immunofluorescence-based trafficking assays, staining for CCR5, R a b l l  
and p230 (Figure 3-X).
In unstimulated cells, R a b l l  and p230 staining were largely separate, 
although a small amount o f overlap was observed. This is consistent with 
the findings o f Ullrich et at. (1996), who observed some R a b l l  
colocalisation with a-2,6-SialylT, a marker o f the trans-Golgi cisterna and 
the TCN (Roth, Taatjes et al. 1985) in CHO cells. In cells stimulated with 
^  RANTES for 60 min, overlap o f both CCR5 and R a b l l ,  and CCR5 and p230 
was observed in the perinuclear region. Some overlap between all three 
proteins was also observed. This may represent CCR5 in R ab l l-co n ta in in g  
regions o f the TGN, or may result from close apposition o f the TGN and 
R ab ll-po s it ive  recycling endosomes, one o f which containing CCR5. CCR5- 
positive puncta that were negative for both R a b l l  and p230 were also 
found in the perinuclear region, which presumably represents CCR5 in 
R ab ll-nega tive  recycling endosomes.
Treatment with nocodazole led to the dispersal o f R a b l l  and p230 puncta, 
which, interestingly, were often observed closely apposed but not 
overlapping. This suggests that the compartments are distinct but that there 
may be some sort of physical link between them, which maintains their 
association despite disruption o f the microtubule network. This pattern o f 
R a b l l  and p230 staining was maintained after 60 min RANTES treatment. 
Intriguingly, CCR5 colocalised well with p230 under these conditions but 
showed a much-reduced overlap with R a b l l  compared with the overlap in 
RANTES-treated cells in the absence of nocodazole. This suggests that 
microtubules may be involved in the trafficking o f CCR5 and that their 
disruption may lead to a slightly altered steady-state distribution in the 
presence o f agonist.
Finally, as is best illustrated in the dual channel merged images in Figure
3-X, RANTES treatment did not alter the extent o f p230 and R a b l l  overlap.
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Figure 3-X In the constant presence of agonist, CCR5 accumulates in both 
Rabl 1- and p230-positive structures
C H O  CCR5 cells w ere  e ith e r tre a te d  fo r 3 h w ith  n o co d azo le  o r D M SO  in n o rm a l 
gro w th  m e d iu m . For th e  last tw o  hours o f th is in cu b atio n , CHX w as a d d e d  to  c le a r  
new ly synthesised  CCR5 fro m  th e  b io syn th e tic  p athw ay. Cells w ere  th e n  e ith e r  f ix e d  
(u n s tim u la te d ) or tre a te d  w ith  RANTES in BM co n ta in in g  CHX and e ith e r  n o c o d a zo le  
or DMSO fo r 6 0  m in (6 0  m in  RANTES), b e fo re  being  fix e d . C ells w e re  th e n  
p erm eab ilised  in b lock ing  b u ffe r and in cu b ated  w ith  M C -5, a n ti-R a b l l a ,  o r a n ti-  
p 2 3 0  p rim a ry  an tib o d ies  to  d e te c t CCR 5, R abl 1 o r p 2 3 0 , respective ly . M C -5 , a n ti- 
R abl l a  and a n ti-p 2 3 0  w ere  d e te c te d  w ith  A le x a  4 8 8  C AM  lgG 2a, A le x a  5 9 4  GAR  
and 6 4 7  C A M  Ig C l ,  respective ly . S ingle confocal sections are show n. D ual c h an n e l, 
green -red  m erges b e tw een  CCR5 and R ab l 1 o r p 2 3 0  fo r  R A N TE S -treated  cells a re  
show n, as are dual ch ann e l, g re e n -re d  m erges b e tw een  R ab l 1 and p 2 3 0 . Bar, 5 ^ m .
CCR5 traffics through the TCN in HOS cells
The above data suggests that, unexpectedly, in CHO cells, CCR5 traffics 
through the TGN. To determine if this is a general feature o f CCR5
trafficking, or whether the result is specific to CHO cells, I followed the
agonist-induced trafficking o f CCR5 in human osteosarcoma (HOS) cells 
stably expressing CCR5 as well as CD4 (Figure 3—XI).
I firstly investigated where CCR5 was located in unstimulated HOS CD4 
CCR5 cells and whether the agonist-activated receptor trafficked in a similar 
manner to when expressed in CHO cells (Figure 3—XI A).
In unstimulated cells, CCR5 staining o f permeabilised cells was almost 
exclusively restricted to the cell surface. After 60 min RANTES treatment, the 
receptor redistributed from the cell surface mainly into perinuclear puncta, 
although some of the receptor was seen in puncta throughout the rest o f 
the cytoplasm. When cells that had been treated with RANTES were
incubated for 60 min in TAK-779, conditions under which the receptor
recovers to the cell surface in CHO cells, practically all o f the CCR5 was 
observed on the cell surface, demonstrating that CCR5 recycled in this cell- 
line. Overall, in HOS cells, agonist-activated CCR5 traffics in a similar way to 
when it is expressed in CHO cells.
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Figure 3-XI In the constant presence of agonist, some CCR5 accumulates in the 
TGN in HOS cells
A. HOS C D 4 CCR5 cells w ere e ith e r fix e d  (u n s tim u la ted ), trea ted  w ith  RANTES in BM 
fo r 6 0  m in and fixed  (6 0  m in RANTES), or trea ted  w ith  RANTES in BM fo r 6 0  m in  
fo llow ed by a 6 0  m in in cubation  in BM con ta in in g  T A K -7 7 9  b e fo re  being  fix e d  (6 0  m in  
RANTES + 6 0  m in T A K -7 7 9 ). Cells w ere  th en  p erm eab ilised  and in cubated  w ith  M C -5  
p rim ary  a n tib o d y  to  d e tec t C CR 5, w hich was subseq u en tly  visualised  w ith  A le x a  4 8 8  
GAM. Epifluorescence im ages are  show n. Bar, 5 pm . B. HOS C D 4 CCR5 cells w ere  
trea ted  w ith  RANTES in BM fo r 6 0  m in , f ix e d , p erm eab ilised  and sta ined fo r CCR5 and  
p 2 3 0  using M C-5 and a n ti-p 2 3 0  p rim ary  an tib o d ies  and A lexa  4 8 8  GAM  lg G 2a  and  
A lexa  5 9 4  GAM IgG l secondary a n tib o d ie s , respective ly . A s ing le  confoca l section  is 
show n. Bar, 5 pm .
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To investigate whether CCR5 traffics through the TGN in HOS cells, I stained 
cells that had been treated with RANTES for 60 min for p230 and CCR5 
(Figure 3-XI B). CCR5 showed a very strong overlap with p230 in the 
perinuclear region, suggesting that, like in the CHO cells, CCR5 traffics 
through the TGN in HOS cells. As observed in the CHO cells, nearly all o f the 
p230-associated fluorescence was co-incident with CCR5 fluorescence, 
suggesting that at steady-state, agonist-activated CCR5 occupies most o f 
the TGN elements in CHO cells. Some CCR5-positive only puncta were also 
observed around the perinuclear region and more peripherally in the 
cytoplasm, but these were in far lower abundance compared with the CCR5- 
and p230-positive puncta. The CCR5-positive only puncta may represent 
CCR5 present in recycling endosomes (perinuclearly-located) or CCR5 in 
early endosomes (peripherally-located).
Discussion
In this chapter I have described a series of experiments designed to chart 
the post-endocytic course taken by agonist-activated CCR5. I have shown 
that shortly after internalisation, CCR5 passes through early endosomes and 
that in the constant presence o f agonist, the receptor accumulates in a 
perinuclear compartment. There is no agonist-induced receptor 
degradation: CCR5 recycles efficiently back to the cell surface, a process 
that is revealed by removal o f agonist and incubation with the CCR5 
antagonist, TAK-779. I have subsequently shown that R a b l l  is involved in 
regulating CCR5 intracellular trafficking, but I have also been able to show 
that as well as trafficking through R ab ll-p o s it ive  recycling endosomes, 
CCR5 also traffics through the TGN. To my knowledge, this is the first 
evidence for the trafficking o f a G protein-coupled receptor (GPCR) through 
the TGN after agonist-induced internalisation.
R a b ll as a regulator of CCR5 trafficking
R a b l l  is a protein that is principally localised to perinuclear recycling 
endosomes and has been shown to play a role in regulating the traff icking 
o f several receptors through this compartment, including the TfR (Ullrich, 
Reinsch et al. 1996; Ren, Xu et al. 1998) and the chemokine receptor,
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CXCR2 (Fan, Lapierre et al. 200B; Fan, Lapierre et al. 2004). The results o f 
the experiment where mutant forms o f R a b l l  were expressed in CHO CCR5 
cells suggest that Rabll.GTP is required for CCR5 to access perinuclear 
recycling endosomes, because down-modulated CCR5 showed a far greater 
colocalisation with constitutively-active R a b l l  Q70L than w ild -type R a b l l ,  
but failed to colocalise with R a b l l  S25N or cluster around the nucleus in the 
presence o f this dominant-negative R a b l l  mutant. This is similar to the 
functioning o f R a b l l  described for the TfR (Ren, Xu et al. 1998). 
Presumably, the more dispersed, punctate CCR5 staining observed in 
RANTES-treated cells expressing R a b l l  S25N represents CCR5 held up in 
early endosomes, since this CCR5 staining did not colocalise with R a b l l  
S25N and Ullrich et al. (1996) found that despite R a b l l  S25N expression 
leading to a dispersal o f recycling endosomes throughout the cytoplasm, 
R a b l l  S25N still labelled the compartment. It would be interesting to co­
stain R a b l l  S25N-expressing cells for EEA1, to confirm whether CCR5 exit 
from early endosomes is slowed in the presence of R a b l l  S25N.
Despite seemingly not being able access recycling endosomes, CCR5 was, 
nevertheless, able to recycle in R a b l l  S25N-expressing cells with only a 
partial inhibition o f recycling observed after 60 min incubation in TAK-779. 
If CCR5 tru ly did not reach recycling endosomes in R a b l l  S25N-expressing 
cells, this suggests that CCR5 may be able to traffic directly from early 
endosomes to the plasma membrane. Alternatively, CCR5 trafficking to 
recycling endosomes at a reduced rate in the R a b l l  S25N-expressing cells 
(mediated by endogenous R a b l l  that can bind GTP) may be fast enough to 
result in a large amount o f CCR5 having recycled after 60 min.
Also in keeping with the functioning o f R a b l l  in TfR trafficking described by 
Ren et al., I found that the recycling o f CCR5 was inhibited in the presence 
of Rabll:GTP but not by over-expression o f w ild-type R a b l l ,  w ith a 
significant proportion o f receptors remaining in R a b l l  Q70L-positive 
clusters after 60 min incubation in TAK-779. This suggests that the 
recycling of CCR5 may require the hydrolysis of R a b l l -b o u n d  GTP to GDP. 
The chemokine receptor, CXCR2, also undergoes agonist-induced 
internalisation and recycles back to the cell surface via a perinuclear, 
R ab ll-po s it ive  compartment. Interestingly, recycling o f this receptor was 
strongly inhibited by the expression o f R a b l l  S25N, whereas the expression
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of a constitutively active R a b l l  mutant (R a b l l  S20V) had little effect on 
recycling (Fan, Lapierre et al. 2003). The reason why CXCR2 recycling is not 
inhibited by the constitutively-active R a b l l  mutant, whereas CCR5 recycling 
is inhibited, is unclear but one possible explanation may lie in a differential 
ability to recycle from early endosomes: under conditions where CXCR2 
recycling through the R a b l l-p o s it ive  recycling endosome was blocked by 
constitutively active RhoB expression, internalised CXCR2 could apparently 
recycle from early endosomes via a Rab4-controlled pathway (Neel, Lapierre 
et al. 2007). Perhaps R a b l l  S25N expression blocks CXCR2 exit from early 
endosomes, whether en route to the recycling endosome or directly back to 
the cell surface, whereas CXCR2 can still recycle from early endosomes to 
the plasma membrane in the presence o f Rabll:GTP, where the recycling 
block is at the recycling endosome. Indeed, Ren et al. (1998) concluded that 
Rabll:GTP is required for TfR exit from early endosomes whether en route 
to the plasma membrane or recycling endosome.
That R a b l l  S25N apparently had a more severe effect on CXCR2 recycling 
than it did on CCR5 recycling is most simply explained by considering that 
S25N expression did have a small inhibitory effect on CCR5 recycling and 
perhaps only assaying CCR5 recycling at one tim e-po in t missed a larger 
inhibitory effect o f the mutant. A fuller kinetic analysis o f recycling in the 
presence o f R a b l l  w ild-type and mutants may resolve this issue.
Finally, it must be borne in mind that the role o f R a b l l  in regulating CCR5 
trafficking through recycling endosomes is complicated by the f inding that 
the receptor also traffics through the TGN (see below), which may account 
for differences between CCR5 and CXCR2 trafficking. Moreover, from 
experiments following the retrograde trafficking o f TGN38 and Shiga tox in  
in HeLa cells, it has been suggested that R a b l l  may function in the sorting 
of proteins from recycling endosomes to the TGN (Wilcke, Johannes et al. 
2000).
R a b ll and recycling endosomes
Yamashiro et al. (1984) demonstrated that the majority o f the transferrin 
receptor population in CHO cells is present in recycling endosomes, making 
perinuclear TfR a good marker for the compartment. R a b l l  is an accepted 
marker for recycling endosomes and has become synonymous with the
126
Chapter 3: Morphological Outl ine  of CCR5 T ra f f ick ing
compartment (van Ijzendoorn 2006). Here, though, I have shown that only a 
small fraction of perinuclear TfR in CHO cells colocalises with R a b l l ,  and, 
moreover, that this partial overlap in the perinuclear region is not restricted 
to CHO cells, demonstrating the same staining pattern in HeLa and HOS 
cells. Some of the lack o f colocalisation (R ab ll-pos it ive , TfR-negative 
puncta) can be explained by the presence o f a small amount o f R a b l l  on 
the TCN (Ullrich, Reinsch et al. 1996). However, I found significant amounts 
o f perinuclear, TfR-containing endosomes that were R a b l l  negative. This is 
in keeping with the demonstration in A431 cells that R a b l l  is restricted to 
certain endosomal domains (Sonnichsen, De Renzis et al. 2000). It is 
important to be clear about terminology when referring to the recycling 
endosome and thus, I would suggest that the original description o f a 
recycling endosomes as a perinuclear endosomal compartment with more 
tubular morphology than early endosomes, a higher pH (~ 6.5) and 
enrichment for recycling receptors but far lower levels o f flu id phase 
material destined for the lysosome (Yamashiro, Tycko et al. 1984; Hopkins, 
Gibson et al. 1994; Marsh, Leopold et al. 1995), is a more complete 
definition than a compartment defined solely by the presence o f R a b l l .  By 
this definition, R a b l l  is only associated with a subset o f the recycling 
endosome membranes. Moreover, the large amount of R a b l l  staining in 
CHO, HeLa and HOS cells that does not colocalise with TfR, if not all 
labelling the TCN (which seems unlikely given the small overlap between 
R a b l l  and p230 in CHO CCR5 cells), suggests some sort o f functional 
compartmentalisation within the recycling endosome - R a b l l-co n ta in in g  
domains through which the TfR does not pass or passes very rapidly.
Model for the trafficking itinerary of agonist-activated CCR5
A model for CCR5 trafficking integrating the results of previous studies and 
all the data presented in this chapter is shown below in Figure 3—XII.
After agonist-activation, CCR5 molecules are internalised through c la th rin - 
coated pits and delivered to early endosomes. From there, receptors are 
sorted to a perinuclear recycling compartment and escape sorting to the 
lysosome. It was previously believed that the recycling compartment -  the 
perinuclear compartment from which CCR5 recycles to the plasma 
membrane and in which down-modulated receptors accumulate at steady-
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state -  was the recycling endosome. However, from the immunofluorescence 
data presented in this chapter, the recycling compartment, by the above 
defin ition, appears to comprise membrane elements from both the recycling 
endosome and TCN. Moreover, as discussed above, the recycling endosome 
appears to contain elements tha t are both are positive and negative fo r 
R a b l l .  Agonist-activated CCR5 seems to traffic through both R a b l l -  
positive and negative recycling endosomes, since it can be found in both 
populations o f recycling endosomes as well as the TCN in cells stained fo r 
R a b l l  and p230. To which com ponent o f the recycling compartment 
receptors sorted from  early endosomes are initially delivered cannot be 
determined from the results o f  the experiments presented in this chapter. 
Nor can it be determined w hether there is a sequential transfer o f CCR5 
between the recycling endosome and TGN components o f this compartment, 
or from  which element o f the com partm ent CCR5 finally exits en route to 
the plasma membrane. However, it is tem pting to speculate that as dow n- 
modulated CCR5 colocalises w ith p230 but not R a b l l  when cells are treated 
with nocodazole, that CCR5 exits the recycling compartment from the TCN 
in a m icrotubu le-dependent fashion - microtubules are believed to be 
involved in the extrusion o f post-G o lg i carriers from the TCN and their 
subsequent cytosolic transport (De Matteis and Luini 2008). It would be 
interesting to see if CCR5 is capable o f recycling in nocodazole-treated 
cells.
The description o f the role o f R a b l l  in CCR5 tra ff icking detailed above is 
compatible w ith a recycling com partm ent comprising recycling endosome 
and TCN components, where R ab ll :G T P  is required for trafficking to the 
perinuclear recycling com partm ent (litt le perinuclear clustering o f CCR5 was 
observed in cells expressing R a b l l  S25N) and hydrolysis o f GTP on R a b l l  is 
required for exit from the com partm ent. However, further morphological 
analysis is required here: o f particu lar interest is the effect o f the R a b l l  
mutants on TCN localisation o f agonist-activated CCR5 at steady-state. 
Again, the results o f the experim ent w ith the R a b l l  mutants shed no light 
on the specific sequence o f tra ff ick ing  events to, within and from  the 
recycling compartment.
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Figure 3-XII Model for CCR5 intracellular trafficking in CHO CCR5 cells
T he  fig u re  show s a c a rto o n  re p re s e n tin g  th e  m ost p ars im on ious m odel fo r the  
in tra c e llu la r tra ffic k in g  ro u te  ta k e n  by ag o n is t-a c tiv a te d  CCR5 based on p reviously  
pub lish ed  d a ta  and  th e  resu lts  p re s e n te d  in th is  ch ap te r. See m ain te x t fo r deta ils . 
T he  s ite(s) o f c h e m o k in e  d isso c ia tio n  and  re c e p to r d ep h o sp h o ry la tio n  are unclear. 
T h e  M TO C  is show n in th e  b o tto m  rig h t co rner; d o tte d  g rey  lines rep resen t 
m icro tu b u les  e m a n a tin g  fro m  th e  M T O C . T h e  T fR  cartoo n  rep resen ta tio n  is 
p os ition ed  in th e  c o m p a rtm e n ts  in w h ich  th e  T fR  can be read ily  found  in CHO CCR5 
cells.
Interestingly, the Rabl 1-positive recycling endosomes and the TGN are 
maintained in close proxim ity by a mechanism that appears to be, at least in 
part, independent o f microtubules, since R a b l l  and p230 puncta dispersed 
together in closely apposed, paired puncta in nocodazole-treated cells. This 
close proximity, which has also been observed by electron microscopy, may 
facilitate the transfer o f CCR5 between the two compartments. The recycling 
endosome and TGN are morphologically hard to distinguish, and also have a 
similar pH of -6 .5  (Yamashiro, Tycko et al. 1984; van Ijzendoorn 2006; De 
Matteis and Luini 2008). The compartments are only really distinguished by
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the markers they contain, a lthough even many of these, e.g. AP-1 and 
R a b l l ,  are common to  the two compartments. This may be the reason that 
down-m odu la ted  CCR5 was not reported to localise to the TCN by Signoret 
et al. (2000): a lthough CCR5 was observed in tubules and vesicles close to 
Colgi stacks on immunolabelled cryosections, no markers for the TCN were 
included in this study.
To my knowledge, this is the f irs t  evidence fo r a CPCR trafficking through 
the TCN after agon is t-s t im u la t ion . A lthough the data presented here is very 
suggestive, it needs to be verif ied by u ltrastructural analysis, e.g. electron 
microscopic observations o f cryosections immunolabelled for CCR5 and 
p 2 3 0 /R a b l l ,  to see i f  the observations at the light level hold true. The 
hypothesis that CCR5 traffics th rough  the TCN could also be assessed by 
taking advantage o f the fact that CCR5 is post-transla tionally modified by 
O -linked glycosylation o f its N -te rm inus , preferentially on Ser6 (Farzan, 
M irzabekov et al. 1999; Bannert, Craig et al. 2001). The O-linked 
oligosaccharides covalently attached to CCR5 contain terminal sialic acid 
residues that could be enzymatically removed before inducing CCR5 
internalisation and then receptors recycling back to the plasma membrane 
could be assayed fo r the re -add it ion  o f  sialic acid residues. This reaction 
would be predicted to occur in the TGN and would act as a tag 
demonstrating that the receptor had passed through the compartment. 
Indeed, the importance o f the maintenance o f N-term inal glycosylation for 
agonist binding may be the reason fo r  CCR5 traff icking through the TCN 
(Bannert, Craig et al. 2001).
The clathrin adaptor protein, AP-1, as well as being present on the TCN 
elements to which CCR5 tra ff icked, also colocalised with down-modulated 
CCR5 on endosomal structures. Interestingly, AP-1 appeared to show an 
enhanced association with T fR -pos it ive  endosomes after RANTES treatment, 
which suggests that AP-1 is recruited to endosomes containing CCR5. A role 
for AP-1 in mediating CCR5 tra ff ick ing  is fu r the r explored in Chapter 5.
Influence of antibody binding on CCR5 trafficking
As discussed in the results section, p re -b ind ing  the anti-CCR5 antibody, 
MC-5, to receptors before treating w ith  agonist appears to subtly alter the 
steady-state d is tr ibu tion  o f agonist-activated receptors. Pre-binding MC-5
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before RANTES treatment led to  a strong overlap o f down-m odula ted CCR5 
with TfR in the perinuclear region (as seen in Figure 3-11) and very little 
overlap w ith y-adaptin was observed (data not shown). In contrast, dow n- 
modulated CCR5 colocalised strong ly w ith  perinuclear y-adaptin in cells 
where CCR5 was labelled pos t- f ixa t ion , some o f which did not label fo r TfR 
(Figure 3—VIII), which led to the series o f  experiments showing that CCR5 
traffics to the TGN (Figure 3—IX and Figure 3-X). Unfortunately, this 
difference between the two labelling methods and the ability o f CCR5 to 
tra ff ic  through the TGN were only appreciated towards the end o f the 
experimentation phase o f this PhD project. This has had three 
consequences: (1) many immunofluorescence experiments described in the 
thesis were performed w ith  pre-labe ll ing  o f CCR5; (2) many experiments 
described in subsequent chapters were performed with the view that CCR5 
traff icked to recycling endosomes and not the TGN; and (3) I have not had 
enough time to repeat tra ff ick ing  experiments where CCR5 was pre-labelled 
with pos t- f ixa t ion  staining o f CCR5, to fu lly assess the effects o f antibody 
pre-labell ing.
However, in cells pre-labelled fo r CCR5 and stained with TfR and y-adaptin, 
although the overlap o f down-m odula ted CCR5 with y-adaptin is very 
limited, a very small am ount o f CCR5 in some cells does appear to colocalise 
with y-adaptin in TfR-negative structures, suggesting that down-m odula ted 
CCR5 can access the TGN when MC-5 is p re-bound  (data not shown). In 
addition, given that CCR5 pre -bound  w ith MC-5 is not targeted fo r 
degradation and recycles w ith similar kinetics to unbound CCR5, it is likely 
that an tibody-bound  CCR5 traffics th rough the same pathway as ‘naked’ 
CCR5, but that the tra ff ick ing rates w ith in  the recycling compartment are 
subtly altered.
CCR5 trafficking in other ce ll-lin es
As well as supporting the notion that agonist-activated CCR5 traffics 
th rough the TGN, the demonstration that CCR5 internalises and recycles in 
HOS CD4 CCR5 cells in a manner sim ilar to that observed in CHO cells, 
suggests that this ce ll- l ine could form  a useful system fo r RNAi screens o f 
proteins involved in CCR5 recycling. CHO cells suffer in this respect from
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the fact that the hamster genome has not been sequenced. I have created a 
HOS ce ll- l ine  in which only CCR5 (not CD4) is stably expressed, as there 
have been reports o f CCR5-CD4 interactions, and the ce ll- l ine used for the 
experiments described above also expressed CD4 (Xiao, Wu et al. 1999). 
The observation that down-m odu la ted  CCR5 accumulates in the TGN in HOS 
CD4 CCR5 cells at steady-state should be repeated with this cell- l ine to rule 
out CD4 having an effect on CCR5 tra ff ick ing .
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The data presented in Chapter 3 showed that soon after agonist activation, 
CCR5 molecules are internalised and tra ff ic  through early endosomes en 
route to a perinuclear recycling compartment. From this compartment, 
receptors recycle effic iently to the cell surface. As fo r  many activated CPCRs, 
p-arrestins effect CCR5 internalisation by coupling receptors to the c la th rin - 
mediated endocytic machinery (Huttenrauch, Nitzki et al. 2002; Fraile- 
Ramos, Kohout et al. 2003; Huttenrauch, Pollok-Kopp et al. 2005). There is 
also a growing body o f evidence that suggests that the nature o f the 
interaction o f an activated GPCR with p-arrestins -  transient or sustained - 
correlates w ith, and may in part dictate, the subsequent tra ff ick ing itinerary 
o f a receptor (Oakley, Laporte et al. 2000; Oakley, Laporte et al. 2001). Here, 
I describe morphological and biochemical experiments investigating the 
nature o f the interaction o f CCR5 w ith p-arrestins 1 and 2. I then explore 
the role o f C-ta il phosphorylation in supporting p-arrestin association and 
the role that this phosphorylation plays in the tra ff ick ing o f the receptor.
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p-arrestins remain bound to CCR5 as it internalises and 
traffics to early endosomes
Mueller et al. previously showed by immunofluorescence o f CHO CCR5 cells 
transiently transfected with G FP-p-a rres tin l,  that treatment fo r 60 min with 
the CCR5 agonist, M IP - la ,  led to the redistribution o f CCR5 from the 
plasma membrane into vesicular compartments and that GFP-parrl was 
found to colocalise with the internalised receptor (Mueller, Kelly et al. 2002). 
However, the authors did not determine in which intracellular compartment 
the down-m odu la ted  CCR5 was located, only observed a single t im e -po in t 
o f agonist stimulation, and did not assess whether p-arrestin2 showed a 
similar agon ist- induced redistribution.
To fu rthe r study the nature o f the interaction between agonist-activated 
CCR5 and p-arrestins, I performed a series o f morphological tra ff ick ing 
experiments using CHO CCR5 cells stably expressing bovine p -a rre s t in l  or 
p-arrestin2, C -te rm ina lly  tagged with yellow fluorescent protein (VFP) and 
green fluorescent protein (GFP), respectively. In addition to the Mueller et al. 
(2002) study, both N - and C -term ina lly  CFP-tagged p-arrestins have been 
used extensively fo r fluorescence studies o f p-arrestin recruitment to 
CPCRs: indeed, fluorescently-tagged p-arrestins were used fo r live-cell 
imaging performed by Oakley et al. in the experiments that led to the initial 
defin it ion o f two classes o f CPCR that differed in the stability o f their 
interaction w ith p-arrestins (Oakley, Laporte et al. 2000). Fluorescently- 
tagged p-arrestins are also routinely used fo r  f ixed-ce ll fluorescence 
imaging since endogenous p-arrestins are d if f icu lt to detect -  principally 
due to a paucity o f available antibodies that recognise the native forms o f p- 
arrestins 1 and 2 in vivo.
I f irst looked by immunofluorescence to see whether agonist-activated 
CCR5 maintained an interaction w ith p-arrestins in early endosomes (Figure 
4-1). Here, and in all the experiments described in this chapter, cells were 
pre-labelled for cell surface CCR5 with MC-5 before treating with agonist. In 
unstimulated cells, receptors were d iffusely d istr ibuted at the cell surface 
and EEA1, a marker o f early endosomes, had a punctate, cytoplasmic 
d is tr ibu tion. p -a rres t in l-YFP  was present in both the cytoplasm and the 
nucleus; in contrast, p-arrestin2-GFP was largely excluded from the
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nucleus. This is consistent w ith the report that p-arrestin2 has a 
hydrophobic-r ich  region at its C -te rm inus that serves as a nuclear export 
signal (NES), resulting in an extra -nuc lear p-arrestin2 localisation; in p- 
a rres t in l ,  there is a single amino acid difference in sequence in this region 
that renders it incapable o f supporting  nuclear export, hence the difference 
in subcellular localisation (Wang, Wu et al. 2003). Pairs o f juxtanuclear, 
fluorescent spots were also frequently  observed in p-arrestin2-GFP- 
expressing cells, which likely represent p-arrestin2-GFP located at the 
m icrotubu le-organ is ing  centre (MTOC) (A. Benmerah, unpublished results). 
A fter 5 min RANTES treatment, some CCR5 remained d iffusely distributed at 
^ the plasma membrane, but most was observed in punctate structures at or 
below the cell surface. Both p-arrestins 1 and 2 were recruited to the cell 
surface and clearly colocalised w ith  CCR5 puncta, which presumably 
represent receptors recruited into c la thrin-coated pits or flat clathrin lattices 
at the plasma membrane. Moreover, p-arrestins 1 and 2 colocalised with all 
o f the cytoplasmic CCR5 puncta, many o f which also colocalised with EEA1, 
demonstrating that p-arrestins 1 and 2 were bound to CCR5 in early 
endosomes. Peripheral cytoplasmic puncta that were positive fo r both CCR5 
and p-arrestins but negative fo r EEA1, presumably represent internalised 
vesicles en route to early endosomes. Altogether, these data suggest that p- 
arrestins remain bound to CCR5 as it internalises and passes into early 
endosomes.
It is interesting to note that after 5 min RANTES treatment, much less 
diffuse cell-surface CCR5 staining was observed in CHO cells also 
expressing p -a rres t in l-YFP  or p-arrestin2-GFP than in those with ju s t  
endogenous levels o f p-arrestins (Figure 3-1). Over-expression o f p- 
arrestins apparently led to an increase in the rate o f CCR5 internalisation, 
which suggests that endogenous levels o f p-arrestins are lim iting for CCR5 
internalisation in CHO CCR5 cells, which is not that surprising given the 
high levels o f CCR5 expression.
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unstimulated 5 min RANTES
Figure 4-1 p-arrestins remain bound to CCR5 as it internalises and traffics to 
early endosomes
C H O  CCR5 p a rrl -YFP o r C H O  CCR5 parr2-G FP cells w ere  p re -lab e lled  fo r cell su rface  
CCR5 w ith  M C-5 and th en  e ith e r fix e d  (u n s tim u la te d ) o r in cu b ated  w ith  RANTES in 
BM fo r 5 m in b e fo re  being  fix e d  (5 m in  RANTES). Cells w ere  th en  in cu b ated  in 
p e rm e a b ilis in g  b lo ck in g  b u ffe r w ith  an ti-E E A l p rim a ry  an tib o d y . M C-5 and EEA1 
p rim a ry  a n tib o d ies  w ere  d e tec ted  w ith  A le x a  4 8 8  GAM lgG 2a and 6 4 7  GAM  Ig G l,  
respective ly . S ingle confocal sections a re  sh ow n . Bars, 5 pm
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p-arrestins remain bound to internalised CCR5 as it traffics 
to a perinuclear, TfR-positive compartment
To determine whether p-arrestins remain bound to CCR5 as it traffics to a 
perinuclear recycling compartment, I treated CHO CCR5 parrl-YFP (Figure
4-11) or CHO CCR5 parr2-GFP (Figure 4—III) cells with RANTES for d ifferent 
t im e-periods and co-sta ined fo r steady-state transferrin receptor (TfR), the 
majority o f which is located in perinuclear recycling endosomes in CHO cells 
(Yamashiro, Tycko et al. 1984).
In unstimulated cells, CCR5 was d iffusely d is tr ibuted over the cell surface 
and the TfR population was often found clustered in the perinuclear region, 
a lthough there was significant punctate staining observed throughout the 
rest o f the cytoplasm. As before, p -a rres t in l-YFP  was found both in the 
cytoplasm and the nucleus, whereas p-arrestin2-GFP was largely excluded 
from the nucleus.
A fter 5 min RANTES stimulation, both p-arrestins were recruited to the cell 
surface and found in puncta together with CCR5. CCR5 was also found in 
punctate structures in the cytoplasm, all o f which colocalised with parrl-YFP 
or parr2-GFP. Some cytoplasmic puncta also colocalised with TfR, most 
likely present in early endosomes, given the results presented in Figure 4-1. 
In support o f this conclusion, the confocal section through the middle o f the 
o f CHO CCR5 parr2-GFP cells treated with RANTES for 5 min, shows how 
most o f the cytoplasmic TfR-conta ining, CCR5-positive puncta did not 
colocalise w ith TfR located in the perinuclear region, so were likely early 
endosomal in nature.
A fter 30 min RANTES-treatment, in both CHO CCR5 parrl-YFP and CHO 
CCR5 parr2-GFP cells, CCR5 had accumulated in the perinuclear region and 
showed a very strong overlap w ith TfR, whose own distr ibution appeared 
more concentrated around the nucleus compared with unstimulated cells. 
The d is tr ibu tion  o f CCR5 after 60 min RANTES-treatment was 
indistinguishable from  that seen after 30 min, suggesting that a steady- 
state d is tr ibu tion  fo r CCR5 under constant agonist stimulation was 
established by 30 min RANTES-treatment. The d is tr ibu tion  o f internal CCR5 
after 60 min RANTES treatment was also the same as in CHO CCR5 cells 
treated in the same way (Figure 3-11). Both p-a rres tin l-YFP and p-
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arrestin2-GFP showed a strong colocalisation w ith CCR5 in the perinuclear 
region, suggesting that both p-arrestins maintained an interaction with 
CCR5 as it passed into perinuclear recycling endosomes. However, from 
these results it cannot be determined whether the p-arrestins were 
permanently bound to CCR5 th roughou t tra ff icking to the recycling 
endosome or underwent cycles o f dissociation and re-association with the 
receptor -  a situation that would provide a w indow for binding o f other 
CCR5 C -ta il- in te rac t ing  proteins.
CCR5 recycling to the cell surface was also fo llowed by treating cells fo r 60 
min w ith RANTES to down-m odu la te  CCR5 and then allowing receptors to 
recycle back to the plasma membrane in the presence o f the CCR5 
antagonist, TAK-779. Full recovery o f CCR5 cell-surface fluorescence was 
seen in both CHO CCR5 parrl-YFP and CHO CCR5 parr2-GFP cells, although 
a little perinuclear CCR5 was observed in a m inority  o f CHO CCR5 parr2-GFP 
cells, which colocalised with p-arrestin2-GFP (data not shown). This 
suggests that over-expression o f p-arrestins did not dramatically alter the 
tra ff ick ing itinerary o f the receptor. A fter the incubation with TAK-779, p - 
arrestin l-YFP and p-arrestin2-GFP adopted similar d is tr ibutions to that 
seen in unstimulated cells and no longer colocalised w ith CCR5, consistent 
with recycled, cell-surface-located receptors being stabilised in an inactive 
conformation in the presence o f TAK-779. The TfR population also adopted 
a d is tr ibu tion  sim ilar to that observed in unstimulated cells, with a 
relaxation o f the concentration o f TfR staining around the nucleus seen in 
30, 60 and 120 min RANTES-treated cells.
Recycling o f CCR5 in cells treated w ith  RANTES for 60 min followed by a 60 
min incubation in TAK-779 contrasted w ith cells treated with RANTES fo r 
120 min, where the CCR5 d is tr ibu tion  and colocalisation with both p- 
arrestins and TfR was similar to that seen after 60 min RANTES treatment. 
This supports the conclusion drawn from  the data presented in Chapter 3, 
that after long periods o f RANTES treatment, CCR5 is not routed to a 
degradative pathway.
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C
Figure 4-11 p-arrestinl-YFP remains bound to agonist-activated CCR5 as it 
traffics to a perinuclear, TfR-containing compartment
C H O  CCR5 p a rrl-Y F P  cells w ere  p re -la b e lle d  fo r cell surface CCR5 w ith  M C -5 and  
th en  tre a te d  w ith  RANTES in BM fo r th e  in d ica ted  tim e -p e rio d s  or tre a te d  w ith  
RANTES fo r 6 0  m in  fo llo w ed  by an in c u b a tio n  in BM co n ta in in g  T A K -7 7 9  fo r  6 0  m in .
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Cells w ere  th en  fixed  and in cu b ated  in p e rm e a b ilis in g  b lo ck ing  b u ffe r w ith  H 6 8 .4  
(an ti-T fR ) p rim a ry  a n tib o d y . M C -5 and H 6 8 .4  p rim a ry  an tib o d ies  w ere  d e tec ted  w ith  
A le x a  4 8 8  GAM  lg G 2a  and 6 4 7  GAM Ig G l,  resp ective ly . S ingle confocal sections are  
show n. Bars, 5 pm
A
5 min RANTES
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120 min RANTES
Figure 4-III p-arrestin2-GFP remains bound to agonist-activated CCR5 as it 
traffics to a perinuclear, TfR-containing compartment
C H O  CCR5 parr2-G FP cells w ere  p re -la b e lle d  fo r cell surface CCR5 w ith  M C-5 and  
th en  tre a te d  w ith  RANTES in BM fo r th e  in d ica ted  tim e -p e rio d s  o r tre a te d  w ith  
RANTES fo r 6 0  m in  fo llo w ed  by an in cu b a tio n  in BM co n ta in in g  T A K -7 7 9  fo r 6 0  m in .
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Cells w e re  th en  f ix e d  and  in c u b a te d  in p e rm e a b i l is in g  b lo ck in g  b u f fe r  w i th  H 6 8 .4  
(an ti -T fR ) p r im a ry  a n t ib o d y .  M C -5  and  H 6 8 .4  p r im a ry  a n t ib o d ie s  w e re  d e te c te d  w i th  
A le x a  4 8 8  C A M  lg C 2 a  and  6 4 7  C A M  I g C l , resp ec t ive ly . S ingle co nfoca l sections are  
sh ow n . Bars, 5 ^m
Endogenous p-arrestins are stably recruited to CCR5 in RBL 
cells
Above, I have described experiments where I followed the association o f 
over-expressed, tagged p-arrestins w ith agonist-activated CCR5. In order to 
determine whether endogenous p-arrestins exhibited the same pattern o f 
sustained association with CCR5, immunofluorescence traff icking 
experiments were performed with rat basophilic leukaemia cells stably 
A- expressing CCR5 (RBL CCR5 cells), stained for endogenous p-arrestins. RBL 
CCR5 cells were chosen fo r this experiment fo r two reasons. Firstly, as CCR5 
is endogenously expressed in a subset o f leukocytes (Blanpain, Libert et al. 
2002), RBL cells, being o f a haematopoietic lineage, are a relevant system 
for studying physiological CCR5 tra ff ick ing. Secondly, RBLs have been 
utilised in studies o f the traff icking o f other GPCRs as they express high 
levels o f p-arrestins (Santini, Penn et al. 2000).
CCR5 is expressed on the surface o f unstimulated RBL CCR5 cells but, in 
contrast to CHO cells, RBL CCR5 cells have a significant intracellular pool o f 
CCR5. This pool is located in compartments that label fo r the rat lysosomal 
membrane glycoproteins, Ig p l0 0 / lg p 8 0  (Silene Wavre, Endocytic Regulation 
o f Chemokine Receptor Expression, PhD thesis, 2006), and correspond to 
secretory granules. Therefore, here, as w ith the CHO CCR5 cells, cell surface 
CCR5 was pre-labelled with MC-5 before inducing internalisation with 
RANTES.
As can be seen in Figure 4-IV, after 60 min RANTES treatment, CCR5 that 
was initia lly on the cell surface had accumulated in intracellular structures. 
Both p -a rre s t in l  and p-arrestin2, which did not colocalise with CCR5 in 
unstimulated cells, strongly colocalised with intracellular CCR5 after 60 min 
RANTES treatment, suggesting stable recruitment o f the two proteins to 
agonist-activated CCR5.
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C C R 5  P-arrestinl m e rg e  C C R 5  p-arrestin2 m e rg e
Figure 4-IV Endogenous p-arrestins are stably recruited to agonist-activated 
CCR5 in RBL CCR5 cells
RBL CCR5 cells w ere  pre -labe lled  fo r  cell surface CCR5 w ith  MC-5 and then  e ithe r  
f ixed  (u n s t im u la te d )  o r  t rea ted  w ith  RANTES in BM for 6 0  min be fo re  being  f ixed  (6 0  
m in  RANTES). Cells w ere  th en  incu bated  in p erm eab il is ing  b locking  b u ffe r  w ith  
p r im a ry  an tib o d ies , 1 7 8  (a n t i -p -a r re s t in l ) an d  1 8 2 -4  (an ti-p -arrestin2). MC-5 was  
d etec ted  w ith  A lexa  4 8 8  GAM and 1 7 8  and 1 8 2 -4  w ere  d e tec ted  w ith  A lexa  5 9 4  
GAR secondary  an t ib o d y . Single confocal sections are show n. Bar, 5 pm
Similar results were obtained in CHO CCR5 cells, but the p-arrestin staining 
was much weaker, especially for p-arrestin2 (data not shown). This is 
probably a reflection o f lower endogenous p-arrestin levels in CHO cells 
than in RBL cells, and also possibly a lower affinity o f the antibodies for 
hamster p-arrestins, the protein sequences o f which are undetermined. 
Overall, these data support the view that the stable recruitment of 
fluorescently-tagged p-arrestins to CCR5 was not an over-expression 
artefact.
Stable recruitm ent o f  p -a rres tin s  to CCR5 is not ag o n ist- 
specific
CCR5 is activated upon binding o f the CC chemokines, CCL3 (macrophage 
inflammatory protein [MIP]-la), CCL4 (MIP-ip), CCL5 (regulated on 
activation normal T-cell expressed and secreted [RANTES]) and CCL8 
(monocyte chemoattractant protein [MCP]-2) (Murphy, Baggiolini et al.
2000). The results presented above show that p-arrestins are stably
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recruited to RANTES (CCL5)-activated CCR5. To determine if this is an effect 
specific to RANTES activation or is a general property o f agonist-activated 
CCR5, I performed immunofluorescence trafficking experiments with CHO 
CCR5 parrl-YFP/parr2-GFP cells treated with MIP-lcx (CCL3) or M IP-lp  
(CCL4). As shown in Figure 4-V, both M IP - la  and M IP-lp  induced down- 
modulation o f cell surface-labelled CCR5 into a perinuclear, TfR-positive 
compartment after 60 min treatment. In addition, both p-arrestin l-YFP and 
p-arrestin2-GFP colocalised with CCR5 in this compartment. Hence, the 
stable recruitment o f p-arrestins to CCR5 is a property common to CCR5 
activated by 3 out o f its 4 natural agonists, that is, it is a general property o f 
agonist-induced CCR5 trafficking. Moreover, the staining pattern for CCR5 
treated with M IP -la  and M IP-ip  fo r 60 min strongly resembled that of 
RANTES-treated CCR5, suggesting that trafficking to a perinuclear recycling 
compartment is also a general feature o f agonist-activated CCR5 trafficking.
CCR5 parr TfR merge
F ig u re  4 -V  p -a r r e s t in s  a r e  s ta b ly  re c r u i te d  to  M I P - l a -  an d  MIP-1 p -a c t iv a te d  C C R 5
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C H O  CCR5 p a r r l -Y F P  o r  C H O  CCR5 parr2-GFP cells w e re  p re - la b e l le d  fo r  cell surface  
CCR5 w ith  M C -5 and  th e n  t re a te d  w ith  e i th e r  M I P - l a  o r M IP - lp  in BM fo r  6 0  m in .  
Cells w e re  th en  f ix e d  and in cu b a ted  in p e rm e a b i l is in g  b lock ing  b u f fe r  w ith  an t i-T fR  
p r im a ry  a n t ib o d y  (H 6 8 .4 ) .  M C-5 and  H 6 8 .4  p r im a ry  a n t ib o d ie s  w e re  d e te c te d  w ith  
A le x a  4 8 8  C A M  lg C 2 a  and  6 4 7  C A M  I g C l ,  resp ective ly . Single confoca l sections are  
s h o w n . Bars, 5 nm
Biochemical evidence for a stable interaction between CCR5 
and p-arrestins
The morphological data presented above suggest that p-arrestins remain 
bound to CCR5 as it internalises, passes through early endosomes and 
traffics to perinuclear recycling endosomes. However, colocalisation data 
only indicate that two proteins are present on the same intracellular 
structure and do not formally prove an interaction between two proteins. To 
confirm  that p-arrestins maintain a sustained interaction with agon is t- 
activated CCR5 as it traffics within the cell, I performed a series o f co- 
immunoprecip ita tion experiments w ith CHO CCR5, CHO CCR5 parrl-YFP 
and CHO CCR5 parr2-GFP cells that had been treated with RANTES for 
various tim e-periods in a similar fashion to the immunofluorescence assays 
described above.
I was unable to co-im m unoprec ip ita te  p-arrestins (endogenous or over­
expressed) with agonist-activated CCR5 using a variety o f lysis buffers. This 
was probably because the membrane environment o f CCR5 is crucial for 
maintaining a receptor conformation that supports high affin ity p-arrestin 
b inding and detergent solubilisation o f membranes may influence receptor 
conformation. However, I was able to successfully co-im m unoprec ip ita te  p - 
arrestins with CCR5 using the membrane-permeant cross-link ing agent, 
d ith iobissuccin im idylpropionate (DSP). DSP comprises two N - 
hydroxylsuccinimde (NHS) esters separated by a spacer o f 12 A length. The 
NHS esters react with primary amine groups (e.g. the primary amine group 
on lysine side-chains) to form covalent amide bonds with the release o f N - 
hydroxysuccinimide. The spacer contains a central disulphide bond, which 
can be cleaved under reducing conditions so that cross-linked proteins can 
be separated on a gel.
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Figure 4-VI A, shows a blot o f an immunoprecip itation o f CCR5 from CHO 
CCR5 p-a rres tin l-YFP  cells treated w ith RANTES for various t im e-periods. In 
unstimulated cells, a very small amount o f p -a rrestin l-YFP co- 
immunprecip itated with CCR5. The bands fo r  CCR5 and p-arrestin l-YFP 
were specific since they were both absent from  a CCR5 immunoprecip itation 
from CHO-K1 cells, which express neither o f the proteins, and the p- 
arrestin l-YFP band was absent from  the lane containing the product o f an 
immunoprecip itation o f CCR5 from CHO CCR5 cells, which do not express 
p-arrestin l-YFP. RANTES-treated cells showed a reduction in CCR5 mobility, 
almost certainly due to phosphorylation (Oppermann, Mack et al. 1999), 
which was maintained th roughout RANTES-treatment up to 120 min. p- 
arrestin l-YFP strongly associated w ith  CCR5 after 5 min RANTES treatment, 
showing an approximately 7 -fo ld  increase in association over unstimulated 
cells. This degree o f association was maintained th roughout RANTES 
treatment, confirm ing a sustained interaction between p-arres tin l-YFP and 
CCR5 in RANTES-treated cells. In cells that had been treated with RANTES 
fo r 60 min followed by an incubation w ith TAK-779 for 60 min, the 
interaction between p-arres tin l-YFP and CCR5 was largely lost, w ith the 
amount o f p-a rrestin l-YFP  co-im m unoprec ip ita t ing  with CCR5 reduced to a 
level below that seen in unstimulated cells. TAK-779 binding stabilises the 
receptor in an inactive conformation (Baba, Nishimura et al. 1999) and, 
hence, a small amount o f basal activation o f CCR5 was probably responsible 
for some o f the p-arrestin l-YFP  association with CCR5 in unstimulated 
cells.
As shown in Figure 4-VI B, p-arrestin2-GFP also co-immunoprecip ita ted 
with CCR5 in an agonist-dependent manner, the degree o f association 
remaining approximately constant over time from 5 to 120 min. As w ith p- 
arrestin l-YFP, the interaction o f p-arrestin2-GFP with CCR5 was reduced to 
below that detected in unstimulated cells after incubation o f RANTES- 
treated cells in TAK-779 for 60 min.
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Figure 4-VI The stable interaction between CCR5 and p-arrestins can be 
followed by co-immunoprecipitation
A, B, C + D. C H O  K 1 , C H O  CCR5, C H O  CCR5 parr l  -YFP or C H O  CCR5 parr2-GFP cells 
w ere  incubated  fo r  various t im e  periods w ith  RANTES in BM at 37°C  (num bers  above  
lanes indicate leng th  o f  incubation  in m inutes; cells in C w ere  treated  w ith  RANTES 
for 10  min) or t rea ted  w ith  RANTES fo r  6 0  m in  fo llow ed  by a 6 0  m in incubation  in 
BM conta in ing  T A K -7 7 9  (lanes m arked  TAK). Cells w ere  then  trea ted  w ith  the  cross- 
l inking agent , DSP before  lysis and im u u n o p re c ip ita t io n  o f  e ithe r  CCR5 or GFP, as 
ind icated. Im m u n o p re c ip i ta te s  and lysates w ere  run on gels und er reducing  
conditions and separated  prote ins transferred  to  n itrocellu lose m e m b ranes . Blots 
w ere p robed  w ith  e ithe r  M C -5 , anti-CFP or  1 7 8  p r im ary  an tibod ies  to  de tec t C CR5,
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p a rr l -Y F P /p a r r2 -G F P  or p a r r l ,  resp ective ly . Blots in A  + D w e re  s u b s e q u e n t ly  
in c u b a te d  w ith  IR D y e ®  8 0 0  G A M  (reco g n ises  MC*5 and anti-GFP) or IR D ye®  6 8 0  GAR  
(recogn ises  1 7 8 )  an d  p ro te ins  v isu a lised  using the O dyssey  in fra -red  d e te c t io n  
system . A show s a graysca le  im ag e ;  D show s a dual co lo u r  im a g e ,  w h e re  IR D y e ®  
8 0 0  G A M  signal (C CR 5) is show n  in g re e n  an d  IR D ye®  6 8 0  GAR signal ( p a r r l )  is 
sh ow n in red . T h e  blots sh ow n  in B + C w e r e  in cub ated  w ith  G A M -HR P  s e co nd ary  
a n t ib o d y  and d e v e lo p e d  using a c h e m ilu m in e s c e n t  su bstra te . E. Equal a m o u n ts  o f  
p ro te in s  f ro m  w h o le  cell lysates o f  w i ld - ty p e  or p-arrestin  k n o c k -o u t  MEFs w e re  
lo ad ed  on a gel. S epara ted  p ro te in s  w e r e  tra n s fe r re d  to n itroce llu lose  and  p ro b e d  
w ith  1 7 8  (an ti -parr  1) p r im a ry  a n t ib o d y .  T h e  b lo t  was su b s e q u e n tly  in cu b a ted  w i th  
G A M -HR P  and  d e v e lo p e d  w ith  c h e m i lu m in e s c e n t  su b s tra te .
IP, im m u n o p re c ip i ta te ;  IB, im m u n o b lo t ,  no A b ind icates  a m o ck  im m u n p re c ip ia t io n  
carr ied  o u t  w i th o u t  inc lus ion  o f  th e  im m u n o p re c ip i ta t in g  a n t ib o d y .
To confirm the specificity o f the CCR5-p-arrestin interaction, p -a r re s t in l -  
YFP and p-arrestin2-GFP were immunoprecip itated from CHO CCR5 p- 
arrestin l-YFP and CHO CCR5 p-arrestin2-GFP cells, respectively, using an 
anti-GFP antibody that recognises both GFP and YFP. Immunoprecipitates 
were then probed fo r GFP/YFP and CCR5. As can be seen in Figure 4-VI C, 
CCR5 immunoprecipitated with both p-arres tin l-YFP and p-arrestin2-GFP 
after 10 min RANTES stimulation. More p-arres tin l-YFP was 
immunoprecipitated than p-arrestin2-GFP from a volume of cell lysate 
containing an equal amount o f protein mass, which is most likely due to the 
higher expression level o f p -a rres t in l-YFP  than p-arrestin2-GFP in the CHO 
CCR5 cells used in this experiment (assessed from cell lysates o f CHO CCR 
parrl-YFP and CHO CCR5 parr2-GFP cells probed with anti-GFP antibody; 
data not shown). Despite the larger amount o f p-a rres tin l-YFP 
immunoprecipitated compared with p-arrestin2-GFP, a greater amount o f 
CCR5 co-im m unoprec ip ita ted with p-arrestin2-GFP, suggesting that p- 
arrestin2-GFP has a higher a ffin ity  for agonist-activated CCR5 than p- 
arrestin l-YFP. In this blot, a second, m inor band o f higher mobility was also 
recognised by the anti-GFP antibody in the lanes containing the products o f 
the GFP immunoprecipitations. This band was not seen in the blots in A and 
B and was only observed in experiments where high levels o f p-arrestins 
were present on the blots, hence its detection in an anti-GFP
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immunprecip itation. A recent study by Lee et al. found that p-arrestins 
undergo proteolytic cleavage after angiotensin II type 1 receptor (ATiR) 
activation (Lee, Bhatt et al. 2008). The cleavage sites were determined to 
reside near the C -term in i o f p-arrestins 1 and 2. If the higher mobility  band 
seen here resulted from a proteolytic cleavage, however, it must have 
occurred near the p-arrestin N -te rm in i or in the GFP-protein, since the 
higher mobility  protein was detected on the blot by an anti-GFP antibody. In 
cell lysates from cells where a large am ount o f protein had been loaded on a 
gel so that the lower band was visible, there was no change in the ratio 
between the intensity o f the upper and lower bands between unstimulated 
and RANTES-treated cells, suggesting that CCR5 activation does not lead to 
a proteolytic cleavage event as demonstrated for the AT*R (data not shown). 
Alternatively, the lower band may result from a post-translational 
modification o f the p-arrestin molecule.
It was d iff icu lt to observe the co-im m unoprec ip ita t ion  o f endogenous p- 
arrestins w ith CCR5, because the p-arrestin proteins, being around 50 kDa 
in mass, have a similar electrophoretic mobility  to, and are masked by, the 
antibody heavy chain used in the immunoprecip ita tion (which is recognised 
by cross-reaction o f the secondary antibody used fo r recognition o f the 
an ti-p-a rres tin  antibody). However, the Odyssey infra-red detection system 
offered an advantage here, in that secondary antibodies that recognise 
antibodies from different species can have d ifferent fluorophores attached, 
4— so that closely apposed bands can be more easily resolved. Figure 4-VI D 
shows a blot o f an immunoprecip ita tion o f CCR5 from CHO CCR5 cells 
treated for various t im e-periods w ith RANTES, in which mouse primary 
antibody (MC-5, anti-CCR5) was detected with IR Dye® 800 (pseudo­
coloured green) and a rabbit primary antibody against p -a rre s t in l  (178) was 
detected with IR Dye® 680 (pseudo-coloured red) (178 was specific fo r 
mouse p -a rre s t in l ,  as shown from the b lotting pattern it gave fo r lysates o f 
mouse embryonic fibroblasts knock-ou t fo r p -a rre s t in l ,  2 or 1 and 2; 
Figure 4-VI E). As seen before, agonist stimulation led to a decrease in CCR5 
mobility, likely resulting from C-tail phosphorylation. Although the IR Dye® 
680 an ti- rabb it antibody cross-reacted with the heavy-chain o f the a n t i-  
CCR5 mouse immunoprecip ita ting antibody, MC-5 (yellow band at 50 kDa),
152
part o f the p -a rre s t in l  band was visible above this band (red band in area 
indicated by dashed white box). The blot clearly shows that endogenous p - 
a rres t in l was recruited to agonist-activated CCR5 after 5 min RANTES 
treatment and that the interaction was maintained over 120 min RANTES 
stimulation, in keeping with the data obtained with over-expressed, tagged 
p-arrestin l-YFP.
Despite being able to detect endogenous p -a rre s t in l  by this method, p- 
arrestin2 could not be detected w ith a rabbit immunoserum, since it 
migrates slightly faster than p -a rre s t in l  and is completely masked by the 
antibody heavy chain.
Altogether, the results from these biochemical assays are consistent with 
the morphological data and support the notion that both p-arrestins 1 and 2 
are stably recruited to agonist-activated CCR5 as it traffics to a perinuclear 
recycling compartment.
CCR5 C -ta il phosphorylation correlates with p-arrestin  
association
As is the case fo r numerous CPCRs (Ferguson 2001) C-tail phosphorylation 
has been shown to be required fo r  p-arrestin recruitment to agonis t- 
activated CCR5 (Kraft, Olbrich et al. 2001; Huttenrauch, Nitzki et al. 2002). 
Alanine scanning mutagenesis o f CCR5 identified fou r C-term inal serine 
residues at positions 336, 337, 342 and 349, which are phosphorylated in a 
non-hierarchical manner upon receptor activation (Oppermann, Mack et al. 
1999). Additionally, using phospho-s ite  specific antibodies, Ser337 has 
been identified as a protein kinase C (PKC) substrate and Ser349 as a G 
prote in-coupled receptor kinase (CRK) substrate (Pollok-Kopp, Schwarze et 
al. 2003).
The results presented above demonstrate that p-arrestins remain associated 
with agonist-activated CCR5 as it traffics to a perinuclear recycling 
compartment. To determine whether agonist-activated CCR5 remains 
phosphorylated th roughout this tra ff ick ing, I performed 
immunofluorescence traff ick ing assays with RANTES-treated CHO CCR5 
parrl-YFP/parr2-GFP cells, staining for phospho-serine337 (P-S337) and
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phospho-serine349 (P-S349) residues with the s ite-specific antibodies 
described above.
Figure 4-VII shows the results o f the tra ff ick ing assays using CHO CCR5 
^ p a r r l - Y F P  cells. In unstimulated cells, some P-S337 signal was detected at 
the cell surface (Figure 4-VII A). A lthough some o f this fluorescence signal 
could be explained by low affin ity binding o f the anti-P-S337 antibody to its 
unphosphorylated epitope, in our hands, we find significant background 
activation o f PKC in CHO CCR5 cells (N. Signoret, unpublished observation), 
so there may have been a small level o f phosphorylation o f cell surface 
CCR5. After 5 min RANTES treatment, a typical, punctate surface and 
peripheral cytoplasmic CCR5 staining pattern was observed, with p - 
arrestin l-YFP colocalising well w ith the receptor. The P-S337 signal was 
almost exclusively associated with CCR5 staining and substantially increased 
compared with unstimulated cells, demonstrating that significant 
phosphorylation o f S337 had occurred. This phosphorylation was 
maintained after 60 min RANTES treatment, as receptors accumulated in the 
perinuclear region with p -a rres t in l-YFP  still bound.
Phosphorylation o f S349 (Figure 4-VII B) proceeded in a similar fashion to 
that o f S337. In unstimulated cells, a small amount o f signal resulting from 
anti-P-S349 antibody binding was observed at the cell surface, probably 
reflecting low affin ity  binding o f the antibody to its unphosphorylated 
epitope on CCR5. After 5 min, significant levels o f phsophorylation o f P- 
S349 were observed and this phosphorylation was maintained after 60 min 
RANTES treatment as receptors accumulated in the perinuclear region, all 
the time bound to p-arrestin l-YFP.
Similar results were obtained in CHO CCR5 parr2-GFP cells (Figure 4 —VIII). 
These results are in accordance w ith those o f Pollok-Kopp era/. (2003) who 
showed that phosphorylation o f S337 and S349 was maintained after 30 min 
RANTES treatment in RBL CCR5 cells, w ith the phospho-signal seen to 
accumulate in the perinuclear region (Pollok-Kopp, Schwarze et al. 2003).
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Figure 4-VII C C R 5 phosphorylation correlates with p-arrestinl-YFP association
C H O  CCR5 p a rr l -Y F P  cells w ere  pre - labe l led  fo r  cell surface CCR5 w ith  M C-5 and  
th en  incubated  fo r  the  ind icated  t im e -p e r io d s  in BM co nta in ing  RANTES at 3 7 °C .  
Cells w ere  th en  f ixed  and incubated  in perm eab il is in g  b locking  b u ffe r  w ith  e ith e r  
V I 4 / 2  (anti-P -S337; A) or El 1 /1  9 (anti-P -S349; B) p r im ary  an tib od ies . M C -5, V I 4 / 2  
and El 1 / 1 9  w ere  de tec ted  w ith  A le x a  6 4 7  C A M  lgG 2a, A lexa  5 9 4  C A M  lg C 2b  and  
A le x a  5 9 4  C A M  I g C l ,  respectively. S ingle confocal sections are shown. Bars, 5 pm
P-S337 P-arrestin1-YFP CCR5 merge
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Figure 4-VIII CCR5 phosphorylation correlates with p-arrestin2-GFP association
C H O  CCR5 parr2-YFP cells w ere  p re - labe l led  fo r  cell surface CCR5 w ith  MC-5 and  
then  incubated  fo r  the  ind icated  t im e -p e r io d s  in BM conta in ing  RANTES at 3 7 °C .  
Cells w ere  then  f ixed  and incub ated  in p e rm eab il is ing  b locking  buffe r  w ith  e ith e r  
V I 4 / 2  (anti-P -S337; A) or El 1 / 1 9  (anti-P -S349; B) p r im ary  an tib od ies . M C -5 , V I 4 / 2  
and El 1 / 1 9  w ere  detec ted  w ith  A le x a  6 4 7  C A M  lgG 2a, A lexa  5 9 4  GAM lgG 2b and  
A lexa  5 9 4  GA M  I g G l , respectively. S ingle confocal sections are show n. Bars, 5 pm
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C -ta il phosphorylation is not required for CCRS 
internalisation or recycling
To fu rther investigate the importance o f C-tail phosphorylation for the 
tra ff ick ing o f CCR5, I compared the agonist- induced tra ff ick ing o f a CCR5 
mutant with all 4 C-tail serine residues shown to be phosphorylated upon 
receptor activation mutated to alanines (CCR5 4S-*A), w ith that o f the w i ld -  
type receptor (CCR5 wt) when transiently expressed in CHO-K1 cells (Figure 
4-IX). As expected, 60 min RANTES treatment led to the down-m odu la tion  
o f cell surface CCR5 wt into a perinuclear compartment. CCR5 4S-»A, like 
CCR5 wt, was principally expressed on the surface o f unstimulated cells 
(data not shown). Cell surface-labelled CCR5 4S-»A also underwent agon is t- 
induced down-m odu la tion  to a similar extent as CCR5 w t and the pattern o f 
4- in trace llu la r CCR5 4S-»A staining was indistinguishable from CCR5 wt. This 
suggests that the removal o f the phosphorylation sites does not significantly 
alter the tra ff icking itinerary o f the receptor. These results are in keeping 
with the report from Huttenrauch et al. (2002), who showed that CCR5 
mutants with 3 or 4 phosphorylatable C-ta il serine residues mutated to 
alanine, despite not being able to recruit p-arrestins to membranes, were 
able to internalise, albeit at a slower rate than the w ild -type  receptor 
(Huttenrauch, Nitzki et al. 2002).
In cells incubated with RANTES fo r 60 min to down-m odula te  CCR5, 
followed by incubation in TAK-779 to assay recycling, CCR5 wt, as 
expected, recycled fu lly to the cell surface in all cells. CCR5 4S-»A also 
showed significant recovery to the cell surface, fu lly  recycling in the majority 
o f cells after a 60 min incubation in TAK-779, although a few cells showed 
incomplete recycling. These results demonstrate that receptor 
^  phosphorylation is not required for recycling.
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CCR5 wt CCR5 4S->A
unstimulated
60 min RANTES + 
60 min TAK-779
60 min RANTES
Figure 4-IX CCR5 C-tail phosphorylation is not required for internalisation or 
recycling
CHO-K1 cells tran s ien t ly  transfected  w ith  e ith e r  CCR5 w t  or CCR5 4S — A w ere  p re ­
labelled fo r  cell surface CCR5 w ith  MC-5 and th en  e ithe r  f ixed  (u n s t im u la ted ) ,  
trea ted  w ith  RANTES in BM fo r  6 0  m in  and then  fixed  (6 0  m in  RANTES), or trea ted  
w ith  RANTES fo r  6 0  m in  fo llow ed  by an in cub atio n  in BM conta in ing  T A K -7 7 9  fo r  6 0  
m in, b e fo re  being f ixed  (6 0  min RANTES + 6 0  min T A K -7 7 9 ) .  Cells w ere  then  
incu b ated  in p e rm eab il is ing  b lock ing  b u ffe r  w ith  A le x a  4 8 8  GAM secondary  
an t ib o d y  to  de tec t  M C -5 . M a x im u m  in ten s ity  p ro jections o f  stacks o f  confocal  
sections (step size, 0 .5  pm ) are  show n. Bars, 5 pm
The internalisation o f  CCR5 4S-»A is fi-a rres tin -d e p en d e n t
The phosphorylation o f CCR5 C-tail serine residues has been shown to be 
necessary for p-arrestin binding (Kraft, Olbrich et al. 2001), with at least 2 
intact phosphorylation sites determined to be necessary for p-arrestin 
recruitment to agonist-activated CCR5 (Huttenrauch, Nitzki et al. 2002). 
Moreover, CCR5 has been shown to internalise in a p-arrestin-dependent
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fashion (Fraile-Ramos, Kohout et al. 2003). However, consistent with other 
reports, the data shown above indicate that C-tail phosphorylation (at least 
o f the 4 previously reported phosphorylation sites) is not required for 
internalisation. To further clarify the dependency o f CCR5 internalisation on 
p-arrestins and assess whether the phosphorylation-defic ient mutant, CCR5 
4S-*A, internalises in a p-arrestin-dependent fashion, I transiently 
expressed either CCR5 wt or CCR5 4S-*A in mouse embryonic fibroblasts 
(MEFs) isolated from mice where p -a rre s t in l ,  p-arrestin2 or p-arrestins 1 
and 2 had been knocked out, and assessed the ability o f the receptors to 
internalise upon agonist stimulation.
Figure 4-X A shows a blot o f whole cell lysates from the different MEFs, 
probed with an antibody that recognises both p-arrestins 1 and 2, 
confirming that the cell—lines showed the correct pattern o f p-arrestin 
expression.
Figure 4-X B shows the results o f the trafficking assay. In all the cell-lines, 
CCR5 wt could be detected on the surface o f unstimulated cells. A fter 60 
min RANTES treatment, CCR5 wt accumulated in a perinuclear compartment 
in w ild -type  MEFs and in the single p-arrestin knock-ou t MEFs. Down- 
modulation proceeded to a significant extent in these cells, with practically 
no CCR5 found on the cell surface after 60 min RANTES treatment. There 
were also no gross differences in the d istr ibution o f down-modulated CCR5 
in the w ild -type and single p-arrestin knock-out MEFs. In contrast, CCR5 
did not internalise in the p-arrestin 1 and 2 knock-ou t MEFs, confirm ing the 
result o f Fraile-Ramos et al. (2003) that CCR5 internalisation, at least in 
MEFs, is p-arrestin dependent. However, I cannot rule out the unlikely 
possibility that CCR5 did internalise in the p-arrestin 1 and 2 double knock­
out MEFs but that the recycling rate was very much enhanced compared with 
MEFs expressing p-arrestins, which could also result in an exclusively cell 
surface CCR5 d istr ibution after 60 min RANTES treatment.
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MEF KO
MEF wt Pam Parr2
IB: C-HC
M (kD a)
IB: Parr
B
unstim ulated
60 min RANTES
unstim ulated
CCR5 wt
w ild-type p a rrl KO parr2 KO p a r r l+2 KO
*
CCR5 4S->A
wild-type P arrl KO Parr2 KO P a rr l+2 KO
Q SI
60 min RANTES
Figure 4-X Agonist-induced internalisation of CCR5 wt and CCR5 4S-*A is p- 
arrestin-dependent
A. Equal a m o u nts  o f  p rote ins  f ro m  w h o le  cell lysates o f  w ild -type  or kn ock-ou t MEFs 
w ere loaded on a gel. Separated  prote ins  w ere  transferred  to  n itrocellu lose and  
p robed  w ith  pan-arrestin  (recognises p -a rres tin l and p -arrestin2) and 23  (anti-
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cla thr in  h eavy  cha in ) p r im a ry  a n t ib o d ie s .  Blots w ere  s u b s e q u e n tly  in c u b a te d  w ith  
GAM-HRP an d  d e v e lo p e d  w ith  c h e m ilu m in e s c e n t  su bstra te . Bands re p re s e n t in g  p- 
a r re s t in l  an d  p -arres tin 2  are  in d ica ted  w ith  arrow s. IB, im m u n o b lo t  B. MEFs 
t ra n s ie n t ly  t ra n s fe c te d  w ith  e i th e r  CCR5 w t  or CCR5 4 S -> A  w e re  p re - labe l led  fo r  cell 
surface C C R 5 w ith  M C -5 and th en  e i th e r  f ix e d  (u n s t im u la te d )  or t re a te d  w ith  
RANTES in BM fo r  6 0  m in  and  th e n  f ix e d  (6 0  m in  RANTES). Cells w e re  th en  
in cu b a ted  in p e rm e a b il is in g  b lo ck in g  b u f fe r  w ith  A le x a  4 8 8  C A M  s e c o nd ary  
a n t ib o d y  to  d e te c t  M C -5 . E p if luo rescen ce  im ages  are sh ow n . Bar, 5 urn
CCR5 4S-*A was also highly expressed on the cell surface o f all o f the 
unstimulated MEFs and the pattern o f CCR5 4S-»A down-m odula tion  
directly matched that o f the w ild - type  receptor. CCR5 4S-*A accumulated in 
the perinuclear region after 60 min RANTES treatment in the w ild -type  and 
single p-arrestin  knock-out MEFs, but failed to undergo down-m odula tion 
in the double p-arrestin knock-ou t cells. Again, the intracellular d istr ibution 
o f down-m odu la ted  CCR5 4S-*A was indistinguishable in the wt and single 
p-arrestin knock-ou t MEFs and was also indistinguishable from CCR5 wt in 
the same cells, suggesting similar trafficking itineraries for the mutant and 
w ild -type  receptors.
In conclusion, these results suggest that CCR5 4S-»A internalises in a p- 
arrestin-dependent fashion.
f}-arrestin recruitment to agonist-activated CCR5 4S-»A
Given that CCR5 4S-*A internalised in a p-arrestin-dependent fashion in 
MEFs, I assessed whether the recruitment o f p-arrestins to the mutant 
receptor could be observed by immunofluorescence and whether the 
interaction w ith p-arrestins was sustained during redistribution o f the 
receptor into the recycling compartment, as seen for the w ild -type  receptor. 
CCR5 wt or CCR5 4S-*A were transiently co-expressed in combination with 
either p -a rres t in l-YFP  or p-arrestin2-GFP in CHO-K1 cells and treated with 
RANTES fo r e ither 5 or 60 min. As expected, both p-arrestin l-YFP and p- 
arrestin2-GFP were strongly recruited to CCR5 wt after 5 min RANTES 
treatment in all cells and this interaction was maintained after 60 min
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RANTES treatment as w ild-type receptors accumulated in a perinuclear 
compartment (Figure 4-XI A).
A
CCR5 wt P-arrestin merge
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Figure 4-XI p-arrestin recruitment to CCR5 wt and CCR5 4S-*A
C H O  CCR5 cells w ere  trans ien t ly  t ransfec ted  w ith  e ither  CCR5 w t  (A) or CCR5 4 S - * A  
(B) in co m b in a t io n  w ith  e ithe r  p -a rres tin l-Y F P  o r p-arrestin2-GFP. Cells w ere  p re ­
labelled fo r  cell surface CCR5 w ith  MC-5 and then  incubated  for the  ind icated  t im e -  
periods in BM conta in ing  RANTES at 37°C . Cells were then  f ixed  and incubated  in
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p e rm e a b il is in g  b lo ck in g  b u f fe r  w i th  A le x a  5 9 4  C A M  second ary  a n t ib o d y  to  d e te c t  
M C -5 . Single confoca l sections  are  show n . Bars, 5
Interestingly, as shown in Figure 4-XI B, p-arrestin2-GFP was also recruited 
to CCR5 4S-*A after 5 min RANTES treatment, and, moreover, this 
association was observed after 60 min RANTES treatment. However, the 
strength o f the recruitment o f p-arrestin2-GFP to CCR5 4S-*A at both t im e - 
points was variable in d iffe rent cells, suggesting that the interaction was not 
as strong as that between p-arrestin2-GFP and CCR5 wt. p-arrestin l-YFP 
was also recruited to CCR5 4S-*A after 5 min RANTES treatment, although 
far more weakly, w ith only a small amount o f colocalisation seen, and after 
60 min RANTES treatment, p-a rrestin l-YFP  failed to show an association 
with CCR5 4S—*A, which had accumulated in the perinuclear region. 
Moreover, after 5 min RANTES treatment, CCR5 4S-»A did not cluster at the 
plasma membrane or internalise to the same extent in cells co-expressing 
p-arrestin l-YFP as in cells co-expressing p-arrestin2-GFP. This suggests 
that p-arrestin2-GFP expression can accelerate the rate of CCR5 4S-*A 
internalisation above that supported by endogenous levels of p-arrestins, 
whereas p-arrestin l-YFP, which is only poorly recruited to agonist-activated 
CCR5 4S-»A, is less capable o f doing so. CCR5 also co-immunoprecipitated 
to a greater extent w ith p-arrestin2-GFP than p-arrestin l-YFP in RANTES- 
treated cells (Figure 4-VI C). Together, these observations are consistent 
with the notion that p-arrestin2 has a higher affinity for the activated 
conformation o f CCR5 than p -a rre s t in l .
The key point from  this experiment, though, is that both p-arrestin l-YFP 
and p-arrestin2-GFP were recruited to agonist-activated CCR5 4S-»A, 
strengthening the notion that phosphorylation is not strictly required fo r p- 
arrestin binding to CCR5.
Discussion
In this chapter I have presented morphological and biochemical data that 
demonstrate that p-arrestins, after facilitating the internalisation o f agon is t- 
activated CCR5, remain bound to receptors as they traffic to a perinuclear
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recycling compartment. This association appears to be a general effect o f 
CCR5 agonist-activation, since the stable interaction was observed for 
RANTES-, M IP - la -  and M IP -lp -s tim ula ted  CCR5. As expected by the 
prevailing view that like most CPCRs, CCR5 C-tail phosphorylation is 
required for h igh -a ff in ity  p-arrestin binding, phosphorylation o f the C-tail 
serine residues, S337 and S349, was detected while CCR5 remained bound 
to p-arrestins. However, contrary to the dogma, a CCR5 mutant with all 4 
serine residues shown to be phosphorylated upon receptor activation 
mutated to alanines, internalised in a p-arrestin-dependent manner and was 
observed to form  a stable association with p-arrestin2-GFP co-expressed in 
the same cells.
Association o f CCR5 with p-arrestins
p -a rre s tin  association w ith  CCR5 in the recycling com partm ent
In Chapter 3, I provided evidence suggesting that the perinuclear 
compartment to which agonist-activated CCR5 traffics may comprise 
elements o f the TCN as well as the recycling endosome. Moreover, I 
described how pre-b ind ing  o f MC-5 to cell surface receptors before 
inducing internalisation, may subtly perturb the steady-state dow n- 
modulated d is tr ibu tion  o f CCR5, with fewer receptors residing in the TCN. 
All the immunofluorescence experiments in this chapter were performed 
with pre-labelling o f cell surface receptors, as the effect o f antibody pre­
binding was not known at the time. Here, I have shown that p -arres tin - 
bound CCR5 traffics to a perinuclear compartment that shows a good 
overlap with TfR at the level o f light microscopy. The distribution o f internal, 
down-m odula ted CCR5 in CHO CCR5 cells stably expressing either p- 
arrestin l-YFP or p-arrestin2-GFP after 60 min RANTES treatment was 
indistinguishable from that in CHO CCR5 cells expressing only endogenous 
levels o f p-arrestins (Figure 3-11). This suggests that the receptor traffics to 
the same compartment in the presence of high levels o f p-arrestins.
However, from these experiments I can only conclude that CCR5 remains 
bound to p-arrestins in recycling endosomes and, w ithout the inclusion of 
TGN markers in sim ilar tra ff ick ing experiments, I cannot determine whether 
p-arrestins maintain an association with CCR5 in the TGN. However, given
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that antibody pre-b ind ing  only subtly affects the steady-state dow n- 
modulated receptor d is tr ibu tion  and that the recycling endosome and TGN 
are often d if f icu lt  to d istinguish, it would not be surprising if the interaction 
o f CCR5 with p-arrestins were maintained in the TGN.
Re-enforcing a point made in Chapter 3, in the CHO CCR5 parr l-YFP/parr2 - 
GFP cells, the TfR population showed a concentration around the nucleus as 
CCR5 accumulated in the compartment, consistent with that observed in 
CHO CCR5 cells. This fu r the r illustrates the plasticity of the compartment 
and highlights a general property o f endosomes, that, to paraphrase Ira 
Mellman in his discussion o f  early to late endosome maturation in 
Endosomes Come o f  Age, ‘given the prolific amounts of membrane known 
to move through the [endosomal] system each hour (Steinman, Mellman et 
al. 1983), it is almost a semantic impossibility to consider the endosomal 
apparatus as being anything other than subject to dynamic remodelling’ 
(Mellman 2006).
CCR5 as a Class C receptor
p-arrestins couple numerous agonist-activated CPCRs to the c la thrin - 
mediated endocytic machinery and there is various evidence to suggest that 
the nature o f the interaction o f a CPCRwith p-arrestin may, in part, regulate 
the subsequent tra ff ick ing itinerary o f the receptor. Initial work by Laporte 
and co-workers fo llow ing fluorescently-tagged p-arrestins, led to the 
identification o f  2 major classes o f GPCRs, which differed in the nature o f 
their interaction with p-arrestins (Oakley, Laporte et al. 2000). Class A 
receptors, including the p2-adrenergic receptor (p2AR), ^-op io id  receptor 
(MOR), and endothelin type A receptor, have a higher affinity for p-arrestin2 
compared with p -a rre s t in l  and they dissociate from the p-arrestin during, 
or immediately after, endocytosis. These receptors then recycle rapidly to 
the plasma membrane. Class B receptors, including the angiotensin II type 1 
receptor, vasopressin type 2 receptor (V2R) and neurotensin receptor, bind 
both p -a rre s t in l  and p-arrestin2 with equally high affinity and maintain an 
interaction with p-arrestins into endosomes. These receptors recycle very 
slowly, if at all. Receptor mutagenesis performed on the C-tails o f a variety 
o f Class B receptors showed that specific clusters o f phosphorylated
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serine/threonine residues (Ser/Thr residues occupying 3 /3 , 3/4 , or 3 /5  
consecutive positions), which are conserved in their position relative to the 
NPXXY motif, are responsible for the sustained p-arrestin association 
(Oakley, Laporte et al. 1999; Oakley, Laporte et al. 2001). These clusters are 
absent from Class A receptors, although potential phosphate acceptor sites 
are present. Interestingly, swapping the C-tails o f the Class A receptor, 
p2AR, and the Class B receptor, V2R, not only reversed the stability o f the 
receptor-p-arrestin  complex but also the corresponding rates o f receptor 
dephosphorylation, recycling and resensitisation, which are much faster fo r 
the p2AR than the V2R (Oakley, Laporte et al. 1999). Hence, it was suggested 
that the stability o f the receptor-p-arrestin  interaction regulates the rate o f 
receptor dephosphorylation, recycling and resensitisation, presumably via 
bound p-arrestins restricting the access to the receptor o f phosphatases. 
However, unmentioned by the authors is that the results o f these studies do 
not rule out the possibility that the interaction with p-arrestins may be co­
incidental and that the phosphorylated serine residues dictate these 
properties by some other mechanism.
This classification o f CPCRs into two classes and the simple role o f p- 
arrestins in impeding receptor recycling and resensitisation has proved too 
simplistic (see below), and, moreover, does not accurately describe the 
trafficking behaviour o f  CCR5 as presented in this chapter. Although CCR5 
forms a stable interaction w ith p-arrestins as it traffics to a perinuclear 
recycling compartment, typical o f a Class B receptor, CCR5 recycles rapidly 
to the plasma membrane, a process that can be seen upon agonist washout 
and incubation w ith the CCR5 antagonist, TAK-779. This is in stark contrast 
with other Class B CPCRs, which recycle very slowly, if at all (Oakley, Laporte 
et al. 1999; Anborgh, Seachrist et al. 2000). Moreover, CCR5 does not 
contain (a) cluster(s) o f serine/threonine residues as defined by Oakley et al.
(2001), supposed to mediate the stable p-arrestin association. Indeed, 
based on the results o f the tra ff ick ing experiments with CCR5 4S-*A, CCR5 
appears to be able to stably associate with p-arrestin2-GFP in a non- 
phosphorylated state (see below for further discussion). Finally, CCR5 
appears to have a higher affin ity  for p-arrestin2 than p -a rre s t in l  -  a 
hallmark o f Class A receptors -  although, unlike the p2AR, a typical Class A
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receptor, it does not show a significantly impaired internalisation rate in p- 
arrestin2 knock-ou t MEFs (Kohout, Lin et al. 2001). Whether this differential 
affin ity fo r the two p-arrestins has a regulatory bearing on CCR5 tra ff ick ing 
is open to investigation.
Other reports have recently emerged o f receptors that show similar 
behaviour to CCR5 in terms o f p-arrestin association, including members o f 
the kinin family. The bradykinin type 2 receptor (B2R) also internalises into 
endosomes with p-arrestins but upon agonist removal, the receptor is 
efficiently recycled to the plasma membrane. Interestingly, expression o f a 
p-arrestin2 mutant that has an increased affin ity for agonist-activated 
receptors, prevented recycling o f the B2R, which remained colocalised with 
the mutant p-arrestin2 on endosomes after agonist wash-out. From this, it 
was concluded that the dissociation o f p-arrestins from the B2R is necessary 
for its recycling (Simaan, Bedard-Goulet et al. 2005). The neurokinin 1 
receptor also behaves like the B2R in terms o f its p-arrestin association and 
recycling behaviour (Garland, Grady et al. 1996; McConalogue, Dery et al. 
1999). The activity o f these receptors has led Laporte and colleagues to 
suggest an extension o f the ir initial classification system to include a th ird 
group, the so-called Class C receptors (Simaan, Bedard-Goulet et al. 2005). 
These GPCRs internalise w ith p-arrestins into endosomes but the p-arrestin 
can dissociate from the receptor in endosomes and the receptor can recycle 
rapidly to the cell surface. The SST2A somatostatin receptor also exhibits 
behaviour consistent with this definition (Tulipano, Stumm et al. 2004).
By this updated classification system, CCR5 would have to be included as a 
Class C receptor, although in contrast to CCR5, the aforementioned Class C 
receptors have serine/threonine clusters in their C-tails like those described 
for Class B receptors.
p -a rre s tin s  as regu lators  o f GPCR in tracellu lar tra ffick in g
The original description o f Class B receptors suggested that p-arrestin 
association with a receptor on endosomes impedes receptor recycling and 
more recent reports have linked sustained p-arrestin interaction with 
receptor ubiquination and lysosomal targeting (Shenoy, McDonald et al. 
2001; Martin, Lefkowitz et al. 2003). Moreover, the experiments described
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above with the B2R, a Class C receptor like CCR5, suggest that dissociation 
o f p-arrestins from  the B2R is required fo r recycling. There is evidence, 
however, fo r p-arrestins acting as facilitators o f GPCR recycling fo r  the A2B 
adenosine receptor (Mundell, Matharu et al. 2000) and A/-formyl peptide 
receptor (FPR) (Vines, Revankar et al. 2003). In the case o f the FPR, although 
p-arrestins are not required fo r  its internalisation, it nevertheless co- 
internalises with p-arrestins and maintains this interaction into a R a b l l -  
positive compartment. From there, the FPR recycles efficiently to the plasma 
membrane. Interestingly, there is a complete inhibition o f recycling in p- 
arrestin 1 and 2 knock-ou t MEFs, which can be relieved by co-expression o f 
either p -a rre s t in l  or p-arrestin2, suggesting that p-arrestins are required 
for the recycling o f the FPR. In support o f this notion, the authors also found 
a greater concentration o f the FPR in the perinuclear recycling compartment 
in p-arrestin 1 and 2 knock-ou t cells compared with w ild -type MEFs. 
However, a subsequent study from the same group also concluded that 
dissociation o f p-arrestin from the FPR is required fo r its recycling (Key, 
Vines et al. 2005).
Although a clear description o f the role o f p-arrestins in the intracellular 
traffick ing o f CPCRs is lacking, these studies do suggest that p-arrestins 
may well be playing a regulatory role and that this function is likely to be 
different for particular receptors. For CCR5, I have clearly shown a sustained 
interaction with p-arrestins into the perinuclear recycling compartment. 
Unfortunately, these observations do not indicate where the receptor and p- 
arrestin dissociate, and as such, I have tried to fo llow CCR5 trafficking and 
p-arrestin2-GFP association in live cells. However, these experiments were 
hampered by the photo-sensitiv ity  o f the CHO cells used and no conclusive 
results were obtained, so this remains an open question.
In Chapter 6, I expand on the observations reported in this chapter and 
describe experiments where I have attempted to determine if p-arrestins 
regulate CCR5 intracellular traff icking.
p -a rre s tin  ub iqu itination  and association w ith GPCRs
Besides the pattern o f serine/threonine clusters in the C-tails o f GPCRs, 
another potential regulatory mechanism governing transient versus stable
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association o f p-arrestins w ith GPCRs has emerged, in that there appears to 
be a correlation between the stability o f p-arrestin ubiquitination and the 
stability o f the p-arrestin association (Shenoy and Lefkowitz 2003; Shenoy 
and Lefkowitz 2005). Indeed, expression o f p-arrestin2 with ubiquitin fused 
to its C-tail imparts Class B characteristics on the p2AR, a Class A receptor 
(Shenoy and Lefkowitz 2003). It may be that post-translational 
modifications are superimposed on the intrinsic binding affinities o f p- 
arrestin-receptor complexes to regulate their association. It would be 
interesting, therefore, to fo llow  p-arrestin ubiquitination throughout CCR5 
trafficking.
Studying a regu latory  role fo r p -a rre s tin s  in CCR5 tra ffick in g  in p -  
arrestin  kn o c k -o u t MEFs
Unfortunately, although the p-arrestin knock-out MEFs are an ideal system 
to study a differential role fo r p -a rre s t in l  and p-arrestin2 in CCR5 recycling, 
little recycling was observed in the transiently-transfected MEFs (data not 
shown). This may partially account fo r the high extent o f CCR5 dow n- 
modulation observed in these cells. Also, this may or may not reflect an 
inability o f the receptor to recycle in MEFs, per se: in my hands, CCR5 
recycled poorly in a variety o f transiently-transfected cell-lines so this may 
be more a reflection o f the inability o f transiently-transfected cells to 
support robust CCR5 recycling.
CCR5 phosphorylation and recycling 
P h osphory la tio n -independent p -a rre s tin  binding
Consistent with sustained p-arrestin binding to agonist-activated CCR5, I 
have shown by immunofluorescence that CCR5 molecules remain 
phosphorylated on serines 337 and 349 as they traffic to the perinuclear 
recycling compartment. That the intensity o f the phospho-antibody signals 
was maintained from 5 to 60 min RANTES treatment and a sustained change 
in electrophoretic mobility  o f CCR5 on polyacrylamide gels over long 
periods o f RANTES treatment was observed (Figure 4-VI), suggests that the 
majority o f receptors maintain their phosphorylated status as they pass into
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the perinuclear recycling compartment. These results are consistent w ith 
those o f Pollok-Kopp et al. (2003), who showed a sustained phosphorylation 
o f serines 337 and 349 in RBL CCR5 cells in the constant presence o f 
RANTES for 30 min. Moreover, they are harmonious with data obtained in 
CHO cells, showing that a 10 min incubation with RANTES induced a rapid 
and sustained phosphorylation o f CCR5 for at least up to 4 h (Signoret, 
Christophe et al. 2004).
I have also shown that a CCR5 m utant with all 4 serines shown to undergo 
agonist-induced phosphorylation mutated to alanines (CCR5 4S-»A), can 
undergo internalisation, again, in keeping with previous reports (Kraft, 
Olbrich et al. 2001). However, my find ing that fluorescently-tagged p- 
arrestins were recruited to agonist-activated CCR5 4S-»A is in contrast to 
previous reports demonstrating the requirement o f intact phosphorylation 
sites fo r high affin ity p-arrestin  binding. Firstly, fo llowing the interaction 
between CCR5-ECFP and p-arrestin-EYFP in HEK293 cells using fluorescence 
resonance energy transfer (FRET), Kraft et al. (2001) found that although an 
interaction between w ild -type  CCR5 and p-arrestin could be detected after 
agonist treatment, there was no significant change in the FRET ratio upon 
RANTES stimulation o f cells expressing CCR5 4S-»A-ECFP and p -a rres t in - 
EYFP. However, the authors remarked on the relative inefficiency o f this 
particular system using transiently transfected cells, with only a modest 
increase in FRET ratio seen in RANTES-treated cells expressing w ild -type  
CCR5-ECFP and p-arrestin-EYFP. Thus, perhaps the assay was not sensitive 
enough to detect an interaction between CCR5 4S->A and p-arrestin, which 
would be predicted to be weaker than binding to w ild -type  CCR5. Moreover, 
the proteins were C-term inally tagged: the addition o f CFP to the C-tail o f 
CCR5 might have weakened the strength o f p-arrestin binding, resulting in 
undetectable binding o f p-arrestin to CCR5 4S^A.
Secondly, through im m unob lo t detection o f the presence o f endogenous p- 
arrestins in membranes isolated from whole cell lysates o f RBL cells 
expressing various serine to alanine mutants o f CCR5, Huttenrauch e t al.
(2002) found that at least two intact phosphorylation sites were required to 
support p-arrestin binding. Again, the difference between these authors ’ 
results and mine is most simply explained by the difference in assay, where
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it may be argued that the assay used by Huttenrauch et al. was not sensitive 
enough to detect binding o f endogenous p-arrestins to CCR5 mutants 
lacking 3 or 4 phosphorylation sites, which would be assumed to have a 
lower affin ity fo r  p-arrestins than w ild -type  CCR5. Conversely, it could be 
argued that the association o f p-arrestins with CCR5 4 S ^A  in my assay was 
an over-expression artefact. However, I favour the first explanation, since 
CCR5 4S-*A did not internalise in MEFs lacking endogenous p-arrestins, 
whereas it did internalise in w ild - type  MEFs or MEFs lacking either p-arrestin 
1 or p-arrestin2, suggesting that p-arrestins do mediate its internalisation.
A surprising number o f CPCRs have been shown to bind p-arrestins (and in 
most cases also internalise) in the absence o f phosphorylation, including the 
^ D 6  non-signall ing chemokine receptor (Galliera, Jala et al. 2004), protease 
activated receptor 2 (Stalheim, Ding et al. 2005), lutropin receptor 
(Mukherjee, Palczewski et al. 1999; Min and Ascoli 2000; Min, Calet et al. 
2002; Mukherjee, Gurevich et al. 2002), substance P receptor (Richardson, 
Balius et al. 2003), orexin 1 receptor (Milasta, Evans et al. 2005), leukotriene 
B4 receptor 1 (Jala, Shao et al. 2005) and several splice variants o f the 
serotonin 5-HT4 receptor (Barthet, Caven et al. 2005). However, fo r the 
substance P, o rex in -1  and protease activated 2 receptors, phosphorylation 
has been shown to enhance the stability o f the p-arrestin -receptor complex 
(Richardson, Balius et al. 2003; Milasta, Evans et al. 2005; Stalheim, Ding et 
al. 2005). Likewise, it does seem that phosphorylation o f CCR5 enhances the 
affin ity and stability o f its association with p-arrestins, especially with p- 
a rres t in l:  p -a rrestin l-YFP was only weakly recruited to CCR5 4 S ^A  and the 
receptor appeared to have undergone less endocytosis after 5 min RANTES 
treatment than the w ild -type receptor (CCR5 wt). Moreover, no association 
between p -a rre s t in l  and CCR5 4S-»A was observed after 60 min RANTES 
treatment, when the receptor had accumulated in the perinuclear recycling 
compartment. A stronger interaction was observed between p-arrestin2-GFP 
and CCR5 4S-»A, which was maintained into the recycling compartment, but 
the strength o f this interaction was variable between cells and was not as 
consistently strong as the interaction between CCR5 wt and either o f the p- 
arrestins. So although agonist binding may push CCR5 into a conformation 
where it can bind p-arrestins in a phosphorylation-independent manner,
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phosphorylation may further stabilise this state and /o r increase the aff in ity  
or stability o f the interaction.
What should be made clear, though, is that jus t because agonist-activated 
receptors are capable o f binding p-arrestins and internalising in a 
^  phosphorylation-independent manner, this mechanism may not operate in 
vivo, where phosphorylation occurs rapidly after agonist-activation. This is 
also goes fo r most o f the receptors shown to undergo p-arrestin-dependent 
internalisation in the absence o f receptor phosphorylation, where this ability 
has mainly been demonstrated using phosphorylation-defic ient receptor 
mutants, although the D6 chemokine receptor, which undergoes 
constitutive p-arrestin -dependent internalisation, does not appear to be 
phosphorylated in vivo (Galliera, Jala et al. 2004).
One final consideration w ith respect to phosphorylation-independent p- 
arrestin binding is that, although unlikely, there is the possibility that CCR5 
is phosphorylated on residues other than serines 336, 337, 342 and 349 in 
CHO cells and MEFs. The C-term inus o f CCR5 contains 5 serine and 2 
threonine residues that could be phosphorylated upon receptor activation. 
The phospho-am ino acid analysis that revealed that agonist-induced 
phosphorylation o f CCR5 occurs exclusively on serine residues and alanine 
scanning mutagenesis that showed that only serines 336, 337, 342 and 349 
undergo agonist-induced phosphorylation, were carried out in COS-7 cells 
(Oppermann, Mack et al. 1999). Moreover, the subsequent experiments that 
showed that S337 is a PKC substrate and S349 is a GRK substrate were 
conducted in RBL cells (Pollok-Kopp, Schwarze et al. 2003). Although S325 
would be an unlikely candidate for phosphorylation due to its proxim ity to 
cysteines 321, 323 and 324, which have been shown to be palmitoylated 
(Blanpain, Wittamer et al. 2001; Kraft, Olbrich et al. 2001; Percherancier, 
Planchenault et al. 2001), it remains to be determined if the threonine 
residues are phosphorylated upon agonist activation in CHO cells or MEFs. 
32P-lablleing o f RANTES-treated cells expressing CCR5 4S-»A could confirm 
whether this is the case.
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Phosphorylation, resensitisation and recycling
As alluded to above, internalisation and recycling is generally considered to 
be necessary for CPCR resensitisation, which involves agonist dissociation, 
dephosphorylation o f C-tail Ser/Thr residues and recycling back to the 
plasma membrane (Hanyaloglu and von Zastrow 2007). For instance, f32AR, 
the prototypical CPCR, undergoes agonist dissociation in the low pH o f the 
early endosome, and dephosphorylation and recycling o f the receptor are 
inhibited by raising endosomal pH (Krueger, Daaka et al. 1997; Signoret, 
Christophe et al. 2004). Recycled receptors are competent to respond to 
further rounds o f agonist stimulation. However, unlike the p2AR, a pH- 
dependent agonist-dissociation mechanism does not operate fo r CCR5 
agonists and the recycling o f CCR5 is not affected by raising endosomal pH 
(Signoret, Christophe et al. 2004). Moreover, receptors can recycle to the 
plasma membrane in an agon is t-bound form, which results in their re­
internalisation (Signoret, Pelchen-Matthews et al. 2000). Dephosphorylation 
o f CCR5 does not appear to be required for recycling either (nor is it 
inhibited by raising endosomal pH (Signoret, Christophe et al. 2004)), since 
an N -term inally  modified form o f RANTES, AOP-RANTES, which shows an 
enhanced association with CRKs and increased phosphorylation o f C-tail 
serine residues (Oppermann, Mack et al. 1999; Vila-Coro, Mellado et al. 
1999), recycles with similar kinetics to RANTES-treated CCR5 (Signoret, 
Pelchen-Matthews et al. 2000).
The results presented in this chapter are consistent with these previous 
observations, in that most receptors appear to remain phosphorylated as 
they traffic  to the perinuclear recycling compartment, but both a 
phosphorylation-defic ient receptor and a w ild -type  receptor, which has the 
potential to remain phosphorylated, are able to recycle. The results also 
demonstrate that a dephosphorylated receptor could traffic to the recycling 
compartment and also engage the recycling machinery, since agon is t- 
activated CCR5 4S-*A was seen to accumulate in the recycling compartment 
under constant agonist stimulation and was also able recycle back to the 
plasma membrane. This raises the possibility that dephosphorylation could 
occur as early in post-endocytic traff icking as in the early endosome, 
w ithout perturbing the traff icking itinerary o f the receptor. Whether 
phosphorylation actually plays a role in regulating post-endocytic CCR5
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trafficking, though, is not certain. The simplest role for phosphorylation in 
controlling tra ff icking o f a GPCR is one exercised through p-arrestin binding 
(as described above), although dephosphorylation may be more controlled 
by p-arrestin dissociation, allowing phosphatases to access phosphorylated 
residues, rather than the other way round (although perhaps not fo r CCR5, 
given the accessibility o f phospho-sites to antibodies -  see below). This 
simple view o f phosphorylation exerting its effect through p-arrestin 
binding has been challenged, though, by mutational analysis o f the V2R, 
which has shown that phosphorylated residues in the C-tail required fo r a 
sustained association w ith p-arrestins are distinct from those slowing 
receptor recycling (Innamorati, Le Gouill et al. 2001; Le Gouill, Innamorati et 
al. 2002). Moreover, a recent study with the MOR (a Class A receptor), 
suggests that phosphorylated and non-phosphorylated MORs recycle 
through distinct pathways mediated by Rab4 and R a b l l ,  respectively (Wang, 
Chen et al. 2008). Despite this, fo r most GPCRs, dephosphorylation may 
simply be a requisite step in their resensitisation process and specific 
sequences present in their C-tails may be far more important in mediating 
recycling (Hanyaloglu and von Zastrow 2007). However, there is some data 
suggesting that phosphorylation may control the interaction o f regulatory 
proteins with these sequences (see below).
Unfortunately, the phosphorylation assays described in this chapter provide 
little kinetic data for either down-m odu la tion  or recycling. The dow n- 
modulation o f CCR5 wt and CCR5 4S-»A were only assessed after 60 min 
RANTES treatment in both CHO-K1 cells and MEFs, and recycling only after 
60 min in CHO-K1 cells. These t im e-po in ts  were chosen as they have been 
shown to be sufficient to allow a steady-state down-modulated d istr ibution 
o f CCR5 to be established and allow enough time for the recovery o f the 
vast majority o f CCR5 molecules to the cell surface in CHO CCR5 cells, 
respectively. The immunofluorescence results may belie significant 
differences in traff icking rates fo r the two receptors and for the receptors in 
the absence o f either p -a rre s t in l  or p-arrestin2. These differences may be 
revealed by a kinetic analysis o f cell surface CCR5 levels at numerous t im e -  
points by flow cytometry, as has been employed in Chapters 5 and 6 for 
other investigations.
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Certainly, though, CCR5 does seem to be unique among CPCRs, in that a 
significant proportion o f agonist-activated, internalised receptors recycle to 
the plasma membrane in an agonist-bound, activated form, escaping 
resensitisation. Why this should be the case is unclear, but it may have 
something to do with its role in chemotaxis. Perhaps a migrating cell 
exposed to a chemokine gradient regulates the rate o f resensitisation o f its 
chemotactic receptors as part o f its gradient-sensing mechanism. 
Alternatively, both vesicles emanating from the recycling endosome and the 
TCN have been shown to be delivered to the front o f the lamellipodium in 
migrating cells (Hopkins, Gibson et al. 1994; Schmoranzer, Kreitzer et al. 
2003; Prigozhina and Waterman-Storer 2004), and there is evidence fo r the 
accumulation o f CCR5 at the leading edge o f migrating T cells (Nieto, Frade 
et al. 1997). Moreover, there is growing recognition that p-arrestins may 
scaffold signalling molecules involved in cytoskeletal reorganisation to 
promote localised actin assembly events leading to the formation o f a 
leading edge (Defea 2006), so perhaps the lack o f CCR5 resensitisation (and 
continued p-arrestin association) is a mechanism to deliver bound p- 
arrestins to the lamellipodium via targeted exit from the recycling 
compartment.
CCR5 recycling and sequence-d irected  recycling
A recent study conducted by Delhaye e t al. identified the last four amino 
acids o f the CCR5 C-term inus as crucial fo r receptor recycling (Delhaye, 
Gravot et al. 2007). Removal o f these residues resulted in a re -rou ting  o f 
internalised receptors to lysosomes fo r degradation. These last four amino 
acids, SVGL, which contain Ser349, conform to a type II PDZ ligand (X -^-X -^ , 
where X is any amino acid and 4> is a hydrophobic amino acid). The authors 
propose that this putative PDZ-ligand may engage PDZ domain-conta in ing 
proteins, such as the Na+/H + exchanger regulatory factor / 
ez r in /rad ix in /m oes in -b ind ing  phosphoprotein o f 50 kDa (NHERF/EBP50), 
which regulates recycling o f the p2AR by binding to a type I PDZ ligand 
(DSLL) at its C-term inus (Cao, Deacon et al. 1999). Interestingly, recycling o f 
the p2AR is inhibited by the phosphorylation o f the serine residue after GRK5 
over-expression, which may prevent NHERF/EBP50 binding. Moreover,
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replacement o f Ser411 with a phospho-m imetic  aspartic acid residue 
blocked the interaction o f the receptor with NHERF and also inhibited 
recycling, leading to the degradation o f internalised receptors. In contrast, 
Delhaye et al. found that CCR5 recycling seemed to be independent o f the 
phosphorylation state o f S349: in Jurkat cells, a CCR5 phospho-m im etic  
mutant in which Ser349 had been mutated to Glu, recycled jus t as well as 
the w ild -type  receptor and the recycling o f a Ser349->Ala mutant was only 
partially inhibited in its ability to recycle. The results o f this study are 
compatible with the data presented herein, as the CCR5 4S-»A mutant would 
effectively contain an intact PDZ ligand with the serine residue mutated to 
alanine. PDZ ligand-based recycling signals have been suggested to regulate 
the recycling o f numerous other GPCRs, such as the MOR (Tanowitz and von 
Zastrow 2003) and the endothelin type A receptor (Paasche, Attramadal et 
al. 2005), and a sequence conform ing to a type II PDZ ligand is present in 
the chemokine receptor, CCR2b (Hung and Sheng 2002). Such a sequence- 
dependent recycling mechanism may operate for CCR5, perhaps 
superimposed on a p-arrestin-dependent regulatory mechanism (see 
below).
Accessibility o f ph o sp h o -s ites  and im plications fo r control o f CCR5 
tra ffick in g
Despite the observation that p-arrestin2-GFP is stably recruited to CCR5 
4S-*A, C-tail serine phosphorylation probably participates in high affin ity p - 
arrestin binding, as is the case for numerous other GPCRs (Gurevich and 
Gurevich 2006). As such, it may be expected that p-arrestin binding would 
preclude the binding o f phosphosite-specific antibodies. That antibody 
binding was observed in the immunofluorescence experiments described 
above can be explained in at least two ways.
The first explanation is related to the ability o f CCR5 to dimerise, which has 
been reported by several d ifferent groups (Blanpain, Vanderwinden et al. 
2002; Chelli and Alizon 2002; Issafras, Angers et al. 2002; Huttenrauch, 
Pollok-Kopp et al. 2005). In a CCR5 dimer, perhaps only one activated 
receptor need bind p -a r re s t in l /2  to effect internalisation, leaving a p- 
arrestin-free C-tail that is accessible to phospho-site specific antibodies.
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The second explanation is that the phosphorylated residues, a lthough 
required for h igh -a ff in ity  p-arrestin binding, may become accessible 
(solvent exposed) after transition o f the p-arrestin molecule from its basal, 
cytosolic conformation into its active, h igh-a ff in ity  receptor binding 
conformation upon engagement with an activated, phosphorylated receptor. 
Phospho-residues on the receptor are believed to disrupt the polar core o f 
the p-arrestin molecule, a process necessary for p-arrestin activation. 
Interestingly, mutation o f the phosphate-sensitive residue, A rg l6 9 ,  in the 
polar core o f p -a rre s t in l  results in an arrestin molecule that binds agon is t- 
activated but non-phosphorylated p2AR w ith similar affin ity to which w i ld -  
type p -a rre s t in l  binds the agonist-activated, phosphorylated receptor 
(Kovoor, Celver et al. 1999). This suggests that after the conformational 
change in the p-arrestin molecule promoted by phosphate binding, ionic 
interactions between the phospho-residues and the p-arrestin molecule in 
the finally rearranged receptor-p-arrestin  complex are not required for 
h igh-a ff in ity  binding. Moreover, this also appears to be true fo r  the 
sustained interaction o f p-arrestins with Class B receptors (Oakley, Laporte 
et al. 2001). Oakley e t al. showed that p -a rre s t in l  formed stable complexes 
with agonist-activated neurotensin receptor (NTR) and V2R as they 
trafficked into endosomes (Class B receptors), whereas mutation o f one o f 
the serine clusters in their C-tails, which are phosphorylated upon agonist- 
activation, prevented this stable interaction (p -a rres tin l dissociated at or 
near the plasma membrane). However, a truncated p-arrestin mutant, in 
which the structural constraint o f the p-arrestin C-tail involved in 
maintaining p-arrestin in its basal conformation was removed, stably 
associated with the mutant receptors as they redistributed into endosomes, 
suggesting that ionic interactions between the phospho-residues and the p- 
arrestin molecule in the finally rearranged receptor-p-arrestin complex are 
not required fo r the sustained, h igh-a ff in ity  p-arrestin interaction but that 
the phospho-residues may, instead, function to promote conformational 
changes in the p-arrestin molecule that promote this sustained interaction.
If, after a stable CCR5-p-arrestin complex has been formed, the 
phosphorylation status o f the CCR5 C-tail serine residues becomes 
redundant fo r h igh -a ff in ity  p-arrestin binding - and phospho-residues
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become solvent-exposed - CCR5 dephosphorylation and p-arrestin 
dissociation may not be t igh tly  coupled, as is suggested fo r other GPCRs 
(Oakley, Laporte et al. 1999). A second intriguing implication is that the 
putative PDZ ligand at the extreme C-term inus, which includes S349, would 
also be accessible on a p-arrestin-engaged receptor. This would also be the 
case in a receptor dimer w ith only one CCR5 C-tail bound to p-arrestin. 
Either way, the fact that at least some o f the P-S349 epitopes are accessible 
to antibody binding demonstrates that a PDZ sequence-directed regulatory 
mechanism could act alongside a p-arrestin-dependent regulatory 
mechanism fo r CCR5 trafficking.
Summary of CCR5 C -ta il phosphorylation and trafficking with p -  
arrestins
Although many aspects o f the phosphorylation o f CCR5 and its association 
with p-arrestins are unclear, Figure 4—XII shows a cartoon model o f CCR5 
trafficking and association with p-arrestins that attempts to integrate the 
data presented in this chapter with previous reports.
In this model, agonist binding leads to receptor activation but CCR5 
molecules are rapidly desensitised, a process initiated by phosphorylation o f 
C-tail serine residues by PKC and CRKs 2 and 3. This increases the affin ity  
o f receptors fo r p-arrestins 1 and 2, which bind and couple CCR5 molecules 
to the c lathrin-mediated endocytic machinery. Receptors internalise with p- 
arrestins and traffic  through early endosomes to a perinuclear recycling 
compartment, maintaining an interaction with p-arrestins throughout this 
trafficking. A significant proportion o f the receptors reaching this 
compartment appear to be phosphorylated. From here, receptors recycle 
back to the plasma membrane. Some receptors returning to the cell surface 
are agonist-free, dephosphorylated and, presumably p-arrestin -free (i.e. 
resensitised), although the site(s) o f these resensitisation processes are 
unclear - an agonist-free, dephosphorylated receptor is tentatively drawn in 
the perinuclear recycling compartment in the model. Some CCR5 molecules, 
however, recycle back to the plasma membrane in an agon ist-bound and 
presumably phosphorylated state. In this case, they can re-engage the 
clathrin-mediated endocytic machinery and undergo a further round o f
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internalisation and recycling. Whether p-arrestins remain engaged with 
agonist-bound receptors as they recycle back to the cell surface is 
unknown. It may take several cycles o f internalisation and recycling for the 
average receptor to be resensitised.
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Figure 4-XII Cartoon illustrating the association of p-arrestins with CCR5 
throughout intracellular trafficking
See m ain  te x t fo r d e ta ils . R eceptor ac tiva tio n  is in d icated  by a co lour change fro m  
black to  red . T h e  recycling c o m p a rtm e n t, w h ich  m ay com prise  e lem ents  o f th e  TG N  
and recycling en d o so m e (see C h a p te r 3 ) is show n in a s im p lified  fo rm . T he  M T O C  is 
show n in th e  b o tto m  rig h t corner; d o tte d  g rey  lines rep resen t m ic ro tu b u les  
e m an atin g  fro m  the  M TO C .
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The data presented in the previous two chapters demonstrate that after 
agonist activation, CCR5 is internalised and traffics to a perinuclear 
recycling compartment comprising recycling endosome and TCN elements, 
p-arrestins, which are recruited to activated receptors at the cell surface, 
remain bound to CCR5 molecules as they traff ic  to this compartment. In this 
chapter, I focus on the tra ff icking machinery that may operate to bring 
about CCR5 recycling from the recycling compartment, providing evidence 
that the passage o f CCR5 through this compartment is both c la th rin - and 
dynamin-dependent.
Down-modulated CCR5 accumulates in compartments 
decorated with clathrin
Very little is currently known about the mechanisms operating at the 
recycling compartment fo r sorting internalised CCR5 for recycling. Indeed, 
the experiments showing that CCR5 likely traffics through the TGN in 
addition to the recycling endosome (see Chapter 3) do not indicate whether 
the recycling endosome or TGN is the site o f this sorting mechanism. A clue 
to a possible sorting mechanism, though, comes from the observations o f 
immunolabelled cryosections by Signoret e t al. (2000), where after 60 min
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RANTES treatment in CHO CCR5 cells, CCR5 was observed in tubules and 
vesicles in the perinuclear region, with the vesicles often displaying a 
prominent coat, highly reminiscent o f clathrin. However, no 
immunolabelling was carried out to confirm the nature o f the coat. 
Endosomal clathrin-coated buds (which label positively fo r TfR) have been 
observed in A431 and HeLa cells (Stoorvogel, Oorschot et al. 1996; van Dam 
and Stoorvogel 2002), and TfR recycling from recycling endosomes (but not 
early endosomes) appears to involve the formation o f c lathrin-coated 
vesicles in a dynamin-dependent manner (van Dam and Stoorvogel 2002). In 
addition, endosomal c lathrin-coated buds have been observed in polarised 
Madin-Darby canine kidney (MDCK) cells, where they have been proposed to 
play a role in basolateral TfR tra ff ick ing (Futter, Gibson et al. 1998). More 
recently, there has also been a report that ACAP1 (ARFGAP with coiled coil, 
ANK repeat, and pleckstrin homology domains), which has been shown to be 
involved in the recycling o f the TfR from the recycling endosome (Dai, Li et 
al. 2004), acts as a clathrin adaptor in stimulation-dependent integrin 
recycling and insulin-stimulated recycling o f glucose transporter type 4 
(GLUT4) from the recycling endosome (Li, Peters et al. 2007). Clathrin has 
long been known to be present at the TGN, although its role has been best 
described in terms o f mediating sorting from the TGN to endosomes 
(Robinson 2004).
Based on the above evidence, a reasonable hypothesis is c lathrin-coated 
^ves ic le  formation at the recycling compartment is involved in CCR5 
recycling, perhaps with CCR5-containing vesicles being directly targeted to 
the plasma membrane. I have also shown that p-arrestins, which internalise 
with CCR5, remain bound to receptors in the recycling compartment, so a 
more tantalising hypothesis is that p-arrestins function as clathrin adaptors 
for CCR5 at the recycling compartment.
To test the plausibility o f the hypothesis that CCR5 transit through the 
recycling compartment requires clathrin, I initially assessed by 
immunofluorescence the extent to which clathrin could be found on steady- 
state down-modulated CCR5-containing compartments (Figure 5-1). Figure 
5-1 A shows the results o f an experiment using CHO CCR5 cells stably 
expressing clathrin light chain a fused to dsRed (CHO CCR5 CLCa-dsRed 
cells), which has previously been shown to label c lathrin-coated pits w ithou t
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interfering with c lathrin-mediated endocytosis (Gaidarov, Santini et al. 
1999; Merrifield, Feldman et al. 2002; Perrais and Merrifield 2005). This 
experiment was performed in a similar manner to experiments fo llow ing the 
association o f p-arrestins w ith CCR5, in that cell surface CCR5 was pre­
labelled with MC-5 and cells were co-stained fo r TfR. The figure shows 
representative single confocal sections through the middle o f cells. In 
unstimulated cells, CCR5 was present diffusely over the cell surface. Clathrin 
signal was localised to punctate structures that were predominantly located 
in the perinuclear region. Clathrin puncta were also observed at the plasma 
membrane, but these were only really visible in basal sections, where a 
greater proportion o f the plasma membrane was covered in the field o f view 
(data not shown). TfR staining was punctate and frequently concentrated in 
the perinuclear region, although, as previously noted in CHO cells used in 
the experiments described in this thesis, significant amounts o f punctate 
staining was seen throughout the rest o f the cytoplasm. TfR and clathrin 
exhibited a partial overlap in both the perinuclear region and in the rest o f 
the cytoplasm; separate TfR-positive and c lathrin-positive puncta were 
observed in both regions. Perinuclear c la thrin - and TfR-positive puncta 
presumably represented clathrin-decorated recycling endosomes; more 
peripheral puncta positive for both proteins were more likely early 
endosomes. The perinuclear clathrin signal that did not colocalise with TfR 
was likely localised to the TGN.
After 60 min RANTES treatment, CCR5 redistributed from the cell surface 
mainly into the perinuclear region, although some more peripherally- 
located CCR5 puncta were observed and some cell surface CCR5 was also 
seen. As observed in CHO CCR5 and CHO CCR5 |3arrl-YFP/(3arr2-GFP cells, 
CCR5 showed an almost complete overlap with TfR, which appeared more 
concentrated around the nucleus than in unstimulated cells. Significantly, 
clathrin colocalised well w ith CCR5 that had accumulated in the perinuclear 
region, suggesting the presence o f clathrin on CCR5-containing recycling 
endosomes. Clathrin was also present on many o f the more peripheral 
CCR5- and TfR-positive puncta. As in unstimulated cells, some clathrin 
puncta that did not colocalise with TfR and CCR5 were also observed in both 
the perinuclear region and more peripheral cytoplasm.
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Figure 5-1 In the constant presence of agonist, down-modulated CCR5 
accumulates in intracellular compartments decorated with clathrin
A. C H O  CCR5 c la th rin  LCa-dsRed cells w ere  p re -labe lled  fo r  cell surface CCR5 w ith  
M C-5 and th en  e ith e r fixed  (u n s tim u la te d ) o r incubated  w ith  RANTES in BM fo r 6 0  
m in b e fo re  being  fix e d  (6 0  m in  RANTES). Cells w ere  then  in cu b ated  in 
p erm eab ilis in g  b lock ing  b u ffe r w ith  H 6 8 .4  (an ti-T fR ) p rim ary  an tib o d y . M C -5 and  
H 6 8 .4  w ere  d e tec ted  w ith  A le x a  4 8 8  GAM lg G 2a  and A lexa  6 4 7  G AM  Ig G l 
secondary an tib o d ie s , respective ly . B. C HO  CCR5 cells w ere  p re -labe lled  fo r  cell 
surface CCR5 w ith  M C-5 and th en  e ith e r  fix e d  (u n s tim u la te d ) o r tre a te d  w ith  
RANTES in BM fo r 6 0  m in and th en  fix e d  (6 0  m in RANTES). Cells w ere  th en  
incubated  in p e rm eab ilis in g  b lock ing  b u ffe r w ith  M C -5 (an ti-C C R 5) and X 2 2  (an ti- 
cla thrin  heavy chain ) p rim a ry  a n tib o d ie s . M C -5 and X 2 2  w ere  d e tec ted  w ith  A le x a  
4 8 8  GAM lg G 2a  and A lexa  5 9 4  G AM  Ig G l,  respective ly . C. C HO  CCR5 cells w ere
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tre a te d  w ith  C HX to  c lear n ew ly  syn th es ised  CCR5 fro m  th e  b io s y n th e tic  p a th w a y . 
C ells w e re  th e n  tre a te d  w ith  RANTES in BM c o n ta in in g  CHX fo r 6 0  m in , b e fo re  b e in g  
fix e d . C ells w ere  th e n  p e rm e a b ilis e d  in b lo ck in g  b u ffe r and in cu b a ted  w ith  M C -5  
(an ti-C C R 5) and  X 2 2  (a n ti-c la th r in  heavy  ch a in ) p rim a ry  a n tib o d ie s . M C -5 and  X 2 2  
w ere  d e te c te d  w ith  A le x a  4 8 8  C A M  lg C 2 a  and  A le x a  5 9 4  C A M  Ig G l,  res p e c tiv e ly . 
Single co n foca l sections a re  show n in A , B and C. Bars, 5 ^ m .
To ensure that the overlap between down-modulated CCR5 and clathrin was 
not an overexpression artefact, I repeated the trafficking assay in CHO CCR5 
cells, staining fo r endogenous clathrin heavy chain (Figure 5-1 B; TfR 
staining was omitted from this experiment). In unstimulated cells, clathrin 
staining was very similar to that o f CLCa-dsRed in the CHO CCR5 CLCa- 
dsRed cells: punctate and strongest in the perinuclear region, with some 
puncta found in the rest o f the cytoplasm and at the plasma membrane. 
CCR5 was present over the whole o f the cell surface. After 60 min RANTES 
treatment, CCR5 accumulated in the perinuclear region and showed a 
significant overlap with clathrin staining, in agreement with the overlap 
observed between CCR5 and CLCa-dsRed in the CHO CCR5 CLCa-dsRed 
cells.
I also performed the experiment w ithout pre-b inding MC-5 (Figure 5-1 C). 
Here, CHO CCR5 cells were pre-treated with CHX to clear CCR5 from the 
biosynthetic pathway, treated with RANTES, fixed and labelled for CCR5 with 
MC-5 post-fixa tion . Under these conditions, a significant amount o f down- 
modulated CCR5 staining was observed to overlap with a TGN marker, p230 
(Figure 3—IX). As expected, CCR5 and clathrin distributions in unstimulated 
cells were indistinguishable from cells pre-labelled for CCR5 as in Figure 5-1 
B (data not shown). After 60 min RANTES treatment, CCR5 accumulated in 
the perinuclear region and, again, showed a strong overlap with clathrin. 
This suggests that regions o f the TGN containing CCR5 are probably also 
coated with clathrin.
Altogether, these data show that the recycling compartment through which 
CCR5 passes is extensively coated with clathrin at the point CCR5 is 
traversing it.
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Down-modulated CCR5 accumulates in intracellular 
compartments positive for AP-1
In Chapter 3, I showed that after 60 min RANTES treatment, dow n- 
modulated CCR5 accumulated in compartments that were positive for AP-1. 
This colocalisation is again illustrated in Figure 5-11 A, where CHO CCR5 
cells were either untreated or treated with RANTES fo r 60 min, fixed and 
subsequently stained fo r CCR5 and y-adaptin, a component o f AP-1. Not 
only did CCR5 colocalise with y-adaptin in the perinuclear region, but some 
more peripherally located CCR5 puncta also colocalised with y-adaptin, 
which perhaps represents AP-1 on CCR5-containing early endosomes. In 
Chapter 3, I also showed that some o f the perinuclear CCR5- and y-adap tin -  
positive puncta were largely negative fo r TfR (this is illustrated with another 
example in Figure 5-11 B; most easily observed in the dual channel, green- 
red merges) and that significant overlap o f down-modulated CCR5 with 
p230, a TGN marker, could be observed. However, some CCR5 could also be 
detected in y-adaptin-positive but p230-negative perinuclear puncta, so 
altogether, after 60 min RANTES treatment, CCR5 could be found in the TGN 
and recycling endosomes, which are both positive for AP-1. Overall, the 
clear message is that agonist-activated CCR5 certainly passes through 
multiple A P - l-p o s it ive  compartments.
In keeping with the data presented in this chapter, S. Wavre, by electron 
microscopy (EM) observations o f immunolabelled cryosections, has more 
recently observed down-modulated CCR5 in A P - l-po s it ive  coated vesicles 
adjacent to other CCR5-containing coated structures in the perinuclear 
region, whose coat also labels for AP-1 (Silene Wavre, Endocytic Regulation 
o f Chemokine Receptor Expression, PhD thesis, 2006). The presence o f AP- 
1 in these coats provides strong evidence that the coat is clathrin.
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Figure 5-11 In the constant presence of agonist, down-modulated CCR5 
accumulates in intracellular compartments positive for AP-1
A + B. C H O  CCR5 cells w ere  tre a te d  w ith  CHX to  c lear new ly  synthesised CCR5 fro m  
the  b io syn th e tic  pathw ay. Cells w ere  th en  e ith e r  fixed  (u n s tim u la te d ) or tre a te d  w ith  
RANTES in BM co n ta in in g  CHX fo r  6 0  m in b e fo re  being  fixed  (6 0  m in RANTES). Cells  
in A w ere  th en  p erm eab ilised  in b lock ing  b u ffe r and incu b ated  w ith  M C -5 (an ti- 
C CR5) and M ary  (an ti-y -adap tin ) p rim a ry  an tib o d ie s . M C-5 and M ary w ere  d e te c te d  
w ith  A lexa  4 8 8  C A M  and A lexa  5 9 4  CAR, respective ly . Cells in B w ere  p e rm e a b ilis e d  
in b locking  b u ffe r and incubated  w ith  M C-5 (an ti-C C R 5), M ary (an ti-y -ad ap tin ) and  
H 6 8 .4  (an ti-T fR ) p rim ary  a n tib o d ies . M C -5 , M ary and H 6 8 .4  w ere  d e te c te d  w ith  
A lexa  4 8 8  G A M  lg C 2a , A lexa  5 9 4  CAR and A lexa  6 4 7  C A M  Ig G l , respective ly . S ing le  
confocal sections are show n. D ual ch annel, g reen -red  m erges b etw een  CCR5 and y- 
a d ap tin , and CCR5 and TfR  are  a lso  show n. Bars, 5 pm .
Significantly, there is evidence from other systems for AP-1 acting as a 
clathrin adaptor protein at both the recycling endosome and TGN. For 
recycling endsomes, the strongest evidence comes from polarised cells,
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where a variant o f AP-1 containing the ^ilB subunit, AP-1B (Folsch, Ohno et 
al. 1999), has been shown to mediate TfR recycling to the basolateral 
membane (Rodriguez-Boulan, Musch et al. 2004) and has been suggested to 
function in the basolateral delivery o f newly synthesised proteins in 
epithelial cells (Folsch 2005). In non-polarised cells, AP-1 has been shown 
to be involved in TGN to endosome sorting (Robinson 2004), although no 
role has been demonstrated for AP-1 in TGN to plasma membrane 
trafficking in non-polarised cells. Interestingly, The Alliance for Cellular 
Signaling (www.signaling-gateway.org) recently reported a yeast tw o-hybrid  
interaction between p -a rres t in l and the p i  subunit o f AP-1. Moreover, in 
COS cells over-expressing GFP-tagged p-arrestin 1 or 2, AP-1 co - 
immunoprecipitates with the tagged p-arrestins (Julie Pitcher, personal 
communication), although AP-1 shows a stronger interaction w ith p - 
a rres t in l than p-arrestin2. I also have preliminary data suggesting an 
interaction between p-arrestin l-YFP and AP-1 in CHO CCR5 parrl-YFP cells 
using the same immunoprecipitation protocol as for the CCR5-p-arrestin 
co-immunoprecip itations described in Chapter 4 (data not shown). However, 
the extent o f this interaction did not appear to be agonist dependent. Given 
that p-arrestins accompany CCR5 as it traffics to the perinuclear 
compartment, there is the possibility fo r a situation highly analogous to that 
which exists at the plasma membrane, where p-arrestins couple CCR5 to 
both AP-2 and clathrin, in that p-arrestins could couple CCR5 to AP-1 and 
clathrin in the recycling compartment, resulting in the formation o f 
transport vesicles involved in the recycling o f the receptor to the plasma 
membrane.
Brefeldin A partially inhibits CCR5 recycling
To investigate a role fo r AP-1 in CCR5 recycling, I initially assessed CCR5 
recycling in the presence o f the fungal metabolite, brefeldin A (BFA). BFA 
interferes with the CTP exchange function o f GTP exchange factors (CEFs) 
for ADP-ribosylation factor (ARF) family proteins (Donaldson, Finazzi et al. 
1992; Helms and Rothman 1992). This prevents the binding o f ARF proteins 
to membranes and the proteins they, in turn, recruit (Klausner, Donaldson et 
al. 1992). AP-1 is recruited to membranes in part by the action o f ARF
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proteins and, indeed, BFA treatment causes the loss o f y-adaptin from  the 
TGN (Robinson and Kreis 1992; Wong and Brodsky 1992; Wagner, 
Rajasekaran et al. 1994) and from endosomes (Futter, Gibson et al. 1998). 
Moreover, in MDCK cells, where Tf was found in y-adaptin-conta in ing, 
endosomal clathrin-coated buds, BFA treatment led to the loss o f y-adaptin  
from endosomes and an inhibit ion o f the basolateral sorting o f Tf, w ith a 
corresponding apical Tf release (Futter, Gibson et al. 1998).
To determine whether BFA treatment led to the loss o f AP-1 from 
membranes in CHO CCR5 cells and to determine the lowest concentration 
that gave a rapid redistribution (to avoid concentration-dependent non­
specific effects), I assessed the effect o f various concentrations o f BFA on y- 
adaptin distribution by immunofluorescence (Figure 5—III A). After 1 min 
treatment with 10 ^g /m l BFA, a significant redistribution o f y-adaptin from a 
principally punctate, perinuclear d istr ibution to a disperse, cytoplasmic 
staining pattern had occurred; however, some punctate, perinuclear staining 
remained. Treatment with 100 ng/m l BFA for 1 min did not result in any 
additional redistribution, but the loss o f punctate, perinuclear y-adaptin 
staining was far less in cells treated with 1 ^g /m l BFA, where the y-adaptin 
distribution was largely unchanged. After 5 min incubation with 1 ^g /m l 
BFA, y-adaptin staining had largely become diffuse and cytoplasmic, but 
some perinuclear puncta still remained. In cells treated with 10 or 100 
^g /m l BFA, nearly all o f the y-adaptin staining had become diffuse, 
suggesting that the majority o f AP-1 had been lost from TGN and 
endosomal membranes after 5 min.
From these results, 10 [xg/ml BFA was chosen for use in subsequent CCR5 
recycling assays given the faster loss o f y-adaptin membrane staining than 
with 1 ng/m l BFA but no apparent increase in rate of loss o f y-adaptin 
membrane-association with 100 ^g /m l BFA.
To assay recycling, I firstly used a FACS-based recycling assay. In this assay, 
CHO CCR5 cells were treated in suspension with RANTES for 60 min in order 
for CCR5 to reach a down-modulated steady-state. Cells were then washed 
and incubated with TAK-779 for 60 min. Aliquots o f cells were removed 
from suspension at various t im e-po in ts  during the RANTES and TAK-779 
incubation phases and their cell surface CCR5 levels measured by FACS.
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As previously shown in this thesis by immunofluorescence, after 60 min 
RANTES treatment, the majority o f the internal receptor pool is located in 
the perinuclear region (recycling compartment). In addition, Signoret e t al. 
(2000) estimated that at least 75% o f the internal CCR5 under these 
conditions was present in perinuclear tubules and vesicles, by morphometric 
analysis o f immunolabelled cyrosections. Hence, a subsequent incubation o f 
60 min RANTES-treated cells with the CCR5 antagonist, TAK-779, which 
prevents re-internalisation o f receptors (and internalisation o f receptors 
transiently present at the cell surface at the end o f this 60 min RANTES 
treatment), allows receptor recycling from the recycling compartment to the 
cell surface to be followed.
Figure 5—III B shows the results o f a FACS-based trafficking experiment, 
where BFA has been included in, or omitted from, the TAK-779 incubation. 
Here, cell surface CCR5-associated fluorescence has been expressed as a 
percentage o f the initial cell surface fluorescence. Unfortunately, individual 
experiments showed a variable extent o f recycling after 60 min incubation 
with TAK-779 (120 min t im e -po in t on graph). In all cases, the recycling 
curve reached a plateau by 120 min or began to plateau by this t im e-po in t. 
Why all o f the initial cell surface fluorescence was not recovered in all 
experiments is unknown, but this variation with respect to the extent o f 
recycling was a problem experienced in FACS-based recycling experiments 
reported in the remainder o f this chapter and in Chapter 6.
Figure 5-III B is representative o f multiple experiments, though, in the 
proportional difference between recycling in the presence and absence o f 
BFA. As can be seen in the graph, BFA had a partial inhibitory effect on CCR5 
recycling, with the curves diverging to an increasing extent over time. Over 
multiple experiments, BFA treatment led to an average reduction in 
recycling after 60 min incubation in TAK-779 o f 33.2 ± 9.6% (where the 
difference in cell surface CCR5 level at 120 min and 60 min in the absence 
o f BFA = 100%; n = 6).
The shapes o f the recycling curves suggest that CCR5 recycles via a single 
pathway in both the presence and absence o f BFA. In order to test this 
argument, I used the fo llowing equation to describe the recycling process:
fl = f u - u  -  flm"  '  f '° )
* *m ax
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The equation assumes that the rate o f recycling is proportional to a single, 
f irs t-o rde r rate constant (krec) and the difference between the maximum cell 
surface fluorescence reached after recycling (flmax) and the cell surface 
fluorescence at any t im e -po in t (fl) (see Chapter 2 for derivation o f equation). 
This equation was linearised to give:
In flmax '  ^ -kre<r t + In f l m a x  f  10
The data from the recycling phases in the presence and absence o f BFA were 
used in a plot o f In((flmax—f l ) / f lmax) against t, as shown in Figure 5-111 C. 
Curves were fitted to the data by linear regression and an R2 value, the 
coefficent o f determination (the square o f the correlation coefficent; takes 
values between 0 and 1) obtained. This gives an indication o f how well the 
obtained data describe the recycling equation and thus, whether CCR5 
recycling from the recycling compartment likely occurs through a single 
pathway. In the absence o f BFA, R2 was 0.98, indicating that the data 
strongly describe a single-pathway recycling process. In the presence o f 
BFA, R2 was 0.79: a good, but nonetheless weaker fit. This analysis requires 
the arbitrary definition o f the f lmax value. In this first analysis, it was set to 
100, as in the absence o f BFA, all o f the initial cell surface fluorescence was 
recovered. However, in the presence o f BFA, extrapolation o f the recycling 
curve would predict a plateau at around 75%. If a f lmax o f 75 is used for the 
data o f recycling in the presence o f BFA, an R2 value o f 0.95 is obtained, 
suggesting that recycling in the presence o f BFA occurs via a single pathway 
but that a certain amount o f CCR5 is retained within cells/recycles 
extremely slowly (Figure 5—III D).
As can be inferred from the linearised equation, the slope o f the line from 
such a plot corresponds to the rate constant for recycling, krec. As would be 
predicted from the recycling curves in Figure 5-III B, krec is reduced in the 
presence o f BFA.
Next, I performed a morphological recycling assay by immunofluorescence 
to determine the effect o f BFA on recycling (Figure 5-111 E). Cell surface CCR5 
was pre-labelled with MC-5 and then cells were treated fo r 60 min with
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RANTES to down-modulate CCR5 before incubation in BM containing TAK- 
779 with or without BFA for 60 min to assess recycling. In keeping with the 
FACS results, CCR5 showed an almost complete recovery to the cell surface 
after 60 min incubation in TAK-779 in the absence of BFA; however, in the 
presence o f BFA, although some CCR5 recycled to the plasma membrane, 
internal CCR5 signal was also observed, frequently concentrated in 
perinuclear clusters. The pattern o f staining is slightly unexpected, since 
other studies have shown that BFA causes tubulation of endosomes 
(Stoorvogel, Oorschot et al. 1996; Futter, Gibson et al. 1998; Sonnichsen, De 
Renzis et al. 2000) and the TGN (Lippincott-Schwartz, Yuan et al. 1991).
In summary, BFA partially inhibited CCR5 recycling, suggesting that AP-1 
may be involved in this process.
A
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A. C H O  CCR5 cells w ere  e ith e r  u n tre a te d  or tre a te d  w ith  1, 1 0  o r 1 0 0  n g /m l BFA in 
BM at 3 7 °C  fo r  1 o r 5 m in , b e fo re  be ing  fix e d  and sta ined  fo r  y -ad ap tin  w ith  A d a p tin  
y p rim a ry  a n tib o d y  and A le x a  4 8 8  C A M  seco nd ary  a n tib o d y  in p e rm e a b ilis in g  
b lock ing  b u ffe r. E pifluorescence im ages  a re  show n . Im ages  w ere  c a p tu re d  w ith  th e  
sam e a c q u is itio n  se ttin gs  and  processed  id e n tic a lly . T w o  fie ld s  o f u n tre a te d  cells  
are show n; 1 fie ld  o f cells is show n fo r  each BFA tre a tm e n t. Bar, 5 urn. B. FACS- 
based tra ffic k in g  assay. C H O  CCR5 cells w ere  tre a te d  w ith  RANTES in BM fo r  6 0  m in  
b efo re  be in g  w ash ed  and fu r th e r  in cu b a ted  in BM co n ta in in g  T A K -7 7 9  and  e ith e r  10  
n g /m l BFA (+BFA) or e th an o l (-BFA) fo r 6 0  m in . A liq u o ts  o f cells w ere  rem o ved  a t 
various tim e -p o in ts  and assayed fo r  cell su rface  C C R 5-associa ted  flu o re s c e n c e  by  
FACS, using  488M C -5 to  d e te c t C C R 5. C ell su rface  CCR5 flu o rescen ce  is e x p re s s e d  as 
a p ercen tag e  o f the  in itia l cell su rface  CCR5 flu o rescen ce  and p lo tte d  a g a in s t t im e . 
A re p re s e n ta tiv e  e x p e r im e n t is show n , w ith  in d iv id u a l d a ta  poin ts  re p re s e n tin g  the  
m ean o f tr ip lic a te  sam ples; e rro r bars re p re s e n t 1 s tan d ard  d ev ia tio n  o f th e  m eans. 
C. G raph  show ing  a p lo t o f  In ((fI —f I / f I  ) a g a in s t tim e  [t] fo r the  d a ta  in B co vering  
th e  recycling  phase (T A K -7 7 9  in c u b a tio n , 6 0  to  1 2 0  m in ). f lmax, th e  m a x im u m  e x te n t  
o f recyc ling , w as set to  1 0 0 . C urves w ere  f itte d  by lin ear reg ress ion  and  s tra ig h t- 
line e q u a tio n s  are show n n e x t to  the  f itte d  curves. R2, th e  c o e ffic ie n t o f  
d e te rm in a tio n , o b ta in e d  by reg ress ion  analysis , is also show n. T h e  c o e ffic ie n t o f t  is 
th e  recycling  ra te  co n s tan t, k , w ith  units  o f m in '.  D . G raph  show ing  a p lo t o f  
ln ((flm - f l / f l  ) ag a in s t tim e  [t] fo r  recycling  in the  p resence o f BFA, w ith  fl set to  
e ith e r 1 0 0  o r 7 5 . E. Im m u n o flu o re s c e n c e -b a s e d  tra ffic k in g  assay. C H O  CCR5 cells  
w ere  e ith e r  fix e d  (u n s tim u la te d ), tre a te d  w ith  RANTES fo r 6 0  m in and th en  fix e d  (6 0  
m in RANTES) or tre a te d  w ith  RANTES fo r 6 0  m in fo llo w e d  by an in c u b a tio n  in BM 
co n ta in in g  T A K -7 7 9  and e ith e r  1 0  n g /m l BFA (+BFA) or e th a n o l (-BFA). S ingle  
confocal sections a re  show n fo r u n s tim u la te d  and 6 0  m in  RANTES tre a te d  cells; 
series o f co n foca l sections a re  show n fo r cells tre a te d  fo r 6 0  m in w ith  RANTES  
fo llo w ed  by a 6 0  m in  in cu b a tio n  w ith  T A K -7 7 9 . Bar, 5 ^im.
AP-1 knock-down does not inhibit CCR5 recycling
The above data suggest that AP-1 may play a role in CCR5 recycling. 
However, although it has been shown that BFA prevents the formation o f 
clathrin-coated buds at the recycling endosome and inhibits the recycling o f 
TfR from this compartment (Stoorvogel, Oorschot et al. 1996; van Dam and 
Stoorvogel 2002; van Dam, Ten Broeke et al. 2002), the same group 
reporting these findings also reported that endosomal clathrin-coated buds
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were largely devoid of y-adaptin (Stoorvogel, Oorschot et al. 1996). Hence, 
the BFA result could be interpreted as an inhibitory effect on clathrin-coated 
pit formation, rather than on the function of AP-1. Moreover, BFA has 
multiple other effects, such as the release o f COPI components from the 
Golgi (Donaldson, Lippincott-Schwartz et al. 1990; Wong and Brodsky 1992) 
and redistribution o f Golgi elements into the endoplasmic reticulum 
(Lippincott-Schwartz, Donaldson et al. 1990), and may also have an effect 
on other ARF effectors.
I therefore performed a knock-down of an AP-1 subunit as an alternative 
approach to assess the role o f AP-1 in CCR5 recycling. AP-1 is a 
heterotetrameric protein complex, whose clathrin adaptor activity can be 
effectively removed by knock-down o f its ^ ilA  subunit (Hirst, Motley et al. 
2003). However, the most commonly used siRNA oligonucleotide against the 
p lA  subunit, described in Hirst et al. (2003), failed to knock down the 
protein in CHO CCR5 cells (data not shown). As the hamster genome has not 
yet been sequenced, I designed three siRNA oligos against the mouse p lA  
DNA sequence. I also checked that the target sequences were conserved in 
rat, as mice, rats and hamsters belong to the Momorpha sub-order o f 
rodents. As can be see in Figure 5-IV A, the three oligonucleotides, 
Dharmal, Dharma2 and Inv, all showed a partial knock-down of p lA -  
adaptin, with the Dharma2 oligonucleotide giving the highest efficiency of 
knock-down.
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F ig u re  5 -IV  K n o ck -d o w n  o f  AP-1 d o es  n o t a ffe c t  CCR 5 in te rn a lis a t io n  o r  
recyc lin g
A. CHO CCR5 cells w ere transfec ted  w ith  th e  ind icated  siRNA o ligo n u cleo tid es  using  
the O lig o fec tam in e  protocol described in M ateria ls  and M ethods. Cell lysates w ere  
prepared  in RIPA b u ffe r and vo lum es o f cell lyatses conta in ing  equal am o u nts  o f 
proteins loaded on a gel. Separated  proteins w ere transferred  to  n itroce llu lose  and  
probed w ith  23  (an ti-c la thrin  heavy chain , C-HC), A dap tin  y (an ti-y -adaptin ) and p i A  
(a n ti-p lA ) p rim ary  an tib o d ies . The b lo t was subsequently  incubated  w ith  IR D ye®  
8 0 0  GAM to  d e tec t 23  and A dap tin  y, and IR D ye®  6 8 0  GAR to  d e tec t p i A , and  
proteins visualised using the  O dyssey in fra-red  de tec tion  system . B. CHO CCR5 cells 
w ere transfected  w ith  e ith e r AllStars negative contro l or D harm a2 p i A siRNA  
o ligo nucleo tides  using the  O lig o fec tam in e  protocol described in M ateria ls  and  
M ethods. Cells w ere e ith e r fix e d  (u n stim u la ted ), trea ted  w ith  RANTES in BM fo r 6 0  
m in and th en  fixed  (6 0  m in RANTES), or trea ted  w ith  RANTES fo r 6 0  m in and th en  
fu rth e r incubated  in BM co nta in in g  T A K -7 7 9  fo r 6 0  m in, before  being fixed  (6 0  m in  
RANTES + 6 0  m in T A K -7 7 9 ). Cells w ere  th en  incubated  in perm eab ilis ing  b locking  
b uffe r co nta in ing  M C-5 (an ti-C C R 5) or M ary (anti-y-adaptin ) p rim ary  an tib o d ies . MC- 
5 and M ary w ere  de tec ted  w ith  A lexa  4 8 8  GAM and A lexa  5 9 4  GAR, respective ly . 
Single confocal sections are show n. K nock-dow n cells are indicated w ith  w h ite  
asterisks. Bar, 5 pm . C. C H O  CCR5 cells w ere transfected  w ith  e ith e r A llS tars  
negative contro l or D h arm a2  p i A siRNA o ligonucleo tides  using th e  O lig o fe c ta m in e  
protocol described  in C h ap te r 2 and assayed fo r CCR5 tra ffick in g  by FACS. A  b lo t 
show ing the e x te n t o f  p lA -a d a p tin  knockdow n, p repared  as in A, excep t w ith  a
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tu b u lin  lo ad in g  co n tro l (b lo t p ro bed  w ith  a n ti-tu b u lin  p rim a ry  a n tib o d y  fo llo w e d  by  
in cu b atio n  w ith  IR D ye®  8 0 0  C A M ) is show n . For the  FACS-based tra ff ic k in g  assay, 
C HO  CCR5 cells w ere  tre a te d  w ith  RANTES in BM fo r 6 0  m in  b e fo re  be ing  w ash ed  
and fu r th e r  in cu b a ted  in BM co n ta in in g  T A K -7 7 9  fo r 6 0  m in . A liq u o ts  o f cells w ere  
rem oved  at variou s  tim e -p o in ts  and assayed fo r cell su rface C C R 5-asso c ia ted  
fluo rescen ce  by FACS, using 488M C-5 to  d e te c t C C R 5. Cell surface CCR5 flu o re s c e n c e  
is exp ressed  as a p ercen tag e  o f the  in itia l cell surface CCR5 flu o rescen ce  and  
p lo tte d  a g a in s t t im e . D a ta  points  re p re s e n t the  m ean o f tr ip lic a te  sam ples  fro m  a 
sing le  e x p e rim e n t; e rro r bars re p re s e n t 1 s tan d ard  d e v ia tio n  o f the  m ean s . A lso  
show n is a b ar g rap h  show ing  the  in itia l cell surface  CCR5 flu o rescen ce  in th e  
A llStars negative  co n tro l siRNA- and |a.l A  s iR N A -tran sfec ted  cells, as a p e rc e n ta g e  o f  
th e  CCR5 fluo rescen ce  in th e  A llS tars  n egative  co n tro l s iR N A -tran sfec ted  cells . T h e  
d a ta  re p re s e n t th e  m eans o f  tr ip lic a te  sam ples  fro m  th e  sam e e x p e rim e n t; e rro r  
bars rep re s e n t 1 s tan d ard  d e v ia tio n  o f th e  m eans.
Using the Dharma2 siRNA oligonucleotide, I performed trafficking assays on 
control and knock-down cells, initially by immunofluorescence (Figure 5—IV 
B). Although I could assess the knock-down efficiency by immunoblot by 
detection o f the ^ ilA  subunit, I was unable to detect any specific staining in 
CHO CCR5 cells with the a n t i -p lA  antibody by immunofluorescence. I 
therefore used y-adaptin staining to identify knock-down cells. Hirst e t al. 
(2003) reported that a p lA  knock-down in COS cells resulted in the 
formation o f partial AP-1 complexes that lacked the (31 and ^ilA subunits 
and that knock-down cells had diffuse rather than membrane bound y -  
adaptin. To assess whether y-adaptin levels were changed by knocking 
down u lA -adap tin  in CHO CCR5 cells, I additionally probed cell lysates o f 
knock-down and control cells with an anti-y-adaptin antibody (Figure 5—IV 
A). In accordance with Hirst e t al., y-adaptin levels were unchanged in ^ ilA  
knock-down cells.
In unstimulated control siRNA treated cells, y-adaptin staining was punctate 
and largely concentrated in the perinuclear region, although smaller, more 
peripheral puncta were also observed. After 60 min RANTES treatment, 
CCR5, which was initially present on the cell surface, accumulated in the 
perinuclear region, where it showed a significant overlap with y-adaptin. 
After a subsequent incubation with TAK-779, the vast majority o f CCR5 
recycled to the cell surface.
201
In cells transfected with ^ ilA  siRNA, although around 50% o f cells showed a 
similar punctate, perinuclear y-adaptin staining pattern to that o f control 
siRNA-transfected cells, the other 50% showed no perinuclear punctate y- 
adaptin staining and instead, a faint, diffuse cytoplasmic staining pattern 
was observed (cells marked with white asterisks). This is consistent with 
these cells having ^ lA -a da p t in  knocked down: at least some y-adaptin 
remained but it was unable to localise to membranes in the absence o f ^ ilA  
adaptin. The immunofluorescence also suggested that the partial knock­
down effect observed at the population level by immunoblot was a result o f 
near complete knock-down in a fraction o f the cells. Transfection efficiency 
was, thus, the limiting factor to knock-down efficiency. It was also likely 
that only around 50% o f the control siRNA-transfected cells contained the 
control siRNA. In knock-down cells, there was no obvious effect on cell 
surface CCR5 levels in unstimulated cells. In cells treated with RANTES for 
60 min, CCR5 internalised in knock-down cells, although perhaps did not 
cluster so t igh tly  around the nucleus as in untransfected cells or in control 
siRNA-transfected cells. A fter 60 min TAK-779 incubation, CCR5 recycled 
fully to the cell surface in ^ ilA  knock-down cells, suggesting that AP-1 may 
not be involved in CCR5 recycling.
I next performed a FACS-based trafficking assay to compare the trafficking 
^ o f  CCR5 in control and ^ ilA  knock-down cells. Figure 5—IV C shows the 
result o f this experiment, which remains unrepeated. Here, as shown in the 
immunoblot, an approximately 55% ^1A knock-down was achieved, which, 
given the results of the immunofluorescence in Figure 5—IV B, probably 
meant that a near complete knock-down occurred in around 50% o f cells, 
but that 50% o f cells probably were not transfected. This was probably also 
the case for the control siRNA-transfected cells. Cell surface CCR5 levels 
were unaffected by ^1A knock-down, as shown in the bar graph, which is in 
accordance with the immunofluorescence results. Also in agreement with 
the immunofluorescence results, CCR5 down-modulated in the ^ ilA  knock­
down cells to a similar extent as control cells, although very slightly less 
down-modulation was seen in the ^ilA knock-down cells. Recycling was 
quite similar in both knock-down and control cells, although the knock­
down cells showed a slightly greater recovery o f cell surface CCR5 
fluorescence after 60 min incubation in TAK-779 and a greater initial
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recycling rate, measured over the firs t 10 min o f recycling (2.61 ± 0.02% 
m in '1 versus 2.21 ± 0.02% m in '1).
Overall, these results show that AP-1 knock-down had little  effect on CCR5 
recycling; indeed, if anything, recycling occurred slightly faster in knock­
down cells.
Dynasore blocks CCR5 recycling
C lathrin-coated vesicle form ation at the recycling compartment would be 
predicted to require the GTPase, dynamin, in the ‘pinching o ff ’ o f nascent 
clathrin-coated pits to form  clathrin-coated vesicles. There are 3 isoforms 
o f dynamin, o f which dynam in-2 is ub iquitously expressed (Cook, Urrutia et 
al. 1994; Sontag, Fykse et al. 1994). Dynamins -1  and -3  have more 
restricted d istributions, w ith  dynam in-1 being a neuron-specific isoform  
(Nakatax, Iwamoto et al. 1991) and dynam in-3 found prim arily in the brain, 
lung and testis (Nakata, Takemura et al. 1993; Cook, Mesa et al. 1996). 
Hence, only dynam in-2 would be expected to be expressed in CHO cells. 
Although best characterised fo r its role in endocytosis (Conner and Schmid 
2003), dynamin has been shown to act at the recycling endosome in TfR 
recycling, in the form ation o f TfR-containing clathrin-coated vesicles (van 
Dam and Stoorvogel 2002), and is also present at the TGN (McNiven, Cao et 
al. 2000), where it functions, fo r instance, in the export o f the mannose 6 - 
phosphate receptor (Cao, Weller et al. 2005).
CCR5 internalisation in CHO CCR5 cells is clathrin-dependent (Signoret, 
Hewlett et al. 2005) and, as such, would most probably require dynamin. 
Hence, methods o f inh ib iting  dynamin activity, such as expression o f 
dom inant-negative dynamin mutants, would inh ib it the internalisation o f 
CCR5 and prevent an assessment o f dynam in’s involvement in receptor 
recycling. So, to determ ine whether dynamin plays a role in CCR5 recycling, I 
^ in i t ia l ly  used the membrane-perm eant drug, dynasore, which has been 
reported to be a non-com petitive inh ib ito r o f the CTPase function o f 
dynamin (Macia, Ehrlich et al. 2006). This reagent has also been shown to 
inh ib it the internalisation o f transferrin  and low density lipoprote in, ligands 
whose uptake is completely dependent on the action o f dynamin (Macia, 
Ehrlich et al. 2006).
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(+dynaso re ) or DMSO (-dynasore) fo r  2 0  min a t  3 7°C. Cells w e re  th en  w a s h e d  and  
e ither  f ixed  (u n s t im u la ted )  o r fu r th e r  incubated  in BM co nta in ing  e ith e r  d y naso re  
(+dynaso re ) or D M SO  (-dynasore) w ith  1 2 5  nM RANTES fo r  4 0  min at 3 7 °C ,  b e fo re  
being f ixed . Cells w ere  then  in cu bated  in p erm eab il is ing  b locking  b u ffe r  w i th  A le x a  
5 9 4  C A M  to d e tec t  M C -5 . Epif luorescence im ages  are  show n. Bar, 5 ^im. B. C H O  
CCR5 cells w ere  e ith e r  f ixed  (u n s t im u la te d ) ,  trea ted  w ith  RANTES in BM fo r  6 0  m in  
and f ixed  (6 0  min RANTES) or t rea ted  w ith  RANTES fo r  6 0  min fo l lo w ed  by an  
incubation  in BM co nta in in g  T A K -7 7 9  and e ith e r  dynasore (+dyn asore ) or D M S O  (- 
dynasore) fo r  6 0  m in , b e fo re  being  f ixed  (6 0  min RANTES + 6 0  min T A K -7 7 9 ) .  Cells  
w ere  th en  p erm e a b il is e d  in b lock ing  b u f fe r  and incubated  w ith  MC-5 to  d e te c t  
CCR5, fo l lo w ed  by incubation  w ith  A lexa  5 9 4  C A M  to d e tec t M C-5. Single confoca l  
sections are show n. Bar, 5^m . C. C H O  CCR5 cells w ere  t rea ted  w ith  RANTES fo r  6 0  
min fo l lo w ed  by an incu bation  in BM co nta in ing  T A K -7 7 9  and dynaso re  fo r  6 0  m in.  
Cells w ere  then  f ixed  and in cu bated  w ith  M C -5 and M ary  in perm eab il is ing  b lo ck in g  
b uffe r  to  d e tec t CCR5 and y -adaptin , respective ly . MC-5 and M ary  w ere  d e te c te d  
with  A lexa  5 9 4  C A M  and A le x a  6 4 7  CAR, respectively. A  single confocal section is 
show n. Bar, 5 urn. D. C H O  CCR5 cells w e re  t re a te d  w ith  RANTES in BM fo r  6 0  min  
before  being  w ash ed  and fu r th e r  incubated  in BM co nta in in g  T A K -7 7 9  fo r  6 0  min.  
A liquots  o f  cells w e re  rem oved  at various t im e -p o in ts  and assayed fo r  cell surface  
C C R 5-associa ted  f luorescence by FACS, using M C-5 p r im ary  a n t ib o d y  and A le x a  6 4 7  
C AM  seco n d ary  an tib od y . Cell surface CCR5 fluo rescen ce  is exp ressed  as a 
percen tag e  o f  the  initial cell surface CCR5 f lu o rescen ce  and p lo tted  ag a in s t  t im e .  
D ata  points re p re s e n t  the m ean  o f  tr ip lica te  sam ples  f ro m  a s ingle e x p e r im e n t ;  
error  bars re p re s e n t  1 s tan dard  dev ia tion  o f  th e  m eans.
Firstly, I tested the effect o f dynasore on CCR5 internalisation by 
immunofluorescence (Figure 5-V  A). Cells were pre-treated w ith MC-5 fo r 
20 min at 37°C to label cell surface CCR5 w ith or w ithout dynasore and then 
treated w ith RANTES fo r 40 min in the presence or absence o f dynasore. 
Dynasore pre-treatm ent did not affect the initia l cell surface d is tribu tion  o f 
CCR5 but continued treatm ent w ith dynasore led to a significant inh ib ition  
o f CCR5 internalisation (compare RANTES-treated cells + / -  dynasore). 
Interestingly, bright fluorescent puncta were observed at the plasma 
membrane after 40 min RANTES in the presence o f dynasore. This suggests 
that some CCR5 m ight have entered clathrin-coated pits or fla t c lathrin
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lattices, but that the pits failed to pinch o ff into vesicles, which is consistent 
w ith an inh ib ition o f dynamin.
I next assessed the effect o f dynasore on the recycling o f CCR5 (Figure 5-V  
B). CHO CCR5 cells were treated w ith RANTES fo r 60 min and then incubated 
in BM containing TAK-779 w ith or w ithou t dynasore. The inclusion o f 
dynasore in the recycling step led to  an almost complete inh ib ition  o f CCR5 
recycling, w ith the d is tribu tion  o f CCR5 being very sim ilar to cells ju s t 
treated w ith RANTES fo r 60 min, suggesting that CCR5 had been prevented 
from  exiting the recycling com partm ent. In agreement w ith this, when cells 
were co-stained fo r y-adaptin, CCR5 showed a strong overlap w ith  y- 
adaptin in the perinuclear region after 60 min TAK-779 incubation in the 
presence o f dynasore (Figure 5-V  C). However, some relatively large 
intracellular accumulations o f CCR5 that did not colocalise w ith y-adaptin 
were also observed in cells treated in this manner.
Finally, I performed a FACS-based tra ffick ing assay to assess the effect o f 
dynasore on CCR5 recycling (Figure 5-V  D). In keeping w ith the 
immunofluorescence results, inclusion o f dynasore in the recycling phase 
led to an almost complete inhib ition o f CCR5 recycling, w ith the recycling 
curve fo r CCR5 in the presence o f dynasore fa iling to show any increase in 
cell surface CCR5-associated fluorescence after 10 min o f recycling, 
suggesting tha t most o f the CCR5 was trapped inside the cells.
In summary, dynasore strongly inhib ited CCR5 recycling, which suggests 
that dynamin is involved in CCR5 exit from  the recycling compartment.
Dyngo-4a, but not B is-T-23, inhibits the recycling o f CCR5
Although the results described above suggest a role fo r dynamin in CCR5 
recycling, the specificity o f dynasore has recently been brought into 
question by P. Robinson and co-workers (personal communication, 
unpublished results). They found that although dynasore inhibited c la th rin - 
mediated endocytosis, it had little  inh ib itory effect on dynamin GTPase 
activity, as in itia lly  reported by Macia et al. (2006), suggesting that it targets 
a d ifferent component o f the c lathrin-m ediated endocytic machinery. Based 
on this result, the inh ib ition  o f CCR5 recycling by dynasore could indicate
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that there is a shared component between the machinery effecting c la th rin - 
mediated CCR5 internalisation and that mediating its recycling.
Robinson and colleagues have recently generated a series o f dynamin 
inhibitors, the two most potent being Dyngo-4a {Dev. Cell, in review), which 
is structurally sim ilar to dynasore, and B is-T-23, which is an unrelated 
bistyrphostin molecule (Hill, Odell et al. 2005). Initial results suggest that 
both target the dynamin ring assembly domain (P. Robinson, personal 
communication). Significantly, B is-T-22, another bistyrphostin, h ighly 
related to  B is-T-23, has been shown to inh ib it the epidermal growth factor 
receptor (EGFR) tyrosine kinase (IC50 = 0.4 ^M) and block EGF-induced cell 
proliferation (IC50 = 3 ^M) (Gazit, Osherov et al. 1996). B is-T-23 may also 
exh ib it activity against tyrosine kinases.
I used these inhib itors in tra ffick ing  assays to fu rthe r investigate whether 
dynamin plays a role in CCR5 tra ffick ing . I firs tly  assessed the effect o f the 
inhibitors on agonist-induced CCR5 internalisation in CHO CCR5 cells, 
including whether the drugs could inh ib it dynamin activity rapidly after 
addition to the extracellu lar medium. I used a concentration o f D yngo-4 and 
B is-T-23 that produced maximal inh ib ition  o f transferrin uptake in U20S 
cells (P. Robinson, personal communication): the drugs had not previously 
been tested on CHO cells. CHO CCR5 cells were incubated w ith  MC-5 to 
label cell surface receptors fo r 15 min at 37°C, followed by a 5 min 
incubation at 37°C in BM containing either the dynamin inhib itors or DMSO 
(the solvent fo r the two drugs) as a control. Cells were then treated w ith 
RANTES fo r 30 min in the presence or absence o f the drugs. As shown in 
Figure 5 —VI A, both Dyngo-4a and B is-T-23 completely inhibited CCR5 
internalisation. However, unlike the results seen w ith the inh ib ition  o f 
internalisation in the presence o f dynasore, clustering o f CCR5 was not 
observed at the cell surface. Moreover, as shown in Figure 5-VI B fo r 
unstimulated cells, when the dynamin inhib itors were included th roughou t a 
20 min pre-incubation w ith  MC-5, a significant reduction in CCR5 staining 
intensity was seen, suggesting that, remarkably, given the ir d iffe ren t 
chemical structures, both drugs interfered w ith MC-5 binding. At the 
concentrations used, B is-T-23 appeared to interfere more strongly w ith 
MC-5 binding than Dyngo-4a, w ith very little  specific cell surface CCR5 
staining visible above background staining. MC-5 binds to the extreme N-
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term inus o f CCR5 (Blanpain, Vanderwinden et al. 2002) and although MC-5 
binding does not interfere w ith RANTES binding (Blanpain, Vanderwinden et 
al. 2002), the N-term inal domain o f CCR5 has been shown to participate in 
RANTES binding and the interaction o f RANTES with this domain is required 
for RANTES-induced CCR5 signalling (Blanpain, Doranz et al. 1999). Thus, 
although it appeared that the uptake o f the drugs into cells occurred very 
quickly and that the drugs rapidly inhibited the action o f hamster dynamin, 
thus preventing CCR5 internalisation, there is the possibility that the 
dynamin inhibitors caused an inh ib ition o f internalisation by interfering with 
RANTES binding and therefore activation o f CCR5.
D M S O  same settings enhanced same settings enhanced
DMSO Dyngo-4a Bis-T-23
Dyngo-4a Bis-T-23
F ig u re  5-VI T h e  e f f e c t  o f  th e  d y n a m in  in h ib i to rs ,  D y n g o -4 a  an d  B is -T -23 , on  
C C R 5 in te r n a l is a t io n
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A. C H O  CCR5 cells w e re  in cu b a ted  in BM conta in ing  M C -5  fo r  15 m in at 3 7 °C  
fo llo w ed  by 5 min in c u b a t io n  in BM conta in ing  e ither  DMSO, D y n g o -4 a  or B is - T - 2 3  
at 37 °C . Cells w ere  th en  w a s h e d  and e ither  f ixed  (u n s tim u la ted ) or fu r th e r  
incubated  in BM co n ta in in g  1 2 5  nM RANTES with  e ither DMSO, D y n g o -4 a  or B is - T -  
23 fo r  3 0  m in  at 3 7 °C , b e fo re  being f ixed . Cells w ere  then in cu b a ted  in 
p erm eab il is ing  b lock ing  b u f fe r  w ith  A lexa  5 9 4  C A M  to d e tec t M C -5 .  Epif luorescence  
im ages are show n. Bar, 5 ^ m . B. C H O  CCR5 cells w ere  incubated in BM co n ta in in g  
M C -5  and e i th e r  D M SO , D y n g o - 4 a  or B is - T - 2 3  fo r 2 0  min at 37°C  b efore  being  
f ixed . Cells w e re  th en  in cu b a ted  in perm eab il is ing  b locking buffe r  w ith  A le x a  5 9 4  
CAM  to  d e te c t  M C - 5 .  Epif luorescence im ages are shown. Images w ere  acqu ired  w ith  
the sam e m ic roscope  sett ings . ‘ E nhan ced ’ im ages show the same fields o f  cells b u t  
w ith  increased e x p o s u re  t im e  ( lo n g e r  exp o su re  t im e  for B is - T - 2 3 - t r e a t e d  cells than  
D y n g o - 4 a - t r e a t e d  cells, as s ignal was w eaker) .  Bar, 10 |xm.
Although the effects o f the dynamin inhibitors on CCR5 internalisation were 
inconclusive, I nevertheless tested the ir effect on CCR5 recycling. In this 
assay, I also included dynasore fo r comparison. Here, CHO CCR5 cells were 
treated w ith  RANTES fo r 60 min and then incubated in BM containing TAK- 
779 w ith the various drugs or DMSO as a control, fo r either 30 or 60 min to 
assess recycling. CCR5 was labelled post-fixation. As can be seen in Figure 
5-VII, a fter 60 min incubation in BM containing TAK-779 and DMSO, almost 
full recycling was achieved w ith  most o f the CCR5 population present on the 
cell surface; a s ligh tly  lower extent o f recycling seen after 30 min. Inclusion 
o f dynasore in the recycling phase severely inhibited CCR5 recycling, w ith 
the d is tribu tion  o f CCR5 after 30 and 60 min TAK-779 incubation being 
very sim ilar to cells ju s t treated w ith RANTES for 60 min, again, suggestive 
o f a block in ex it from  the recycling compartment. Inclusion o f Dyngo-4a in 
the recycling phase also led to a strong inhib ition o f CCR5 recycling. 
However, the intracellu lar d istribu tion o f CCR5 was altered compared w ith 
^ce lls  treated only w ith  RANTES fo r 60 min, in that a tubulation o f the CCR5- 
containing com partm ent was observed. This suggests that the mechanism 
o f inh ib ition o f CCR5 recycling is d ifferent fo r Dyngo-4a and dynasore. In 
contrast to the inh ib ito ry  effects o f dynasore and Dyngo-4a on CCR5 
recycling, B is-T -23  did not inh ib it CCR5 recycling. Since the internalisation 
assay did not prove the ab ility  o f B is-T-23 to rapidly and potently inh ib it
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dynamin at the concentration used in CHO cells, the inability o f B is-T -23  to 
inh ib it recycling could be due to either slow uptake o f the drug into CHO 
cells (slow enough fo r most o f the internal CCR5 population to have 
returned to the cell surface) or lack o f efficacy on hamster dynamin.
unstim ulated 60 min RANTES
dynasoreDMSO Dyngo-4a
Figure 5-VII The effect of various dynamin inhibitor drugs on CCR5 recycling
C HO  CCR5 cells w e re  e ith e r  f ix e d  (unstim ulated ),  t reated  w ith  RANTES in BM fo r  6 0  
m in and th e n  f ixed  (6 0  m in  RANTES) or treated  w ith  RANTES in BM fo r  6 0  min  
fo llow ed  by an incu b a tio n  in BM conta in ing  T A K -7 7 9  and e ithe r  DM SO, D y n g o -4 a ,  
Bis-T-23 or dynaso re  fo r  3 0  or 6 0  m in, before  being f ixed  (3 0  min T A K -7 7 9  and 6 0  
min T A K -7 7 9 ,  respective ly). Cells w ere  then incubated w ith  MC-5 in p e rm e a b il is in g  
blocking  bu ffe r .  M C -5  was de tec ted  w ith  A lexa  5 9 4  C A M . Epif luorescence im ag es  
are show n. Bar, 5 pm .
I also performed the recycling assay with pre-labelling o f cell surface CCR5 
molecules w ith MC-5: the results were essentially identical (data not shown).
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In summary, the inh ib ition  o f CCR5 recycling by Dyngo-4a strongly 
suggests the involvement o f dynamin in CCR5 recycling. The difference in 
the internal CCR5 d is tribu tion  in cells where recycling was blocked by either 
dynasore or Dyngo-4a suggests that dynasore is probably h itting  a d iffe rent 
target from  dynamin, likely another component o f the machinery involved in 
clathrin-coated vesicle form ation.
Discussion
In this chapter I have shown that the recycling compartment through which 
agonist-activated CCR5 recycles to the plasma membrane is extensively 
coated w ith  clathrin at the point that CCR5 traverses it. AP-1 also shows a 
strong colocalisation w ith  down-m odulated CCR5, but despite BFA partia lly 
inh ib iting  CCR5 recycling, an AP-1 knock-down had no effect on the ab ility 
o f the receptor to recycle. The dynamin inhib itor, Dyngo-4a, did, however, 
have a strong inh ib ito ry  effect on the ability o f down-m odulated CCR5 to 
recycle, suggesting that dynamin functions in CCR5 tra ffick ing  at the 
recycling com partm ent. Dynasore, a drug previously shown to inh ib it the 
dynamin GTPase, also completely blocked CCR5 recycling, although new 
data from  the lab o f Phil Robinson suggests that dynasore may target a 
d ifferent com ponent o f the clathrin-coated vesicle-form ing machinery. 
These results, together w ith the electron microscopy observations o f dow n- 
modulated CCR5 in coated vesicles in the perinuclear region o f the cell, w ith 
the coat likely being clathrin (Silene Wavre, Endocytic Regulation o f 
Chemokine Receptor Expression, PhD thesis, 2006), suggest that the 
form ation o f clathrin-coated vesicles in a dynam in-dependent fashion at the 
recycling com partm ent is involved in CCR5 recycling. To my knowledge, this 
is the firs t evidence fo r such a mechanism functioning in the post-endocytic 
tra ffick ing o f a GPCR.
A role for clathrin and dynamin in CCR5 intracellular trafficking
Several lines o f evidence suggest that CCR5 recycling from  the recycling 
compartment involves clathrin and dynamin. The firs t indication fo r clathrin 
involvement came from  observations o f immunolabelled cryosections by 
Signoret et al. (2000), where after 60 min RANTES treatm ent in CHO CCR5
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cells, CCR5 was observed in tubules and vesicles in the perinuclear region, 
with the vesicles often displaying a prom inent coat, highly rem iniscent o f 
clathrin. Here, I have shown that the recycling compartment is extensively 
coated w ith clathrin at the time CCR5 is passing through it. Recently, using 
a sim ilar EM technique to  that used by Signoret et al., S. Wavre, has 
observed dow n-m odulated CCR5 in A P -l-p o s itive  coated vesicles adjacent 
to other CCR5-containing coated structures in the perinuclear region, whose 
coats also labels fo r AP-1 (Silene Wavre, Endocytic Regulation o f Chemokine 
Receptor Expression, PhD thesis, 2006). Given that AP-1 is a clathrin 
adaptor, th is suggests that the coat is, indeed, clathrin and the presence o f 
coated vesicles containing CCR5 adjacent to  larger coated structures also 
containing CCR5 suggests that these vesicles have arisen from  these 
structures. C lathrin-coated vesicle form ation at the plasma membrane 
requires the action o f dynamin functioning as a mechano-enzyme to 
constrict the neck o f a nascent clathrin-coated pit, resulting the release o f a 
clathrin-coated vesicle from  the plasma membrane (McNiven, Cao et al. 
2000; Mears, Ray et al. 2007). Dynamin has also been shown to act at the 
recycling endosome in TfR recycling, in the form ation o f T fR-containing 
clathrin-coated vesicles (van Dam and Stoorvogel 2002), and is present at 
the TGN (McNiven, Cao et al. 2000), where it functions, fo r instance, in the 
export o f the mannose 6-phosphate receptor (Cao, Weller et al. 2005). In 
this chapter I have shown that the dynamin inh ib itor, Dyngo-4a, potently 
inhibits CCR5 recycling. Moreover, Dyngo-4a caused a tubulation o f the 
intracellular compartment from  which CCR5 exit is blocked. This is 
reminiscent o f the tubulation o f recycling endosomes that van Dam et at. 
(2002) observed by immunofluorescence upon shifting cells expressing a 
temperature sensitive dynamin mutant to the non-perm issive temperature. 
W hole-m ount EM confirmed that in temperature sensitive dynamin m u tan t- 
expressing cells at the non-perm issive temperature, endosomal tubules o f 
the recycling endosome increased in length, and also showed that they had 
greater numbers o f clathrin-coated buds and labelled more strongly fo r 
dynamin than cells over-expressing w ild -type  dynamin.
Dynasore also inhibited CCR5 recycling from  the recycling com partm ent. In 
contrast to Dyngo-4a, though, no tubulation effect was seen in dynasore- 
treated cells: cells in which CCR5 had been down-m odulated fo r 60 min
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with RANTES and then subsequently incubated in BM containing TAK-779 
and dynasore, looked remarkably sim ilar to cells treated only w ith RANTES 
fo r 60 min. My prelim inary EM data also suggest that there are no gross 
morphological differences between cells in which dynasore or DMSO has 
been included in the recycling phase (data not shown). This suggests that 
although dynasore inhib its recycling, it does so in a different manner from  
Dyngo-4a. Indeed, P. Robinson and colleagues found that although 
dynasore inhib ited clathrin-m ediated endocytosis, it had little  inh ib ito ry  
effect on dynamin CTPase activity, as in itia lly  reported by Macia et at. 
(2006), suggesting that it targets a d ifferent component o f the c la th rin - 
mediated endocytic machinery. Thus, the inh ib ito ry effect o f dynasore on 
CCR5 recycling can be interpreted as an inh ib ition o f a component o f the 
machinery responsible fo r the form ation o f CCR5-containing c la th rin - 
coated vesicles involved in receptor recycling. If Dyngo-4a and dynasore 
inh ib it CCR5 exit from the same compartment, the tubulation effect caused 
by Dyngo-4a is probably more a function o f dynamin inh ib ition, rather than 
the inh ib ition  o f clathrin-coated vesicle form ation, and may reflect a w ider 
role fo r dynamin in the form ation o f other (CCR5-negative) carriers, 
independently o f clathrin. The inh ib itory effect o f BFA on CCR5 recycling 
may also be indicative o f the involvement o f clathrin in CCR5 recycling (see 
below).
B is-T-23, another dynamin inh ib ito r from  the laboratory o f Phil Robinson, 
failed to show an inh ib itory effect on CCR5 recycling. However, nothing is 
known about the speed at which this drug is taken up into CHO cells or its 
effect on hamster dynamin at the concentration used. Experiments designed 
to assess the effects o f the dynamin inhib itors from  Dr. Robinson on CCR5 
internalisation, which should have acted as a positive control fo r the rapid 
action o f the drugs, were inconclusive. Remarkably, both Dyngo-4a and Bis- 
T -23 were found to interfere w ith MC-5 binding to CCR5. Although the MC- 
5 epitope is located at the extreme N-term inus o f CCR5 and MC-5 binding 
does not interfere w ith RANTES binding (Blanpain, Vanderwinden et al.
2002), the N-term inal domain o f CCR5 participates in RANTES binding and 
the interaction o f RANTES w ith this domain is required fo r RANTES-induced 
CCR5 signalling (Blanpain, Doranz et al. 1999). Thus, the inh ib itory effect on 
CCR5 internalisation that both drugs exhibited could be explained by an
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inh ib ition o f RANTES binding rather than an inhib ition o f dynamin. Indeed, if 
dynamin were being targeted, it may be expected that activated CCR5 
molecules would still redistribute w ithin the plane o f the membrane into fla t 
clathrin lattices, as observed shortly after agonist addition by Signoret et al. 
(2005), or c lathrin-coated pits, which are prevented from pinching o ff from  
the membrane due to the inh ib ition o f dynamin. In the presence o f 
dynasore, CCR5 that was prevented from  internalising was observed to  
cluster at the membrane. To determine if RANTES can bind to receptors in 
the presence o f Dyngo-4a and B is-T-23, cells treated with RANTES in the 
presence o f the dynamin inhib itors could be fixed and stained w ith  the 
antibodies that recognise the phosphorylated forms o f serines 337 and 349, 
which should be phosphorylated if receptors have been activated. 
Interference w ith RANTES binding is not an issue with the effect o f the drugs 
on recycling, as in th is situation, receptors have already internalised before 
the drugs are added. The simplest explanation, therefore, fo r the d ifferentia l 
effects o f Dyngo-4a and B is-T-23 on CCR5 recycling is that Dyngo-4a is 
able to enter CHO cells rapidly and inhib it hamster dynamin, whereas B is-T - 
23 is e ither taken up slowly into cells or is a poor inh ib ito r o f hamster 
dynamin. Presumably, as CCR5 was detectable w ith no apparent loss o f 
staining intensity in cells in which recycling had been assayed in the 
presence o f Dyngo-4a or B is-T-23, free drug molecules were removed in 
the wash steps before antibody labelling w ith MC-5.
The kinetic data o f CCR5 recycling fit very well to an equation describing a 
single pathway recycling process, suggesting that CCR5 molecules recycling 
to the cell surface only exit through one element o f the recycling 
compartment, e ither from  the TCN or the recycling endosome. The most 
stra ightforward conclusion from  all o f the data as a whole, is that dynam in- 
dependent c la thrin -coated vesicle formation at the recycling com partm ent 
participates in CCR5 recycling. However, the site at which CCR5-containing 
clathrin-coated vesicles are formed (TGN or recycling endosome) and what 
exactly the ir role is in CCR5 recycling is unclear. The almost complete 
inhib ition o f CCR5 recycling in the presence o f Dyngo-4a and dynasore is 
consistent w ith such vesicle form ation being involved in the direct 
tra ffick ing o f CCR5 to the plasma membrane. Additionally, an inh ib ito ry  
effect on CCR5 recycling could be produced if the vesicles were involved in
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transport w ith in the recycling compartment - from the recycling endosome 
to the TGN, or vice versa - because inhib iting the ir formation could block 
transfer to the particular component o f the recycling compartment from  
which recycling carriers are born. However, inhibition o f intra-recycling 
compartment tra ffick ing in isolation would probably only produce a partial 
inhib ition o f CCR5 recycling, since down-modulated CCR5 is present in both 
recycling endosomes and the TGN at steady-state. Thus, it is likely that 
dynam in-dependent clathrin-coated vesicle formation is involved at least in 
exit from  the recycling compartment, but may also play a role in in tra ­
recycling compartment tra ffick ing. Also, although highly likely that clathrin 
and dynamin function in the same clathrin-coated vesicle form ation step, 
dynamin could, in addition, function in a clathrin-independent step 
occurring at the recycling compartment, which Dyngo-4a may inh ib it. Figure 
5-VIII shows a cartoon illustrating the possible sites o f dynam in-dependent 
clathrin-coated vesicle formation (clathrin-independent, dynam in- 
dependent events are not shown).
rfy endosomeT clathrin 
V .  dynamin 
C  I> p-arrestin
nucleus
perinuclear
recycling
compartment
recycling
endosome
Figu re  5 -V I I I  P oss ib le  s ites  o f  d y n a m in -d e p e n d e n t  c la th r in -c o a te d  v e s ic le  
fo r m a t io n  a t  th e  re c y c l in g  c o m p a r tm e n t
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CCR5 tra f f ic k in g  th ro u g h  the perinuc lear recycling c o m p a r tm e n t  is l ikely  to  involve  
d y n a m in -d e p e n d e n t  c la thr in -coated  vesicle fo rm atio n . T ra n s p o rt  vesicles m a y  be  
fo rm e d  at th e  recycling e n d o s o m e  or at the  TG N  and d irectly  ta rge ted  to w ard s  the  
plasm a m e m b r a n e .  In ad d it io n , t ransp ort  vesicles so fo rm ed  m ay m e d ia te  CCR5  
tra ff ick in g  in e i th e r  d irec t io n  be tw een  recycling endosom es and the T G N . CCR5-  
conta in ing  c la th r in -c o a te d  pits in a late stage o f d eve lo p m en t w ith  d y n a m in  
assem b led  a t  th e ir  necks are shown to il lustrate the possible sites o f  c la thr in -  
coated vesicle  fo rm a t io n ,  p -arrestins, which rem ain  bound to CCR5 m o lecu les  as 
th ey  tra ff ic  to  th e  p e r in u c le a r  recycling c o m p a rtm e n t ,  m ay function  as c la thr in  
adaptors  in th e  c o m p a r tm e n t .  CCR5 molecules are shown in a p ho s p h o ry la te d  
state because m o s t recep to rs  a p p e a r  to rem ain phosphory la ted  in the recycling  
c o m p a r tm e n t ,  b u t th e  site(s) o f  receptor depho spho ry la t ion  is unclear.
T h e  M T O C  is show n in th e  b o tto m -r ig h t  corner; dashed g rey  lines ind icate  
m icro tu b u les  e m a n a t in g  f ro m  the MTOC.
Im m unostaining o f cells in which CCR5 is down-m odulated and then 
allowed to recycle in the presence o f Dyngo-4a or dynasore w ith antibodies 
against R a b ll,  TfR and p230, may help to determine the site at which these 
drugs inh ib it CCR5 tra ffick ing  and thus, where CCR5-containing transport 
vesicles are form ed. Moreover, further ultrastructural analysis is desirable to 
confirm  the involvement o f clathrin and dynamin in CCR5 recycling and 
perhaps provide fu rthe r details o f the site o f c lathrin-coated vesicle 
form ation and the potential role o f dynamin in this process. EM analysis o f 
the effect o f Dyngo-4a on CCR5 recycling, should, if the drug is tru ly  
specific fo r dynamin, and the hypothesis that a dynam in-dependent 
clathrin-coated vesicle form ation step is correct, show CCR5 trapped in 
coated pits that have failed to undergo scission. Labelling w ith an ti-c la th rin  
antibodies could then confirm  if the coat is clathrin and labelling w ith 
com partm ent markers could determine whether the vesicles are form ed at 
the TGN or recycling endosome. This sort o f analysis would also assess the 
possibility tha t CCR5 recycling is c la th rin - and dynam in-independent but 
that dynamin inh ib itors block CCR5 recycling by tying up accessory proteins 
in arrested c lathrin-coated pits elsewhere in the cell, which may also be 
required fo r c la th rin - and dynam in-independent CCR5 recycling.
Lastly, CCR5 recycling in a clathrin-dependent fashion suggests a possible 
role fo r CCR5-bound (3-arrestins, which I have shown accompany CCR5 to
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the recycling compartment, as clathrin adaptors at the recycling 
compartment. This is also illustrated in Figure 5-VIII. A potential role fo r p- 
arrestins in CCR5 recycling is further investigated in Chapter 6.
A role for A P -1  in CCR5 intracellular trafficking
There is evidence from  other systems fo r AP-1 acting as a clathrin adaptor 
protein at both the recycling endosome and TGN (Folsch, Ohno et al. 1999; 
Robinson 2004; Rodriguez-Boulan, Musch et al. 2004; Folsch 2005). 
Interestingly, The Alliance for Cellular Signaling (www.signaling­
gateway.org) recently reported a yeast tw o-hybrid  interaction between p- 
a rres tin l and the p i  subunit of AP-1, and in COS cells over-expressing 
GFP-tagged p-arrestin  1 or 2, AP-1 co-im m unoprecip itates w ith the tagged 
p-arrestins CJulie Pitcher, personal communication). Given that p-arrestins 
accompany CCR5 as it traffics to the perinuclear compartment, there is the 
possib ility fo r a situation where p-arrestins could couple CCR5 to AP-1 and 
clathrin in the recycling compartment. My immunofluorescence data shows 
that agonist-activated CCR5 passes through multiple A P -l-p o s itive  
compartments, including both components o f the perinuclear recycling 
com partm ent -  recycling endosomes and the TGN. I therefore investigated 
the potential involvement o f AP-1 in CCR5 recycling.
Although BFA partia lly inhibited the recycling o f CCR5, a knock-down o f the 
\ i lA  subunit o f AP-1 did not show any inhib ition o f CCR5 recycling after 60 
min TAK-779 incubation. The FACS-based tra ffick ing assay also suggests 
that, if anything, recycling proceeded at a slightly faster rate and to a 
slightly greater extent in knock-down cells. In addition, the ^ ilA  knock­
down efficiency in the FACS-based recycling assay was only about 5 5% and 
given that this assay does not, w ithin a population o f ^ ilA  siRNA-transfected 
cells, d iscrim inate between knock-down cells and cells that have normal 
levels o f ^ lA ,  this experiment may have underestimated any effect on CCR5 
recycling. However, I have only conducted this FACS-based tra ffick ing  assay 
once and, especially given the very small difference between CCR5 
tra ffick ing in control and knock-down cells, repeats are necessary before 
firm  conclusions are made. I can only conclude at this stage tha t a ^1A 
knock-down has no inh ib itory effect on CCR5 recycling.
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A small effect o f the ^1A knock down was that down-m odulated CCR5 was 
not quite as concentrated around the nucleus as in control siRNA-treated 
cells or cells treated w ith ^ ilA  siRNA that failed to show a knock-dow n (i.e. 
cells that probably did not take up the ^ilA  siRNA). Moreover, CCR5 and AP- 
1 showed some colocalisation on structures in the periphery o f the 
cytoplasm after 60 min RANTES treatment (Figure 5-11 and Figure 3-VIII), 
which could be early endosomes. It is possible that AP-1 is involved in 
tra ffick ing to  the recycling compartment and that this is why ^1A knock­
down leads to a s lightly more dispersed steady-state down-m odulated 
CCR5 d is tribu tion . Further immunofluorescence experiments w ith early 
endosomal markers and markers o f the recycling compartment may be able 
to confirm  th is proposal.
A lthough these results suggest that AP-1 is not required fo r recycling 
because CCR5 recycles in its absence, I cannot rule out the possibility that 
either there is enough residual ^ ilA  protein in knock-down cells to be able 
to form  suffic ient functional AP-1 complexes to support an A P -1 - 
dependent CCR5 recycling pathway or that partia lly-form ed AP-1 complexes 
could function adequately in this regard. If CCR5 is considered to recycle in 
a c la thrin -dependent fashion, though, the second proposal is unlikely, since 
im m unoprecipitated AP-1 complexes (using an anti-y-adaptin  antibody) 
lacked the p i  and jx lA  subunits in ^ilA  knock-down cells (Hirst, Motley et al. 
2003) and the p i  subunit is responsible fo r clathrin binding (Kirchhausen 
2000). Despite its im plausibility, this possibility could be addressed by 
simultaneous knock-dow n o f multiple AP-1 subunits. However, this would 
not rule out the fu rthe r possibility that AP-1 is ord inarily involved in CCR5 
tra ffick ing, but tha t in its absence, another recycling route can be taken. 
Indeed, the knock-dow n protocol used might have allowed cells to adapt to 
the absence o f th is adaptor protein complex.
Despite the caveats associated with the ^ilA  knock-down, given the m ultip le  
effects o f BFA (see Brefeldin A partia lly inhib its CCR5 recycling) the u lA  
knock-down is a more reliable indicator o f the role o f AP-1. Actually, that 
an AP-1 knock-dow n did not inhib it CCR5 recycling but BFA did, chimes 
well w ith the description o f TfR recycling from recycling endosomes by 
Stoorvogel and co-workers, where AP-1 does not appear to play a role 
(Stoorvogel, Oorschot et al. 1996). Visualising endosomes by w ho le -m oun t
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EM using a technique fo r the selective fixation o f the endosomal apparatus, 
they found that BFA treatm ent led to a loss o f clathrin-coated buds from  
endosomal tubules and, moreover, they found that BFA treatm ent inh ib ited 
TfR recycling from  recycling endosomes to the plasma membrane 
(Stoorvogel, Oorschot et al. 1996; van Dam and Stoorvogel 2002). In 
addition, using the ir w ho le-m ount EM technique, they also reported that 
clathrin-coated buds containing Tf on tubular endosomes are largely devoid 
o f y-adaptin, although it could be argued that this study was biased towards 
the observation o f peripheral endosomal tubules rather than perinuclear 
ones, which are more likely to represent bone fide recycling endosomes 
(Stoorvogel, Oorschot et al. 1996). In summary, the authors essentially 
describe a BFA-sensitive, but probably A P -l-independent .recycling event 
fo r the TfR, which is what the above results suggest fo r CCR5. Given the 
effect Stoorvogel and colleagues see o f BFA treatment on the loss o f clathrin 
from  endosomal tubules, the inhibition o f CCR5 recycling in the presence o f 
BFA may argue simply fo r the involvement o f clathrin in this process. 
However, the authors also found that BFA led to a tubulation o f the TfR- 
containing endosomal network (Stoorvogel, Oorschot et al. 1996; van Dam 
and Stoorvogel 2002). In contrast, CCR5 that had been prevented from  
recycling back to the plasma membrane in the presence o f BFA did not 
appear to occupy extended tubular structures, suggesting a difference in 
the way BFA affects CCR5 trafficking. Others have also witnessed a 
tubulation o f the endosomal network in the presence o f BFA (Stoorvogel, 
Oorschot et al. 1996; Futter, Gibson et al. 1998; Sonnichsen, De Renzis et 
al. 2000) as well as a tubulation o f the TGN (Lippincott-Schwartz, Yuan et al. 
1991; Futter, Gibson et al. 1998). However, Futter et al. (1998) saw a far less 
marked tubu la tion  o f the TGN compared with the endosomal network in the 
presence o f BFA in MDCK cells, so perhaps BFA treatm ent prevents CCR5 
exit from  the TGN. Repetition o f this experiment w ith markers o f the TGN 
and recycling endosome, e.g. p230 and R a b ll, respectively, may shed some 
light on the point o f inh ib ition o f CCR5 tra ffick ing by BFA. Also, it is 
interesting to  note that Sonnichsen et al. (2000) reported that although 
R a b ll and Rab4 redistributed into a tubular network in the presence o f BFA, 
a fraction o f Rab4-containing endosomes did not form  tubules but 
remained in d istinct g lobular structures. In conclusion, a lthough BFA
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inhib ition o f CCR5 recycling suggests the involvement o f clathrin in this 
process, the exact mechanism o f BFA inhib ition remains unclear.
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Chapter 6: The R ole  
OF p-ARRESTINS IN THE 
In t r a c e l lu la r  
T ra ffic k in g  o f  CCR5
“She/ xuore/ a/ bhort bktrt and/ a/ t ig h t sweater and / her figure/ 
described/ a/ bet o f parabola# th a t could/ caAWbe/ ca rd tao  a rres t in  a/ 
yalo.”
Woxytly AUew, Actor
There is evidence that p-arrestins play a role in contro lling the intracellular 
tra ffick ing  o f several GPCRs, although a clear description o f the ir function is 
currently lacking. In Chapter 4, I showed that CCR5 is best described as a 
Class C GPCR in terms o f its association with p-arrestins: p-arrestins 
maintain an interaction with agonist-activated CCR5 molecules as they 
tra ffic  to a perinuclear recycling compartment, from where they recycle 
rapidly to the cell surface. Moreover, the data in the previous chapter 
suggest that CCR5 recycling from the recycling compartment is c la th rin - 
and dynam in-dependent. Thus, there is the possibility that p-arrestins 
couple CCR5 to clathrin at the recycling compartment in a process required 
for recycling. Here, I describe experiments that begin to address the 
hypothesis that p-arrestins regulate CCR5 intracellular tra ffick ing.
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The effect o f over-expression o f wild-type fi-arrestin2 and 
expression o f constitutively active p-arrestin2 mutants on 
CCR5 recycling
One o f the strongest pieces o f evidence that p-arrestins are involved in 
GPCR recycling is the demonstration that the A/-formyl peptide receptor 
(FPR) does not recycle in p-arrestin 1 and 2 knock-out MEFs (Vines, 
Revankar et al. 2003). This demonstration was only possible, though, 
because the FPR can internalise in a p-arrestin-independent manner. CCR5 
internalisation, however, is p-arrestin-dependent (Fraile-Ramos, Kohout et 
al. 2003), so a p-arrestin  knock-ou t/knock-dow n approach to the role o f p- 
arrestins in CCR5 intracellular tra ffick ing is not feasible. An alternative 
approach is to assay the effect o f p-arrestin over-expression or expression 
o f characterised p-arrestin mutants on CCR5 intracellular tra ffick ing . 
Indeed, two studies have used constitutively active p-arrestin mutants to 
investigate a role fo r p-arrestins in the tra ffick ing  o f the FPR and the 
bradykinin 2 receptor (B2R), two Class C GPCRs (Key, Vines et al. 2005; 
Simaan, Bedard-Goulet et al. 2005).
Simaan et al. (2005) used a constitutively active p-arrestin2 mutant 
truncated at residue 381 (p -a rres tin2 (l-381 )). In th is mutant, the structural 
constraint imposed by the p-arrestin C-tail, which is involved in stabilising 
the p-arrestin  molecule in the ‘closed’ , inactive conform ation through 
intramolecular interactions with the globular domains, is removed. An 
equivalent truncation mutant o f p -a rre s tin l, showed a greatly enhanced 
affin ity fo r phosphorylated, agonist-activated p2-adrenergic receptor (p2AR) 
(Kovoor, Celver et al. 1999) and translocated to the p2AR faster and to a 
greater extent than w ild -type  p -a rre s tin l (Oakley, Laporte et al. 2001). In 
addition, whereas w ild -type  p -a rre s in l dissociated from  the agon is t- 
activated p2AR during, or shortly after endocytosis, the C -te rm ina lly  
truncated p -a rre s tin l remained bound to the p2AR in endosomes, 
suggesting a higher a ffin ity  fo r the receptor (Oakley, Laporte et al. 2001). 
Expression o f p -a rre s tin 2 (l-3 8 1 ) prevented recycling o f the B2R, which 
remained associated w ith p -a rre s tin 2 (l-3 8 1 ) in endosomes after agonist 
wash-out. Thus, making the assumption that the truncated p-arrestin2
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mutant also had a higher a ffin ity  fo r the activated B2R, the dissociation o f p- 
arrestins from  the B2R was proposed to be required fo r its recycling. 
However, it must be noted that as well as showing a higher a ffin ity  fo r 
agonist-activated, phosphorylated p2AR, the p -a rre s tin l truncation m utant 
also bound activated, non-phosphorylated p2AR w ith equal a ffin ity  to that 
which w ild -type  p -a rre s tin l bound activated, phosphorylated CCR5 (Kovoor, 
Celver et al. 1999), as one m ight predict from  the mechanism o f p-arrestin  
activation (see Chapter 1). Thus, the effects o f this p-arrestin m utant may 
be more complicated.
Key et al. (2005) used both a truncated form  o f p -a rre s tin l and a mutant 
where an IVF m otif in the C -ta il was mutated to 3 alanines (p- 
arrestinl(IVF/AAA)). Through its interaction w ith a hydrophobic pocket on 
the N-term inal globular domain, this m otif participates in locking the C -ta il 
back onto the globular domains in the inactive, ‘closed’ conform ation 
(Granzin, Wilden et al. 1998; Hirsch, Schubert et al. 1999; Han, Gurevich et 
al. 2001; Milano, Pace et al. 2002), and has been demonstrated to 
contribute significantly towards the basal inactivity o f the protein 
(Vishnivetskiy, Schubert et al. 2000). Both o f these mutants displayed a 
slightly enhanced a ffin ity  in vitro  fo r agonist-activated, phosphorylated FPR, 
compared with w ild -type  p -a rre s tin l, and displayed significant a ffin ity  fo r 
an agonist-activated, partially phosphorylated mutant, in contrast to w ild -  
type p -a rre s tin l, which did not bind this m utant.8 In this study, expression 
o f the p-arrestin 1(IVF/AAA) mutant inhibited the recycling o f both w ild -type  
FPR and the partially phosphorylated mutant; however, expression o f the 
truncation mutant had no effect on recycling o f w ild -type  or the partially 
phosphorylated mutant. Based on the results w ith the p-arrestin 1(IVF/AAA) 
mutant, the authors argued that, as w ith the B2R, the dissociation o f p- 
arrestins from  the FPR is a critical determ inant in receptor recycling. The
8 In a separate study, p -arrestin  1(IVF/AAA) also showed stronger binding to  activated, phosphorylated 
p2AR than w ild -type  p -a rre s tin l, and bound the activated, non-phosphorylated p2AR w ith  as high a ffin ity  
as w ild -type  p -a rre s tin l binds activated, phosphorylated paAR (Pan, L., E. Gurevich, et al. (2003). "The 
Nature o f the Arrestin-Receptor Complex Determines the U ltimate Fate o f the Internalized Receptor." 
Biol. Chem. 278(13): 11623-11632.).
In the FPR study, the constitu tive ly active p -a rre s tin l mutants showed no enhanced b ind ing over w ild -  
type p -a rre s tin l to  agonist-activated, non-phosphorylated FPR.
223
Chapter 6: The Role of p-arrestins in the Intracellular Trafficking of CCR5
observation that the truncation mutant did not affect FPR recycling may be 
explained by the possible presence o f regulatory sites in the p -a rre s tin l C- 
tail.
To investigate whether p-arrestins play a regulatory role in CCR5 recycling, I 
initia lly assayed CCR5 tra ffick ing in CHO CCR5 cells over-expressing GFP- 
tagged versions o f the constitutively active p-arrestin2 mutants, p - 
arrestin2(IVF/AAA)-GFP and G FP-p-arrestin2(l-380), a C -term inal 
truncation mutant. I also assayed tra fficking in cells expressing the 
equivalent w ild -type proteins, p-arrestin2-GFP and GFP-p-arrestin2. In 
Chapter 4, I showed that both p -a rre s tin l and p-arrestin2 are capable o f 
individually supporting CCR5 internalisation and that both p-arrestins tra ffic  
with the receptor to the recycling compartment. Thus, the choice o f p - 
arrestin2 over p -a rres tin l fo r this analysis was quite arbitrary, although the 
fact that p-arrestin2 binds down-m odulated CCR5 4S-*A in the recycling 
compartment, whereas p -a rre s tin l does not, gives it the potential to 
interact w ith a wider population o f CCR5 molecules in terms o f 
phosphorylation status.
w t
IVF/AAA 
1-380
c lathrin  b ind ing  box
raaiduaa diractty inwotvad in p2 -adaptin  aar dom ain binding  
[ [ raaiduaa raquirad fo r NES activity
Figure 6-1 Diagram of the C-termini of wild-type p-arrestin2 and constitutively 
active p-arrestin2 mutants
A m in o  acid sequences fro m  residue 3 7 0  to  the C -term in i o f  p -arrestin2 w i ld - typ e  
and m u ta n t  proteins are shown; GFP is not shown. Point m utations  are ind icated  in 
red. Residues dem o nstra ted  to  partic ipate  in c lathrin (Krupnick, G o o d m a n  e t  al. 
1 9 9 7 )  and AP-2 b ind ing  (Laporte , O ak ley  et al. 2 0 0 0 ;  Kim and Benovic 2 0 0 2 ;  Burtey, 
Schmid et al. 2 0 0 7 )  are show n, as are residues required  fo r  NES activ ity  (Scott, Le 
Rouzic e t  al. 2 0 0 2 ;  W ang, Wu et al. 2 0 0 3 ) .
Diagrams o f the C-term inal residues o f w ild-type p-arrestin2 and the two 
constitutively active mutants can be seen in Figure 6-1. It is noteworthy that
370 VDTNLIEFDTNYATDDDIViEDpuU*! 
370 v d t n l i e f d t n y a t d d d a a I eeT
370 VDTNLIEFDTN 380
CGMKDDDCDDQLC 410 
IliKGMKDDDCDDQLC 410
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the IVF m otif has, since the publication o f the reports by Simaan et al. 
(2005) and Key et at. (2005), been shown to participate in AP-2 binding, 
with the phenylalanine directly binding the p2-adaptin ear domain and the 
isoleucine and valine residues appearing to negatively regulate this 
interaction (Burtey, Schmid et al. 2007). Mutation o f all 3 residues, as in the 
mutant used in this study, resulted in a p-arrestin2 mutant w ith s ign ificantly  
attenuated AP-2 binding capacity (Burtey, Schmid et al. 2007). The p- 
arrestin2 (1-380) mutant would also be expected to show impaired or 
completely abolished binding to AP-2, since all o f the residues shown to 
participate in binding to p2-adaptin are removed from  this mutant. Both 
mutants, however, retain the ir ability to couple activated CPCRs to clathrin, 
since the clathrin binding box, responsible fo r this interaction is intact in 
both mutants.
Initially, I transiently transfected the p-arrestin2 proteins and CFP alone into 
CHO CCR5 cells and assayed CCR5 tra ffick ing by FACS, as described in 
Chapter 5. Cells were treated in suspension with RANTES fo r 60 min to 
down-m odulate CCR5, before being washed and resuspended in medium 
containing TAK-779 fo r 120 min, to fo llow  CCR5 recycling. A liquots o f cells 
were removed at various tim e-po in ts  and cell surface CCR5-associated 
fluorescence determined. Since the transfection efficiency was quite low, I 
gated fo r cells expressing the exogenous proteins based on the ir GFP 
fluorescence. Using this method, the tra ffick ing o f CCR5 in cells not 
expressing detectable levels o f the exogenous proteins was almost identical 
in the d ifferentia lly  transfected samples (data not shown).
Figure 6-11 shows the pooled results o f a series o f tra ffick ing experiments. 
As can be seen in Figure 6-11 A, expression o f p-arrestin2 w ild -type  or 
mutant proteins did not greatly a lter the cell surface expression o f CCR5 
relative to expression o f CFP alone, although cell surface CCR5 levels were 
slightly lower in both p-arrestin2 w ild -type  and mutant expressing cells. 
This suggests that |3-arrestin2 w ild -type  or constitutively active m utant 
protein expression does not grossly affect basal CCR5 tra ffick ing  or CCR5 
biosynthetic tra ffick ing.
Figure 6-11 B and C show the results o f CCR5 tra ffick ing assays w ith  the 
transfected cells. For clarity, the data fo r the two mutant |3-arrestin2 
proteins and their w ild -type  counterparts are displayed over two graphs,
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with the same data fo r the CFP-expressing cells shown on both graphs. The 
tra ffick ing data and rates/rate constants derived from  the data are shown in 
Table 6-1.
^ From Figure 6-11 B, it can be seen that in cells expressing GFP, a 69.13 ± 
0.89% loss o f initial cell surface CCR5 was seen after 60 min RANTES 
treatment. Both cells expressing w ild -type  |3-arrestin2-GFP and |3- 
arrestin2(IVF/AAA)-GFP down-m odulated CCR5 to a greater extent (84.37 ± 
1.55% and 80.30 ± 2.74%, respectively), and there was a smaller percentage 
change in cell surface CCR5 fluorescence between 30 and 60 min RANTES 
treatment compared w ith GFP-expressing cells, suggesting that the 
approach to a steady-state down-m odulated CCR5 d istribu tion was quicker 
in these cells. Cells expressing GFP showed a recovery o f cell surface CCR5 
•f^-after 120 min in the presence o f TAK-779 to 82.14 ± 3.48% o f the in itia l 
level, w ith a plateau reached after 60 min recycling in TAK-779. Why CCR5 
did not recover to 100% o f its initial cell surface level is not known. It was 
assumed fo r the purposes o f this analysis that the maximum cell surface 
CCR5 fluorescence value reached by the GFP-transfected cells in the 
recycling phase represented the maximum level o f CCR5 recycling in all the 
differentia lly transfected cells. In fitting  data to the equation describing a 
single pathway recycling process, detailed in Chapter 5, f lmax was based on 
this value. Using this value, the data describing recycling o f CCR5 in the 
GFP-transfected cells fitted  the equation well (R2 = 0.97, linear regression o f 
a plot o f In((flmax- f l / f lmax) against tim e [t]). krec, the recycling rate constant, in 
GFP-transfected cells was 0.047 ± 0.014 m in '1. In contrast, both w ild -typ e  
p-arrestin2-GFP- and (3-arrestin2(IVF/AAA)-GFP-expressing cells showed 
more sluggish CCR5 recycling, w ith recycling o f CCR5 after 120 min in TAK- 
779 to only 67.84 ± 6.25% and 73.77 ± 5.89% o f the initia l cell surface CCR5 
levels. The recycling curves for CCR5 in these cells had not reached a 
plateau after 120 min in TAK-779, suggesting that CCR5 was still recycling 
^ a t this tim e-po in t. These curves also showed good fits to the single pathway 
recycling equation (R2 = 0.95 and 0.92, respectively) and the ir slower 
recycling o f CCR5 was reflected in reduced recycling rate constants 
compared w ith GFP-transfected cells (krec (wt parr2-GFP) = 0.12 ± 0.0028 
m in 1, krec (|3arr2(IVF/AAA)-GFP) = 0.015 ± 0.0039 m in '1, krec (GFP) = 0.047 ± 
0.014 m in '1; see bar graph in Figure 6-11 D). It could, perhaps, be argued
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that the cells expressing p-arrestin2(IVF/AAA)-GFP recycled CCR5 sligh tly  
faster than cells expressing w ild -type  |3-arrestin2-GFP, which m ight account 
fo r the slightly lower extent o f CCR5 down-m odulation in cells expressing 
p-arrestin2(IVF/AAA)-GFP compared w ith those expressing w ild -typ e  (3- 
arrestin2-GFP, since dow n-m odulation is a balance o f internalisation and 
recycling rates. However, the difference between the two rate constants is 
w ithin the error associated with the data, so cannot be concluded to be 
significant.
One point to note, is that given that d ifferentia lly transfected cells dow n- 
modulated CCR5 to d iffe rent extents, comparing rate constants fo r recycling 
(krec) is more relevant than a comparison o f initia l recycling rates calculated 
fo r the firs t 10 min o f recycling (rrec), as these are, in the ir simplest form , a 
product o f a rate constant and the amount o f internal CCR5, which varied 
between the d ifferentia lly transfected cells. Moreover, the recycling rate 
constant is calculated from  a f it  to all o f the recycling data, which m inim ises 
error compared w ith the in itia l recycling rate, which is calculated from  only 
two values. Nevertheless, this value is listed in Table 6-1 fo r comparison. 
From Figure 6-11 C, it can be seen that the tra ffick ing curve fo r cells 
expressing GFP-|3-arrestin2 w ild -type  closely matched that o f cells 
expressing w ild -type  p-arrestin2-GFP: cells down-m odulated CCR5 to a 
sim ilar extent (84.37 ± 1.78% and 84.37 ± 1.55%, respectively), recovered 
cell surface CCR5 to a sim ilar extent after 120 min incubation in TAK-779 
(71.51 ± 8.97% and 67.84 ± 6.25% o f initial cell surface CCR5, respectively) 
and had sim ilar recycling rate constants (0.014 ± 0.0050 min-1 and 0.012 ± 
0.0028 m in"1). Expression o f G FP-parrestin2(l-380) also led to an enhanced 
CCR5 down-m odulation relative to GFP-expressing cells (76.96 ± 3.58% 
versus 69.13 ± 0.89%) although not as great as cells expressing GFP- 
|3arrestin2 w ild -type  (84.37 ±1.78%). However, in contrast to the inh ib ito ry  
effect on recycling seen in cells expressing w ild -type  p-arrestin2, there was 
only a mild inh ib itory effect on recycling in the presence o f GFP-p- 
a rres tin2 (l-380 ): cell surface CCR5 reached 81.69 ± 2.27% o f the in itia l cell 
surface level after 120 min incubation in TAK-779 (in GFP-expressing cells, 
CCR5 recovered to 82.14 ± 3.48%) and krec was 0.037 ± 0.013 m in '1 (krec 
(GFP) = 0.047 ± 0.014 m in '1). A graphical comparison o f the recycling rate
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constants fo r all o f the d ifferentia lly transfected cells is shown in Figure 6-11 
D. The recycling curves fo r CCR5 in cells expressing GFP-p-arrestin2 w ild - 
type and G FP-p-arrestin2(l-380) also fitted  well to the single pathway 
recycling model (R2 (GFP-0arr2 wt) = 0.96, R2 (GFP-parr2(l-380)) = 0.99).
A
GFP-fJarr2 wt (Jarr2(IVF/AAA)-GFP GFP-fJarr2(1-380)
RANTES
(down-modulation)
TAK-779
(recycling)
Parr2(IVF/AAA)-GFP 
wt Parr2-GFP
0 -----------     1------------1----------- 1----------- 1----------- 1----------- 1------------i
0 20 40 60 80 100 120 140 160 180
time (min)
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Figure 6-II The effect of over-expression of wild-type and constitutively active 
mutants of p-arrestin2 in CHO CCR5 cells
CCR5 traff ick ing  in C HO  CCR5 cells trans ient ly  express ing  w t  0arr2-GFP, GFP-0arr2  
wt, parr2(IVF/AAA)-GFP or G F P -p a rr2 ( l -3 8 0 )  was fo llow ed by FACS, as described  in 
Materia ls  and Methods. A. Bar g raph  show ing m ean cell surface C CR 5-associated  
fluorescence in unst im ula ted  cells expressing  the various e x o g en o u s  pro te in s .  
Mean cell surface CCR5 fluorescence is expressed as a percentage  o f  th e  m ean
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fluorescence from  CHO  CCR5 cells express ing  parr2-CFP. B and C. T ra f f ic k in g  
assays. Cells w ere  treated  w ith  RANTES in BM fo r  6 0  m in befo re  being  w a s h e d  and  
fu r th e r  incubated  in BM co nta in ing  T A K -7 7 9  for 1 2 0  m in. A liquots  o f  cells w e re  
rem oved  at various t im e-p o in ts  and assayed fo r  cell surface C C R 5-assoc ia ted  
f luorescence by FACS, using M C-5 and A lexa  6 4 7  C AM  to  d e tec t C CR 5. Cell surface  
CCR5 fluorescence is expressed  as a p e rcen tage  o f  th e  initial cell surface  CCR5  
f luorescence and p lo tted  ag a in s t  t im e . T he  sam e curve fo r  cells e x p re s s in g  CFP is 
shown in both B and C. T he  d a ta  fo r  CCR5 tra ff ick ing  in cells o ver-e x p re s s in g  p- 
arrestin2  w ild -type  and m u ta n t  prote ins are d isplayed over tw o  graphs fo r  c larity . D. 
Bar graph  show ing the recycling rate constant, k , for  CCR5 in C H O  cells  
express ing  the  various e x o g e n o u s  prote ins, derived  fro m  f itt ing  the d a ta  points  
encom passing  the  recycling phases (6 0  to 1 8 0  min) shown in B and C to  a f irst-  
order rate eq ua t io n .
All d a ta  show n represen t m eans o f  3 o r 4  in d e p e n d e n t e x p e r im e n ts .  Error bars  
rep resen t 1 s tan dard  dev ia tion  o f  the m eans.
In summary, over-expression o f w ild -type  p-arrestin2 led to an enhanced 
down-m odulation o f CCR5 relative to GFP-expressing cells. Moreover, over­
expression o f w ild -type  p-arrestin2 significantly inhibited the recycling o f 
CCR5, suggesting that p-arrestin2 is a negative regulator o f CCR5 recycling. 
Interestingly, in cells expressing G FP-p-arrestin2(l-380), CCR5 was only 
slightly inhibited in its ab ility  to recycle, suggesting that the ab ility to inh ib it 
CCR5 recycling may lie in the C -ta il o f p-arrestin2. That neither 
constitutively active p-arrestin2 mutant led to a complete block in CCR5 
recycling is in contrast to the behaviour o f the FPR and B2R.
It should be noted that w ild -type  p-arrestin2 proteins expressed at s ligh tly  
higher levels than the mutant proteins. A sim ilar analysis gating fo r cells 
expressing low or medium levels o f the exogenous proteins (i.e. excluding 
high-expressing cells that were more frequent in (3-arrestin2 w ild - ty p e - 
transfected cells than m utant-transfected cells) returned almost identical 
results to those where all cells expressing the exogenous proteins were 
considered (data not shown). Hence, the difference in CCR5 recycling 
kinetics in the presence o f the d ifferent (3—arrestin2 w ild -type  and m utant 
proteins was not due to differences in expression levels.
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Table 6-1 The effect of over-expression of wild-type and constitutively active 
mutants of p-arrestin2 on CCR5 trafficking
Protein
over­
expressed
% down- 
modulation 
[100-fleo
mini
fll80 min
(%  initial)
r rec
(% min'1)
krec
(m in1) R 2
w t p a r r2 -GFP 84 .37 ± 1.55 67 .84 ± 6.25 1.39 ± 0.50 0.012 ± 0 .0028 0.95
parr2(IVF/AAA)-
GFP 80.30 ± 2.74 73.77 ± 5.89
2.27 ± 0.34 0.015 ± 0 .0039 0.92
GFP-parr2 w t 84 .37  ± 1.78 71.51 ± 8.97 1.85 ± 0.16 0 .014 ± 0 .0 0 5 0 0 .96
GFP-parr 2(1 - 
380)
76.96 ± 3.58 81 .69 ± 2.27 2.77 ± 0.25 0 .037  ± 0 .013 0 .99
GFP 69.13 ± 0.89 82 .14 ± 3.48 2.96 ± 0.01 0 .047  ± 0 .014 0 .97
The table summarises the data obtained from the quantitative analysis of CCR5 
trafficking in CHO CCR5 cells over-expressing wt parr2-GFP, parr2(IVF/AAA)2-GFP, GFP- 
parr2 wt, or GFP-parr2( 1-380), as shown in Figure 6-II. fit, cell surface fluorescence at 
time, t; rrec, initial rate of recycling (from 60 to 70 min); krec, rate constant for recycling 
obtained by fitting recycling data to a first-order rate equation; R2, coefficient of 
determination from regression analysis of a plot of ln((flmax-fl/flmax) against time [t] (i.e. 
degree of fit of data to a first-order recycling rate equation, R2 max = 1). See Materials and 
Methods for further details. All data represent the mean of 3 or 4 independent 
experiments; errors represent 1 standard deviation of the mean.
I also checked to  see if the mutant (3-arrestin2 proteins could be seen to 
associate w ith CCR5 in RANTES-treated cells and whether there was any 
difference in d istribu tion  o f CCR5 in the |3-arrestin2 m utant-expressing 
cells. Figure 6-111 shows CHO CCR5 cells transiently-transfected w ith  the 
CFP-tagged (3-arrestin2 w ild -type  and mutant proteins, which were pre­
labelled fo r cell surface CCR5 and treated with RANTES fo r 60 min. CCR5 
down-m odulated in both cells expressing the w ild -type  p-arrestin2 proteins 
and those expressing the constitutively active |3-arrestin2 mutants. 
Moreover, both w ild -type  and mutant p-arrestin2 proteins colocalised w ith 
nearly all o f the internal CCR5 after 60 min RANTES treatm ent, 
demonstrating that the like w ild -type  |3-arrestin2, the constitu tive ly active 
mutants are stably recruited to agonist-activated CCR5. In cells expressing 
w ild -type  p-arrestin2, CCR5 was concentrated in the perinuclear region, 
although some punctate CCR5 fluorescence was also observed in the more 
peripheral cytoplasm. In cells expressing p-arrestin2(IVF/AAA)-GFP, CCR5 
also largely accumulated in the perinuclear region, but was sometimes 
observed in slightly larger structures than in w ild -type  p-arrestin2-G FP-
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expressing cells. In cells expressing GFP-|3-arrestin2(l-380), the mutant p- 
arrestin2 was concentrated in the nucleus, most likely as a result o f the 
absence o f the nuclear export signal (NES) that is present after residue 380 
in the C -tail o f w ild -type p-arrestin2 (see Figure 6-1). Interestingly, in cells 
expressing the truncation mutant, CCR5 showed a slightly more scattered 
cytoplasmic distribution, w ith less concentration around the nucleus, 
suggesting a possible defect in intracellular trafficking o f GFP-p- 
a rrestin2 (l-380)-bound CCR5.
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Figure 6-111 The effect of constitutively active p-arrestin2 mutants on the
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distribution of down-modulated CCR5
C H O  CCR5 cells w ere  tra n s ie n tly  transfec ted  w ith  w t parr2-GFP, G FP-parr2 w t, 
parr2 (IV F /A A A )-G FP  or G F P -p a rr2 ( l-3 8 0 ). Cells w ere  p re -labe lled  fo r  cell su rface  
CCR5 w ith  M C -5 and th en  tre a te d  w ith  RANTES in BM a t 37°C  fo r 6 0  m in . C ells  w e re  
th en  fix e d  and in cu b ated  in p erm eab ilis in g  b locking  b u ffe r w ith  A le x a  5 9 4  C A M  
seco n d ary  a n tib o d y  to  d e te c t M C -5 . S ingle confocal sections are show n. Bars, 5 jxm
The effect o f p-arrestin2 mutants defective in clathrin or 
AP-2 binding on CCR5 trafficking
The above results show that unlike the B2R and FPR, constitutively active p - 
arrestin mutants do not block CCR5 recycling. However, over-expression o f 
p-arrestin2 does inh ib it CCR5 recycling and this inhib ition o f recycling was 
partially relieved by truncating the C-tail o f p-arrestin2 to  residue 380. 
Despite the inh ib itory effect o f p-arrestin2 over-expression on CCR5 
recycling, p-arrestins may still be required fo r recycling -  consider the FPR, 
where p-arrestin l(IVF/AAA) inhibits recycling (Key, Vines et al. 2005) but 
recycling does not occur in the absence o f p-arrestins (Vines, Revankar et al.
2003). As previously discussed, one way in which p-arrestins could facilita te 
CCR5 recycling is by coupling receptors to a clathrin-m ediated tra ffick ing  
step required fo r exit from  the recycling compartment. In Chapter 5, I also 
addressed the possibility that CCR5 may, via p-arrestins, couple to the 
clathrin adaptor, AP-1, in the recycling compartment, to effect such a 
c la thrin-m ediated transport step. The binding site fo r p l-a d a p tin  on the p- 
arrestin molecule is not known. However, the p2-adaptin site has been 
mapped and involves Arg396 in p-arrestin2 (see Figure 6—IV, residues in 
blue). Mutation o f this residue to Clu results in a mutant incapable o f 
binding p2-adaptin and thus AP-2. The yeast tw o-hybrid  interaction 
between the p i  subunit o f AP-1 and p-arrestin reported by the Alliance fo r 
Cellular Signaling used residues 190-410 o f p -a rre s tin l as a bait, 
suggesting a site o f interaction between residue 190 and the C -term inus. 
Unpublished data from  Julie Pitcher (MRC LMCB) indicates that an AP-2 
binding mutant o f p -a rre s tin l, w ith Arg395 mutated to Glu (equivalent to
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Arg396 in p-arrestin2), also shows reduced binding to p l-a d a p tin , 
suggesting that p i  and p2-adaptin share closely-related binding sites.
wt 370 VDTNLIEFDTNYATDDDIVlED
LIEF/AAEA 370 VDTNAAKADTNYATDDDIv Ie 
R396A 370 VDTNLIEFDTNYATDDDIVfE
KGMKDDDCDDQLC 410 
GMKDDDCDDQLC 410 
[KGMKDDDCDDQLC 410
clathrin  b ind ing boa
raaiduaa diractly invotvad in ^2-adaptin  aar dom ain binding  
raaiduaa raquirad fo r  NES activity
Figure 6-IV Diagram of the C-termini of wild-type p-arrestin2 and mutants 
defective for clathrin and AP-1/A-2 binding
A m in o  acid sequences fro m  residue 3 7 0  to  the C -term in i o f p -arrestin2  w ild -ty p e  
and m u ta n t p ro te ins  are shown; CFP is not show n. Point m u tations  are in d ica ted  in 
red . R esidues d e m o n s tra te d  to  partic ipate  in c lathrin  and AP-2 b ind ing  are  sh ow n , 
as are res idues req u ired  fo r NES activ ity . See Figure 6-1 fo r references.
To investigate the possibility that p-arrestins couple CCR5 to clathrin in the 
recycling compartment to facilitate recycling, and the possibility that AP-1 is 
involved, I over-expressed in CHO CCR5 cells a GFP-tagged mutant o f p - 
arrestin2 defective fo r clathrin binding, p-arrestin2(LIEF/AAEA) (Goodman, 
Krupnick et al. 1997), and a GFP-tagged Arg396-»Ala mutant, p - 
arrestin2(R396A), which is defective fo r AP-2 binding (Laporte, Oakley et al. 
2000) and likely AP-1 binding.
I in itia lly  assessed the effects o f the p-arrestin mutants using the FACS- 
based tra ffick ing assay. Again, I gated fo r cells expressing the exogenous 
proteins based on their GFP-fluorescence. Figure 6-V  shows the pooled 
results o f a series o f trafficking experiments. In this set o f experiments, 
although consistent between individual experiments, CCR5 did not recycle 
to as great an extent as in the experiments performed w ith the 
constitutively active p-arrestin2 mutants, making possible only relative 
comparisons with that data set. Expression levels o f w ild -type  p -a rres tin2 - 
GFP, p-arrestin2(LIEF/AAEA)-GFP and p-arrestin2(R396A)-GFP were all 
sim ilar (data not shown).
As can be seen in Figure 6-V, although the cells expressing w ild -type  p- 
arrestin2 and the p-arrestin2 mutants had slightly lower cell surface CCR5
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levels than GFP-expressing cells, over-expression o f the p-arrestin  proteins 
did not grossly alter cell surface CCR5 expression levels.
Binding o f p -a rre s tin l/2  to both AP-2 and clathrin are believed facilita te 
c lathrin-m ediated endocytosis. In this series o f experiments, to assess 
whether the over-expression o f (3-arrestin mutants defective in clathrin or 
AP-2 binding affected the internalisation rate o f CCR5, I also assayed cell 
surface CCR5 levels after 10 min RANTES. Little recycling o f CCR5 should 
have occurred in this small tim e-w indow  and, hence, initial internalisation 
rates could be calculated. Perfect comparison o f initial internalisation rates, 
though, would require the d ifferentia lly  transfected cells to have the same 
absolute initial levels o f cell surface CCR5, so this analysis is s ligh tly  
complicated by the fact that the GFP-expressing cells had slightly higher 
levels o f cell surface CCR5 expression. Figure 6 -V  B shows the results o f the 
tra ffick ing assays in cells expressing the exogenous proteins; in itia l 
internalisation rates are compared in the bar graph in Figure 6 -V  C. Over­
expression o f w ild -type  p-arrestin2-GFP enhanced the initial internalisation 
rate compared with GFP-expressing cells (7.36 ± 0.21% m in-1 versus 4.46 ± 
0.34% m in 1, ~ 1.65-fo ld  increase). Expression o f p-arrestin2(LIEF/AAEA)- 
GFP or p-arrestin2(R396A)-GFP also increased the initial rate o f 
internalisation compared w ith cells expressing GFP (rint (parr2(LIEF/AAEA)- 
GFP) = 6.58 ± 0.30% m in"1, rint (parr2(R396A)-GFP) = 6.85 ± 0.17% m in"1), 
although not quite as much as over-expression o f w ild -type  p -a rre s tin 2 - 
GFP. Thus, the amount o f p-arrestins in CHO CCR5 cells was ra te -lim iting  
for CCR5 internalisation.
That expression o f the p-arrestin2 mutants defective in either clathrin or 
AP-2 binding also increased the rate o f CCR5 internalisation, almost to the 
same extent as over-expression o f w ild -type  p-arrestin2, suggests that 
either the clathrin or the AP-2 binding site on the p-arrestin molecule is 
sufficient to effect the clathrin-m ediated internalisation o f CCR5 and e ither 
site can function alone almost as efficiently as both sites together. In 
keeping with the pattern o f initia l internalisation rates, CCR5 dow n- 
modulated to the greatest extent in cells over-expressing w ild -typ e  p - 
arrestin2-GFP (84.06 ± 2.34% down-m odulation), w ith p-arrestin2(R396A)- 
GFP- and p-arrestin2(LIEF/AAEA)-GFP- expressing cells dow n-m odu la ting
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81.70 ± 1.03% and 79.40 ± 3.24% o f cell surface CCR5 after 60 min RANTES 
treatment. The extent o f down-m odulation in the cells expressing the 0 - 
arrestin2 w ild-type and mutant proteins was in excess o f that achieved in 
GFP-expressing cells, where only 73.48 ± 2.79% o f the in itia l cell surface 
CCR5 was down-modulated after 60 min.
A
*  140
w t parr2-G FP fJarr2(LIEF/AAEA)-GFP |3arr2(R396A)-GFP
B
GFP
p a rr2 (L IE F /A A E A )-G F P  
P a rr2 (R 3 9 6 A )-G F P  
w t |Jarr2 -G FP
80 100 
time (min)
TAK-779
(recycling)
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I 1
0 03
c1
wt parr2G fP  0«rr2<LIEFfAAJLA) parr 2<R396A)
Figure 6-V Trafficking of CCR5 in cells expressing p-arrestin2 mutants defective 
in clathrin or AP-2 binding
CCR5 tra ffic k in g  in CHO  CCR5 cells tra n s ie n tly  express ing  w t parr2-G FP, 
parr2(LIEF/AAEA)-CFP or 0arr2(R 396A )-G FP  was fo llo w ed  by FACS, as d escrib ed  in 
M ateria ls  and M ethods. A. Bar g raph  show ing m ean cell surface C C R 5-associa ted  
fluorescence in unstim u la ted  cells express ing  the various exogenous p ro te in s . M ean  
cell surface CCR5 fluorescence is expressed  as a p ercen tage o f th e  m ean  
fluorescence from  CHO CCR5 cells express ing  parr2-GFP. B. T ra ffic k in g  assay. C ells  
w ere  tre a te d  w ith  RANTES in BM fo r 6 0  m in befo re  being  w ashed and fu r th e r  
incubated  in BM conta in ing  T A K -7 7 9  fo r  1 2 0  m in . A liquots  o f  cells w ere  rem o ved  a t 
various tim e -p o in ts  and assayed fo r cell surface C C R 5-associated flu o rescen ce  by  
FACS, using MC-5 and A lexa  6 4 7  GAM to  d e tec t CCR5. Cell surface CCR5  
fluorescence is expressed  as a p ercen tag e  o f th e  in itia l cell surface  CCR5  
fluorescence and p lo tted  a g a in s t tim e . C. Bar g raph  show ing in itia l rates o f  CCR5  
in te rna lisa tio n  (over firs t 10  m in o f  RANTES tre a tm e n t) in C HO  CCR5 cells  
express ing  the  various exo gen o u s  p ro te in s , derived  fro m  the  d a ta  show n  in B. D . 
Bar graph  show ing the  recycling rate co nstant, k e , fo r CCR5 in C HO  cells exp re s s in g  
the  various exogenous p ro te ins , derived  fro m  fittin g  th e  da ta  points e n co m p ass in g  
the  recycling phases (6 0  to  1 8 0  m in ) show n in B to  a firs t-o rd e r rate  e q u a tio n .
All d a ta  show n rep resen t m eans o f 4  in d e p e n d e n t e x p e rim e n ts . Error bars re p re s e n t  
1 s tandard  d ev ia tion  o f the m eans.
Consistent with the effects o f w ild -type p-arrestin2-GFP and GFP-p- 
arrestin2 w ild -type shown in Figure 6-11, over-expression o f p -a rres tin2 - 
GFP in this series o f experiments led to a decreased rate o f recycling 
compared with GFP-expressing cells (krec (parr2-GFP) = 0.015 ± 0.0081 min" 
\  krec (GFP) = 0.032 ± 0.018 min"1). For this analysis, I also based f lmax fo r 
recycling on the maximum cell surface fluorescence value reached by the
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GFP-expressing cells. All o f the curves describing the recycling o f CCR5 in 
the d iffe rentia lly  transfected cells fitted  well to the single pathway recycling 
equation. Cells expressing the p-arrestin2 clathrin or AP-2 binding mutants 
also had a reduced recycling rate compared with GFP-expressing cells (krec 
(parr2(LIEF/AAEA)-GFP) = 0.018 ± 0.0067 m in '1, krec (|3arr2(R396A)-GFP) = 
0.018 ± 0.0075 m in’ 1, krec (GFP) = 0.032 ± 0.018 min’ 1). However, the p- 
arrestin2 clathrin and AP-2 binding mutant-expressing cells had a s lightly 
faster rate o f CCR5 recycling than cells expressing w ild-type (3-arrestin2- 
GFP (krec (parr2-GFP) = 0.015 ± 0.0081 min"1), although this difference was 
well w ith in  the errors associated with the data, so cannot be considered 
significant. Unfortunately, given the poor extent o f CCR5 recycling in this 
series o f experiments, only large effects, like the inhib itory effect o f p - 
arrestin2-GFP expression on CCR5 recycling, would likely fall out o f the 
range o f the error associated with the data. A graphical comparison o f the 
recycling rate constants is shown in Figure 6-V  D.
Table 6-11 The effect of p-arrestin2 mutants defective for clathrin or AP-2 
binding on CCR5 trafficking
Protein
over­
expressed
% down- 
modulation 
[100-fleo
mini
fll80 min 
(% 
initial)
r int
(% min’1)
Free
(% min-1)
krec
(m in1) R2
w t parr2-GFP
p a rr  2 (LIEF/A 
AEA)-GFP 
parr2(R 396A  
)-GFP
84 .06  ± 2.34  
79 .40  ± 3.24  
81 .70  ± 1.03
52.33 ± 
11.58 
55.24 ± 
10.17 
55.15 ± 
5.41
7.36 ± 0.21 
6.58 ± 0.30  
6.85 ± 0 .17
1.45 ± 0 .24  
1.71 ± 0.27  
1.50 ± 0.20
0.015  ± 
0.0081  
0 .018  ± 
0 .0067  
0 .018  ± 
0 .0075
0 .97
0.95
0.95
GFP 73.48 ± 2 .79 58.49 ± 
4.63
4.46 ± 0 .34 2.03 ± 0 .24 0 .032  ± 
0 .018
0 .94
The table summarises the data obtained from the quantitative analysis of CCR5
trafficking in CHO CCR5 cells over-expressing wt parr2-GFP, (3arr2(LIEF/AAEA)2-GFP or 
(3arr2(R396A)-GFP, as shown in Figure 6-V. flt) cell surface fluorescence at time, t; rint, 
initial rate of internalisation (from 0 to 10 min); rmc, initial rate of recycling (from 60 to 
70 min); kmc, rate constant for recycling obtained by fitting recycling data to a first-order 
rate equation; R2, coefficient of determination from regression analysis of a plot of 
l n ( ( f l m a x - f l / f l m a x )  against time [t] (i.e. degree of fit of data to a first-order recycling rate 
equation, R2 max = 1). See Materials and Methods for further details. All data represent 
the mean of 4 independent experiments; errors represent 1 standard deviation of the 
mean.
I also checked to see whether the p-arrestin2 clathrin and AP-2 binding
mutants formed stable associations with down-m odulated CCR5 by
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immunofluorescence (Figure 6-VI). In CHO CCR5 cells transiently- 
transfected w ith either w ild -type  p-arrestin2-GFP, p-arrestin2(LIEF/AAEA)- 
GFP or p-arrestin2(R396A)-GFP and treated with RANTES for 60 min, CCR5 
accumulated in the perinuclear region, where it colocalised with the w ild - 
type and mutant p-arrestin2 proteins, suggesting that CCR5 trafficked 
normally in complex with the clathrin or AP-2 binding defective p-arrestin2 
mutants. The only difference between the down-modulated CCR5 
d istribution in m utant- and w ild-type-expressing cells, was that in cells 
expressing p-arrestin2(LIEF/AAEA)-GFP, much of the CCR5 was often found 
concentrated in a single, large perinuclear cluster (as shown in Figure 6-VI), 
which was rarely observed in cells expressing w ild-type p-arrestin2-GFP or 
0-arrestin2(R396A)-GFP.
CCR5 Parr2 merge
Figure 6-VI The effect of p-arrestin2 mutants defective for clathrin and AP-2 
binding on the distribution of down-modulated GCR5
CHO CCR5 cells w ere  tra n s ie n tly  transfected  w ith  w t parr2-GFP, p a rr2 (R 3 9 6 A ) or
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parr2(L IEF/A A EA )-G FP. Cells w e re  p re -labe lled  fo r cell surface CCR5 w ith  M C -5 and  
th en  tre a te d  w ith  RANTES in BM a t 37 °C  fo r 6 0  m in. Cells w ere  th en  fix e d  and  
in cu b a ted  in p e rm e a b ilis in g  b locking  b u ffe r w ith  A lexa  5 9 4  GAM  seco n d ary  
a n tib o d y  to  d e te c t M C -5 . S ing le confocal sections are show n. Bars, 5 pm
Overall, th is series o f experiments strengthens the argument that p - 
arrestin2 is a negative regulator o f CCR5 recycling. Although not excluding 
the possib ility  that p-arrestins act as facilitators o f CCR5 recycling by 
coupling to clathrin and /o r AP-1, they provide no support fo r this 
hypothesis.
Discussion
In this chapter I have presented biochemical data showing tha t over­
expression o f p-arrestin2 impedes CCR5 recycling in CHO CCR5 cells. In 
contrast to the ir previously demonstrated inhibitory effect on the recycling 
o f the Class C receptors, B2R and FPR, expression o f two constitu tive ly 
active p-arrestin2 mutants did not prevent CCR5 recycling. Indeed, 
truncation o f the p-arrestin2 C -tail partially relieved the inh ib itory effect o f 
p-arrestin2 over-expression and morphological analysis showed that the 
pattern o f down-m odulated CCR5 complexed with the truncated p-arrestin2 
mutant was sligh tly d ifferent from  CCR5 bound to w ild -type p-arrestin2. p - 
arrestin2 over-expression also increased the rate o f CCR5 internalisation 
and, unexpectedly, given the accepted role o f p-arrestin interaction w ith 
AP-2 and clathrin in endocytosis, expression of p-arrestin2 mutants 
defective in AP-2 or clathrin binding also increased the rate o f CCR5 
internalisation. These mutants, however, did not significantly affect the rate 
o f CCR5 recycling compared w ith over-expression of w ild -type p-arrestin2. 
A ltogether, although not excluding the possibility that p-arrestins facilitate 
CCR5 recycling through a clathrin-dependent mechanism, these 
experiments provide no evidence in support o f this theory.
p-arrestin2 is a negative regulator of CCR5 recycling
Over-expression o f p-arrestin2-GFP/GFP-p-arrestin2 s ignificantly slowed 
the recycling o f CCR5, w ith  around a 3.5-fo ld  decrease in the rate constant
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fo r recycling compared w ith  cells expressing GFP. As previously shown by 
immunofluorescence, over-expression of GFP-tagged p-arrestin2 does not 
alter the d is tribu tion  o f CCR5 after 60 min RANTES treatment compared w ith 
cells expressing endogenous levels o f p-arrestin and in this chapter I have 
shown that the recycling o f CCR5 in cells over-expressing p-arrestin2 is ju s t 
as well described by a single pathway recycling process as CCR5 recycling in 
cells expressing endogenous levels o f CCR5. Together, these data argue 
that p-arrestin2 over-expression retards the rate o f CCR5 recycling but does 
not alter its tra ffick ing  itinerary. This suggests that in the normal tra ffick ing  
o f CCR5, p-arrestins function  as negative regulators of CCR5 recycling. This 
is in accordance w ith  the original proposition by Oakley et a/., tha t p - 
arrestins function to  impede receptor recycling (Oakley, Laporte et al. 1999). 
However, in CHO CCR5 cells expressing endogenous levels o f p-arrestins, 
CCR5 recycles w ith  very sim ilar kinetics to the prototypical Class A receptor, 
p2AR, which does not maintain an interaction with p-arrestins in endsomes 
(Oakley, Laporte et al. 1999; Anborgh, Seachrist et al. 2000; Signoret, 
Christophe et al. 2004). Of particular note is that Signoret et al. expressed 
CCR5 and p2AR in CHO cells, so if p-arrestins function as negative 
regulators o f CCR5 recycling, then other factors must either negatively 
regulate the recycling o f p2AR or positively regulate the recycling o f CCR5 to 
account fo r the s im ilarity in the ir recycling rates.
Another im plication o f CCR5 recycling being slowed in cells over-expressing 
p-arrestin2 is that p-arrestin  expression levels in d ifferent cellular 
backgrounds may modulate the CCR5 recycling rate. Im portantly, when 
considering the physiological relevance of CCR5 expression in CHO cells, 
the rate o f CCR5 recycling in this cell-line is similar to that in lymphocytes 
and monocytes, where CCR5 is endogenously expressed (Mack, Luckow et 
al. 1998).
One sign ificant lim ita tion  o f this study is that only the effect p-arrestin2 
over-expression has been assessed, and not that o f p -a rre s tin l. Most 
studies addressing the role o f p-arrestins in intracellular GPCR tra ffick ing  
have not addressed whether there may be differential roles fo r p -a rre s tin l 
and p-arrestin2. However, the expression o f p-arrestin anti-sense 
constructs in HEK293 cells led to significant defects in A2B adenosine
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receptor recycling, which although restored by either p -a rre s tin l or p- 
arrestin2 reconstitu tion, was faster when rescued with p-arrestin2 compared 
with p -a rre s tin l (Mundell, Matharu et al. 2000). Hence, redundancy o f the 
functions o f the two p-arrestin  proteins should not be assumed and the 
effect o f p -a rre s tin l over-expression should be separately assessed.
As yet, I have no data concerning the mechanism through which p-arrestin2 
negatively regulates the recycling o f CCR5. One interesting observation 
made through electron microscopy observations o f immunolabelled 
cryosections, is tha t a fter 60 min RANTES treatment, a small amount o f 
CCR5 was found in large, fla t-coated patches on endosomal structures. 
Interestingly, these coated areas also labelled fo r AP-1, suggesting that the 
coat m ight be clathrin (Silene Wavre, Endocytic Regulation o f Chemokine 
Receptor Expression, PhD thesis, 2006). Flat clathrin coats have also been 
observed on early endosomes, which contain hepatocyte growth factor 
regulated tyrosine kinase substrate (HRS) and mediate sorting o f proteins 
fo r lysosomal degradation (Raiborg, Wesche et al. 2006). Perhaps p- 
arrestin2 couples CCR5 to fla t clathrin patches to retain it in endosomes and 
inh ib it its recycling. However, the rate of CCR5 recycling was very s im ilar in 
cells expressing the clathrin binding mutant o f p-arrestin2 and those over­
expressing w ild -type  p-arrestin2, suggesting that either this mechanism 
does not operate or that p-arrestins also couple CCR5 to clathrin to 
facilitate recycling (through the formation of CCR5-containing c la th rin - 
coated vesicles), so that an inability o f p-arrestin2 to couple to c lathrin has 
both positive and negative effects on the ability o f CCR5 to recycle, which 
cancel out.
The function  o f a p-arrestin-dependent retention mechanism is uncertain, 
a lthough it may have something to do with the maintenance o f s ignalling 
from  the p-arrestin  molecule; fo r instance, p-arrestins have been shown to 
scaffold m itogen-activated protein kinases (MAPKs) (Shenoy and Lefkowitz 
2005).
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The p -arrestin  C -ta il may contain regulatory site(s) for CCR5 
trafficking
The expression o f constitu tive ly active p-arrestin2 mutants did not inh ib it 
the recycling o f CCR5 to a greater extent than over-expression o f w ild -type  
p-arrestin, in apparent contrast w ith results obtained with B2R and FPR (Key, 
Vines et al. 2005; Simaan, Bedard-Goulet et al. 2005). There are several 
caveats w ith the expression o f these mutants and the interpretation o f the ir 
effects is not stra ightforw ard. Firstly, although I have demonstrated that the 
constitutively active mutants bind agonist-activated CCR5 and remain stably 
associated w ith  receptors as they tra ffic to endosomes, I have not 
determined the ir CCR5 binding affin ities in relation to w ild -type p-arrestin2. 
Moreover, rather than increasing the affin ity fo r agonist-activated, 
phosphorylated GPCRs, probably the most significant effect o f truncating 
the p-arrestin  C -ta il or mutating the IVF m otif is to render the p-arrestin  
molecule’s binding to activated GPCRs phosphorylation insensitive: both o f 
the p-arrestin  mutants have been shown to bind agonist-activated, non- 
phosphorylated p2AR w ith  sim ilar affin ity to that which w ild -type  p -a rre s tin l 
shows towards activated, phosphorylated p2AR (Kovoor, Celver et al. 1999; 
Pan, Gurevich et al. 2003). Both mutants also bound activated, partially 
phosphorylated m utant FPR with high affin ity (Key, Vines et al. 2005). 
Furthermore, it is d ifficu lt to compare the data presented in th is chapter 
w ith tha t o f the B2R and FPR studies because these studies did not assess 
the effect o f w ild -type  p-arrestin over-expression compared w ith  
endogenous p-arrestin  expression on the rate o f receptor recycling.
For the B2R, the expression o f a p -a rres tin l truncation mutant s ign ificantly 
reduced the rate o f recycling relative to w ild-type p -a rre s tin l over­
expression, suggesting that dissociation o f the p-arrestin is required fo r 
recycling (Simaan, Bedard-Goulet et al. 2005). In contrast, the expression o f 
the constitu tive ly active mutants did not further inhib it CCR5 recycling over 
the effect produced by w ild -type  p-arrestin2 expression. This difference, 
and the apparent need fo r p-arrestin dissociation from  the B2R before 
recycling, may well be a reflection o f the requirement fo r B2R to be 
dephosphorylated before it is recycled. It has been shown that agon ist- 
induced phosphorylation o f B2R is followed by its rapid dephosphorylation
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(Blaukat, Alla et al. 1996). Perhaps, in keeping with the classical model o f p- 
arrestins im peding GPCR recycling, the presence o f a p -a rre s tin l mutant 
w ith higher a ffin ity  fo r the B2R prevents its dephosphorylation and, as a 
consequence, its recycling. CCR5, on the other hand, seems to be able to 
recycle in a phosphorylated state, so such a mechanism is unlikely to exist 
(Signoret, Pelchen-Matthews et al. 2000).
The effect o f the constitu tive ly active mutants are perhaps more easily 
reconcilable w ith those o f the FPR, considering the effects o f the 
constitutively active mutants in the ir own right, rather than relative to w ild -  
type p-arrestin2, since the FPR study did not assess the effect o f w ild -type  
p-arrestin over-expression, only the expression of the constitutively active 
mutants. The affin ities o f the constitutively active p -a rres tin l mutants fo r 
activated, phosphorylated FPR were only slightly higher than w ild -type  p - 
a rres tin l anyway (Kd fo r constitutively active mutants = 0.22 |iM and 0.18 
M,M, Kd fo r w ild -typ e  p -a rre s tin l = 0.6 ^M) (Key, Vines et al. 2005). By th is 
method o f comparison, the results o f this study and that w ith the FPR are 
strik ing ly sim ilar, since p-arrestin 1(IVF/AAA) inhibited the recycling o f the 
FPR and p-arrestin2(IVF/AAA) inhibited the recycling of CCR5, whereas the 
expression o f p -a rre s t in l( l-3 8 2 )  did not affect the recycling o f the FPR and 
p -a rre s tin 2 (l-3 8 0 ) expression led to a much reduced inh ib itory effect on 
CCR5 recycling (perhaps this small inhibitory effect on CCR5 recycling 
reflects a greater sensitivity o f CCR5 to p-arrestin over-expression than the 
FPR). Given tha t the constitutively active p -a rres tin l mutants had sim ilar 
affin ities fo r the activated, phosphorylated FPR (and fo r partially 
phosphorylated mutants), the reason for the difference between the effects 
o f the mutants may lie in the residues deleted from the p-arrestin C -ta il in 
the truncated mutants. Similarly, such an explanation can be invoked fo r 
CCR5 recycling: C -ta il residues in p-arrestin2 may be required fo r the 
negative regulation o f CCR5 recycling. Immunofluorescence analysis showed 
that a fter 60 min RANTES treatment, internalised CCR5, which colocalised 
strongly w ith p -a rre s tin 2 (l-3 8 0 ), had a slightly more dispersed cytoplasm ic 
staining pattern than CCR5 down-modulated in cells over-expressing w ild - 
type p-arrestin2, suggesting an alteration in tra ffick ing. A lthough quite 
speculative, one interpretation o f these results is that residues in the C -ta il
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o f p-arrestin2 are responsible fo r directing the trafficking o f CCR5 to the 
perinuclear recycling com partm ent where an inhibitory mechanism operates. 
However, co-sta in ing  o f CHO CCR5 cells expressing p -a rre s tin 2 (l-3 8 0 ) 
treated w ith RANTES fo r 60 min w ith recycling compartment markers is 
needed to confirm  this (a lack o f colocalisation would be expected). 
Directing CCR5 to the recycling compartment is probably not the inh ib ito ry  
mechanism in itself, since CCR5 recycling was faster in cells expressing GFP, 
where it passes through th is compartment (data not shown), than in those 
expressing p -a rre s tin 2 ( l-3 8 0 ). The recycling data for CCR5 in the presence 
o f p -a rre s tin 2 (l-3 8 0 ) fitted  well to the equation describing single pathway 
recycling mechanism, suggesting that CCR5 still recycled prim arily through 
a single pathway in the presence o f the p-arrestin2 truncation mutant. 
Whether th is is the same pathway as it ordinarily takes cannot be 
determ ined from  th is analysis.
It is unlikely that the AP-2/AP-1 binding site, which is removed in the p- 
arrestin2 truncation  m utant, is involved in regulating CCR5 intracellu lar 
tra ffick ing, such as mediating trafficking to the perinuclear recycling 
com partm ent, since in cells expressing either p-arrestin2(IVF/AAA) or p - 
arrestin2(R396A), which have mutations in the AP-2/AP-1 b inding site 
resulting in attenuated AP-2 binding (and presumed reduction in binding to 
AP-1), CCR5 recycling was inhibited almost to the same extent as cells 
over-expressing w ild -type  p-arrestin2, and immunofluorescence analysis 
revealed that down-m odulated CCR5 accumulated in the perinuclear region. 
One potential regulatory site present in the p-arrestin2 C -tail is Thr383. 
Cytoplasmic p-arrestin2  is constitutively phosphorylated on Thr383 (rodent 
amino acid sequence numbering, as shown in Figure 6-1 and Figure 6-IV ; 
bovine Thr382) by casein kinase II (CKII) (Lin, Krueger et al. 1997; Kim, 
Barak et al. 2002). Both p-arrestin2 and p -a rre s tin l, which is 
phosphorylated by extracellu lar-re lated kinase 1/2 (ERK1/2) on Ser412 
become dephosphorylated upon recruitment to activated p2AR (Lin, Krueger 
et al. 1997; Lin, M iller et al. 1999; Kim, Barak et al. 2002). However, whereas 
p -a rre s tin l dephosphorylation regulates interaction w ith clathrin (Lin, 
Krueger et al. 1997; Lin, M iller et al. 1999), the dephosphorylation o f p-
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arrestin2 has not been linked with any functional consequence other than 
interaction w ith an unidentified protein (Kim, Barak et al. 2002).
It is interesting tha t the tra ffick ing  behaviour o f CCR5 in the presence o f the 
p-arrestin mutants more closely resembled that o f the FPR than the B2R, as 
it suggests a s im ila rity  in the regulatory role o f p-arrestins for chemotactic 
GPCRs (CCR5 and FPR) versus non-chemotactic GPCRs (B2R). This is 
especially noteworthy as there is growing evidence for p-arrestins as master 
regulators o f chemotaxis.
Crucially, although these data suggest that p-arrestin2 is a negative 
regulator o f CCR5 recycling, they do not rule out the possibility that p- 
arrestins may be required fo r recycling. Without the potential to perform  p- 
arrestin knock-dow ns to assess the requirement for CCR5 in recycling -  
because CCR5 does not internalise in their absence - determ ining whether 
p-arrestins are required fo r CCR5 recycling will be d ifficu lt. It may be 
necessary to  engineer an alternative internalisation motif, such as the AP-2 
binding m o tif o f CXCR4, which can mediate CXCR4 internalisation in a 
phorbol myristate acetate- (PMA-) inducible manner (Signoret, Rosenkilde et 
al. 1998).
p-arrestin  binding to AP-2 and clathrin in CCR5 internalisation
The rate o f CCR5 internalisation was enhanced by p-arrestin2 over­
expression, indicating that p-arrestins are lim iting for CCR5 internalisation. 
This is in keeping w ith immunofluorescence data presented in Chapter 4, 
where a greater degree o f internalisation and plasma membrane clustering 
o f CCR5 was visible a fter 5 min RANTES-treatment in CHO CCR5 cells stably 
over-expressing GFP-tagged p-arrestins compared with CHO CCR5 cells. 
This is unsurprising given the high levels o f CCR5 expression in the CHO 
CCR5 cells used in this study. Given the accepted role o f p-arrestins in 
coupling to AP-2 and clathrin to effect GPCR clathrin-m ediated endocytosis, 
it was, however, s ligh tly surprising that expression o f both p - 
arrestin2(LIEF/AAEA) and p-arrestin2(R396A), mutants defective in clathrin 
and AP-2 b inding, respectively, led to an increased rate o f CCR5 
internalisation over GFP-expressing cells, almost to the same extent as 
over-expression o f w ild -type  p-arrestin2. This suggests that fo r CCR5
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internalisation, e ither AP-2 or cla thrin -b ind ing by CCR5-bound p-arrestins 
is suffic ient to mediate internalisation. Nevertheless, the possibility that 
both AP-2 and clathrin binding sites are required for p-arrestin-sponsored 
CCR5 internalisation but tha t in p-arrestin2 mutant-expressing cells, there 
are suffic ient numbers o f w ild -type  p-arrestin molecules that can bind 
activated CCR5 molecules and provide either the AP-2 or clathrin binding 
site in nascent clathrin-coated pits, cannot be excluded.
p-arrestin -m ediated coupling of CCR5 to clathrin and A P -1 in 
CCR5 recycling
Previous data presented in this thesis has pointed to the form ation o f CCR5- 
containing clathrin -coated vesicles at the recycling compartment as a step 
involved in CCR5 recycling. As p-arrestins are bound to CCR5 in the 
recycling com partm ent, they may facilitate this step by direct b inding to 
clathrin heavy chain. A lthough the data hitherto presented have provided no 
evidence fo r the additional involvement o f AP-1 in this process, the recent 
find ing tha t AP-1 binds p-arrestins 1 and 2 warranted investigation o f th is 
possibility. Expression o f p-arrestin2 mutants defective in clathrin or AP-2 
binding (assumed from  various lines o f evidence to be also defective in AP-1 
binding, as discussed above), did not inhibit CCR5 recycling any more than 
over-expression o f w ild -type  p-arrestin2, suggesting that neither clathrin 
nor AP-1 binding are essential fo r CCR5 recycling. However, a lthough 
clathrin and AP-2 binding have been shown to be involved in p -a rre s tin - 
mediated CPCR internalisation, expression of p-arrestin2 mutants defective 
in either clathrin or AP-2 binding led to an enhancement o f the rate o f CCR5 
internalisation over cells expressing GFP, albeit a s ligh tly  smaller 
enhancement than that produced by w ild-type p-arrestin2 over-expression. 
By analogy, if p-arrestins couple CCR5 to AP-1 and clathrin in the recycling 
com partm ent to facilitate a clathrin-dependent tra ffick ing step, ablation o f 
p-arrestin  interaction with jus t one o f these proteins may not s ign ificantly 
affect recycling.
If, however, it is assumed that AP-1 plays no role in CCR5 recycling (the 
simplest interpretation o f the data presented in Chapter 5) it could be
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argued that p-arrestin-m ediated coupling to clathrin is not required fo r 
CCR5 recycling.
Potential roles fo r p -a rrestins  in CCR5 tra ffick ing
Figure 6-VII shows a cartoon illustrating the potential involvement o f p - 
arrestins in regulating the trafficking of CCR5.
perinuclear
recycling
compartment
nucleus
Figure 6-VII Possible roles for p-arrestins in regulating CCR5 trafficking
p-arrestins may control several steps in CCR5 trafficking. (1) p-arrestins couple 
agonist-activated CCR5 to the clathrin-mediated endocytic machinery. (2) The C- 
terminal region of p-arrestins may regulate trafficking from early endosomes to the 
perinuclear recycling compartment. (3) p-arrestins appear to act as negative 
regulators of CCR5 recycling, perhaps by coupling receptors to flat clathrin coats in 
the perinuclear recycling compartment (4) p-arrestins may couple the receptor to 
clathrin, as part of mechanism for progress through the recycling compartment,
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e.g . fin a l e x it  fro m  th e  c o m p a rtm e n t, as show n in the  cartoo n . H ow ever, th e  d a ta  
presen ted  in th is  c h a p te r p ro v id e  no ev idence fo r the occurrence o f such a 
m ech an ism . See m ain  te x t  fo r  fu r th e r  d e ta ils .
T he  p e rin u c le a r recyc ling  c o m p a rtm e n t, w hich  m ay com prise  e lem ents  o f the  T C N  
and recycling  e n d o s o m e , is show n in s im p lified  fo rm . T h e  M TO C  is show n in the  
b o tto m  rig h t co rn er; d o tte d  g re y  lines rep re s e n t m icro tu bu les  e m an a tin g  fro m  the  
M TO C .
The data presented in th is thesis clearly support the notion that p-arrestins 
facilitate the agon ist-induced internalisation o f CCR5 (Step 1 in Figure 
6-VII). In addition, p-arrestins maintain an interaction with CCR5 as it 
traffics to a perinuclear recycling compartment, raising the possibility that 
they may play a fu rthe r regulatory role in contro lling CCR5 intracellular 
tra ffick ing . The exact role tha t p-arrestins play is hard to discern from the 
data presented in th is chapter, but the clearest conclusion is that p- 
arrestin2 acts as negative regulator o f CCR5 tra ffick ing and that residues in 
the C -ta il o f p -arrestin2 are required fo r this inh ib itory function, p- 
arrestin2 may be responsible fo r directing tra ffick ing o f CCR5 to the 
recycling com partm ent, a function requiring the C -ta il o f p-arrestin2 (Step 
2), where an inh ib ito ry  mechanism operates. As speculated above, this 
inh ib ito ry mechanism may involve coupling the receptor to fla t clathrin 
lattices (Step 3). A lthough providing no evidence fo r a role o f p-arrestins in 
facilita ting CCR5 recycling at the recycling com partm ent (Step 4), the data 
presented above do not exclude such a role.
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Chapter 7: F inal 
Discussion
ujMtMy cxrvney later tha^ vAlVS, but I decline'ter call 
that p r&grefry. ”
Mct&on/Cooley, US ocphorLtt (cb. 2002)
The notion that dow n-regu la ting  CCR5 cell surface expression could be an 
effective an ti-H IV  strategy has driven research that has mapped out a basic 
tra ffick ing  pathway fo r agonist-activated CCR5, teased out some o f the 
molecular players involved in its internalisation, and determined several 
properties o f its recycling behaviour (Mack, Luckow et al. 1998; Signoret, 
Rosenkilde et al. 1998; Signoret, Pelchen-Matthews et al. 2000; Signoret, 
Christophe et al. 2004; Signoret, Hewlett et al. 2005). Since its discovery as 
a co-receptor fo r R 5-trop ic strains o f HIV, CCR5 has been the target o f 
several sm all-m olecule HIV e n try -inh ib ito r drugs. One o f the firs t o f these 
was TAK-779, whose interaction w ith CCR5 blocks that o f the viral envelope 
protein, g p l2 0 , but its poor pharmacological and toxicological profile  has 
relegated it to a more humble role in laboratory experiments, such as those 
described in th is thesis (Baba, Nishimura et al. 1999; Dragic, Trkola et al.
2000). A more prom ising CCR5 antagonist is Pfizer’s compound, Maraviroc 
(orig inally designated UK-427857), which has been approved fo r use by the 
US Food and Drug Adm in istra tion (FDA) and the European Commission (EC) 
(Dorr, Westby et al. 2005). But the notion o f down-regulating CCR5 cell 
surface expression by interfering w ith its intracellular tra ffick ing is yet to be 
realised and is unlikely to  be while the waters beneath the cell surface 
remain murky. Moreover, a more complete description o f CCR5 intracellular 
tra ffick ing  is needed to understand how CCR5 performs its physiological 
role in recruiting subsets o f leukocytes to sites o f inflammation.
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In this study I have added to  the current understanding of CCR5 trafficking 
by providing a fu lle r description o f the path taken by internalised CCR5 
molecules, focusing on the nature o f the perinuclear recycling compartment 
through which they pass en route to the cell surface, and I have identified 
some o f the molecules involved in CCR5 progression through this 
compartment. Moreover, I have shown that like a growing number of 
GPCRs, p-arrestins, which participate in CCR5 internalisation, remain 
associated w ith  the receptor during its intracellular tra fficking w ith potential 
regulatory consequences.
CCR5 recycling: endocytic meets biosynthetic
Much o f the data regarding CCR5’s post-endocytic tra ffick ing itinerary has 
been obtained using CHO cells stably expressing the receptor. In these cells, 
it has been shown tha t a fter clathrin-m ediated internalisation, CCR5 
molecules tra ffic  th rough early endsomes en route to a perinuclear recycling 
com partm ent, whence they recycle back to the cell surface (Signoret, 
Pelchen-Matthews et al. 2000; Signoret, Christophe et al. 2004; Signoret, 
Hewlett et al. 2005). It was previously thought that the recycling 
com partm ent -  the perinuclear compartment from which CCR5 recycles to 
the plasma membrane and in which down-m odulated receptors accumulate 
at steady-state -  was the recycling endosome. Indeed, CCR5 was the firs t 
GPCR demonstrated to tra ffic  through the recycling endosome (Signoret, 
Pelchen-Matthews et al. 2000). However, my morphological analysis o f 
CCR5 tra ffick ing  in CHO CCR5 cells suggests that in addition to tra ffick ing  
through recycling endosomes, CCR5 also traffics through the TGN and the 
perinuclear recycling com partm ent defined as above may be considered to 
comprise membrane elements from  both the recycling endosome and TGN. 
To my knowledge, this is the firs t evidence for an agonist-activated GPCR 
tra ffick ing  through the TGN.
Although the data presented herein are reasonably convincing, fo llow -up  
experiments should be conducted to confirm the passage o f CCR5 through 
the TGN. These could e ither take the form  o f an ultrastructural analysis, fo r 
instance electron m icroscopy performed on cryosections immunolabelled fo r 
p 2 3 0 /R a b ll,  or a biochemical assay taking advantage o f the fact that CCR5
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has O -linked oligosaccharides added to its N-term inus (Farzan, M irzabekov 
et al. 1999; Bannert, Craig et al. 2001). In the latter case, the term inal sialic 
acid residues associated w ith  these oligosaccharides could be removed from  
cell surface receptors by enzymatic cleavage and receptors returning to the 
cell surface after agon is t-induced  internalisation assayed fo r re -add ition  o f 
sialic acid.
It should be noted tha t a lthough the demonstration o f CCR5 tra ffick ing  
through the TGN is presented in Chapter 3, this tra fficking behaviour was 
only fu lly  appreciated towards the end o f the experimental stage o f the 
thesis project in com bination w ith  a realisation o f the effects o f antibody 
pre-labelling o f cell surface CCR5 on its subsequent agonist-induced 
tra ffick ing (discussed in Influence o f  antibody b inding on CCR5 tra ffick ing  in 
Chapter 3). Thus, many immunofluorescence experiments described in this 
thesis, particularly those investigating the role o f p-arrestins, were 
performed w ith  p re -labe lling  o f CCR5 and w ith the view that CCR5 
trafficked th rough recycling endosomes and not the TGN. Thus, I have had 
to re -in te rp re t some data in the context o f CCR5 tra ffick ing to a recycling 
com partm ent composed o f recycling endosome and TGN components, 
which both complicates in terpretation and begs fu rther experim entation.
The obvious question tha t sorting to the biosynthetic pathway raises is what 
is the order o f the tra ffick ing  events taking place in the perinuclear region o f 
the cell? Unfortunately, the experiments described in this thesis do not 
provide the answer to th is question. It may be expected from  previously 
described tra ffick ing  itineraries o f other recycling membrane proteins that 
the pathway is likely early endosome to recycling endosome to TCN, since 
there are examples o f proteins tra ffick ing from  recycling endosomes to the 
TGN, whereas recycling membrane proteins taking an early endosome to 
TGN route are not well documented (Maxfield and McGraw 2004). In 
addition, there may be bidirectional transport o f CCR5 between the TGN and 
recycling endosomes. From which element o f the recycling com partm ent 
CCR5 molecules destined fo r the plasma membrane exit, is also unclear. 
Kinetic data o f CCR5 recycling from  the recycling compartment f it  very well 
to an equation describing a single-pathway recycling process. The sim plest 
interpretation o f this analysis is that exit o f CCR5 molecules destined fo r the 
plasma membrane only occurs from one o f the two components o f the
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recycling com partm ent -  either from  the TGN or the recycling endosome -  
but it is also consistent w ith CCR5 recycling from both the TGN and 
recycling endosome w ith  the same kinetics, perhaps w ith  the same 
machinery required fo r ex it functioning on both compartments. It should be 
noted that CCR5 recycling from  the recycling compartment had a ha lf-tim e  
o f around 10 min, which is very sim ilar to previous reports o f TfR recycling 
from  recycling endosomes (Mayor, Presley et al. 1993).
The tra ffick ing  o f TfR through recycling endosomes, and that o f several 
other recycling membrane proteins, such as the chemokine receptor, 
CXCR2, is regulated by R a b ll  (Ullrich, Reinsch et al. 1996; Ren, Xu et al. 
1998; Fan, Lapierre et al. 2003). In this thesis, I have shown that R a b ll also 
regulates CCR5 tra ffick ing . R ab ll:G TP  was found to be necessary for 
tra ffick ing  o f CCR5 to recycling endosomes and hydrolysis o f the bound GTP 
to GDP required fo r CCR5 recycling, which is in keeping with the proposed 
role o f R a b ll in TfR recycling (Ren, Xu et al. 1998). My data are also 
completely compatible w ith  a description o f R abll:G TP being required for 
tra ffick ing  to a perinuclear recycling compartment com prising TGN and 
recycling endosome elements and hydrolysis o f R a b ll-b o u n d  GTP to GDP 
being required fo r exit from  this compartment. Thus, the problem o f not 
knowing the exact tra ffick ing  route that CCR5 takes means that I cannot 
exclude the possib ility that R a b ll plays an additional role in tra ffick ing 
w ith in  the perinuclear recycling compartment. Interestingly, results o f 
experiments fo llow ing the retrograde tra ffick ing o f TGN38 and Shiga toxin  
in HeLa cells, suggest that R a b ll may function in the sorting o f proteins 
from  recycling endosomes to the TGN (Wilcke, Johannes et al. 2000); it is 
possible that this is also the case fo r CCR5.
This discussion demonstrates the need fo r fu rther clarification o f the 
tra ffick ing  pathway taken by CCR5. This could begin w ith a quantitative 
immunofluorescence assay, sim ilar to those performed by Ghosh et al. 
(1998) and Ghosh et al. (2003) to elucidate the tra ffick ing itineraries of 
TGN38 and CI-MPR, respectively. By fo llow ing the patterns o f association of 
CCR5 w ith  com partm ental markers after agonist treatm ent fo r various 
periods o f tim e, perhaps in com bination w ith pulses o f chemokine 
stim ulation fo llowed by chase periods in the absence o f stim ulation, it may 
be possible to ascertain the direction o f the tra ffick ing  steps. Also, the
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in triguing observation that in the presence o f the m icrotubule 
depolymerising agent, nocodazole, down-modulated CCR5 was found only 
to colocalise w ith  the TGN marker, p230, and not the recycling endosome 
marker, R a b ll,  warrants fu rthe r investigation as this may suggest a 
m icrotubule dependent ex it pathway fo r CCR5 from the TGN, as has been 
shown to function fo r many other proteins (De Matteis and Luini 2008).
Why CCR5 tra ffics th rough the TGN in addition to recycling endosomes is an 
open question. Perhaps CCR5 must cycle through this compartment to 
maintain carbohydrate m odifications and sulphation o f its N -term inus, 
which are critical fo r agonist binding (Farzan, Mirzabekov et al. 1999; 
Bannert, Craig et al. 2001; Farzan, Chung et al. 2002). Turnover o f these 
post-transla tional m odifications is not well understood. Interestingly, 
tyrosine sulphation contributes significantly to  HIV envelope protein binding 
and HIV co-receptor activ ity (Farzan, Mirzabekov et al. 1999; Cormier, 
Persuh et al. 2000; Farzan, Chung et al. 2002; Huang, Lam et al. 2007). 
Thus, if CCR5 tra ffick ing  through the TGN is required to maintain this 
m odification, th is may represent a potential target fo r an an ti-v ira l strategy. 
A lternative hypotheses fo r the need to tra ffic  through the TGN are the same 
as those fo r CCR5 recycling through recycling endosomes: why CCR5 
recycles back to  the cell surface through recycling endosomes and not 
simply via early endosomes is not clear. For CXCR2, at least, passage o f 
recycling receptors through recycling endosomes and not ju s t recycling per 
se, is crucial fo r chemotaxis. Perturbation o f CXCR2 recycling w ith a 
constitu tive ly active mutant o f RhoB, which prevented tra ffick ing  through 
R a b ll-p o s itiv e  recycling endosomes but did not affect the extent o f 
receptor recycling (which, under these conditions probably occurred through 
a Rab4-controlled pathway from  early endosomes), led to impaired 
chemotaxis in HEK293 cells (Neel, Lapierre et al. 2007).
At least 2 reasons can be postulated fo r why CCR5 tra ffics th rough the 
recycling endosome. Firstly, tra ffick ing through this com partm ent may be a 
necessary step in CCR5 resensitisation, which appears to be very d iffe rently  
regulated compared w ith the prototypical GPCR, the p2AR. A fter agon ist- 
induced internalisation o f the |32AR, agonist dissociation and 
dephosphorylation are promoted by the low pH o f early endosomes; raising 
endosomal pH inh ib its dephosphorylation and recycling to the cell surface
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(Pippig, Andexinger et al. 1995; Krueger, Daaka et al. 1997). From early 
endosomes, the receptor can recycle to the plasma membrane in a process 
controlled by PDZ dom ain-conta in ing proteins (Cao, Deacon et al. 1999; 
Cong, Perry et al. 2001; Cage, Kim et al. 2001; He, Bellini et al. 2005); 
however, it must be noted tha t there is some evidence for the p2AR recycling 
through recycling endosomes after prolonged agonist stimulation (Moore, 
Millman et al. 2004). In contrast, the recycling o f CCR5 is not regulated by a 
pH-dependent agonist dissociation mechanism and may not require 
dephosphorylation (Signoret, Pelchen-Matthews et al. 2000; Signoret, 
Christophe et al. 2004). Also, CCR5 molecules, which can recycle back to the 
plasma membrane in an agonist-occupied state (Signoret, Pelchen- 
Matthews et al. 2000), probably undergo m ultip le rounds o f internalisation 
and recycling before they are returned to -  and remain at -  the cell surface 
in a fu lly  resensitised form . A condition o f the previous statement, though, 
is that resensitisation does take place, albeit inefficiently. Given that 
resensitisation does not seem to require the low pH o f the early endosome, 
the events involved in this process may occur -  ineffic iently -  in recycling 
endosomes, perhaps involving proteolytic degradation o f bound chemokines 
by recycling endosome-located proteases. In a sim ilar fashion, one could 
argue that passage through the TGN may be involved in CCR5 
resensitisation. Indeed, passage through the recycling endosome may ju s t 
be necessary fo r endocytosed receptors to reach the TGN, where such a 
mechanism could operate.
A requirement fo r passage through the recycling endosome fo r 
resensitisation may not be the only reason fo r passage th rough the 
compartment. Indeed, the resensitisation o f CXCR2, which also passes 
through recycling endosomes, appears to be quite d iffe rent from  that o f 
CCR5, suggesting that a common mechanism involved in chemokine 
receptor desensitisation in the recycling endosome does not exist. CXCR2 
has been shown to associate w ith okadaic-acid sensitive protein 
phosphatase 2A (PP2A) after endocytosis, an interaction responsible fo r its 
dephosphorylation. D isruption o f this interaction not only abrogated 
receptor dephosphorylation but also impaired chemotaxis (Fan, Yang et al.
2001). Dephosphorylation o f Ser337 (a PKC-substrate) on CCR5, on the 
other hand, although being sensitive to okadaic acid, can occur w ithou t
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endocytosis and dephosphorylation o f Ser349 (a CRK substrate) is not 
sensitive to okadaic acid (Pollok-Kopp, Schwarze et al. 2003). An alternative 
hypothesis fo r the reason tha t CCR5 traffics through recycling endosomes is 
that this is responsible fo r targeted recycling o f endocytosed CCR5 
molecules to the leading edge o f cells. CCR5 has been seen to accumulate at 
the leading edge o f leukocytes undergoing RANTES-induced chemotaxis 
(Nieto, Frade et al. 1997; Gomez-Mouton, Lacalle et al. 2004) and in 
m igrating fibroblasts, recycling TfR has been shown to be selectively 
delivered from  recycling endosomes to the leading lamellae (Hopkins, 
Gibson et al. 1994). Moreover, passage through the TGN may fu lfil a sim ilar 
leading edge targeting role. In Swiss 3T3 fibroblasts it was found that 
protein kinase D (PKD)-mediated anterograde membrane tra ffic  from  the 
TGN to the plasma membrane is required fo r localised Raci-dependent 
leading edge activity and fib rob last locomotion (Prigozhina and Waterman- 
Storer 2004) and by fo llow ing newly-synthesised low density lipoprotein 
receptor (LDLR) tagged w ith  GFP using total internal reflection fluorescence 
microscopy (TIR-FM), exocytic events were observed to be polarised towards 
the leading edge in m igrating fibroblasts (Schmoranzer, Kreitzer et al. 
2003). Thus, although speculative, CCR5 may engage a targeted recycling 
pathway from  recycling endosomes and /o r the TGN fo r delivery to the 
leading edge o f cells undergoing chemotaxis. However, despite CCR5 having 
been observed to accumulate at the leading edge o f m igrating leukocytes, 
concentration o f chemotatic receptors at the leading edge o f m igrating cells 
is a controversial issue, w ith several studies suggesting tha t other 
chemotactic receptors are evenly distributed across the surface o f m igrating 
cells (Xiao, Zhang et al. 1997; Servant, Weiner et al. 1999; Jin, Zhang et al. 
2000; Janetopoulos, Jin et al. 2001). The simplest explanation fo r these 
observations is that d iffe rent receptors are regulated in d iffe rent ways.
My results also go a fa ir way towards describing the machinery that may 
operate to bring about CCR5 recycling. The simplest conclusion from  my 
morphological data and functional data using various drugs to  inh ib it CCR5 
recycling, and the EM observations o f others, is that dynam in-dependent 
clathrin-coated vesicle form ation at the recycling com partm ent is involved 
in CCR5 recycling. A c la th rin - and dynam in-dependent recycling pathway 
from  recycling endosomes to the plasma membrane has been described for
256
L h a p t e rmai Discussion
TfR (van Dam and Stoorvogel 2002; van Dam, Ten Broeke et al. 2002), but 
this is the firs t evidence fo r the involvement o f clathrin and dynamin in the 
recycling o f a GPCR. One key experiment is necessary to test my hypothesis, 
though. U ltrastructural analysis o f the effect o f Dyngo-4a on CCR5 
recycling, should, if the drug is tru ly  specific fo r dynamin, and the above 
hypothesis correct, show CCR5 trapped in coated pits that have failed to 
undergo scission. Labelling w ith anti-c la thrin  antibodies could then confirm  
if the coat is clathrin and labelling w ith compartment markers could be used 
to determ ine the site o f th is inh ib ition  -  TGN or recycling endosome - which 
is currently unknown. A lthough transport vesicles formed in such a process 
could be targeted d irectly to the plasma membrane, my data do not 
discount the possib ility tha t such a mechanism also operates in in tra­
recycling com partm ent transport, i.e. tra ffick ing from  the recycling
endosome to TGN or vice versa. With the ultrastructural analysis and a 
better understanding o f the precise tra ffick ing pathway taken by CCR5, 
which could be provided from  the quantitative immunofluorescence assay 
described above, it may be possible to discern on which step in CCR5 
tra ffick ing  th is c la th rin - and dynam in-dependent process acts.
Lastly, if CCR5 does use a clathrin-dependent tra ffick ing step, then there is 
likely to be an adaptor protein to link CCR5 to such a pathway. Given that 
ACAP1 has been shown to be involved in TfR recycling (Dai, Li et al. 2004) 
and that it has subsequently been shown to function as a clathrin adaptor in 
s tim ula tion-dependent integrin recycling and insulin-stim ulated recycling o f 
glucose transporter type 4 (GLUT4) from  recycling endosomes (Li, Peters et 
al. 2007), a potential role fo r its involvement in such a capacity fo r CCR5 
should be investigated. That p-arrestins remain bound to CCR5 in the 
recycling com partm ent also raises the possibility that in a beautiful
symmetry w ith the ir role as clathrin adaptors in CCR5 endocytosis at the 
plasma membrane, p-arrestins couple CCR5 to a c la thrin -m edia ted
tra ffick ing  step involved in CCR5 recycling.
p-arrestins: regulators o f CCR5 intracellular trafficking
There is now much evidence suggesting that in addition to sponsoring 
c lathrin-m ediated endocytosis o f many agonist-activated GPCRs, p-arrestins
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also play a role in regulating the ir subsequent tra ffick ing itineraries. Initial 
experiments defined two classes o f GPCRs, Class A and Class B, which d iffe r 
in the nature o f the ir association w ith p-arrestins in that Class A receptors 
have a higher a ffin ity  fo r p-arrestin2 than p -a rre s tin l and dissociate from  
the p-arrestin  molecule during, or immediately after, endocytosis, whereas 
Class B receptors have an equally high affin ity fo r both p -a rre s tin l and p- 
arrestin2 and maintain an interaction w ith p-arrestins into endosomes 
(Oakley, Laporte et al. 2000). Also, whereas Class A receptors recycle rapidly 
to the plasma membrane a fter internalisation, Class B receptors recycle very 
slowly, if  at all, presumably undergoing eventual degradation (Oakley, 
Laporte et al. 1999; Anborgh, Seachrist et al. 2000). Experiments swapping 
the C -ta ils o f the Class A receptor, p2AR, and the Class B receptor, V2R, not 
only reversed the stab ility  o f the receptor-p-arrestin  complex but also 
reversed the corresponding rates o f receptor dephosphorylation, recycling 
and resensitisation, leading to the idea that p-arrestins impede receptor 
recycling, presumably by restricting the access o f phosphatases to receptors 
(Oakley, Laporte et al. 1999). Along the same lines o f p-arrestins inh ib iting 
recycling, it has, more recently, been shown that p-arrestin binding can 
facilitate receptor ub iqu itina tion, targeting receptors fo r degradation 
(Shenoy, McDonald et al. 2001; Martin, Lefkowitz et al. 2003). However, 
despite the data linking sustained p-arrestin interaction w ith very slow 
receptor recycling/degradation (Oakley, Laporte et al. 1999; Anborgh, 
Seachrist et al. 2000), more recent studies have identified receptors that 
despite maintaining an interaction with p-arrestins in endosomes, 
nevertheless recycle rapidly to the cell surface - the so-called Class C 
receptors (Garland, Grady et al. 1996; McConalogue, Dery et al. 1999; 
Mundell, Matharu et al. 2000; Vines, Revankar et al. 2003; Tulipano, Stumm 
et al. 2004; Simaan, Bedard-Goulet et al. 2005). Although there is evidence 
that dissociation o f p-arrestins from Class C receptors may be required fo r 
the ir recycling (Key, Vines et al. 2005; Simaan, Bedard-Goulet et al. 2005), 
which is in keeping w ith the early view that a sustained interaction w ith  p- 
arrestins inh ib its  recycling, evidence from p-arrestin knock-ou t and knock­
down studies have demonstrated the requirement fo r p-arrestins in the
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recycling o f the A/-formyl peptide receptor (FPR) and the A2B adenosine 
receptor (Mundell, Matharu et al. 2000; Vines, Revankar et al. 2003). 
Following on from  the observation by Mueller et al. (2002) that GFP-p- 
a rres tin l red istributed w ith  agonist-activated CCR5 into endosomes, I have 
shown that both p-arrestins 1 and 2 stably associate with CCR5 as it tra ffics 
through early endosomes and on to  the perinuclear recycling compartment. 
Given that CCR5 rapidly recycles from  the recycling compartment to the cell 
surface, CCR5 can thus be classified as a Class C receptor. Whether this 
sustained interaction between p-arrestins and CCR5 plays a role in 
regulating CCR5 tra ffick ing  and what this role is has been harder to pin 
down. A tanta lis ing hypothesis is that p-arrestins could act as facilitators o f 
CCR5 recycling by coupling the receptor to  a clathrin-m ediated tra ffick ing 
step that my data suggest operates at the recycling compartment. However, 
over-expression o f p-arrestin2 resulted in an inh ib ition o f CCR5 recycling, 
suggesting that p-arrestins act as negative regulators o f CCR5 recycling. 
A lthough the significance o f the results o f CCR5 recycling in the presence o f 
p-arrestin2 mutants is unclear, one o f the simplest interpretations o f the 
data as a whole is that residues in the C -ta il o f p-arrestin2 are responsible 
fo r mediating tra ffick ing  o f CCR5 to the recycling com partm ent and, 
perhaps, the recycling com partm ent is the site where a p-arrestin -m edia ted 
inh ib itory mechanism operates. The mechanism through which p-arrestins 
would exercise th is role is unclear but it may involve the coupling o f the 
receptor to fla t clathrin patches, since on immunolabelled cryosections, 
down-m odulated CCR5 has been observed in large, fla t coated patches on 
endosomal structures, which contained the clathrin adaptor protein 
complex, AP-1 (Silene Wavre, Endocytic Regulation o f Chemokine Receptor 
Expression, PhD thesis, 2006).
It is also interesting to note that p -a rre s tin l has been implicated in early 
endosome to lysosome targeting o f CXCR4, which is related to its ab ility  to 
interact d irectly w ith the E3 ubiquitin  ligase, AIP4 (Bhandari, Trejo et al. 
2007). Thus, p-arrestins may play a crucial sorting role at the early 
endosome, dictating whether receptors are targeted fo r degradation or to a 
recycling pathway.
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A major critic ism  o f the experiments addressing the role o f p-arrestins in 
CCR5 post-endocytic tra ffick ing  is that I have only assessed the effect on 
CCR5 recycling o f p-arrestin2 over-expression, and not that o f p -a rre s tin l. 
For the A2B adenosine receptor, expression of p-arrestin anti-sense 
constructs in HEK293 cells led to significant defects in recycling, which 
although restored by e ither p -a rre s tin l or p-arrestin2 reconstitution, was 
faster when rescued w ith  p-arrestin2 compared with p -a rre s tin l (Mundell, 
Matharu et al. 2000), so there may be differential roles for the two p- 
arrestin proteins in in tracellu lar tra ffick ing  o f GPCRs. Although CCR5 did not 
recycle in transiently-transfected MEFs, experience with transient versus 
stably-transfected cell lines suggests that this inability to support CCR5 
recycling may be a function  o f transient transfection rather than MEFs in 
particular. Hence, a MEF ce ll-line  stably expressing CCR5 should be made to 
see if the receptor can recycle in these cells. If it can, p-arrestin knock-out 
MEFs stably-expressing CCR5 should also be made, which may be useful in 
determ ining whether there are d ifferentia l effects o f the p-arrestin  proteins 
on CCR5 recycling. Moreover, a p-arrestin knock-ou t background would be 
more desirable fo r assessing the effect o f p-arrestin mutants on CCR5 
tra ffick ing . If CCR5 were unable to recycle in MEFs stably expressing the 
receptor, th is would be an interesting result in itself, since it would suggest 
that MEFs lack (or express very low levels of) a component(s) o f the recycling 
machinery. This would also suggest that CCR5 recycling is quite a 
specialised process as presumably other recycling membrane proteins, such 
as TfR and TGN38 can recycle in MEFs. Of course, an absolute requirem ent 
fo r p-arrestins in CCR5 recycling could still not be assessed in p -arrestin  1 
and 2 knock-ou t MEFs stably-expressing CCR5, since CCR5 does not 
internalise in the absence o f p-arrestins. More am bitious experim ents may 
be necessary here, such introducing an alternative internalisation m o tif into 
CCR5, such as the AP-2 binding m otif o f CXCR4, which can mediate CXCR4 
internalisation in a phorbol myristate acetate- (PMA-) inducible manner 
(Signoret, Rosenkilde et al. 1998).
The sustained association o f CCR5 w ith p-arrestins must also be viewed in a 
physiological context, particularly w ith a consideration o f the potential role 
o f p-arrestins in chemotaxis by scaffolding signalling molecules involved in
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cytoskeletal reorganisation to promote localised actin assembly events 
leading to the form ation o f a leading edge (Defea 2006). As discussed 
above, CCR5 has been seen to accumulate at the leading edge o f m igrating 
cells (Nieto, Frade et al. 1997; Gomez-Mouton, Lacalle et al. 2004) and there 
is evidence fo r targeted tra ffick ing  o f other proteins from recycling 
endosomes and the TGN to the leading edge o f cells during cell m igration 
(Hopkins, Gibson et al. 1994; Schmoranzer, Kreitzer et al. 2003; Prigozhina 
and Waterman-Storer 2004). Moreover, increased rates o f clathrin-m ediated 
internalisation at the leading edge compared with the tra iling edge have also 
been observed in m igrating cells (Rappoport and Simon 2003), so in 
leukocytes undergoing chemotaxis, CCR5 may effectively be constrained to 
a recycling loop between the leading edge and the perinuclear recycling 
compartment. Such a model, including the additional proposal that there is 
slow lateral d iffusion in the plasma membrane at the leading edge, has been 
proposed to contribute to the generation o f polarity in m igrating cells 
(Jones, Caswell et al. 2006). Thus, signalling from  p-arrestins bound to 
CCR5 may, as a consequence, be restricted to  w ith in  th is loop. Moreover, a 
significant proportion o f agonist-activated, internalised CCR5 molecules 
recycle to the plasma membrane in an agon ist-bound, activated form , 
escaping resensitisation (Signoret, Pelchen-Matthews et al. 2000). It is 
possible, therefore, that p-arrestins accompany agon is t-bound receptors 
back to the cell surface and may thus target signalling complexes to the 
leading edge that are responsible fo r actin reorganisation. O f course, this 
could also be achieved through retention o f CCR5 complexed w ith p- 
arrestins at the cell surface but this would not allow fo r CCR5 
resensitisation, which would be predicted to play a role in gradient sensing. 
Thus, a recycling mechanism with some CCR5 molecules recycling in a p- 
arrestin -bound state and some being returned in a resensitised state may 
fu lfil both the requirement fo r localised p-arrestin  signalling at the leading 
edge and enable the population o f CCR5 molecules to collectively ‘sense’ a 
chemokine gradient. Interestingly, constant retargeting o f internalised EGFR 
(epidermal growth factor receptor) and PVR (p la te le t-derived growth 
factor/vascular endothelial growth factor [PDGF/VEGF] receptor) to the 
leading edge o f Drosophila  border cells, which keeps downstream signalling 
localised, is crucial fo r the ir m igration Qekely, Sung et al. 2005).
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Alternatively, but not mutually exclusive w ith the previous proposal, p- 
arrestin-m ediated signalling in the recycling compartment may control 
some other aspect o f cell m igration or physiological response to chemokine 
challenge. This may explain why p-arrestins act as negative regulators o f 
recycling: retention o f CCR5 in the recycling compartment may be a 
mechanism to prolong p-arrestin -m edia ted signalling at the recycling 
compartment.
I have tried to  address the issue o f whether p-arrestins accompany CCR5 in 
CHO cells as it recycles back to the cell surface by live-cell fluorescence 
microscopy but have experienced problems w ith severe phototoxicity in 
CHO cells. This could perhaps be overcome by using a m ulti-photon  
microscope.
Despite over-expression o f p-arrestin2 impeding CCR5 recycling, the data 
presented in Chapter 6 do not rule out the possib ility that p-arrestins also 
function to facilitate CCR5 recycling, perhaps in a clathrin adaptor role. 
However, the sequential m u lti-s ite  binding model o f p-arrestin  interaction 
w ith an activated GPCR proposes that agonist-d issocia tion leading to a 
conformational change in the receptor is the catalyst fo r p-arrestin 
dissociation (Gurevich and Benovic 1993). A lthough I have presented data 
that p-arrestin  binding may be able to occur independently o f receptor 
phosphorylation, receptor activation is a p re-requ is ite  o f p-arrestin  binding, 
since agonist-free receptors (w ild -type or phosphoryla tion-defic ient) on the 
cell surface do not bind p-arrestins. A fter agonist dissociation, wherever 
that may occur, the theory would suggest that CCR5 molecules should not 
retain an interaction w ith p-arrestins, or at least the complex should be 
severely destabilised. A lthough CCR5 molecules can return to  the surface in 
an agonist-bound state and may undergo several cycles o f internalisation 
and recycling before returning to the surface in a resensitised state, agonist 
dissociation must occur at some stage in th is iterative cycling, since 
resensitised receptors do re-appear on the cell surface after agonist wash­
out (Signoret, Pelchen-Matthews et al. 2000). If agonist dissociation were to 
occur p rio r to the p-arrestin-m ediated tra ffick ing  step, then th is would 
require an alternative mechanism to effect CCR5 tra ffick ing  at this particular 
step. Thus, a p-arrestin-m ediated recycling mechanism may be a
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specialised form  o f recycling restricted to agonist-bound receptors. The 
significance o f th is is not clear.
In keeping w ith  the previously-dem onstrated importance o f receptor 
phosphorylation in supporting h igh -a ffin ity  p-arrestin binding, most CCR5 
molecules that tra ffic  to  the recycling compartment seem to remain 
phosphorylated on serines 337 and 349. However, I have also shown that a 
CCR5 mutant w ith  all 4 serine residues previously demonstrated to undergo 
agonist-induced phosphorylation mutated to alanines, is also capable of 
recruiting p-arrestins and undergoing internalisation when stimulated with 
agonist. Moreover, its ab ility  to  recruit p-arrestins was not an over­
expression artefact, since it failed to undergo agonist-induced 
internalisation in p-arrestin  1 and 2 knock-out MEFs, yet underwent 
internalisation in w ild -type  and single p-arrestin knock-ou t MEFs. Although 
it is necessary to  confirm  that this mutant is, indeed, not phosphorylated on 
other threonine residues when expressed in CHO cells or MEFs, these data 
suggest that CCR5 can bind p-arrestins independently o f phosphorylation. 
My data do, however, suggest that phosphorylation increases the a ffin ity  
and -  particularly in the case o f p -a rre s tin l -  the stability o f the interaction. 
CCR5 is not alone in its ability to bind p-arrestins in the absence o f 
phosphorylation: a surprising number o f GPCRs have been shown to bind p- 
arrestins (and in most cases also internalise) in the absence o f 
phosphorylation, including the D6 non-signalling chemokine receptor 
(Galliera, Jala et al. 2004), protease activated receptor 2 (Stalheim, Ding et 
al. 2005), lu tropin receptor (Mukherjee, Palczewski et al. 1999; Min and 
Ascoli 2000; Min, Galet et al. 2002; Mukherjee, Gurevich et al. 2002), 
substance P receptor (Richardson, Balius et al. 2003), orexin 1 receptor 
(Milasta, Evans et al. 2005), leukotriene B4 receptor 1 (Jala, Shao et al. 2005) 
and several splice variants o f the serotonin 5-HT4 receptor (Barthet, Gaven 
et al. 2005). Whether phosphorylation-independent p -arrestin  binding to 
CCR5 actually occurs in vivo, though, is questionable. It is likely that 
because receptors are rapidly phosphorylated after agon is t-activa tion , that 
most receptors binding p-arrestins are phosphorylated. Indeed, most o f the 
experiments showing that the above receptors can undergo p -a rres tin -
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dependent internalisation in the absence o f receptor phosphorylation have 
used phosphory la tion-defic ient receptor mutants, so it is not known 
whether any non-phosphorylated receptors are internalised in a p -a rre s tin - 
dependent fashion in vivo. However, there remains the possibility that some 
CCR5 molecules could engage p-arrestins w ithout having undergone 
phosphorylation. What the significance o f this would be is unclear.
Similar to CCR5, fo r the substance P, o rex in -1  and protease activated 2 
receptors, phosphorylation has been shown to enhance the stability o f the 
p -a rrestin -recep tor complex; that is, mutation o f key phospho-acceptor 
residues converts the receptors from  a Class B to a Class A phenotype 
(Richardson, Balius et al. 2003; Milasta, Evans et al. 2005; Stalheim, Ding et 
al. 2005). It should be noted, though, that although the stab ility o f the 
interaction between p -a rre s tin l and phosphorylation-defic ient CCR5 was 
clearly reduced compared w ith w ild -type  CCR5, phosphorylation-defic ient 
CCR5 showed only a m ild ly reduced stab ility w ith p-arrestin2, maintaining 
an interaction w ith p-arrestin2 into the recycling compartm ent in most cells 
observed. Thus, CCR5 seems to be unique in its ab ility to maintain an 
interaction w ith p-arrestins into endosomes w ithou t receptor 
phosphorylation. Additionally, CCR5 differs from  the previously 
characterised Class B and Class C receptors in that it does not contain (a) 
cluster(s) o f serine/threonine residues (Ser/Thr residues occupying 3 /3 , 
3 /4 , or 3 /5  consecutive positions), so does appear to be very d iffe ren t from  
other previously characterised receptors w ith respect to its interaction w ith 
p-arrestins. Stable p-arrestin binding has been linked to ub iqu itina tion  o f 
the p-arrestin molecule. Rapid internalisation o f the p2AR, a Class A 
receptor, requires transient ubiquitination o f p-arrestin2 and the tim e - 
course o f ub iqu itina tion is consistent w ith p-arrestin2 carrying a ub iqu itin  
moiety only when bound to the receptor (Shenoy, McDonald et al. 2001). 
Activation o f the V2 vasopressin receptor (V2R), a Class B receptor, results 
in more prolonged p-arrestin ubiquitination and switching the C -ta ils  o f the 
p2AR and V2R reverses the kinetics o f p-arrestin ub iqu itina tion  (Shenoy and 
Lefkowitz 2003). Importantly, expression o f a p -a rre s tin 2 -ub iqu itin  fusion 
protein, which cannot be de-ubiquinated in the cell and mimics the stably 
ubiquitinated form  o f arrestin, imparts Class B characteristics on the p2AR
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(Shenoy and Lefkowitz 2003). Perhaps agonist-activated CCR5 can interact 
w ith p-arrestins in a way that induces a p-arrestin conform ation that 
promotes its stable ub iquitination despite the receptor lacking 
serine/threonine clusters in its C -ta il. At least fo r p-arrestin2, it would be 
predicted that this conform ation can be achieved w ithout the requirement 
fo r C -tail phosphorylation o f CCR5.
p-arrestin b inding to  unphosphorylated receptors at all requires an 
explanation consistent w ith  the activation mechanism o f p-arrestin. The D6 
chemokine receptor does not appear to be phosphorylated in vivo but 
nevertheless undergoes constitu tive p-arrestin-dependent internalisation 
(Galliera, Jala et al. 2004). For this receptor, an acidic region in its C- 
term inus is involved in p -arrestin  binding, presumably activating the p- 
arrestin phosphate sensor in the absence o f phospho-residues on the 
receptor (Galliera, Jala et al. 2004). There are several glutam ic acid residues 
in the CCR5 C -ta il tha t may function in a sim ilar way, although they are 
spread along the length o f the tail and do not constitute a cluster.
One particularly interesting result, which was a by-product o f the 
experiment dem onstrating that CCR5 molecules remain phosphorylated on 
serines 337 and 349 as they tra ffic  to the perinuclear recycling 
compartment, is that at least serines 337 and 349 appear to be accessible 
after p-arrestin  binding. Whether this is due to these residues becoming 
solvent-exposed after the conformational change in the p-arrestin  molecule 
associated w ith  the transition to its active, h igh -a ffin ity  receptor-b ind ing 
state or whether in a dim er only one receptor binds a p-arrestin  molecule, 
this means that CCR5 dephosphorylation and p-arrestin dissociation may 
not be tigh tly  coupled, as has been suggested for other GPCRs (Oakley, 
Laporte et al. 1999). Moreover, the putative PDZ ligand at the extreme C- 
term inus, which includes S349 and whose integrity has been shown to be 
necessary fo r CCR5 recycling (Delhaye, Gravot et al. 2007), would also be 
accessible despite sustained p-arrestin interaction w ith internalised 
receptors and thus a PDZ sequence-directed regulatory mechanism could 
act alongside a p-arrestin-dependent regulatory mechanism fo r CCR5 
tra ffick ing . This may also be the case fo r other GPCRs.
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The way forward
This study and others have demonstrated various features o f CCR5 
tra ffick ing in CHO cells. However, the major lim itation o f this ce ll-line  is the 
d ifficu lty  w ith  perform ing routine siRNA knock-down studies because the 
hamster genome has not been sequenced. I have established a human 
osteosarcoma (HOS) ce ll- line  that appears to tra ffic  the receptor sim ilarly to 
CHO cells and should prove useful fo r investigating the role o f candidate 
proteins in CCR5 recycling -  given the likely involvement o f clathrin in a 
CCR5 recycling pathway, investigating a role for ACAP1 should be 
prioritised. When a clearer molecular picture o f CCR5 intracellular tra ffick ing 
has emerged in non -m o tile  cells, the relevance o f this tra ffick ing fo r 
physiological processes such as chemotaxis should then be assessed. 
However, more sophisticated assays than the simple Boyden chamber assay 
commonly used to  assess chemotaxis should be explored, which can better 
reflect the 3-d im ensiona l cellular matrix through which leukocytes must 
migrate w ith in  an inflamed tissue and also recapitulate the in vivo situation 
where chemokines are presented on the surface o f cells through interaction 
with glycosaminoglycans (GACs). Moreover, chemotaxis assays that assess 
the ab ility  o f cells to undergo chemotaxis in a gradient o f chemokine, 
although perhaps being relevant fo r the chemotactic m igration o f leukocytes 
w ith in an inflamed tissue, do not really reflect well the other steps involved 
in the recruitm ent o f leukocytes to sites o f inflammation including the steps 
prior to extravasation, where the recruitment o f leukocytes from  the blood 
stream begins w ith  the selectin-mediated capture and rolling o f leukoctyes 
to the vessel wall, which allows immobilised chemokines to interact w ith 
the ir cognate receptors on the leukocyte, resulting in integrin activation and 
firm  arrest. Moreover, chemokines also promote transendothelial m igration 
in a process that may involve leukocyte movement down an im m obilised 
chemokine gradient -  so-called haptorepulsion - since the highest 
concentrations o f chemokines are found on the luminal surface. Indeed, 
CXCR3 has been shown to mediate the migration o f plasmacytoid dendritic 
cells, which required the encounter o f its cognate ligands im m obilised, 
optim ally by heparan sulfate, in the form  o f a negative gradient (Kohrgruber, 
Groger et al. 2004).
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Additionally, leukocytes express CCR5 along w ith many other GPCRs, 
including many Gar coupled chemoattractant receptors, which may be 
simultaneously activated during a response to inflam m ation. Interestingly, 
the activation o f CXCR1 and FPR have been shown to not only lead to cross­
phosphorylation and desensitisation o f CCR5 but also cross-internalisation 
o f CCR5 in cells co-expressing the receptors (Shen, Li et al. 2000; Li, Wetzel 
et al. 2001; Richardson, Tokunaga et al. 200B). Moreover, CCR5 has been 
shown to heterodimerise w ith the complement 5a receptor (C5aR) in RBL 
cells and agonist-induced internalisation o f C5aR led to the co­
internalisation o f CCR5. Importantly, internalisation o f CCR5 was also 
observed in C5a-stim ulated macrophages, demonstrating tha t such a co­
internalisation mechanism operates in cells where CCR5 is endogenously 
expressed. How such hetero-oligomerisation affects the intracellu lar 
tra ffick ing  o f CCR5 is unknown, as is the extent o f heterodim erisation and 
cross-regulation in leukocytes. Thus, once the fundamental properties o f 
CCR5 tra ffick ing  have been determined in cell—lines, the task o f 
understanding how the receptor traffics in cells where it is endogenously 
expressed can start and this is where the real fun w ill begin!
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